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 i 
Abstract 
Prognostic models are used to predict an individual’s future health outcomes, including 
the risk of disease progression and the development of further complications. The 
statistical methodology used to develop these models is often naïve to the presence 
of competing events, these are events which prevent or alter the probability of an 
outcome of interest from occurring. Not appropriately accounting for competing events 
is known to produce inflated absolute risk predictions for time-to-event outcomes, this 
bias is known as competing risks bias. However, there has been relatively little 
research about competing events in prognostic model research, for which absolute risk 
predictions are a key outcome. 
This thesis investigates the presence and impact of competing events on prognostic 
model research. To begin, two reviews were conducted to determine the presence, 
reporting, and management of competing events in current prediction model literature. 
Then competing risks statistical regression methods were applied to develop and 
internally validate a prognostic model using existing study data. These models were 
compared to models developed using standard time-to-event analysis techniques, 
naïve to competing events, with an external validation study. Finally, a simulation study 
was performed to identify the circumstances for which competing risks bias affects the 
predictive ability and calibration of prognostic models, with an overall aim to provide 
guidance for the optimal approaches to incorporate competing risks in prognostic 
model research. 
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 1 
1 INTRODUCTION 
1.1 Thesis overview 
Prognostic models provide personalised estimates of the risk of future events for 
patients in a given health state (Harrell, 2015, Steyerberg et al., 2013). Clinicians and 
patients may utilise prognostic models to predict the risks of future events, enhancing 
informed decision making and enabling tailored treatment strategies (Steyerberg et al., 
2013). In order to enhance decision making, prognostic models should produce reliable 
(i.e. accurate) estimates of the absolute risk of the event. Ideally, prognostic models 
estimate the risk of a clinically relevant outcome, often through the development of a 
statistical equation, such as via multivariable regression techniques (Steyerberg et al., 
2013). Time-to-event analysis (also known as survival analysis) methods are utilised 
when both the occurrence of an event of interest and the time until the occurrence are 
of interest (Harrell, 2015). 
However, it is common in clinical practice to have multiple events that could 
occur, which preclude or alter the probability of the event of interest occurring (Koller 
et al., 2012). These so-called competing events, if not appropriately accounted for 
when developing prognostic models, can result in inflated absolute risk estimates 
(Andersen et al., 2012, Berry et al., 2010, Koller et al., 2012, Wolbers et al., 2009), 
referred to as “competing risks bias” (Schatzkin and Slud, 1989, Schumacher et al., 
2016, Walraven and McAlister, 2016). For example, the risk of second hip fracture at 
10 years was estimated to be 21% when ignoring the competing risk of death. This is 
1.75 times greater than the true risk of 12%, estimated by appropriately accounting for 
deaths (Berry et al., 2010). Such biases in absolute risk predictions may result in 
inaccurate individual risk predictions which could impact the decisions and treatment 
strategies initiated by clinicians and their patients. This may be a particular issue when 
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developing prediction models in frail populations, such as the elderly, those with 
multimorbidities, or the critically ill, as in these settings individuals are more likely to 
experience a number of competing outcomes prior to the outcome of interest (Koller et 
al., 2012). 
In order to avoid competing risks bias, the appropriate competing risks statistical 
methods, rather than standard time-to-event methods, should be applied. However, 
while the theory of competing risks has been around since the 1760s (Bernoulli, 1760), 
investigations have revealed that the methods are not being applied adequately. A 
systematic review of scientific articles published in high-impact clinical journals 
between 2007 and 2010 found competing risks bias was present in 67% (24/35) of 
eligible studies (Koller et al., 2012). Additionally, a recent systematic review of articles 
that reported Kaplan-Meier estimates, published in prominent medical journals in 2013, 
revealed almost half (46/100) of the studies were susceptible to competing risks bias 
(Walraven and McAlister, 2016). An update of this review, focusing on articles 
published in the New England Medical Journal in 2015, similarly found almost half 
(25/51) of studies were susceptible to this bias (Schumacher et al., 2016). Finally, a 
systematic review of reports of randomized controlled trials published in 2015 found 
77.5% (31/40) of the studies were susceptible to competing risks bias (Austin and Fine, 
2017). Thus, it is likely that competing risks bias is present in prediction model 
research, but this needs to be formally examined. 
Though the potential impact of competing events on prognostic model research 
could be substantial, limited research has been conducted in this area. Therefore, the 
focus of this thesis is the investigation of the presence and impact of competing events 
on prognostic model research. This chapter lays the foundations on which the thesis 
is built. An overview of prognosis research is presented, followed by an introduction to 
statistical methods for standard time-to-event analysis and competing risks analysis. 
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Methods for developing and validating prognostic models are presented, and the aims 
of the thesis are outlined. 
1.2 Prognosis research 
Prognosis, a key concept in evidence based medicine, refers to the risks of future 
health outcomes in patients with a given disease or health condition (Hemingway et 
al., 2013). The focus of a number of clinical actions (including screening, diagnosis, 
and therapy) is to understand, predict, and improve individual prognoses (Steyerberg, 
2008). Thus, prognosis research seeks to investigate the relations between future 
outcomes in patients with a given health state, in order to improve health (Hemingway 
et al., 2013). This contrasts with diagnostic research, which investigates the probability 
that a disease or condition is already present in a patient. Prognosis research aids 
understanding of the natural history of the health state, indicating the most likely course 
of progression or recovery, identifying factors associated with the riski of future events, 
and identifying groups of individuals most at risk of these events (Steyerberg, 2008). 
The study of prognosis is crucial for the increased understanding and improvement of 
patient outcomes, and should thus be integral to clinical decision making and 
healthcare policy (Hemingway et al., 2013). 
The PROGnosis RESearch Strategy (PROGRESS) Partnershipii published a 
series of articles focusing on each of four research themes, listed below, which 
together outline a framework for prognosis research (Hemingway et al., 2013): 
                                                     
i The term “risk” is used throughout the thesis to convey the probability of a future event. While the 
connotation is that events are negative, this is not always the case e.g. predicting disease recovery. 
iiThe PROGRESS Partnership is a UK Medical Research Council (MRC) funded, international, 
interdisciplinary collaboration developing understanding in research into quality of care outcomes, 
prognostic factors, risk prediction models, and predictors of differential treatment response. 
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1. Overall prognosis research aims to describe and explain the average prognosis 
of future outcomes in relation to current diagnostic and treatment practices 
(Hemingway et al., 2013). 
2. Prognostic factor research aims to identify any measure (prognostic factor) that 
is associated with a subsequent clinical outcome among people with a particular 
disease or health condition (Riley et al., 2013). 
3. Prognostic model research utilises combinations of multiple prognostic factors 
to predict the risk of future clinical outcomes in individual patients (Steyerberg et 
al., 2013). 
4. Stratified medicine research involves tailoring therapeutic decisions to an 
individual or groups of individuals based on their predicted risk and/or predicted 
response to therapy (Hingorani et al., 2013). 
This thesis focuses on PROGRESS theme three (prognostic model research) as 
methods for the development and validation of multivariable prognostic models for 
time-to-event outcomes are explored. Prognostic models may be referred to as clinical 
prediction models/tools/rules, prognostic indices/scores, prediction models, predictive 
scores, risk scores, scoring systems, risk stratification tools, amongst others. Ideally, 
prognostic models estimate absolute risk predictions of a clinically relevant outcome, 
derived through a formal combination of multiple prognostic factors, typically by 
applying multivariable regression techniques (Steyerberg et al., 2013). Prognostic 
model research can be applied to identify high risk groups for targeted screening or 
prevention interventions, to aid therapeutic decision making and follow-up strategies, 
and in further medical researchi (Steyerberg, 2008). An example of a well-known 
prognostic model with a time-to-event outcome, used in daily clinical practice, is 
provided in Figure 1.1. 
                                                     
i Such as stratification in randomised controlled trials or adjusting baseline imbalance in observational 
studies. 
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Figure 1.1: Example of a prognostic model with time-to-event outcome - GRACE 
The GRACE risk scores (Fox et al., 2006) are NICEi recommended (NICE CG94) 
prognostic models which estimate in-hospital and 6 month risks of death and myocardial 
infarction at admission and discharge for patients presenting with acute coronary 
syndrome. The models were developed using data from 21,688 patients included in a 
prospective multinational observational study. 
 
Cox regression analysis was utilised to develop the models, which contain eight prognostic 
factors, including the patient’s age, heart rate (HR), systolic blood pressure (SBP), and 
serum creatinine (Creat.) measures and whether the patient has congestive heart failure 
(CHF), cardiac arrest at admission, ST-segment deviation, or elevated cardiac 
enzymes/markers. 
 
The GRACE risk scores were developed into an app, depicted below, and have been 
integrated into electronic medical record systems used in daily clinical management of 
acute coronary syndrome patients worldwide. 
 
 
GRACE risk calculator (www.outcomes.org/grace) (Fox et al., 2006)ii 
 
Numerous tutorials for prognostic model research have been published, including 
the BMJiii series “Prognosis and prognostic research” (Moons et al., 2009b, Royston 
et al., 2009, Altman et al., 2009, Moons et al., 2009a), the “Risk prediction models” 
series (Moons et al., 2012b, Moons et al., 2012a), and the “Clinical prediction models” 
(Steyerberg, 2008) and “Prognosis Research in Healthcare: Concepts, Methods, and 
                                                     
iThe National Institute for Health and Care Excellence (NICE) is a public body of the department of 
health in the UK, providing national guidance and advice to improve health and social care. 
ii Reproduced from “Prediction of risk of death and myocardial infarction in the six months after 
presentation with acute coronary syndrome: prospective multinational observational study (GRACE)” 
Fox et al., 333, 2006, with permission from BMJ Publishing Group Ltd. 
iiiThe British Medical Journal (BMJ) is an international peer-reviewed medical journal. 
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Impact” (Riley et al., 2019a) books. Although the number of prognostic models in 
medical and health research have proliferated in recent years, current evidence 
indicates deficiencies in the statistical methods (Hemingway et al., 2009) and poor 
quality of reporting (Collins et al., 2015), prompting the development of the Transparent 
Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis 
(TRIPOD) guidelines (Collins et al., 2015). The above texts discuss the principles and 
methods for prognostic model research, though there remains much debate regarding 
ideal practices. However, it is generally accepted that prognostic model research can 
be split into different stages; these can be categorised as model development (with or 
without internal validation); model validation (with or without updating); and subsequent 
evaluation of impact in clinical practice (Collins et al., 2015, Steyerberg et al., 2013). 
It has been commented that prognostic models are more likely to be accepted 
and successfully implemented if shown to be clinically crediblei (Wyatt and Altman, 
1995), and show evidence of accuracy, generalisability, and effectiveness (Steyerberg 
et al., 2013). Further, a number of general principles for good practice are proposed 
for clinically useful prognostic models (Moons et al., 2012b, Steyerberg, 2008), outlined 
in Box 1.1. A recent review of prognostic models found models were more likely to be 
reliable when; developed using a large, high-quality dataset; based on a study protocol 
with a sound statistical analysis plan; validated in independent datasets obtained from 
different locations (Steyerberg et al. 2013). 
                                                     
i Clinically credible in this context refers to prognostic models which are supported by leading 
professionals and which contain all clinically important prognostic factors. 
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Box 1.1: Principles for good practice for clinically useful prognostic models 
1. There should be a clear aim to predict a clinically meaningful outcome; which 
ought to be assessed objectively and without bias. 
2. Participants should be representative and from a well-defined cohort. 
3. A pre-determined selection of standardised, clinically relevant, and readily-
available prognostic factors should be collected, at their intended moment of use 
(i.e. the time of prediction). 
4. Follow-up time ought to be sufficient for the appropriate number of events to be 
observed, i.e. the sample size should be sufficient. In particular, it is often 
recommended there be at least ten events per candidatei prognostic factor 
(Peduzzi et al., 1995)  
5. There should be an intention to apply the model in practice and/or research. 
 
The remainder of this chapter introduces the statistical considerations for 
prognostic model research, specifically focusing on fundamental statistical concepts 
for time-to-event outcomes, including the presence of competing events, and 
considerations for the development and validation of prognostic models with time-to-
event outcomes. Then from Section 1.7, the aims and objectives of the thesis are 
outlined. 
1.3 Statistical analysis of time-to-event outcomes 
Prognostic models predict the risks of an outcome within a specific time period 
(Steyerberg et al., 2013). When both the occurrence and the time until the occurrence 
of an event are of interest (such as time to next epileptic episode), or when long-term 
outcomes are of interest (such as 10 year risk of cardiovascular disease), the optimal 
approach is to apply time-to-event (also known as survival) analysis techniques 
(Harrell, 2015). Time-to-event analysis examines the time between a suitable starting 
point and the occurrence of an event. In prognosis research the starting point is usually 
patient diagnosis, first presentation of the health condition in clinical practice, or entry 
into a given health state, and the event is clinically relevant and binary (Collins et al., 
                                                     
i Candidate prognostic factors refers to the group of prognostic factors considered for use in the 
prognostic model Thus may include prognostic factors which are not included in the final prognostic 
model due to the application of a selection process (see Section 1.5.2). 
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2015). The response variable, the time to the event, may have an unusual distribution; 
it is usually continuous but is restricted to be positive, thus often has a skewed (not 
normal) distribution. Additionally, it is unlikely that the event of interest will be observed 
for all participants; some participants may not experience the event during the study 
and some may be lost to follow-up. Time-to-event analysis can incorporate 
incompletely determined outcome information (censoring), which is likely to occur with 
long-term outcomes, thus it uses data more efficiently than other regression methods 
(such as logistic regression) (Harrell, 2015). 
1.3.1 Censoring 
Censoring occurs when a participant is not observed to experience the event of 
interest during the study follow-up period. There are a number of censoring 
mechanisms which may result in the reporting of censored observations, including left, 
right, and interval censoring (Harrell, 2015). Left censoring occurs when a participant 
experiences the event prior to the study start time. Interval censoring occurs when the 
event is known to have occurred during a time interval though the exact time is 
unknown, such as when an outcome is assessed at periodic clinical examination. Both 
left and interval censoring are not often present in prognostic model research and are 
thus not considered further in this thesis. Right censoring may occur if participants 
have not experienced the event by the end of follow-up (administrative censoring), or 
if participants stop being observed before the end of the study (loss to follow-up). A 
graphical representation of time-to-event data containing right-censoring is provided in 
Figure 1.2. 
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Figure 1.2: Example of time-to-event data with right censoring. 
 
Participant follow-up time is shown by the solid blue lines. 
Participant A experiences the event of interest after six years. 
Participant B does not experience the event of interest during the study period, so is 
right-censored and contributes ten years of event-free time to the analysis. 
Participant C is lost to follow-up, so is right-censored; and contributes three years of 
event-free time to the analysis. 
Participant D joins the study at two years, and experiences the event at nine years; their 
time-to-event is 9-2 = 7 years. 
Participant E joins the study at five years, and withdraws from the study at eight years, so 
is right-censored and contributes 8-5 = 3 years of event-free time to the analysis. 
 
A key assumption of standard time-to-event analysis is non-informative (or 
independent) censoring; that those participants who are censored have the same 
probability of experiencing the event as others still at risk at the time the censoring 
occurred (Geskus, 2015). Under this assumption, removing those who are censored 
from the analysis at the time of censoring does not affect the overall risk of an event 
going forward. If informative censoring exists, then the time-to-event estimates may be 
biased. For example, if participants who are lost to follow-up withdrew from the study 
because they felt particularly unwell, their risk of experiencing an adverse event might 
be comparably worse than those who remain in the study. Whether the assumption of 
non-informative censoring is reasonable in the presence of other events, particularly 
ones which can alter the risk of the event of interest (competing events), will be 
discussed in detail later in this chapter. 
1.3.2 Introduction of the multi-state structure 
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Time-to-event analysis methods are now described in the context of a multi-state 
modelling structure. Under this structure, participants transition between states 
following the occurrence of an event. The simplest multi-state structure is depicted in 
Figure 1.3, and begins with all participants in a single initial state. Participants remain 
in this state until the occurrence of an event of interest, at which time they transition 
into a second state. Participants then remain in the second state until the end of the 
study, as there is no chance of exiting the second state it is referred to as an absorbing 
state. This structure can be used to describe standard time-to-event analysis 
techniques; for example, when analysing survival, all participants are alive (the initial 
state) until death (the event) after which they are dead (the absorbing state). 
Figure 1.3: Simple multi-state structure. 
 
Boxes represent states and arrows represent transitions. 
All participants begin in the initial state. Following an event, participants transition into the 
absorbing state. 
 
1.3.3 Key functions in time-to-event analysis 
Time-to-event analysis comprises a number of functions which are of interest in 
prognostic model research. These measures are detailed below for a continuous non-
negative random variable T, which represents the time between a defined starting 
point t = 0 and the occurrence of an event of interest. Hence, T has a probability 
distribution with an underlying probability density function f(t). 
1.3.3.1 The survival and cumulative incidence functions 
In prognostic model research, the key outcome of interest is the risk of either 
experiencing or surviving the event of interest before a given time t, for example the 
risk of relapse in the five years following breast cancer surgery. It is common in time-
to-event analysis to define a statistical model using the survival function S(t), a time 
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dependent function which estimates the probability of an individual not experiencing 
(i.e. surviving) the event of interest prior to a given time t, written: 
S(t) = P(T ≥ t),    0 < t < ∞ Equation 1.1 
However, in prognostic model research, it is often more intuitive to communicate risk 
as the probability of an individual experiencing the event prior to time t (such as five-
year mortality risk). This is estimated using the cumulative incidence function F(t), 
written: 
F(t) = P(T < t) = 1 − S(t),     0 < t < ∞ Equation 1.2 
The survival function, and thus the cumulative incidence function, can be 
estimated non-parametrically using the Kaplan-Meier method (Kaplan and Meier, 
1958). This method estimates the probability of survival at each unique event time, 
producing a step-function which is often shown graphically as a Kaplan-Meier curve, 
an example of which is provided in Figure 1.4. 
Figure 1.4: Example of a Kaplan-Meier curve. 
 
A Kaplan-Meier curve depicting survival and cumulative incidence functions for 
disease recurrence and death using a selection of patients from the Rotterdam 
breast cancer study data (Foekens et al., 2000). 
The Kaplan-Meier curve commonly depicts the probability of an event not occuring over 
time, i.e. the survival function (blue line). A curve depicting the risk of an event occuring 
over time, i.e. the cumulative incidence function (red line), is often referred to as the 1 – 
Kaplan-Meier curve. 
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At the study start time, i.e. when t = 0, all of the participants are event free, 
thus S(t = 0) = 1 and F(t = 0) = 0. The probability of experiencing the event (cumulative 
incidence) can only increase over time as more events occur, thus the probability of 
not experiencing the event (survival) can only decrease over time. 
1.3.3.2 The hazard and cumulative hazard functions 
The rate at which these survival and cumulative incidence functions change over time 
is also of interest in prognostic model research. This is measured using the hazard 
function h(t), which estimates the instantaneous rate of experiencing the event of 
interest at time 𝑡, conditional on the individual being at risk at that time (i.e. having not 
experienced the event prior to time t). The hazard function over time, for a small time 
interval 𝛿, is written: 
h(t) = lim
δ→0
P(t ≤ T < t + δ|T ≥ t)
δ
, δ > 0 Equation 1.3 
Another related quantity is the cumulative hazard function H(t), which estimates 
the total amount of hazard experienced up until time t, written: 
H(t) = ∫ h(u)
t
0
du Equation 1.4 
1.3.3.3 Theoretical relationships between key functions 
In time-to-event analysis, there exists a direct relationship between the risk 
(survival and cumulative incidence functions) and rate (hazard and cumulative hazard 
functions) of an event. For example, the survival function can be written as a 
transformation of the hazard function, and vice versa: 
S(t) = exp (− ∫ h(u)
t
0
du) ,     h(t) = −
d
dt
ln[S(t)] Equation 1.5 
Due to the relationship between the survival and cumulative incidence functions 
(Equation 1.2), the above equations can also be written: 
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F(t) = 1 − exp (− ∫ h(u)
t
0
du) ,     h(t) = −
d
dt
ln[1 − F(t)] Equation 1.6 
Similarly, due to the relationships between the hazard and the cumulative hazard 
function (Equation 1.4), these equations can also be written: 
S(t) = exp(−H(t)),     H(t) = −ln[S(t)] Equation 1.7 
These relationships result in what is often referred to as a one-to-one relationship 
between the risk and rate of the event of interest. 
1.3.4 Time-to-event regression 
Prognostic models usually need to incorporate combinations of multiple 
prognostic factors into the statistical model to accurately predict the risk of future 
outcomes (Steyerberg et al., 2013). Regression methods allow for multiple 
independent prognostic factors (variables) to be analysed simultaneously within a 
single multivariable model (Harrell, 2015). The Cox proportional hazard model (Cox, 
1972a) is considered to be the most commonly used model for the analysis of time-to-
event data (Royston and Lambert, 2011). Indeed, it has been shown to be one of the 
most frequently used regression models in prognostic model research, alongside 
logistic regression (Collins et al., 2015, Royston et al., 2009, Snell, 2015). However, 
recent research has highlighted many statistical advantages of using flexible 
parametric models, specifically the Royston-Parmar model (Royston and Parmar, 
2002), rather than Cox models in prognostic model research (Snell, 2015). These two 
models are discussed in greater detail below for the incorporation of 𝐗𝐢 = (x1, x2, … )T, a 
vector of prognostic factors for participant i. 
1.3.4.1 Cox proportional hazards models 
The Cox proportional hazards model estimates regression coefficients on the 
hazards scale: 
hi(t) = h0(t)exp(𝛃
T𝐗𝐢) Equation 1.8 
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In which h0(t) represents the baseline hazard function and 𝛃 = (β1, β2, … ) 
represents a vector of regression coefficient estimates. The Cox model estimates the 
regression coefficients 𝛃 (also referred to as log hazard ratios) by maximising the 
partial likelihood on the hazards scale (Cox, 1972a). Following an exponential 
transformation, these estimates represent hazard ratios, which reflect the relative 
change in hazard rate for a unit increase in the associated prognostic factor. The 
baseline hazard function corresponds to the hazard rate over time when all prognostic 
factors are equal to 0. To make the interpretation of this function more meaningful, 
prognostic factors are often centred about their mean value prior to estimation, or 
similarly the linear predictor 𝛃T𝐗𝐢 (also known as prognostic index) is centred (Royston 
and Altman, 2013). The hazard ratio estimates obtained from the Cox model represent 
a change in hazard rate from a hypothetical “baseline participant”. If prognostic factors 
are centred, this “baseline participant” will be more representative of the participants, 
rather than, for example, a participant aged 0. The relative estimates produced by the 
model are useful for identifying differences in risks between participants with different 
prognostic characteristics, thus are essential for prognostic factor research. An 
example of a well-known prognostic model developed using Cox regression is provided 
in Box 1.4. 
The Cox model does not make any distributional assumptions with regard to the 
shape of the baseline hazard function h0(t), thus is described as a semi-parametric 
model. As a consequence, the model only estimates hazard ratios and does not directly 
estimate absolute risks (Royston and Altman, 2013), the more intuitive and 
interpretable output for prognostic model research. 
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Box 1.2: Example of a prognostic model developed using Cox regression 
The Nottingham Prognostic Index (Haybittle et al., 1982) is a well-known prognostic model 
which estimates the five year risk of death in patients that had a primary operable breast 
cancer. The model was developed using retrospective data from 387 patients from the 
Nottingham Breast Cancer Study. 
 
Cox regression analysis was utilised to develop the model, which contains three 
prognostic factors; tumour size (cms), lymph-node stage (coded A=1, B=2, C=3), and 
tumour grade (coded I=1, II=2, III=3). The model is described using the following linear 
predictor: 
𝐈 =  (𝟎. 𝟏𝟕 × 𝐬𝐢𝐳𝐞) + (𝟎. 𝟕𝟔 × 𝐬𝐭𝐚𝐠𝐞) + (𝟎. 𝟖𝟐 × 𝐠𝐫𝐚𝐝𝐞) 
 
The individual regression coefficients reflect the relationship between the prognostic factor 
and the five year risk of death. A 1cm increase in tumour size results in a hazard ratio 
equal to: 
𝐇𝐑 = 𝐞𝐱𝐩(𝟎. 𝟏𝟕) = 𝟏. 𝟏𝟗 
The hazard of death increases by a factor of 1.19 for each 1cm increase in tumour size. 
 
The index may be used to estimate the risk of death for a participant with a grade II 
tumour (coded II=2) of size 1.5cms and lymph-node stage A (coded A=1) as follows: 
𝐈 =  (𝟎. 𝟏𝟕 × 𝟏. 𝟓) + (𝟎. 𝟕𝟔 × 𝟏) + (𝟎. 𝟖𝟐 × 𝟐) = 𝟐. 𝟔𝟔 
 
This participants hazard of five year death is obtained following an exponential 
transformation of the linear predictor: 
𝐇𝐑 = 𝐞𝐱𝐩(𝟐. 𝟔𝟔) = 𝟏𝟒. 𝟑𝟎 
 
Hence this participant has a 14.3 times increased hazard in comparison to the “baseline 
participant”. 
 
The baseline participant has a tumour of size 0cms with implausible grade and lymph-
node stage classifications (as there exists no categories for grade=0 and stage=0)i.  
 
A key assumption made by the Cox (and other time-to-event) models is of 
proportional hazards (Harrell, 2015), that is the hazard ratios remain constant over 
time. This assumption may be examined using log-log plots (Royston and Lambert, 
2011) or applying a Grambsch-Theneau test (Grambsch and Therneau, 1994) of 
scaled Schoenfeld residuals (Schoenfeld, 1982). The proportional hazards assumption 
may be relaxed through the incorporation of interaction terms between prognostic 
factors and time (Cox, 1972b). 
In prognostic model research, estimates of the absolute risk of an event occurring 
over time are more intuitive and easier to communicate to clinicians and patients. A 
                                                     
iIt is not plausible for a real patient to have a tumour of size 0cms, and not providing baseline categories 
for the other two categories causes further problems. The interpretation of the estimated relative risks 
become complicated, thus highlighting the importance of centring prognostic factor values prior to model 
development. 
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commonly used approach to obtain absolute risk estimates from a prognostic model 
developed using Cox regression is through the formation of risk groups (Royston and 
Altman, 2013). The linear predictor 𝛃T𝐗𝐢 derived from the Cox model is split to create 
the risk groups. Kaplan-Meier curves for each risk group can then be utilised to obtain 
absolute risk predictions for each group at given time points, as depicted in Figure 1.5. 
Figure 1.5: Example of Kaplan-Meier curves for risk groups. 
 
Kaplan-Meier curves showing two year relapse-free survival for 2,780 patients with 
primary, operable, invasive breast cancer (Foekens et al., 2000)i. 
Risk groups were created by splitting the Cox model linear predictor at the 10, 25, 50, 75, 
and 90 perecentiles, producing groups a-f. The numbers in parentheses refer to the 
number of events/ patients per group. 
 
The disadvantage of grouping participants into risk groups is that information from 
the prognostic model is lost (Harrell, 2015) and individual predictions are less accurate 
(Steyerberg et al., 2013). An alternative and preferable approach is to utilise the 
relationship between the hazard, cumulative hazard, survival, and cumulative 
incidence functions discussed previously to determine an equation for the absolute risk 
of an event occurring over time, i.e. the cumulative incidence function: 
Fi(t) = 1 − S0(t)
exp(𝛃T𝐗𝐢) Equation 1.9 
                                                     
i Adapted from Cancer Research, 2000, 60/3, 636-643, Foekens et al. “The Urokinase System of 
Plasminogen Activation and Prognosis in 2780 Breast Cancer Patients”, with permission from AACR. 
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Where S0(t) = exp(−H0(t)) represents the baseline survival function and H0(t) =
∫ h0(u)
t
0
du represents the baseline cumulative hazard function. 
Though not directly estimated in Cox regression, it is possible to derive a non-
parametric estimate for H0(t), known as Breslow’s estimate (Breslow, 1972). Let Rj 
denote the set of study participants at event time tj and l represent those at risk (i.e. 
the risk set). Assuming no tied event times, and utilising the estimated regression 
coefficients ?̂? obtained from the Cox regression; the baseline cumulative hazard 
function can be approximated using the following formula: 
H0̂(t) = ∑
1
∑ exp(𝛃T𝐗𝐥)l∈Rj
j:tj≤t  Equation 1.10 
The above formulae estimates H0̂(t) at each unique event time, producing a step-
function. The estimates can be incorporated into Equation 1.9 and transformed to 
provide individual absolute risk estimates for the event of interest. Though the above 
methods are available to develop prognostic models which give absolute risk 
predictions, models built using Cox regression are often reported without estimation of 
the baseline hazard function (Royston and Altman, 2013). This limits the application of 
the prognostic models, as only estimates of relative risks (and not absolute risks) can 
be calculated. 
1.3.4.2 Royston-Parmar flexible parametric models  
Parametric models are fully specified, i.e. they make distributional assumptions 
about the baseline hazard functions. As such the models can directly estimate the 
absolute risks of events occurring over time, making them ideal for prognostic model 
research. Common examples of parametric models include the exponential model 
(Equation 1.11), which assumes a constant (λ) hazard over time, and the Weibull 
model (Equation 1.12), which assumes a monotone increasing or decreasing hazard 
over time: 
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hi(t) = λexp(𝛃
T𝐗𝐢) Equation 1.11 
hi(t) = λγt
γ−1exp(𝛃T𝐗𝐢) Equation 1.12 
Though explicitly defined, the shape of the baseline hazard functions in these models 
are limited and often not considered to be clinically plausible. Flexible parametric 
models, however, utilise spline functions to obtain a smooth estimate of the observed 
baseline hazard function (Royston and Lambert, 2011). These models can capture 
more flexible and clinically plausible baseline hazard functions than standard 
parametric models. Royston-Parmar models (Royston and Parmar, 2002) explicitly 
model the baseline cumulative hazard function with a large degree of flexibility, by 
utilising restricted cubic splines. 
Restricted cubic splines are piecewise cubic functions which join at predefined 
values of t; these points are called knots. Continuity constraints, which force the 
functions to have continuous first and second derivatives, ensure the splines connect 
smoothly at these knots. The functions before the first and after the final knot are 
restricted to be linear (Harrell, 2015). When modelling the time to an event, the first 
knot ηmin is defined at the time to the first observed (uncensored) event, and the final 
knot ηmax is defined at the time of the last observed event, these are the boundary knots 
(Royston and Lambert, 2011). A restricted cubic spline function for ln(t), with M interior 
knots, a vector of knot locations 𝚴 = (ηmin, η1, … , ηM, ηmax), and parameters 𝜸 =
 (𝛾0, … , 𝛾𝑀+1), is written: 
spline{ln[t]|𝛄, 𝐍} = γ0 + γ1z1 + ⋯ + γM+1zM+1 Equation 1.13 
In which the parameters γj are estimated and the variables zj are derived as follows: 
z1 = ln[t]  
zj = (ln[t] − ηj)+
3
− ϕj(ln[t] − ηmin)+
3 − (1 − ϕj)(ln[t] − ηmax)+
3   Equation 1.14 
where ϕ
j
=
η
max
− η
j
η
max
− η
min
⁄ ,  
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for j = 2, … , M + 1 and u+ = {
u,    if u > 0
0,    if u ≤ 0
 (Royston and Lambert, 2011). 
A restricted cubic spline function with M internal knots is estimated with M + 1 
degrees of freedom. The number of knots required to capture the shape of the hazard 
function can be determined through visual inspection of graphs depicting the different 
spline functions or through the comparison of Akaike and Bayesian information 
criterion estimates (AIC and BIC) (Royston and Lambert, 2011). However, functions 
with more than five internal knots are seldom required (Harrell, 2015), and functions 
containing between one and four internal knots have been advised specifically for 
modelling the baseline hazard function (Royston and Lambert, 2011). The position of 
the knots is usually determined using centiles of uncensored event times (Royston and 
Lambert, 2011). Numerous sensitivity analyses in various applications have shown 
that, once a sensible number of knots have been determined, any results are fairly 
robust to changes in knot locations (Hinchliffe, 2013). 
The Royston-Parmar flexible parametric model estimates regression coefficients 
through maximum likelihood on the more stable log cumulative hazard scale:  
ln[Hi(t)] = ln[H0(t)] + 𝛃
T𝐗𝐢 Equation 1.15 
The log baseline cumulative hazard function ln[H0(t)] is modelled as a smooth non-
linear function of log time using restricted cubic splines: 
ln[Hi(t)] = Spline{ln[t]} + 𝛃
T𝐗𝐢 Equation 1.16 
Again in prognostic model research, absolute risks, estimated using the survival 
and cumulative incidence functions, are of greater interest. Utilising the relationship 
between the survival and cumulative hazard functions (Equation 1.7) it is possible to 
determine the survival function for the Royston-Parmar model: 
ln[Si(t)] = −exp(spline{ln[t]} + 𝛃
T𝐗𝐢) Equation 1.17 
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An example of a prognostic model developed using Royston-Parmar flexible 
parametric regression methods is provided in Box 1.3. 
Box 1.3: Example of a Royston-Parmar flexible parametric prognostic model 
A prognostic model to predict post-transplant survival for patients following kidney 
transplantation was developed using data from 12,000 recipients of kidney transplants 
from the UK Transplant Registry (Li et al., 2016). 
 
A flexible parametric proportional hazards model was utilised to develop the model, which 
contains six prognostic factors; recipient age, recipient gender, pre-emptive transplant, 
primary renal diagnosis, donor hypertension, and donor age. 
 
The number of knots required for the restricted cubic spline characterising the baseline 
hazard function was determined through comparisons of AIC. The model with optimal fit 
contained two internal knots (3 d.f.), depicted using the red line in the graph below, knot 
locations were not discussed: 
 
Comparison of smooth hazard functions to observed data (Li et al., 2016)i 
 
The regression coefficients for the spline function are provided below: 
 
Baseline hazard (log hazard scale) Coefficient p-value 95% CI 
Restricted cubic spline 1 1.03 <0.001 0.97 – 1.09 
Restricted cubic spline 2 -0.08 0.001 -0.12 - -0.03 
Restricted cubic spline 3 -0.14 <0.001 -0.16 - -0.12 
Constant -3.97 <0.001 -4.31 - -3.63 
Coefficients for baseline hazard function spline terms, adapted from (Li et al., 2016)i 
 
If the baseline cumulative hazard function is modelled with appropriate degrees of 
freedom, the regression coefficients estimated with a Royston-Parmar model are very 
                                                     
i “Predicting patient survival after deceased donor kidney transplantation using flexible parametric 
modelling”, Li et al., BMC Nephrology, 2016 17:51, CC BY 4.0. 
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similar to those estimated with a Cox model (Snell, 2015). The Royston-Parmar model 
described above assumes proportional hazards. The proportional hazards assumption 
can be relaxed through the incorporation of interaction terms between prognostic 
factors and the spline functions for ln(t). Alternative Royston-Parmar models include 
proportional odds (a generalisation of log-logistic models) and probit (a generalisation 
of log-normal models) models (Royston and Parmar, 2002), however these are not 
covered within this thesis. 
There exist many statistical advantages for using Royston-Parmar models, rather 
than Cox models (Snell, 2015), these include: 
1. The direct estimation of the baseline hazard function; 
2. Practically identical regression coefficient estimates to Cox models; 
3. The ability to graphically represent population-averaged survival curves; 
4. The estimation of differences in absolute survival over time; 
5. Deriving absolute risk predictions for individuals; 
6. Identifying clinically important hazard ratios in relation to the baseline risk. 
1.4 Statistical analysis of competing events 
Competing risks are present when participants may experience an event other 
than the event-of-interest, and the occurrence of this competing event alters the 
probability of the event-of-interest occurring (Koller et al., 2012). The methods to 
appropriately account for competing events have been traced to a study investigating 
the consequences of mandatory vaccination against smallpox and the effects on 
population survival (Bernoulli, 1760). The standard time-to-event analysis methods 
described previously have been adapted to incorporate competing events. 
1.4.1 The multi-state structure with competing events 
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The simple multi-state structure depicted in Figure 1.3 can be extended to 
incorporate multiple absorbing states, allowing participants to experience one of 
multiple (K) mutually exclusive competing events Figure 1.6. 
Figure 1.6: Competing risks multi-state structure 
 
Boxes represent states and arrows represent transitions. 
All participants begin in the initial state. The occurrence of an event of interest causes 
participants to transition into the associated absorbing state. Participants who experience 
competing events transition into a different absorbing state. 
 
This structure can be used to describe competing risks analysis techniques; for 
example, when analysing a specific cause of death (such as cardiovascular deaths) in 
which other causes of death are competing events. All participants are alive (the initial 
state) until death from one cause or another (the events) after which they enter a 
cause-specific state (the absorbing states). When analysing a specific cause of death 
(such as cardiovascular death), other causes of death may be examined separately 
(i.e. have separate absorbing states), or can be combined into one competing state, 
namely other causes of death, such that K = 2. 
All-cause mortality (death) is generally considered a competing event for all non-
fatal events, particularly when studying elderly or frail populations as death prevents 
any non-fatal event from occurring. The analysis of non-fatal events can be 
represented using a simple competing risks multistate structure with K = 2 absorbing 
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states; for example, when investigating disease recurrence following breast cancer 
surgery (Figure 1.7). 
Figure 1.7: Competing risks multi-state structure with K=2 
 
Boxes represent states and arrows represent transitions. 
All participants begin in the initial state (e.g. successful breast cancer surgery). 
Following an event (e.g. disease recurrence, k=1), participants transition into the 
associated state (e.g recurrent cancer). 
Participants who experience competing events (e.g. death) transition into a different 
absorbing state (e.g. dead). 
 
All participants surviving surgery remain in the initial state until transition to 
another state occurs. For example, they may experience a disease recurrence (the 
event of interest, k = 1) which instigates a transition into the recurrent cancer statei. Or 
they may die before disease recurrence (the competing event), and so transition into 
the other absorbing state (dead, k = 2) and are no-longer at risk of experiencing 
disease recurrence (the event of interest). This example (breast cancer recurrence and 
the competing risk of death) will be used to introduce the functions of interest in 
prognostic model research, as the research often focuses on analysing a non-fatal 
event of interest with death as a competing event. 
1.4.2 Key functions in time-to-event analysis with competing events 
Similar to standard time-to-event analysis, competing risks analysis comprises a 
number of key functions which are of interest for prognostic model research. These 
key functions are similar to those obtained from a standard time-to-event analysis, but 
have been extended into the competing risks setting. These measures are detailed 
                                                     
i In this instance the “recurrent cancer” state is not absorbing; a patient may die following cancer 
recurrence, which would trigger a transition from the “recurrent cancer” state to the “dead” state. 
However, events which occur after the event of interest (cancer recurrence, 𝑘 = 1) are often not of 
interest, in which case the state is considered an absorbing state. 
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below for a continuous non-negative random variable T, which represents the time 
between a defined starting point t = 0 and the occurrence of 𝐤 = (1,2) mutually 
exclusive events. Thus, 𝑇 has a probability distribution with an underlying probability 
density function f(t). 
1.4.2.1 All-cause functions 
In prognosis research scenarios where multiple types of events can occur over 
time, the specific type of event is not always of importance or of interest. Rather, the 
research may focus on a combined (composite) outcome of all events (or causes). For 
example, when investigating recurrence-free survival following breast cancer surgery, 
it is not necessary to consider the events (disease recurrence and death) separately; 
instead the more relevant approach would be to investigate the occurrence of either 
disease recurrence or death. The rate of either event occurring is investigated using 
all-cause functions, which are equivalent to functions in standard time-to-event 
analysis (detailed in Section 1.3.3), with all mutually exclusive events combined into 
one composite event (i.e. all events transition into a single state) (Geskus, 2015). 
1.4.2.2 Cause-specific functions 
The cause-specific functions are relevant when the focus of the research is a 
specific event (referred to as the event of interest, k = 1), in the presence of competing 
events. In these instances, it is necessary to distinguish between the different types of 
events, and so allow the risk and rate of each event of interest to be investigated 
independently. For example, consider predicting the risk of disease recurrence (the 
event of interest) following breast cancer surgery; here it is important to account for the 
competing event of death, but predicting the actual risk of death in this instance is not 
of interest. The cause-specific functions provide relevant information about a specific 
event of interest (k = 1) from the K mutually exclusive events. Though the cause-
specific functions are similar to those used in standard time-to-event analysis, a 
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number of subtle differences distinguish between the interpretation of the standard 
time-to-event and competing risks approaches. 
The cause-specific cumulative incidence function 
In the presence of competing events, the key measure of interest for prognostic 
model research is the risk of a participant experiencing the event of interest (k = 1) 
prior to time t, allowing for the presence of competing events. For example, the five-
year risk of disease recurrence following breast cancer surgery, acknowledging that 
some participants may die prior to relapse. This is the estimated the cause-specific 
cumulative incidence function Fk(t), which is written: 
Fk(t) = P(T ≤ t|event = k) Equation 1.18 
The sum of all K cause-specific cumulative incidence functions is equal to the all-cause 
cumulative incidence function: 
F(t) = P(T ≤ t) = ∑ P(T ≤ t|event = k)Kk=1 =  ∑ Fk(t)
K
k=1  Equation 1.19 
The cause-specific cumulative incidence function is not a proper probability 
distribution function, as it does not increase to one over time. This is because the 
competing events prevent the event of interest from occurring (Geskus, 2015). For 
example, it is possible for some participants to die prior to disease recurrence; these 
participants will no longer be at risk of recurrence, and thus the probability of 
recurrence will never reach 100%. 
The cause-specific hazard function 
Another measure of interest in prognostic research is the cause-specific hazard 
function, determined as the rate at which the cause-specific cumulative incidence 
function for the event of interest (k = 1) changes over time. This measure is conditional 
on participants not experiencing any of the K mutually exclusive events prior to that 
time. The cause-specific hazard function hk(t) is written: 
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hk(t) = lim
δ→0
{
P(t ≤ T ≤ t + δ, event = k|T ≥ t)
δ
} Equation 1.20 
The participants that have experienced a competing event prior to time t transition out 
of the initial state at the time the competing event occurs, and are thus censored for 
the event of interest (k = 1). The cause-specific hazard function is equal to the hazard 
function calculated using standard time-to-event analysis methods; competing events 
are not anticipated in a standard time-to-event analysis, thus are typically censored 
when they occur. 
The cause-specific hazard ratio reveals the effect of a prognostic factor directly 
on the event of interest. It ignores (censors) other types of events that can occur 
(competing events), and hence describes the effect of a prognostic factor assuming 
the competing events cannot occur (Koller et al., 2012). Thus cause-specific hazard 
ratios resemble those derived using standard time-to-event analysis methods. These 
direct effects are important for answering etiological questions, where the focus is more 
on causality of a factor, and are typically more of interest in prognostic factor research. 
1.4.2.3 Subdistribution hazard function 
Another measure of interest in prediction model research is the subdistribution 
hazard, determined as the instantaneous rate at which the cause-specific cumulative 
incidence function for the event of interest (k = 1) changes over time, conditional on 
participants not experiencing the event of interest prior to that time. To obtain these 
estimates the multi-state structure is modified (Figure 1.8). 
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Figure 1.8: Competing risks multi-state structure for subdistribution hazards 
 
Boxes represent states and arrows represent transitions. 
All participants begin in the initial state (e.g. successful breast cancer surgery). 
Following the event of interest (e.g. disease recurrence, k=1), participants transition into 
the associated absorbing state (e.g recurrent cancer). 
Participants who experience competing events (e.g. death) remain in the initial state. As 
these participants are not at risk of experiencing the event of interest, they remain in this 
initial state until the end of the study. 
 
All participants surviving surgery remain in the initial state until disease recurrence (the 
event of interest, k = 1), which instigates a transition into the recurrent cancer state. 
Those participants who die before disease recurrence (the competing event) remain in 
the initial state, but are no-longer at risk of experiencing disease recurrence, thus 
remain there until their known but unobserved censoring time (i.e. the end of the study) 
(Fine and Gray, 1999). The subdistribution hazard function λk(t), is written: 
λk(t) = lim
δ→0
{
P(t ≤ T ≤ t + δ, event = k|T ≥ t ⋃  (T ≤ t ⋂ event ≠ k))
δ
} Equation 1.21 
The subdistribution hazard is useful for considering prognostic model research 
questions, where estimation of the absolute risk is of primary importance (Koller et al., 
2012). The subdistribution hazard estimates the “real world” change in the risk of the 
event of interest, as it incorporates the indirect effects of a prognostic factor on the 
competing event. These indirect effects are important in prognostic model research as 
they explain the rate at which the risk of an event changes over time. 
1.4.2.4 Summary of the functions of interest in competing risks analyses 
The functions of interest are summarised below in Table 1.1. 
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Table 1.1: Descriptions of competing risks functions of interest 
Function name Notation Description 
All-cause survival 
𝑆(𝑡) Cumulative probability of not experiencing any 
event before time t 
All-cause cumulative 
incidence 
𝐹(𝑡) Cumulative probability of experiencing any 
event before time t 
All-cause hazard 
ℎ(𝑡) Instantaneous rate of experiencing any event at 
time t 
Cause-specific cumulative 
incidence 
𝐹𝑘(𝑡) Cumulative probability of experiencing event k 
before time t 
Cause-specific hazard 
ℎ𝑘(𝑡) Instantaneous rate of experiencing event k at 
time t, if no events previously 
Subdistribution hazard 
𝜆𝑘(𝑡) Instantaneous rate of experiencing event k at 
time t, if no event k previously 
 
1.4.3 Risk sets for cause-specific and subdistribution hazard functions 
A key difference between the cause-specific and subdistribution hazard functions 
is the set of participants who remain in the initial state just before the time point of 
interest, referred to as the risk set. The risk set changes over time as participants 
experience events or are censored. A graphical representation of the risk sets for the 
two competing risks approaches is given in Figure 1.9. 
In this example, the risk sets are assessed just before the time of an event of 
interest. The risk set for the cause-specific hazard includes the participants who have 
not experienced either the event of interest or competing events, and those who 
experience the competing events are removed (censored). Whereas, the risk set for 
the subdistribution hazard includes those who have yet to experience the event of 
interest, and those who experience the competing event remain in the risk set until the 
end of the study. 
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Figure 1.9: Cause-specific and subdistribution risk sets 
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At the beginning of the study, the risk set contains all 9 participants. 
Over time participants may experience the event of interest (depicted by a red diamond) or 
the competing event (depicted by a green square). 
Those participants that experience a competing event are excluded from the cause-
specific risk set, but remain in the subdistribution risk set. 
Participants that have left the risk set are faded out. 
The risk sets above represent those at risk just before the time of an event of interest 
(𝐭 →). 
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The interpretation of the competing risks hazard measures can be difficult. 
Similarly, the risk sets associated with the competing risks approaches are challenging 
to interpret. Consider the example of disease recurrence following breast cancer 
surgery, again with death as a competing event. When estimating the cause-specific 
hazard, participants who die transition out of the initial state into the competing state 
(Figure 1.7), and are thus removed from the risk set. Unlike standard time-to-event 
analysis, independent censoring is not assumed, as those who die from other causes 
do not have the same risk of disease recurrence as those who are alive and remain in 
the initial state/risk set. When estimating the subdistribution hazard, participants who 
die remain in the initial state/risk set (Figure 1.8). It is impossible for participants that 
died to subsequently experience disease recurrence, yet being in the risk set implies 
that they are still at risk. Though this seems counterintuitive, we can consider those 
who have experienced the competing event as “cured” from the event of interest. 
These participants act as placeholders (Koller et al., 2012) by remaining in the initial 
state with no chance of experiencing disease recurrence, thus preventing all 
participants from transitioning out of the initial state. 
1.4.4 Theoretical relationships between key functions 
Similar to standard time-to-event analysis, the hazard, survival, and cumulative 
incidence functions are related in the competing risks setting. These relationships are 
now described in detail. 
1.4.4.1 Relationships with the all-cause survival function. 
As established previously, the all-cause survival, cumulative incidence, and 
hazard functions are equivalent to the functions derived in the standard setting of time-
to-event analysis (if all events are combined into a single state). Thus, the relationships 
which hold in standard time-to-event analysis remain. 
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By definition, the all-cause hazard function may be written as the sum of all K 
cause-specific hazard functions: 
h(t) = lim
δ→0
P(t ≤ T ≤ t + δ|T ≥ t)
δ
  
         = lim
δ→0
∑ P(t ≤ T ≤ t + δ, event = k|T ≥ t)Kk=1
δ
= ∑ hk(t)
K
k=1  Equation 1.22 
As such, the all-cause survival function may be written as; 
𝑆(𝑡) = 𝑒𝑥𝑝 (− ∫ ℎ(𝑢) 𝑑𝑢
𝑡
0
) = 𝑒𝑥𝑝 (− ∫ ∑ ℎ𝑘(𝑢)
𝐾
𝑘=1  𝑑𝑢
𝑡
0
) Equation 1.23 
Estimates of all K cause-specific hazard functions are required to obtain an estimate of 
the all-cause survival, and thus the all-cause cumulative incidence functions. These 
functions are key to estimating the absolute risk of the events occurring, the primary 
interest of prognostic model research. 
1.4.4.2 Relationships with the cause-specific cumulative incidence function. 
The cause-specific cumulative incidence function represents the risk of 
experiencing the event of interest over time, and is the key function needed to derive 
a prognostic model. This function Fk(t), depends on two values at any time t; the 
probability that the participant remains free from any event until just before time t, and 
the instantaneous probability that event k occurs at time t given that no event occurred 
before that time. The first probability is the all-cause survival function S(t), and the 
second probability is the cause-specific hazard function hk(t). Thus, the cause-specific 
cumulative incidence function can be written: 
Fk(t) =  P(T ≤ t, event = k) = ∫ S(u) × hk(u)
t
0
du Equation 1.24 
Inputting Equation 1.23 for the all-cause survivor function gives; 
Fk(t) =  ∫  hk(u) exp(− ∫ ∑ hj(v)
K
j=1  dv
u
0
)
t
0
du Equation 1.25 
 32 
Estimates of all K cause-specific hazard functions are required to estimate the all-
cause survival function, to then allow for the estimation of the cause-specific 
cumulative incidence function. A consequence of this property is that the one-to-one 
relationship between the rate (cause-specific hazard) and the risk (cause-specific 
cumulative incidence) of the event of interest is lost; the cumulative incidence of the 
event of interest depends on the rate of all possible events. Hence, these hazards 
cannot be interpreted in the same way as those estimated using the standard time-to-
event analyses, as they do not directly correspond with the “real world” risk of the event 
of interest. 
To avoid the added complication of the loss of the relationship between the 
cause-specific hazard and the cause-specific cumulative incidence function, Fine and 
Gray (Fine and Gray, 1999) introduced the subdistribution hazard function λk(t). The 
subdistribution hazard function for event k is equal to the rate of change of the cause-
specific cumulative incidence function; derived by differentiating the natural log of the 
cause-specific cumulative incidence function: 
λk(t) = −
d
dt
 ln[1 − Fk(t)] Equation 1.26 
The subdistribution hazard function preserves a one-to-one relationship with the 
cause-specific cumulative incidence function: 
Fk(t) =  1 − exp (− ∫ λk(u) du
t
0
) Equation 1.27 
Estimation of the cause-specific cumulative incidence function only requires an 
estimate of the subdistribution hazard for the event of interest. Hence, it is more 
straightforward to estimate the cause-specific cumulative incidence function using the 
subdistribution hazard. 
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The relationships between the cause-specific and subdistribution hazard 
functions and the cause-specific cumulative incidence function with two events (the 
event of interest and the competing event) are depicted in Figure 1.10. 
Figure 1.10: Relationships between cause-specific and subdistribution hazard 
functions and cause-specific cumulative incidence function 
 
 
From the figure, both the straightforward relationship between the subdistribution 
function, and the more complex relationship between the cause-specific hazard 
function, and the cause-specific cumulative incidence function are apparent. 
1.4.5 Competing risks regression 
The statistical advantages of flexible parametric models over semi-parametric 
approaches (Snell, 2015) were outlined in Section 1.3.4. Recall, Royston-Parmar 
flexible parametric models (introduced in Section 1.3.4) estimate a smooth baseline 
hazard function using restricted cubic splines alongside estimates of regression 
coefficients, on the log cumulative hazard scale (Royston and Parmar, 2002). These 
methods have been adapted to incorporate competing events using both the cause-
specific (Hinchliffe and Lambert, 2013b) and subdistribution hazards (Lambert et al., 
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2017) approaches. The two approaches are discussed below. Again, for simplicity 
each participant is at risk of experiencing K = 2 mutually exclusive events, the event of 
interest k = 1, and a competing event k = 2. For regression purposes, we include a 
vector of prognostic factors 𝐗k,i = (xk,1, xk,2, … )
T, for each cause k and each individual i. 
The model parameters can be estimated using standard maximum likelihood 
techniques. 
1.4.5.1 Cause-specific hazards approach 
The flexible parametric modelling approach using cause-specific hazards to 
estimate cause-specific cumulative incidence functions (Hinchliffe and Lambert, 
2013b), models on the log cumulative cause-specific hazards scale. Assuming 
proportional hazards, the log cumulative cause-specific hazard function for event k with 
a vector of prognostic factors 𝐗k,i can be written as: 
ln[Hk(t|𝐗k,i)] = Spline{ln[t]|𝛄k, 𝐍k} + 𝛃k
T𝐗k,i Equation 1.28 
Where Spline{ln[t]|𝛄k, 𝐍k} represents a restricted cubic spline function (as given in 
Equation 1.14) with a vector of knot locations 𝚴k modelling the log cumulative baseline 
cause-specific hazard function for event k. The resulting vector of regression 
coefficients 𝛃k, which corresponds to the vector of prognostic factors 𝐗k,i, are estimated 
using maximum partial likelihood techniques (Hinchliffe and Lambert, 2013b). The 
regression coefficients can be interpreted as log cause-specific hazard ratios under 
the proportional hazards assumption, and thus describe the (adjusted) effect of each 
prognostic factor on the risk of the event of interest when competing events cannot 
occur.  
The cause-specific hazard function is obtained by differentiating the cumulative 
cause-specific hazard function with respect to time, and thus involves the derivatives 
of the restricted cubic spline functions: 
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hk(t|𝐗k,i) =
d 
dt
exp(Spline{ln[t]|𝛄k, 𝐍k} + 𝛃k
T𝐗k,i) Equation 1.29 
Estimation of each cause-specific hazard function can be obtained by fitting 
separate models for each of the K events, while censoring all other events. 
Alternatively, it is possible to simultaneously estimate all K cause-specific hazard 
functions using a multi-state data format. Though the two approaches give the same 
results, simultaneous estimation is considered more flexible. It allows for shared 
coefficient estimates and baseline hazard functions across events, and allows for 
convenient testing and comparison of coefficient estimates across event types (Lunn 
and McNeil, 1995). 
To model all K cause-specific hazard functions simultaneously, the dataset to 
which the model is applied must be expanded to mimic the K different datasets used if 
the analyses were performed separately. This is best illustrated using an example. 
When investigating the risk of disease recurrence following breast cancer surgery, 
death is a competing event, as such there are K = 2 mutually exclusive events. The 
original data may look like that depicted in Figure 1.11a, with participant 1 experiencing 
disease recurrence at 3.1 years, participant 2 dying at 4.1 years, and participant 3 
being censored at 5.9 years. To simultaneously analyse all events, the dataset is 
expanded to the multi-state data, depicted in Figure 1.11b. Now each participant 
has K = 2 rows, one for each of the mutually exclusive events. Participant 1 
experiences disease recurrence at 3.1 years (row 1), but is censored at 3.1 years for 
death (row 2). Participant 2 is censored for disease recurrence at 4.1 years (row 3), 
but dies at 4.1 years (row 4). Finally, participant 3 is censored at 5.9 years for both of 
the events (rows 5 and 6). 
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Figure 1.11: Original and multi-state datasets for competing risks analysis 
a) Original data (wide format) 
ID Age Time Disease Recurrence Death 
1 34 3.1 1 0 
2 56 4.1 0 1 
3 42 5.9 0 0 
… … … … … 
 
b) Multi-state data (long format) 
Row ID Age Time Event Status Row 
1 1 34 3.1 Disease Recurrence 1 1 
2 1 34 3.1 Death 0 2 
3 2 56 4.1 Disease Recurrence 0 3 
4 2 56 4.1 Death 1 4 
5 3 42 5.9 Disease Recurrence 0 5 
6 3 42 5.9 Death 0 6 
 … … … … …  
 
 
 
In prognostic model research, the key measure of interest is the cause-specific 
cumulative incidence function, as this returns individual estimates of absolute risk 
predictions. As discussed previously, estimating the cause-specific cumulative 
incidence function using the cause-specific approach requires estimates of all K cause-
specific hazard functions. To estimate for the cause-specific cumulative incidence 
function for event k with a vector of prognostic factors 𝐗k,i recall Equation 1.25: 
Fk̂(t|𝐗k,i) =  ∫  hk̂(u|𝐗k,i) exp(− ∫ ∑ hĵ(v|𝐗j,i)
K
j=1  dv
u
0
)
t
0
du Equation 1.30 
The integral in the above equation cannot be solved analytically, thus additional 
methods, such as numerical integration (Hinchliffe and Lambert, 2013b) or the 
simulation approach (Fiocco et al., 2008, Crowther and Lambert, 2017), are required. 
Briefly, the simulation approach simulates a large sample of participants, and 
calculates a transition probability matrix using Nelson-Aalen estimators of the 
cumulative cause-specific hazard function Hk(t). The simulated participants iterate 
through the transition probability matrix until they all either experience an event or are 
censored (at a specified maximum follow-up time). Cause-specific cumulative 
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incidence function estimates for event k given a prognostic factor vector 𝐗k,i are 
calculated as the proportion of simulated participants with the same vector of 
prognostic factor values that experience event k. The cause-specific flexible parametric 
model can be fitted to all causes simultaneously using the expanded multi-state 
dataset (Crowther and Lambert, 2017). An example of a published model developed 
using the cause-specific approach is provided in Box 1.4. 
1.4.5.2 Subdistribution hazards approach 
The flexible parametric modelling approach using subdistribution hazards to 
estimate cause-specific cumulative incidence functions (Lambert et al., 2017), models 
on the log cumulative subdistribution hazards scale. The cumulative subdistribution 
hazard function is defined as Λk(t) = ∫ λk(u)du
t
0
 for continuous time distributions. 
Assuming proportional subdistribution hazardsi, the log cumulative subdistribution 
hazard function for event k with a vector of prognostic factors 𝐗k,i is written: 
ln[Λk(t|𝐗k,i)] = Spline{ln[t]|𝛄k, 𝐍k} + 𝛃k
T𝐗k,i Equation 1.31 
In this case the restricted cubic spline function is modelled on the log cumulative 
baseline subdistribution hazard scale for event k. The resulting vector of regression 
coefficients 𝛃k, which corresponds to the vector of prognostic factors 𝐗k,i, are estimated 
by maximising the weighted partial likelihood function (Lambert et al., 2017). The 
regression coefficients can be interpreted as log subdistribution hazard ratios under 
the proportional subdistribution hazards assumption. Thus, describe the effect of each 
prognostic factor on the risk of the event of interest, adjusted for the occurrence of 
competing events. 
                                                     
i Note if the proportional cause-specific hazards assumption holds then the subdistribution hazards 
cannot be proportional over time (Beyersmann et al., 2009, Grambauer et al., 2010) 
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Box 1.4: Example of a model developed using cause-specific approach 
The time to death or discharge in neonatal care was examined in a recent study 
(Hinchliffe et al., 2013) using flexible parametric modelling and the cause-specific 
approach. The model was developed using retrospective data from 2,723 babies born 
at 24-28 weeks gestational age, admitted to neonatal care. Flexible parametric methods 
were used to analyse death and discharge alive as competing events. 
 
Gestational age (weeks), sex, and birthweight (centiles) were found to significantly 
effect the time to death or discharge. Cause-specific hazard ratios were not reported. 
 
The cause-specific cumulative incidence for death and discarge alive for female babies 
admitted to neonatal care are provided below for different gestational ages (top to 
bottom) and birthweights (left to right). 
 
 
Absolute probabilities for death (black) and discharge (grey) for female babies 
admitted to neonatal care, by gestational age and birthweight centile. 
(Hinchliffe et al., 2013)i 
 
                                                     
i Reproduced from “Modelling time to death or discharge in neonatal care: an application of competing 
risks” Hinchliffe et al., 426-433, 27, 2013, with permission from John Wiley and Sons. 
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Estimation of the subdistribution hazard function for the event of interest k = 1 can 
be performed without needing to model the competing events. This is achieved by 
utilising the subdistribution risk set, in which participants who experience competing 
events remain in the risk set but are unable to experience the event of interest (Figure 
1.9). If proportional subdistribution hazards are not biologically plausible, alternative 
link functions may be used (e.g. a logit link gives a proportional odds model) (Lambert 
et al., 2017), or time dependent effects can be modelled by incorporating interactions 
between the prognostic factors and the restricted cubic spline function (Hinchliffe and 
Lambert, 2013b). 
The cause-specific cumulative incidence is of key interest in prognostic model 
research. This can be estimated using the subdistribution approach by incorporating 
the subdistribution hazard function (above) into Equation 1.27: 
Fk̂(t|𝐗k,i) =  1 − exp{−exp(Spline{ln[t]|𝛄k, 𝐍k} + 𝛃k
T𝐗k,i)} Equation 1.32 
While it is not necessary to model any event other than the event of interest, it is 
possible to fit the subdistribution flexible parametric model to each cause, either 
separately or simultaneously (Lambert et al., 2017). An example of a published 
prognostic model developed using the subdistribution approach is provided in Box 1.5. 
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Box 1.5: Example of a prognostic model developed using the subdistribution 
approach 
The time to cancer-specific mortality, with other causes death as a competing event, in 
patients with head and neck squamous cell carcinoma was examined in a recent study 
(Shen et al., 2015) using flexible parametric modelling and the subdistribution 
apparoach. The model was developed using a cohort of 23,494 patients with head and 
neck squarmous cell carcinoma. 
 
The following prognostic factors were investigated for each cause: age (years), race 
(white, black, other), marital status (unmarried, married), radiotherapy (none, 
yes),.tumour size (mm), grade, T and N classifications, and site (lip, oral cavity, salivary 
gland, oropharynx, hypopharynx, larynx, other). 
 
Cause-specific cumulative incidences were estimated seperately for each cause. 
Nomograms for predicting 5 and 10 year probabilities of each cause of death are below: 
 
 
Nomogram for predicting 5 and 10 year probability of cancer-specific death. 
(Shen et al., 2015)i 
 
 
Nomogram for predicting 5 and 10 year probability of other causes death. 
(Shen et al., 2015) 
                                                     
iAdapted by permission from Springer Nature: Annals of Surgical Oncology “Cancer-Specific Mortality 
and Competing Mortality in Patients with Head and Neck Squamous Cell Carcinoma: A Competing Risk 
Analysis”, Shen et al., (2015) 
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1.4.5.3 Differences between cause-specific and subdistribution approaches 
A summary of the key differences between the cause-specific and subdistribution 
modelling approaches is provided in Table 1.2. 
Table 1.2: Differences between cause-specific and subdistribution modelling 
approaches 
 Cause-specific approach Subdistribution approach 
Model 
assumptions 
Proportional cause-specific 
hazards hk(t). 
Proportional subdistribution 
hazards λk(t). 
Risk sets 
The same as standard time to 
event analysis: contains 
participants who have not 
experienced either the event of 
interest or any competing event. 
Participants who experience 
competing events are censored. 
Differs from standard time-to-event 
analysis: contains participants who 
have not experienced the event of 
interest. 
Participants who experience 
competing events remain in the risk 
set, and are “cured” from the event 
of interest. 
Interpretation 
of hazard 
(prognostic 
factor 
associations) 
The cause-specific hazard 
measures the direct association of 
prognostic factors on the event of 
interest, assuming the competing 
events cannot occur (i.e ignoring 
the indirect effects of the 
competing events). 
The subdistribution hazard 
measures the association of the 
prognostic factors on the “real 
world” risk of the event of interest, 
incorporating the indirect effects of 
the competing event. 
Link to 
cumulative 
incidence 
(absolute 
risks) 
There is no 1:1 relationship 
between the cause-specific hazard 
and the cumulative incidence 
function. 
Estimation of ALL cause-specific 
hazard functions is required to 
obtain absolute risk estimates. 
There is a 1:1 relationship between 
the subdistribution hazard and the 
cumulative incidence function. 
Need only estimate the 
subdistribution hazard function for 
the event of interest to obtain 
absolute risk estimates. 
When should 
the approach 
be used? 
Prognostic factor research Prognostic model research 
Main 
advantage 
Measures direct associations so 
aids understanding of eitiological 
questions. 
Straightforward link to cumulative 
incidence function, so makes it 
easier to model just the event of 
interest. 
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1.5 Prognostic model development 
This thesis applies the described time-to-event analysis methods to develop 
prognostic models in the competing risks setting. Now that the framework for standard 
and competing risks time-to-event analysis have been described, it is important to 
provide a general overview of other key issues that arise when developing prognostic 
models. Statistical considerations which are generally advocated during the 
development of prognostic models include: evaluating data quality; manipulation and 
selection of candidate prognostic factors; testing model assumptions; and managing 
overfitting and optimism (internal validation) (Moons et al., 2012b, Royston et al., 2009, 
Steyerberg, 2008, Steyerberg et al., 2013). An overview of each of these is now given. 
1.5.1 Evaluating data quality  
The quality of the data is evaluated to ensure the data is fit for purpose with 
minimal measurement error (Royston et al. 2009), to enhance the reliability of the 
prognostic model (Steyerberg et al., 2013). Data should ideally come from a 
prospective cohort study with standardised measurement of the outcome and 
candidate prognostic factors (Moons et al., 2012b). 
Missing values are common in prognostic model research (Moons et al., 2012b), 
and numerous statistical techniques exist to manage these. Complete case analysis 
excludes any participant with missing information, resulting in a loss of statistical power 
and often invalid parameter estimates (Royston et al., 2009, Moons et al., 2012b), thus 
is only advised when few observations (say <5%) are missing (Harrell, 2015). 
Imputation methods utilise multivariable models containing both dependent and 
independent variables to impute plausible values to replace missing information, these 
are typically more efficient than complete case analysis (White and Royston, 2009). 
Multiple imputation methods repeat imputations a number of times to produce multiple 
completed datasets (Harrell, 2015), which incorporates the uncertainty from the 
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imputed values into the results. Each imputed dataset is analysed using standard 
methods, and analysis results are combined using Rubin’s rules (Rubin, 2004); Those 
applicable to prognostic model research (Marshall et al., 2009) are outlined in Table 
1.3. Multiple imputation using chained equations (Buuren and Oudshoorn, 2000) 
utilises iterative applications of regression imputation to recover missing values under 
a missing at random assumption. 
Table 1.3: Rubin's rules for combining estimates from multiply imputed data 
Parameter of Interest Equation for combining estimate 
Regression coefficient  𝛽 𝛽 =
1
𝑀
∑ ?̂?𝑖
𝑀
𝑖=1
 
Estimated within imputation variance 𝑈 𝑈 =
1
𝑀
∑ 𝑈𝑖
𝑀
𝑖=1
 
Between imputation variance 𝐵 𝐵 =
1
𝑀 − 1
∑(?̂?𝑖 − 𝛽)
2
𝑀
𝑖=1
 
Total variance 𝑇 𝑇 =  𝑈 + (1 +
1
𝑀
) 𝐵 
Wald test statistic 𝑊 𝑊 =
𝛽
2
𝑇
 
Degrees of Freedom 𝑣 𝑣 = (𝑀 − 1) (1 +
𝑈
(1 +
1
𝑀) 𝐵
)
2
 
P-value 𝑝 
𝑝 =  𝐹
1,𝑣
(𝑊) 
F-Distribution test. 
The above rules, known as Rubin’s rules (Rubin, 2004), are given for combining estimates 
in 𝑀 > 1 imputed datasets. Where ?̂?𝑖 represents the estimated regression coefficient in 
the 𝑖𝑡ℎ imputed dataset, and 𝑈𝑖 represents its variance. 
The application of these rules specifically for prognostic model research is discussed 
further in (Marshall et al., 2009). 
 
It is advised when imputing missing information with a time-to-event outcome that 
outcome information (a binary variable indicating whether the event occurred and an 
estimate of the cumulative hazard function) is incorporated into the chained equations 
(White and Royston, 2009). When competing events are present the chained 
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equations should include a categorical event indicatori, and Nelson-Aalen estimators 
for each of the K cumulative cause-specific hazard functions over time (Bartlett and 
Taylor, 2016). Logically, when using the cause-specific approach information on all K 
events are incorporated into the chained equations, as all K events are modelled to 
estimate the cause-specific cumulative incidence function. As the subdistribution 
approach only requires the event of interest to be modelled, the chained equations 
need only include a binary event indicator for the event of interest, and Nelson-Aalen 
estimate of the cumulative subdistribution hazard function for the event of interest. 
1.5.2 Manipulation and selection of candidate prognostic factors 
The term “candidate prognostic factor” refers to any prognostic factor which is 
considered during the development of the prognostic model (Moons et al., 2012b). 
Existing prognostic factors with known predictive ability, evidenced by prognostic factor 
research, are usually considered as candidates in prognostic model development 
(Royston et al., 2009). Manipulation of candidate prognostic factors may be required 
to aid statistical modelling. For instance, new prognostic factors can be created through 
the combination of existing ones, such as BMI created from height and weight. 
Categories within ordered categorical prognostic factors that contain small numbers of 
participants may be collapsed to give more stable results (Steyerberg 2008). 
Continuous prognostic factors may require manipulation if not thought to have a linear 
relationship with the outcome. Transformation of the prognostic factor (for example 
using fractional polynomial functions) is preferred over categorisation, as more 
predictive information is retained (Moons et al., 2012b)(Royston et al. 2009). For 
prognostic models with time-to-event outcomes, centering of continuous prognostic 
factors helps to ensure a meaningful baseline hazard function (Royston and Altman, 
2013) aiding interpretation of relative risks. The reference category in categorical 
                                                     
i A categorical variable which indicates which event occurred during the study period; equal to 0 for no 
event (censored), 1 for the event of interest, 2,…,K for all other competing events. 
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factors should also be selected with care (Steyerberg, 2008) to ensure a representative 
baseline to which relative risk comparisons are made (the importance of which is 
highlighted in Box 1.4). 
Often more candidate prognostic factors are available than can sensibly be used 
in a prognostic model (Royston et al., 2009), and selection methods are required to 
reduce the quantity. Parsimonious models, which reach a suitable level of prediction 
but contain fewer prognostic factors, are preferred. Strongly correlated prognostic 
factors can be removed from models, as they contribute little independent information 
and explain the same variation (Harrell, 2015, Royston et al., 2009). Numerous 
selection methods are used in practice (Heinze et al., 2018), however there is no 
consensus on which is the “best” approach (Royston et al., 2009). Fitting the full model 
(i.e. including all candidate prognostic factors) avoids selection bias, reduces the 
potential for overfitting, and leads to reliable confidence intervals, though perhaps at 
the expense of an unnecessarily complex model (Royston et al., 2009). Automated 
selection algorithms are commonly applied to reduce the number of candidate 
prognostic factors included in the final multivariable model, of those available the 
backward selection method is recommended (Collins et al., 2015, Moons et al., 2015). 
Backwards elimination is one such algorithm, in which initially a full model is fitted. An 
iterative process, in which the least statistically significant prognostic factor is 
eliminated and the model is re-fitted, is repeated until all remaining prognostic factors 
are significant at a pre-specified significance level. Alternative approaches which 
combine variable selection with adjustment for overfitting, such as the LASSO, LARS 
and elastic net methods, may be useful for variable selection, but are not considered 
in this thesis. 
When competing events are present, the selection of prognostic factors may also 
depend on the analysis approach. Firstly, all K events are modelled for the cause-
specific approach; hence it is possible for each of the cause-specific hazard model to 
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contain different combinations of prognostic factors. Secondly, the differences in the 
subdistribution and cause-specific hazards could result in different sets of prognostic 
factors being selected for the final model, depending on the approach taken. 
To ensure clinical credibility, prognostic models should include clinically important 
prognostic factors (i.e. those considered to be prognostic by clinicians) regardless of 
statistical significance (Wyatt and Altman, 1995). Additionally, prognostic factors 
representing treatments or therapies should ideally be included in the final prognostic 
models, to circumvent poor prognostic performance if applied to future patients not 
receiving those treatments (Groenwold et al., 2016). 
1.5.3 Testing model assumptions 
General assumptions made in multivariable regression modelling equations 
include linearity and additivity. Linearity refers to the assumption that the effect of a 
single unit increase in a continuous prognostic factor on the log cumulative hazard 
function is constant. If this assumption is not appropriate, non-linear relationships may 
be incorporated by transforming the prognostic factors using fractional polynomial 
functions or splines (Harrell, 2015). Additivity refers to the assumption that the effects 
of one prognostic factor are independent of another. If this assumption is not 
appropriate, interaction terms between prognostic factors can be incorporated into the 
model (Steyerberg 2008). Additionally, prognostic models with time-to-event outcomes 
assume both proportional hazards and non-informative censoring. 
1.5.4 Managing overfitting and optimism  
Statistical overfitting is present when a model is too complex for the amount of 
information in the data (Harrell, 2015), such that the model is too closely adapted to 
the data in which it was developed and regression coefficients are overestimated 
(Royston et al., 2009). Optimism in prognostic models is less likely if developed using 
a sufficient sample size in which few candidate prognostic factors are tested relative 
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to the number of events (Riley et al., 2019b, Royston et al., 2009, Steyerberg et al., 
2013). In particular, it is often recommended that there should be at least ten events 
per candidate prognostic factor (Peduzzi et al., 1995, Peduzzi et al., 1996). Optimism 
is identified through internal validation techniques, discussed below, and can be 
adjusted for using shrinkage methods for a more robust model for the intended 
population (Steyerberg, 2008).  
1.6 Validation of prognostic models 
In prognostic model research, the term validation refers to the statistical process 
for evaluating the predictive performance of a developed prognostic model (Altman 
and Royston, 2000). It is widely accepted that a prognostic model should not be used 
in clinical practice without evidence that it performs a useful role (Moons et al., 2009a), 
i.e. has good validation performance. The reproducibility of the prognostic model and 
potential optimism in model performance estimates are evaluated in the same sample 
of participants used to develop the model, known as internal validation. Whereas, the 
robustness and generalisability (also called transportability) of the model are evaluated 
in an independent sample of plausibly related participants, known as external 
validation (Steyerberg, 2008, Royston and Altman, 2013). Internal validation is 
recommended as a pre-requisite for prediction model development, particularly in the 
case of limited data (Collins et al., 2015). Validation statistics are utilised to evaluate 
the predictive performance of the model by assessing prediction accuracy (calibration) 
and ability to reliably distinguish between those who do and do not experience an event 
(discrimination) in practice. Methods for the validation of prognostic models with time-
to-event outcomes are “not particularly well worked out in the literature” (Royston and 
Altman, 2013) due to the additional challenge of incorporating time and censoring 
information into the model evaluation. Often, prognostic models are validated for 
predictions at a certain time point rather than over the entire prediction horizon. 
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1.6.1 Internal validation  
Internal validation studies utilise all, or subsets of, the participants in which the 
prognostic model was developed to evaluate model reproducibility and optimism. The 
apparent performance of a prognostic model can be evaluated using the exact sample 
of participants from which the model was derived (Steyerberg, 2008). However, as 
model parameters have been optimised to fit this exact sample, the apparent predictive 
performance measures are likely to be optimistic; internal validation is used to assess 
the likely optimism in the model performance and to correct for the resulting overfitting 
of the model (Royston & Altman 2013). This is commonly achieved by splitting the 
sample of participants into development and validation sets (Altman et al., 2009). 
Random splits are generally not advised, as the randomness leads to homogeneity 
between the sets resulting in optimistic results (Altman et al., 2009). Non-random 
splitting may be preferable as it allows for non-random variation between the datasets 
(Collins et al., 2015), however splitting also leads to a loss of power during model 
development (Moons et al., 2012b). Resampling techniques, such as cross-validation 
and bootstrapping, evaluate the predictive performance of a model after development 
(Collins et al., 2015), allowing the model to be developed using the full participant 
sample (Altman et al., 2009). 
Bootstrapping mimics the study sampling process by drawing, with replacement, 
from the sample of participants in the study to create a new sample containing the 
same number of participants as the original. It is useful for validating the modelling 
process used to develop the original prognostic model, as the modelling process is 
repeated in each bootstrap sample. For internal validation, a bootstrap sample is drawn 
and a model is developed using the same modelling process as used to develop the 
original model. The predictive performance of this model is assessed in the bootstrap 
sample (bootstrap apparent performance) and the original sample (test performance). 
The difference of the bootstrap apparent and test performance measures indicates the 
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optimism from the original model (Moons et al. 2012). This process is repeated using 
a number of bootstrap samples and an average optimism estimate for each 
performance measure is calculated. The predictive performance of the original model 
can be adjusted for overfitting and optimism by subtracting the average optimism 
estimates from the original model’s apparent performance measures (Moons et al., 
2012b). Additionally the original model may be adjusted for optimism by multiplying the 
estimated regression coefficients (for the predictors) by a uniform shrinkage factor, 
equivalent to the mean optimism adjusted calibration slope, to produce an optimism 
adjusted model (Moons et al., 2012b, Steyerberg, 2008). Following optimism 
adjustment, the baseline hazard function should be re-estimated for prognostic models 
with time-to-event outcomes, to retain overall calibration. 
1.6.2 External validation 
While internal validation can highlight possible fragilities such as overfitting and 
optimisation, internal data do not provide the heterogeneity expected during external 
applications of the model, for this external validation is required (Royston, 2010). 
External validation refers to the evaluation of the predictive performance of a model in 
an independent sample of plausibly related participants, and is essential to assess the 
model’s clinical value (Altman et al., 2009, Collins et al., 2016). External validation may 
be used to demonstrate the appropriateness of application of a prognostic model 
across different clinical settings, populations, and subgroups of interest, or can 
alternatively identify where model updating and recalibration strategies are required to 
improve predictive performance (Riley et al., 2016, Altman et al., 2009). Though an 
external validation study should be independent, it should also include the same set of 
prognostic factors, comparably defined outcomes with similar follow-up times, and the 
same baseline health state as the development study (Royston, 2010). External 
validation is often a more rigorous assessment of predictive performance, especially 
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in terms of generalisability, compared to internal validation, and often worse predictive 
performance is observed than in the original model development study. 
1.6.3 Validation statistics 
Various statistics are used to quantify the predictive performance of prognostic 
models. Key validation statistics for prognostic model research assess how accurately 
the model predicts the observed risk of participants (calibration) and how well the 
model distinguished between those who do and do not experience the event of interest 
(discrimination) (Steyerberg, 2008). Other measures of predictive performance exist; 
however, a comprehensive review of these methods is beyond the scope of this thesis. 
Instead only those which are relevant to, and thus utilised in, this thesis are discussed 
below. 
1.6.3.1 Measures of calibration 
Calibration reflects the prediction accuracy of the model (Royston and Altman, 
2013), it measures how accurately the expected risks from a prognostic model predict 
the observed risks of the participants. Calibration of prognostic models with time-to-
event outcomes is only possible if the models contain an estimate of the baseline 
survival function, as this is required to calculate participants’ absolute risks (Royston 
and Altman, 2013). For time-to-event outcomes the expected and observed risks of 
the event of interest are evaluated both over time and within specified time periods 
(Moons et al., 2012b). Calibration statistics which can be utilised for models with time-
to-event outcomes include: overall calibration; the expected/observed ratio (at 
particular time-points); and the calibration slope. 
Overall calibration (also known as calibration-in-the-large) compares the 
expected probability of events predicted by the prognostic model to the observed 
probability of events in the study, over the study time period. As censoring is likely to 
be present in prognostic model studies with time-to-event outcomes, estimates of 
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expected and observed risks should account for censoring. The expected risk is 
represented by the predicted cumulative incidence curve from the fitted model, and the 
observed risk is represented by the 1– Kaplan-Meier curve of the study participants’ 
cumulative risk. Overall calibration is assessed by overlaying the curves on the same 
plot (Royston and Altman, 2013), if the curves are similar the model is “well calibrated”. 
This can be assessed for the sample as a whole (calibration-in-the-large) or for risk 
groups, created by grouping participants with similar predicted risks, to assess 
calibration at different levels of risk. Often risk groups are created by splitting at deciles 
of predicted probabilities (Steyerberg, 2008), however it is recommended that risk 
groups contain a minimum of 50 participants for stable Kaplan-Meier estimation 
(Harrell, 2015). The expected/observed ratio (E/O) assesses overall calibration at 
specified time points. Again E/O may be reported for the entire validation sample or 
over risk groups. The ratio of the expected and observed probabilities of an event 
should be close to one for a well calibrated model. 
Calibration plots graphically depict the expected and observed probabilities of an 
event occurring prior to a specified time point for risk groups (Altman et al., 2009), as 
depicted in Box 1.6. The slope of a fitted line in a calibration plot is referred to as the 
calibration slope (Steyerberg, 2008). When assessing prognostic models with time-to-
event outcomes the calibration slope can be assessed as an average slope over time 
by estimating the regression coefficient of a model containing the linear predictor from 
the prognostic model as the only variable (Royston and Altman, 2013). A well 
calibrated model produces a calibration slope estimate close to one and E/O close to 
one at most time-points. Methods of recalibration may be utilised to improve prognostic 
models with poor calibration to improve model fit (Royston, 2010). 
When competing events are present, observed risks are calculated using 
cumulative incidence estimates (rather than survival estimates), as these account for 
censoring and the competing events (Wolbers et al., 2009). 
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Box 1.6: Example of a calibration plot 
 
Calibration plot from the external validation of a prognostic model for 30 day risk 
of mortality following stroke developed using Cox regression (Counsell et al., 
2002)i. 
Deciles of predicted probability were used to form groups in calibration plot.  
The diagonal dashed line represents perfect calibration and the vertical lines represent 
95% confidence intervals for observed risk in each group.  
 
1.6.3.2 Measures of discrimination 
Discrimination refers to the extent to which predicted risk estimates distinguish 
between different patient prognoses (Royston and Altman, 2013). For prognostic 
models with time-to-event outcomes, discrimination not only distinguishes between 
those who do and do not go on to experience the event, but also should distinguish 
between the times at which the events occur. Groups of participants with higher 
predicted risks should have higher event rates and experience events sooner than 
those with lower predicted risks (Royston and Altman, 2013). Discrimination statistics 
                                                     
i Adapted by permission from Wolters Kluwer Health, Inc. “Predicting Outcome After Acute and Subacute 
Stroke”, Counsell et al., Stroke. 2002; 33:1041-1047 
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utilised for models with time-to-event outcomes include Harrell’s C-index (Harrell et al., 
1982), and Royston and Sauerbrei’s D-statistic and RD2  (Royston and Sauerbrei, 2004). 
Harrell’s C-index (Harrell et al., 1982) is the probability that, of two randomly 
chosen participants, the one with the highest expected risk will experience the event 
first. Not all pairs of participants are evaluable; if neither of the participants experience 
the event during study follow-up it is not possible determine which will experience the 
event first. Similarly, if a participant is censored before the other experiences the event, 
it is not possible to determine the order of the pairing. Thus, Harrell’s C-index is known 
to be biased in instances with heavy censoring, (Royston and Altman, 2013). 
Royston and Sauerbrei’s D-statistic is a measure of prognostic separation 
(Royston and Sauerbrei, 2004). This can be interpreted as the log hazard ratio 
comparing two equal-sized groups, created by splitting the sample using the median 
value of the estimated linear predictor from the prognostic model (Riley et al., 2016). 
This is achieved by utilising the linear predictor from the prognostic model to calculate 
each individual’s linear predictor value. These values are ordered, and corresponding 
standard normal order statistics (rankits) are calculated, and then scaled by a factor κ =
√8 π⁄ . The scaled rankits are then regressed on the outcome, the resulting estimated 
regression coefficient is the D-statistic (Royston and Sauerbrei, 2004). Higher values 
of the D-statistic represent more separation, thus greater discrimination. Once 
calculated the D-statistic can be incorporated into a generalisation of the multiple 
correlation coefficient RD2 , representing the proportion of explained variation on the log 
relative hazard scale (Royston and Altman, 2013) as follows: 
 𝑹𝑫
𝟐 =
𝑫𝟐
𝜿𝟐
⁄
𝝈𝟐 + 𝑫
𝟐
𝜿𝟐
⁄
,     𝝈𝟐 =
𝝅𝟐
𝟔
   Equation 1.33 
 
1.7 Aims and overview of the thesis  
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The aim of this thesis is to improve understanding of the influence of competing 
risks issues in prognostic model research. In particular, this thesis aims to; 
1. Investigate the presence of competing events in prognostic model research 
studies, specifically in systematic reviews and development studies. 
2. Develop, externally validate, and compare prognostic models for the risks of 
antenatal adverse events in pre-eclampsia pregnancies which do and do not 
appropriately account for the competing risk of delivery. 
3. Evaluate the impact of not correctly accounting for competing events on prognostic 
performance measures, 
4. Use simulation studies to examine the credibility of a proposed rule of thumb for 
deciding when competing risks should be accounted for. 
This thesis is comprised of eight chapters. The first aim is addressed in Chapters 
2 & 3, where evaluations of published prediction model literature investigate the 
presence, reporting, and management of competing events. The second aim is 
addressed in Chapters 4 to 6, in which semi-parametric and flexible parametric 
regression methods are utilised to develop, and then externally validate, prognostic 
models for patients with pre-eclampsia. The third and fourth aims are addressed in 
Chapter 7, in which multiple simulation studies are utilised to investigate the effect of 
not appropriately accounting for competing events when evaluating prognostic model 
performance measures. The thesis ends with a discussion of key findings, here 
limitations within the thesis and plans for further research are detailed. An outline of 
the chapters is given below. 
In Chapter 2, the presence and reporting of competing events, and potential for 
competing risks bias, in systematic reviews of prediction model studies are 
investigated. The potential for competing risks bias in the included studies is examined 
through assessment of the outcome of interest, characteristics of study populations, 
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and the prediction time spans of included models. The reporting of competing events 
and use of quality assessment tools within the systematic reviews are also 
investigated. 
Chapter 3 reviews the presence, reporting, and management of competing events in 
prediction model development studies that are likely to be affected by competing 
events. Again, the potential for competing risks bias is examined through assessment 
of the outcome of interest, characteristics of study populations, and prediction time 
spans of the included models. The reporting and management of competing events is 
inspected by determining whether statistical regression methods are applied to 
appropriately account for the competing events, and whether participants who 
experienced competing events are censored or excluded from the studies. 
In Chapter 4, both Cox proportional hazards and Royston-Parmar flexible parametric 
modelling methods are applied to develop and internally validate prognostic models 
which predict the risk of antenatal adverse events in pregnancies with early-onset pre-
eclampsia. Multiple imputation methods are implemented to manage missing data, 
fractional polynomial associations between the prognostic factors and outcome are 
investigated, and model selection methods are applied to determine inclusion of 
prognostic factors. The models are internally validated using bootstrap methods, 
uniform shrinkage is applied to correct for optimism, and the optimism adjusted models 
are compared in terms of prognostic factor associations, baseline hazard estimates, 
and individual prediction estimates. 
In Chapter 5 both cause-specific and subdistribution approaches are applied to 
develop and internally validate flexible parametric prognostic models to predict the risk 
of antenatal adverse events in pregnancies with early-onset pre-eclampsia, 
incorporating delivery of the baby as a competing event. Multiple imputation methods 
are implemented, fractional polynomial associations are investigated, and model 
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selection methods are applied. The models are internally validated using bootstrap 
methods, and uniform shrinkage is applied to correct the subdistribution model for 
optimism. The models are compared in terms of prognostic factor associations, 
baseline hazard estimates, and individual prediction estimates. 
In Chapter 6 the flexible parametric prognostic model developed in Chapter 4, and the 
flexible parametric subdistribution model developed in Chapter 5, are externally 
validated using an independent dataset of early-onset pre-eclampsia pregnancies. The 
resulting models, and their measures of prognostic ability, are compared. 
Chapter 7 describes the design and results of a simulation study to assess the effects 
of competing events on measures of prognostic performance. The level of 
miscalibration introduced when assessing overall calibration and not appropriately 
accounting for competing events is investigated for different proportions of the event 
of interest and the competing event. The chapter concludes with recommendations 
regarding which circumstances competing risks methodology significantly alters 
measures of prognostic ability, and thus should be applied, in prognostic model 
research. 
Finally, Chapter 8 concludes the thesis with a summary and discussion of key findings 
and recommendations regarding when and how competing risks should be accounted 
for in prognostic model research. The limitations of the research are discussed, and 
recommendations for future research are provided. 
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2 AN EMPIRICAL EVALUATION OF THE PRESENCE AND 
REPORTING OF COMPETING EVENTS IN SYSTEMATIC 
REVIEWS OF PREDICTION MODEL STUDIES 
2.1 Introduction  
In order for a prediction model to be useful, the model’s estimates of an 
individual’s risk of experiencing a particular outcome in the future need to be as 
accurate as possible. If competing events are present but not correctly accounted for, 
the estimated risk predictions provided by the model may not accurately reflect the 
individual’s real-world risk. The inflation in absolute risk estimates resulting from not 
accounting for competing events is referred to as “competing risks bias” (Schatzkin 
and Slud, 1989, Schumacher et al., 2016, Walraven and McAlister, 2016). 
The presence of competing risks bias in prediction model research could result 
in biased information being used to inform treatment decisions. A study comparing 
prediction models developed using standard time-to-event methods with a model 
developed using competing risks methods found an additional 10% of women were 
classified as high risk for developing coronary heart disease when the competing 
events were not correctly accounted for (Wolbers et al., 2009). Logically, the amount 
of bias in absolute risk estimates is associated with the number of observed competing 
events, more events lead to greater bias. Walraven and McAlister developed an 
(unpublished) model to assess relative bias in Kaplan-Meier based risk estimates 
compared to the “true” (competing risks adjusted) values (Walraven and McAlister, 
2016). The model was applied to 16 studies and estimated the median relative increase 
in absolute risk estimates due to competing risks bias, which was 5.7% (range: 1.2% 
to 65.8%) (Walraven and McAlister, 2016). 
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Furthermore, systematic reviews of prediction model studies are increasing, and 
are being used to synthesise the evidence from primary studies and guide the quality 
of evidence to support existing prediction models (Debray et al., 2017). Such reviews 
need to consider whether competing events are present and appropriately managed 
within the primary studies, to enable a thorough assessment of the quality and risk of 
bias in the primary studies (Wolff et al., 2019). To the author’s knowledge, there has 
been no previous evaluation of the handling of competing events specifically within 
systematic reviews of prediction models. 
2.1.1 Aims 
The aim of this chapter is to empirically investigate the presence and reporting of 
competing events, and competing risks bias, in published systematic reviews of 
prediction model studies. Therefore, this evaluation of systematic reviews will 
investigate: 
• Whether systematic reviews of prediction model studies contain prediction models 
with high potential for competing risks bias; and 
• Whether these biases are reported in the systematic review articles and/or 
acknowledged during quality assessment of the included prediction model studies. 
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2.2 Methods: Evaluation of systematic reviews 
2.2.1 Strategy for searching and selecting relevant systematic review articles 
To identify systematic review articles of prediction model studies, an extensive 
search strategy (Ingui and Rogers, 2001), which includes a broad range of relevant 
search terms and is shown to have a high level of sensitivity (98.2%), was applied. The 
search strategy was refined by specifying the article title must include either the term 
“systematic review” or “meta-analysis”, as suggested in the PRISMAi statement (Moher 
et al., 2009). This adaptation was unlikely to significantly affect the sensitivity of the 
search strategy; a recent review found 94% (239/255) of non-Cochraneii systematic 
review articles include one of these terms in their title (Page et al., 2016). 
The MEDLINE database (through Pubmed) was used to search for articles 
published after the 1st January 2015 to the search date (3rd April 2017) and was 
restricted to human studies. Based on testing searches, it was anticipated that this 
date range would result in approximately 30 systematic review articles being identified. 
After discussion with the research team, 30 articles was considered sufficient to 
provide an overview of the evaluation of competing risks bias within the current 
literature on systematic reviews of prediction model studies. The detailed search 
strategy for the evaluation is listed in Table 2.1. 
                                                     
i The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement is an 
evidence-based minimum set of outcomes for reporting systematic reviews and meat-analyses. 
ii A Cochrane Review is a systematic review of research in health care and health policy that is published 
in the Cochrane Database of Systematic Reviews. 
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Table 2.1: Search strategy for identifying systematic reviews of prediction model 
studies 
Database: MEDLINE (Pubmed) on 03 April 2017. 
(1) Validat*[Title] OR Predict*[Title] OR Rule*[Title] 
(2) Predict*[Title]  
(3) Outcome*[Title] OR Risk*[Title] OR Model*[Title] 
(4) (2) AND (3) 
(5) History[Title] OR Variable*[Title] OR Criteria[Title] OR Scor*[Title] OR 
Characteristic*[Title] OR Finding*[Title] OR Factor*[Title]  
(6) Predict*[Title] OR Model*[Title] OR Decision*[Title] OR Identif*[Title] OR 
Prognos*[Title] 
(7) (5) AND (6) 
(8) Decision*[Title]  
(9) Model*[Title] OR Clinical*[Title] OR Logistic Models[MeSH:noexp, Title] 
(10) (8) AND (9) 
(11) Prognostic[Title]  
(12) History[Title] OR Variable*[Title] OR Criteria[Title] OR Scor*[Title] OR 
Characteristic*[Title] OR Finding*[Title] OR Factor*[Title] OR Model*[Title] 
(13) (11) AND (12) 
(14) (1) OR (4) OR (7) OR (10) OR (13) 
(15) systematic review[Title] OR meta-analysis[Title] 
(16) (14) AND (15) 
Limitations: published between 01 January 2015 and 03 April 2017; Humans 
 
This evaluation focused on systematic review articles which describe the 
development of prediction models for health-related outcomes. The following definition 
was selected to describe a prediction model: “a multivariable (containing two or more 
variables) statistical model developed to predict an individual’s risk of a future outcome 
over a period of time from a given disease or health state”, adapted from (Collins et al., 
2015). This definition allows the inclusion of models which make predictions in healthy 
individuals from the general population, as well as in clinical populations and those in 
specified health states, as competing events and competing risks bias can potentially 
affect these populations too. Diagnostic models, which are used to identify a patient’s 
current disease or health state, are excluded from this definition as competing events 
are unlikely to prevent outcomes, as these are already present or not. Thus, systematic 
review articles were only considered suitable for inclusion in the evaluation if they met 
the following criteria: 
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1. described a systematic review and/or meta-analysis study; and 
2. assessed and/or synthesised two or more primary studies developing prediction 
models. 
These criteria led to the exclusion of systematic review articles that include prediction 
model research articles which: 
1. only identify individual prognostic factors rather than multivariable prediction 
models; or 
2. only validate existing prediction models and do not develop new models; or 
3. only assess diagnostic models and not prediction models. 
Systematic reviews which included a mixture of prediction model development articles 
alongside prognostic factor, validation, or diagnostic research articles were thus 
included in the evaluation. 
The selection of systematic review articles for this evaluation was determined 
through a screening of titles and abstracts, followed by (if necessary) an assessment 
of the full text. Articles that did not meet the above criteria were removed throughout 
this process, and reasons for exclusion were recorded. All articles were examined by 
the first reviewer (LT), and 5% of the articles were additionally independently examined 
by a second reviewer (KS or DvdW). Disagreements concerning the inclusion of 
individual articles were addressed via discussions between the reviewers (LT, KS, and 
DvdW). 
2.2.2 Data extraction 
Information from the included systematic review articles was extracted by the first 
reviewer (LT) using a data extraction form (Appendix I). A second reviewer (KS) 
independently extracted information from 20% of the included systematic review 
articles. Any discrepancies between the data extracted by the two reviewers were 
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resolved by discussion between the reviewers (LT and KS). Information was extracted 
in connection to four key items, as outlined below: 
2.2.2.1 Item 1: What were the characteristics of each systematic review? 
This item aimed to summarise the characteristics of each included systematic 
review. The date restrictions (start and end dates) reported in each systematic review’s 
search strategy were recorded. If no start date was reported within the search strategy 
it was assumed that all research articles published before the end date were included, 
i.e. the start date was recorded as the inception of the database(s) searched within the 
review. Information was recorded regarding whether each systematic review aimed to 
identify prediction model articles which developed models to predict a specific 
outcome(s) (such as stroke or mortality), or which developed models in populations in 
a specific health state (such as those in hospital), or indeed both. Finally, both the 
number of prediction model articles included in each systematic review and the 
reported number of prediction models was recorded. Some systematic reviews 
identified prognostic factor, validation, and diagnostic research articles as well as 
development articles. Additionally, some identified articles which developed multiple 
prediction models; thus the number of prediction model articles and reported number 
of models in each systematic review may not be equal. 
2.2.2.2 Item 2: What is the potential for competing risks bias affecting each 
systematic review? 
The reported characteristics of each prognostic model developed within each 
prognostic model study included in each systematic review were assessed using a 
combination of criteria. These criteria, utilised in published articles addressing 
competing risks bias (Koller et al., 2012, Schumacher et al., 2016, Walraven and 
McAlister, 2016), were considered to assess the risk of competing risks bias within 
each systematic review (further details are provided in the Discussion). The three 
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criteria are outlined below, followed by a description of the process used to assess the 
risk of competing risks bias within each systematic review. 
Criterion for competing risks bias 1: The prediction model investigates 
outcomes other than all-cause mortality 
It is generally accepted that outcomes such as all-cause mortality, and composite 
outcomes which contain all-cause mortality including progression-free survival, are not 
at risk of competing events (Koller et al., 2012, Schumacher et al., 2016, Walraven and 
McAlister, 2016), as nothing can prevent these outcomes from occurring. However, 
death is often considered to be a competing event to a number of other outcomes, 
including: non-fatal disease-specific outcomes (such as antenatal adverse events in 
pre-eclampsia); and cause-specific death (such as death from cancer), as death from 
any other cause prevent these outcomes from occurring. The reported primary 
outcome(s) of interest of each prediction model identified within each systematic 
review were recorded. Systematic reviews were considered to meet this criterion if they 
included prognostic models which predicted outcomes other than all-cause mortality. 
Criterion for competing risks bias 2: The baseline population contains frail 
and/or elderly populations 
It is also generally accepted that frail and elderly populations have an increased 
risk of experiencing competing events (Koller et al., 2012). Disease and health states 
indicating increased morbidity, chronic diseases, and severe or critical illnesses (such 
as populations with cardiovascular disease, in intensive care, or receiving cancer 
therapies) were reasoned to indicate frail populations; as these populations have a 
greater likelihood of experiencing competing events (such as death) (Koller et al., 
2012). Elderly populations are considered susceptible to competing risks bias due to 
increased disease accumulation and frailty (Koller et al., 2012), thus the populations 
have a greater likelihood of experiencing competing events. The reported initial 
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disease or health state and descriptions of the age of the population which the 
prediction models identified within each systematic review were developed in were 
recorded. Systematic reviews were considered to meet this criterion if they contained 
prediction models developed in elderly or frail populations. 
Criterion for competing risk bias 3: The prediction horizon is sufficiently long 
to enable competing events to occur 
A prediction horizon is the time for which an individual’s risk is assessed; for 
example a model which predicts the ten year risk of coronary heart disease (Wolbers 
et al., 2009) has a ten year prediction horizon. A longer prediction horizon enables a 
greater number of competing events to occur. A summary of the prediction horizons of 
the prediction models identified within each systematic review were recorded. Where 
this information was not reported, a summary of follow-up time was recorded as an 
alternative. Systematic reviews which included prediction models with prediction 
horizons of a year or greater were considered to meet this criterion. The cut off at one 
year was a pragmatic decision for the purpose of the thesis, ideally clinical expertise 
should be sought to determine a sensible cut-point for this assessment based on the 
studies health state and outcome of interest. 
Overall assessment of the potential for competing risks bias within each 
systematic review 
The above criteria were evaluated in turn within each systematic review; the 
process is summarised in Figure 2.1. 
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Figure 2.1: Classification system for assessing the potential for competing risks 
bias 
 
 
Systematic reviews which only identified prediction models with all-cause 
mortality (or composites containing all-cause mortality) outcomes were not considered 
susceptible to competing risks bias and were thus classified as no potential for 
competing risks bias. Those systematic reviews which identified prediction models with 
other outcomes (Criterion 1) were evaluated further. Systematic reviews which only 
identified prediction models developed in young and healthy populations were 
considered to have a small chance of competing risks bias, and were thus classified 
as low potential for competing risks bias. Those systematic reviews which identified 
prediction models developed in frail and/or elderly populations (containing participants 
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over 60 years of agei, Criterion 2) were evaluated further. Finally, systematic reviews 
which only identified prediction models with prediction horizons less than one year 
(considered to be sufficiently short to reduce the likelihood of the occurrence of 
competing events) were classified as moderate potential for competing risks bias; 
Whereas those systematic reviews which identified prediction models with prediction 
horizons one year or greater (Criterion 3) were classified as high potential for 
competing risks bias. 
Systematic reviews classified as high potential are likely to contain a large 
proportion of prediction model studies with competing events. Whereas those 
classified as no potential are unlikely to contain any prediction model studies with 
competing events. However, a prediction model study with competing events is not 
necessarily susceptible to competing risks bias. If the prediction model study 
appropriately accounts for the competing events, for example through the use of 
competing risks regression (as outlined in Chapter 1), the results of the study will not 
be biased. However, it is suspected by the reviewers that the appropriate methods are 
scarcely applied in prediction model research, thus the presence of competing events 
is likely to be a strong indicator for the presence of competing risks bias. 
2.2.2.3 Item 3: Were competing events addressed in the systematic review 
article? 
This item aimed to summarise whether any of the included systematic review 
articles directly addressed issues related to competing risks bias. To do this, a search 
of key terms related to competing events (listed in Table 2.2) was conducted in each 
systematic review using the Adobe Acrobat Reader DC Find function. Where key terms 
were identified within the systematic review article, the associated text surrounding the 
term was extracted and reported. Additionally, as competing risks bias is connected to 
                                                     
i 60 is acknowledged as an artificial cut-off point for “elderly” used by the World Health Organisation 
ORGANIZATION, W. H. 1994. Health care for the elderly: a manual for primary health care workers. 
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overestimation of Kaplan-Meier estimates, each systematic review was examined for 
reference to, and/or depiction of, Kaplan-Meier curves. 
Table 2.2: Key terms related to competing events 
Key terms 
competing risk(s); competing event(s); competing cause(s); competing bias; cause 
specific; cause-specific; subdistribution; sub-distribution; cumulative incidence;  
Fine & Gray; Fine and Gray; 
 
2.2.2.4 Item 4: Was competing risks part of the quality assessment performed 
within the systematic review? 
Information was extracted regarding whether each systematic review reported 
performing a quality assessment of the included prognostic model studies. If done, the 
name of the quality assessment tool implemented to perform the assessment was 
recorded. Each quality assessment tool identified was obtained (where possible) and 
examined to determine whether it explicitly mentioned competing risks and the 
potential for competing risk bias. 
2.2.3 Analysis methods 
A narrative synthesis of the information extracted from the systematic review 
articles was conducted, the preliminary synthesis consisted of tabulation and textual 
descriptions of the extracted information. 
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2.3 Results: Evaluation of systematic reviews 
2.3.1 Search and selection of relevant systematic reviews 
A flow diagram depicting the selection process for this evaluation is given in 
Figure 2.2. 
Figure 2.2: Flow diagram of systematic review article selection process for this 
evaluation 
 
 
The initial PubMed search identified 535 articles for consideration. Titles and 
abstracts were screened to identify potentially relevant articles, leading to 480 
irrelevant articles being excluded. Full text manuscripts were retrieved for the 
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remaining 55 articles; of these 24 did not meet the review selection criteria and were 
consequently excluded. The main reasons for exclusion at this stage were systematic 
reviews which: only assessed diagnostic models; only assessed model validation 
studies; and only assessed prognostic factor studies. The remaining 31 systematic 
reviews met the evaluation inclusion criteria and were thus considered suitable for the 
evaluation. Additional reviewers (KS and DvdW) each checked ten randomly selected 
articles, from the initial 535 identified, against the review inclusion criteria. No 
discrepancies were identified between reviewer decisions; thus the 31 systematic 
review articles formed the final set for this evaluation. The findings about items 1 to 4 
are now summarised for these 31 articles. 
2.3.2 Item 1: What were the characteristics of each systematic review? 
The characteristics of the 31 included systematic reviews of prediction model 
studies are summarised in Appendix II. The majority of the systematic reviews (22, 
71.0%) aimed to identify prediction models developed in a specified population, and 
which predict a pre-specified outcome. Two (6.5%) of the systematic reviews specified 
only the prediction model outcomes, specifically lung cancer (Gray et al., 2016) and 
predicting future dementia diagnosis (Tang et al., 2015). Seven (22.6%) systematic 
reviews specified only the population in which the prediction models were developed, 
and not the outcomes predicted by the models. The remaining three articles provided 
very broad definitions for outcomes predicted by the models, including 
“behavioural/psychiatric problems” (Linsell et al., 2016), “adverse outcomes” 
(O'Caoimh et al., 2015), and “late effects” (Salz et al., 2015). All reviews included an 
evaluation of multiple prediction models, with a median of 16 prediction models per 
review (range 3 to 363) identified from a median of 20 published articles per review 
(range 3 to 125). One systematic review (Tang et al., 2015) failed to report the number 
of models included in the review. It was common for the systematic reviews to identify 
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more prediction models than model development articles (13, 41.9%), due to primary 
studies presenting multiple prediction models. 
2.3.3 Item 2: What is the potential for competing risks bias affecting each 
systematic review? 
The risk of competing risks bias within each systematic review was assessed by 
scrutinizing the reported characteristics of the prediction model development studies 
included within each review. Information pertaining to three criteria (prediction model 
outcomes, baseline populations, and prediction horizons) were extracted from each 
systematic review article, these are reported in Table 2.3. Each of the criteria were 
assessed separately prior to being combined to determine an overall potential for 
competing risks bias. The results are provided below. 
Criterion for competing risk bias 1: The prediction model investigates 
outcomes other than all-cause mortality 
Data which summarise the outcomes of the prediction models identified within 
each systematic review is displayed in Table 2.3. The 31 systematic reviews identified 
prediction models with a variety of outcomes, including morbidity (Lim et al., 2015, 
Marufu et al., 2015, Salz et al., 2015), acute kidney injury (Caragata et al., 2016, Wilson 
et al., 2016), asthma (Luo et al., 2015, Smit et al., 2015), and venous thromboembolism 
(Ensor et al., 2016, Mahajerin et al., 2015). Of the 31 systematic reviews, eight (25.8%) 
reported the inclusion of prediction models with all-cause mortality outcomes, yet only 
three (9.7%) (Kohn et al., 2015, Oliver et al., 2015, Warnell et al., 2015) included only 
all-cause mortality outcomes. Hence 28 (90.3%) systematic reviews contained 
prediction models which investigated outcomes other than all-cause mortality and met 
this criterion. 
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Table 2.3: The risk of competing risks bias within each systematic review: based on characteristics of the prediction model 
development studies contained within each systematic review. 
Systematic 
review 
reference 
Criterion for competing risk bias 1: Prediction model 
outcomes 
Criterion for competing risk bias 2: 
Baseline populations 
Criterion for 
competing risk bias 3: 
Prediction horizons 
Outcomes of the prediction models 
identified in the review+ 
Do all 
outcomes 
contain all-
cause 
mortality? 
Disease and health 
states of prediction 
model populations 
Population age 
at baseline 
Prediction horizon of 
models identified in 
the review 
(Ayerbe et al., 
2016) 
Coronary artery disease, myocardial 
infarction, angina, coronary insufficiency, 
unstable angina, cardiac death, arrhythmia, 
revascularisation 
No Chest pain  (recent onset) Not Reported Range 
Discharge to  
4 years 
(Brunelli and 
Prefumo, 
2015) 
Pre-eclampsia No First trimester pregnancy Not Reported Not Reported 
(Caragata et 
al., 2016)  
Acute kidney injury  No Liver transplantation Not Reported Range <48 hours to <10 days 
(Damen et al., 
2016) 
Cardiovascular Disease, with coronary 
heart disease, with stroke, myocardial 
infarction, and atrial fibrillation, all-cause 
mortality 
No General population Range 
30 to 
74 
years 
Range 2 to 45 years 
(Echouffo-
Tcheugui et 
al., 2015)  
Incident heart failure No General population Range 
18 to 
99 
years 
Range* 2.9 to 14 years 
(Ensor et al., 
2016)  
Recurrent venous thromboembolism No 
Cessation of treatment 
venous 
thromboembolism 
Mean 
range 
 
Median 
range 
 
52.3 to 
53.6 
years 
54 to 
63 
years 
Range  3 months to 5 years 
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Systematic 
review 
reference 
Criterion for competing risk bias 1: Prediction model 
outcomes 
Criterion for competing risk bias 2: 
Baseline populations 
Criterion for 
competing risk bias 3: 
Prediction horizons 
Outcomes of the prediction models 
identified in the review+ 
Do all 
outcomes 
contain all-
cause 
mortality? 
Disease and health 
states of prediction 
model populations 
Population age 
at baseline 
Prediction horizon of 
models identified in 
the review 
(Gray et al., 
2016)  
Lung cancer, death from lung cancer, 
survival, lung cancer incidence No General population Range 
20 to 
80 
years 
Range 1 to 10 years 
(Haskins et 
al., 2015)  
Functional outcomes, work related 
outcomes, pain intensity, recovery, 
symptom persistence, need for surgical 
intervention 
No Low Back Pain Mean range 
26 to 
56 
years 
Range  48 hours to  2 years 
(Hilkens et 
al., 2016) 
Intracranial haemorrhage or major 
bleeding, major bleeding, intracerebral 
bleeding, gastrointestinal bleeding 
No Patients on antiplatelet therapy 
Mean 
range  
63 to 
69 
years 
Range 2 to 5 years 
(Kohn et al., 
2015) 
Early all-cause mortality Yes Acute pulmonary embolism 
Mean 
range 
56 to 
71 
years 
Max 90 days 
(Lim et al., 
2015) 
Overall morbidity, all-cause, liver failure 
mortality, overall morbidity and mortality, 
bile leakage, infection, mortality and 
hospital stay, liver failure, infection and 
organ dysfunction, overall morbidity, ascites 
No Patients undergoing liver resection Not Reported Max 90 days 
(Linsell et al., 
2016) 
Neurodevelopment outcomes, general 
behavioural problems, any psychiatric 
disorders, autism spectrum disorders, 
attention deficit/hyperactivity disorder 
No Very preterm or very low birth weight infants Max 
32 
weeks Min  18 months 
(Luo et al., 
2015) 
Asthma development, multi-trigger 
wheezing, persistent wheezing, receiving 
treatment, diagnosis 
No Children  Range 0 to 14 years Range  1 to 19 years 
 73 
Systematic 
review 
reference 
Criterion for competing risk bias 1: Prediction model 
outcomes 
Criterion for competing risk bias 2: 
Baseline populations 
Criterion for 
competing risk bias 3: 
Prediction horizons 
Outcomes of the prediction models 
identified in the review+ 
Do all 
outcomes 
contain all-
cause 
mortality? 
Disease and health 
states of prediction 
model populations 
Population age 
at baseline 
Prediction horizon of 
models identified in 
the review 
(Mahajerin et 
al., 2015) 
Hospital-associated venous 
thromboembolism 
No Pediatric hospital patients  Max 
21 
years Not Reported 
(Mao et al., 
2015) 
Stroke No Coronary artery bypass grafting  
Mean 
range 
 
Median 
range 
 
62 to 
69 
years 
64.7 to 
65.3 
years 
Range  1 to 30 days 
(Marques et 
al., 2015) 
Osteoporotic fracture, hip fracture, major 
osteoporotic fracture, osteoporotic or 
fragility fracture, clinical vertebral fracture, 
mortality 
No General population Range 
40 to 
100 
years 
Range  1 to 10 years 
(Marufu et al., 
2015) 
Mortality, morbidity, mobility No Hip fracture operation Not Reported Range  
In hospital to 
more than 1 
year 
(Meyer et al., 
2015) 
Functional outcomes, Barthel Index or 
Functional Independence Measure. No 
Patients receiving post-
stroke inpatient 
rehabilitation 
Not Reported Max Hospital discharge 
(O'Caoimh et 
al., 2015) 
Hospitalisation, functional-decline, 
institutionalisation, death No 
Community-dwelling 
older adults 
Mean 
range 
64.2 to 
84.6 
years 
Range  4.5 months to 9 years 
(Oliver et al., 
2015) 
Mortality Yes Emergency laparotomy Not Reported Max 30 days 
(Quinlivan et 
al., 2016) 
Repeat self-harm and attempted suicide, 
self-harm, self-poisoning No 
Presenting with self-
harm or attempted 
suicide 
Not Reported Range  3 months to 3 years 
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Systematic 
review 
reference 
Criterion for competing risk bias 1: Prediction model 
outcomes 
Criterion for competing risk bias 2: 
Baseline populations 
Criterion for 
competing risk bias 3: 
Prediction horizons 
Outcomes of the prediction models 
identified in the review+ 
Do all 
outcomes 
contain all-
cause 
mortality? 
Disease and health 
states of prediction 
model populations 
Population age 
at baseline 
Prediction horizon of 
models identified in 
the review 
(Salz et al., 
2015) 
Erectile dysfunction, urinary incontinence, 
arm lymphoedema, psychological morbidity, 
cardiomyopathy or heart failure, cardiac 
event, swallowing dysfunction, breast 
cancer, thyroid cancer. 
No Completing treatment for cancer Not Reported Range  
6 months to  
30 years 
(Silver et al., 
2015) 
Contrast induced nephropathy No 
Undergoing procedure 
using iodinated 
radiocontrast 
Not Reported Range  2 to 7 days 
(Silverberg et 
al., 2015) 
Post-concussion symptom reporting, 
functional outcome, quality of life, 
neuropsychological outcomes 
No Mild traumatic brain injury  Range 
5 to 80 
years Range  
3 to 18 
months 
(Smit et al., 
2015) 
Asthma No Children with asthma-like symptoms  Range 
0 to 5 
years Range  1 to 11 years 
(Tang et al., 
2015) 
Dementia, Alzheimer’s disease No 
Varied, inlcuding 
general population, 
elderly, and with 
diabetes 
Range 
40 to 
99 
years 
Range  1.5 to 17 years 
(Usher-Smith 
et al., 2016) 
Primary colorectal cancer, advanced 
colorectal neoplasia including dysplasia, 
advanced colorectal neoplasia, colon 
cancer (distal and proximal), rectal cancer 
No General population Mean range 
36.4 to 
67.5 
years 
Range* 10 to 20 years 
(Walsh et al., 
2016) 
Falls, multiple or injurious falls No Stroke Mean range 
62.0 to 
76.4 
years 
Range* Discharge to 12 months 
(Warnell et 
al., 2015) 
Perioperative mortality Yes Oesophagectomy for cancer in adults Not Reported Range 0 to 90 days 
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Systematic 
review 
reference 
Criterion for competing risk bias 1: Prediction model 
outcomes 
Criterion for competing risk bias 2: 
Baseline populations 
Criterion for 
competing risk bias 3: 
Prediction horizons 
Outcomes of the prediction models 
identified in the review+ 
Do all 
outcomes 
contain all-
cause 
mortality? 
Disease and health 
states of prediction 
model populations 
Population age 
at baseline 
Prediction horizon of 
models identified in 
the review 
(Williams et 
al., 2016) 
Colorectal cancer, with advanced 
adenoma, with pre-malignant adenomas, 
with other cancers 
No Symptomatic of colorectal cancer 
Range 
 
18 to 
89 
years 
Max 2 years 
(Wilson et al., 
2016) 
Acute kidney injury No Major non-cardiac surgery Not Reported Range 
1 week to 30 
days 
+Text in bold represents the outcome of interest specified by the review. 
* Follow-up measures reported instead of prediction horizon as prediction horizon not reported in the review. 
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Criterion for competing risk bias 2: The baseline population contains frail 
and/or elderly populations 
Data which summarise the baseline populations of the prediction models 
identified within each systematic review is displayed in Table 2.3. The 31 systematic 
reviews included prediction models developed in a variety of populations. Seven 
(22.6%) systematic reviews include prediction models developed in populations which 
have undergone a surgical intervention (Caragata et al., 2016, Lim et al., 2015, Mao 
et al., 2015, Wilson et al., 2016, Marufu et al., 2015, Oliver et al., 2015, Warnell et al., 
2015); six (19.4%) investigate prediction models developed in the general population 
(Damen et al., 2016, Echouffo-Tcheugui et al., 2015, Gray et al., 2016, Marques et al., 
2015, Tang et al., 2015, Usher-Smith et al., 2016); and four (12.9%) include prediction 
models developed in children (Linsell et al., 2016, Luo et al., 2015, Mahajerin et al., 
2015, Smit et al., 2015). Twelve systematic reviews (38.7%) did not contain information 
regarding the baseline age of the study populations in which the prediction models 
were developed. However, of the 19 systematic reviews which did report baseline age 
information, the majority (15, 78.9%) included persons over 60 years of age. Those not 
including persons over 60 were the four articles investigating outcomes in children. All 
but two (6.5%) of the systematic reviews (Luo et al., 2015, Smit et al., 2015) included 
prediction models with baseline populations containing frail and/or elderly populations 
and thus met this criterion. 
Criterion for competing risk bias 3: The prediction horizon is sufficiently long 
to enable competing events to occur 
Data which summarise the prediction horizons of the models identified within 
each systematic review is displayed in Table 2.3. Where information pertaining to the 
prediction horizons of the models was not reported, a summary of follow-up time was 
recorded as an alternative. The systematic reviews included prediction models with 
varying prediction horizons. Five (16.1%) failed to report prediction horizon information; 
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Information on the prediction model follow-up time was used as a proxy measure in 
three (9.7%) instances (Echouffo-Tcheugui et al., 2015, Usher-Smith et al., 2016, 
Walsh et al., 2016). Prediction models with prediction horizons of one year or greater 
were observed in 20 (64.5%) of the systematic reviews, hence met this criterion. 
Further, nine (29.0%) systematic reviews included prediction models with horizons 
which were ten years or longer. The greatest reported prediction horizon was 45 years 
(Damen et al., 2016). 
Overall assessment of the potential for competing risks bias within each 
systematic review 
Based on the three criteria for competing risks bias, an overview of the final 
assessment of the potential for competing risks bias is provided in Table 2.4. Of the 31 
systematic reviews, three (9.7%) only included prediction models with all-cause 
mortality outcomes (Criterion 1 not present). It is unlikely that competing events would 
be present in the prediction model development studies, and thus would be unlikely to 
cause bias in the conclusions of the systematic review. Therefore, these three 
systematic reviews were classified as having no potential for competing risks bias. Two 
(6.5%) of the systematic reviews included prediction models with outcomes other than 
all-cause mortality (Criterion 1 present), but which were developed in young and 
healthy populations (Criterion 2 not present). As competing events (such as death) 
occur less frequently in young, healthy populations, the potential for bias in the 
conclusions of the systematic review are small. These two systematic reviews were 
classified as having low potential for competing risks bias. Seven (22.6%) of the 
systematic reviews included prediction models with outcomes other than all-cause 
mortality (Criterion 1 present), which were developed in elderly or frail populations 
(Criterion 2 present), but with prediction time horizons less than 1 year (Criterion 3 not 
present). As shorter prediction horizons restrict large numbers of competing events 
from occurring, the potential for bias in the conclusions of the systematic review was 
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considered moderate. These seven systematic reviews were classified as having 
intermediate potential for competing risks bias. Finally, the majority (19, 61.3%) of the 
systematic review articles met all three criteria, and were thus classified as high 
potential for competing risks bias. All of the systematic reviews which included 
prediction models developed in the general population (Damen et al., 2016, Echouffo-
Tcheugui et al., 2015, Gray et al., 2016, Marques et al., 2015, Tang et al., 2015, Usher-
Smith et al., 2016) were categorised as high potential for competing risks bias. 
The 19 systematic reviews classified as high potential for competing risks bias 
are expected to contain prediction model studies in which competing events were likely 
to be present. Those nine systematic reviews classified as either low or intermediate 
may also contain prediction model studies with competing events, though the chances 
are reduced. This suggests that competing events are a major issue to consider in 
systematic reviews of prediction model research, as 26 out of 31 systematic reviews 
were classified moderate to high potential for competing risk bias being an issue. The 
presence of competing events is likely to cause bias in the conclusions made by the 
systematic reviews, if not acknowledged or appropriately accounted for. Hence, 
guidance is needed to prompt those undertaking systematic reviews to examine 
competing risks and biases within the prediction model studies included in the review. 
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Table 2.4: An assessment of the potential for competing risk bias in each systematic review 
Systematic 
review 
reference 
Criterion for competing risk 
bias 1: Prediction model 
outcomes 
Criterion for competing risk bias 2: 
Baseline populations 
Criterion for competing risk bias 
3: Prediction horizons Overall 
potential for 
competing 
risks bias 
Outcomes 
other than all-
cause 
mortality? 
Justification 
Frail or elderly 
baseline 
population? 
Justification 
Prediction 
horizon at 
least 1 year? 
Justification 
(Kohn et al., 
2015) 
No 
Only all-cause 
mortality 
outcomes. 
    None 
(Oliver et al., 
2015) 
No 
Only all-cause 
mortality 
outcomes. 
    None 
(Warnell et 
al., 2015) 
No 
Only all-cause 
mortality 
outcomes. 
    None 
(Luo et al., 
2015) 
Yes Includes other outcomes. No 
Children in general 
population have low risk 
of frailty. 
  Low 
(Smit et al., 
2015) 
Yes Includes other outcomes. No 
Children in general 
population have low risk 
of frailty 
  Low 
(Caragata et 
al., 2016) 
Yes Includes other outcomes. Yes 
Transplantation indicative 
of critical illness. No 
Short prediction 
horizon makes 
competing events 
unlikely. 
Moderate 
(Lim et al., 
2015) 
Yes Includes other outcomes. Yes 
Liver rescetion indicative 
of frail population. No 
Short prediction 
horizon makes 
competing events 
unlikely. 
Moderate 
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Systematic 
review 
reference 
Criterion for competing risk 
bias 1: Prediction model 
outcomes 
Criterion for competing risk bias 2: 
Baseline populations 
Criterion for competing risk bias 
3: Prediction horizons Overall 
potential for 
competing 
risks bias 
Outcomes 
other than all-
cause 
mortality? 
Justification 
Frail or elderly 
baseline 
population? 
Justification 
Prediction 
horizon at 
least 1 year? 
Justification 
(Mao et al., 
2015) 
Yes Includes other outcomes. Yes 
Coronary artery bypass 
grafting indicative of frail 
population. 
No 
Short prediction 
horizon makes 
competing events 
unlikely. 
Moderate 
(Meyer et al., 
2015) 
Yes Includes other outcomes. Yes 
Stroke indicative of frail 
population. No 
Short prediction 
horizon makes 
competing events 
unlikely. 
Moderate 
(Silver et al., 
2015) 
Yes Includes other outcomes. Yes 
Investigations using 
iodinated radiocontrast 
indicative of frail 
populations. 
No 
Short prediction 
horizon makes 
competing events 
unlikely. 
Moderate 
(Brunelli and 
Prefumo, 
2015) 
Yes Includes other outcomes. Yes 
First trimester 
pregnancies indicative of 
frail populations. 
Not reported 
Insufficient 
information to 
assess prediction 
horizon. 
Moderate 
(Mahajerin et 
al., 2015) 
Yes Includes other outcomes. Yes 
Patients in pediactric 
hospital indicative of frail 
population. 
Not reported 
Insufficient 
information to 
assess prediction 
horizon. 
Moderate 
(Ayerbe et 
al., 2016) 
Yes Includes other outcomes. Yes 
Chect pain indicative of 
frail population. Yes 
Prediction horizon 
sufficiently long for 
competing events 
to occur. 
High 
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Systematic 
review 
reference 
Criterion for competing risk 
bias 1: Prediction model 
outcomes 
Criterion for competing risk bias 2: 
Baseline populations 
Criterion for competing risk bias 
3: Prediction horizons Overall 
potential for 
competing 
risks bias 
Outcomes 
other than all-
cause 
mortality? 
Justification 
Frail or elderly 
baseline 
population? 
Justification 
Prediction 
horizon at 
least 1 year? 
Justification 
(Damen et al., 
2016) 
Yes Includes other outcomes. Yes 
Population includes 
elderly participants with 
increased frailty. 
Yes 
Prediction horizon 
sufficiently long for 
competing events 
to occur. 
High 
(Echouffo-
Tcheugui et 
al., 2015) 
Yes Includes other outcomes. Yes 
Population includes 
elderly participants with 
increased frailty. 
Yes 
Prediction horizon 
sufficiently long for 
competing events 
to occur. 
High 
(Ensor et al., 
2016) 
Yes Includes other outcomes. Yes 
Venous 
thromboembolism 
indicative of frail 
population. 
Yes 
Prediction horizon 
sufficiently long for 
competing events 
to occur. 
High 
(Gray et al., 
2016)  
Yes Includes other outcomes. Yes 
Population includes 
elderly participants with 
increased frailty. 
Yes 
Prediction horizon 
sufficiently long for 
competing events 
to occur. 
High 
(Haskins et 
al., 2015)  
Yes Includes other outcomes. Yes 
Population includes 
elderly participants with 
increased frailty. 
Yes 
Prediction horizon 
sufficiently long for 
competing events 
to occur. 
High 
(Hilkens et 
al., 2016) 
Yes Includes other outcomes. Yes 
Antiplatelet therapy 
indicative of frail 
population. 
Yes 
Prediction horizon 
sufficiently long for 
competing events 
to occur. 
High 
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Systematic 
review 
reference 
Criterion for competing risk 
bias 1: Prediction model 
outcomes 
Criterion for competing risk bias 2: 
Baseline populations 
Criterion for competing risk bias 
3: Prediction horizons Overall 
potential for 
competing 
risks bias 
Outcomes 
other than all-
cause 
mortality? 
Justification 
Frail or elderly 
baseline 
population? 
Justification 
Prediction 
horizon at 
least 1 year? 
Justification 
(Linsell et al., 
2016) 
Yes Includes other outcomes. Yes 
Very preterm & low birth 
weight infants indicative 
of frail population. 
Yes 
Prediction horizon 
sufficiently long for 
competing events 
to occur. 
High 
(Marques et 
al., 2015) 
Yes Includes other outcomes. Yes 
Population includes 
elderly participants with 
increased frailty. 
Yes 
Prediction horizon 
sufficiently long for 
competing events 
to occur. 
High 
(Marufu et al., 
2015) 
Yes Includes other outcomes. Yes 
Hip fractures indicative of 
elderly populations with 
increased frailty. 
Yes 
Prediction horizon 
sufficiently long for 
competing events 
to occur. 
High 
(O'Caoimh et 
al., 2015) 
Yes Includes other outcomes. Yes 
Population includes 
elderly participants with 
increased frailty. 
Yes 
Prediction horizon 
sufficiently long for 
competing events 
to occur. 
High 
(Quinlivan et 
al., 2016) 
Yes Includes other outcomes. Yes 
Self-harm & suicide 
indicative of frail 
population. 
Yes 
Prediction horizon 
sufficiently long for 
competing events 
to occur. 
High 
(Salz et al., 
2015) 
Yes Includes other outcomes. Yes 
Cancer indicative of frail 
population. Yes 
Prediction horizon 
sufficiently long for 
competing events 
to occur. 
High 
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Systematic 
review 
reference 
Criterion for competing risk 
bias 1: Prediction model 
outcomes 
Criterion for competing risk bias 2: 
Baseline populations 
Criterion for competing risk bias 
3: Prediction horizons Overall 
potential for 
competing 
risks bias 
Outcomes 
other than all-
cause 
mortality? 
Justification 
Frail or elderly 
baseline 
population? 
Justification 
Prediction 
horizon at 
least 1 year? 
Justification 
(Silverberg et 
al., 2015) 
Yes Includes other outcomes. Yes 
Traumatic brain injury 
indicative of frail 
population. 
Yes 
Prediction horizon 
sufficiently long for 
competing events 
to occur. 
High 
(Tang et al., 
2015) 
Yes Includes other outcomes. Yes 
Population includes 
elderly participants with 
increased frailty. 
Yes 
Prediction horizon 
sufficiently long for 
competing events 
to occur. 
High 
(Usher-Smith 
et al., 2016) 
Yes Includes other outcomes. Yes 
Population includes 
elderly participants with 
increased frailty. 
Yes 
Prediction horizon 
sufficiently long for 
competing events 
to occur. 
High 
(Walsh et al., 
2016) 
Yes Includes other outcomes. Yes 
Stroke indicative of frail 
population. Yes 
Prediction horizon 
sufficiently long for 
competing events 
to occur. 
High 
(Williams et 
al., 2016) 
Yes Includes other outcomes. Yes 
Cancer indicative of frail 
population. Yes 
Prediction horizon 
sufficiently long for 
competing events 
to occur. 
High 
(Wilson et al., 
2016) 
Yes Includes other outcomes. Yes 
Major surgery indicative 
of frail population. Yes 
Prediction horizon 
sufficiently long for 
competing events 
to occur. 
High 
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2.3.4 Item 3: Were competing events reported in the systematic review article? 
Despite the large potential for competing risks bias in most of the systematic 
review articles, only a few directly addressed issues related to competing events and 
their associated biases. Two (6.5%) of the included systematic review articles 
specifically mentioned the terms “competing risk” or “competing event” and both were 
considered to have high potential for competing risks bias. The first considered the 
presence of competing events (specifically deaths), and concluded the proportion of 
events “was likely to be very small… and therefore the model predictions would not 
change importantly if a competing risks model had been used” (Ensor et al., 2016). 
The other included a prediction model developed using competing risks regression 
methods (Damen et al., 2016). However, the term “competing risks” only appeared in 
an online supplementary table, and not in the published article. A single (3.2%) 
systematic review article included other key terms associated with competing events; 
the term “cumulative incidence” was used throughout the article to refer to the 
proportions of the prediction model study populations that had asthma (Smit et al., 
2015), and was thus not used in a competing risks context. Finally, three (9.7%) 
systematic reviews included or discussed Kaplan-Meier curves to display risk groups 
as a method for assessing model calibration (Ensor et al., 2016, Salz et al., 2015, 
Walsh et al., 2016). All three were considered to have high potential for competing 
risks bias, and so Kaplan-Meier curves are potentially misleading. 
2.3.5 Item 4: Was competing risks part of the quality assessment performed 
within the systematic review? 
The majority (29, 93.5%) of the systematic reviews reported performing a quality 
assessment of the included prediction model studies. A range of quality assessment 
tools were reported, details are given in Table 2.5. 
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Table 2.5: Quality assessment tools from systematic review articles 
Systematic review reference Quality Assessment Tool 
Ayerbe et al., 2016 QUADAS (Whiting et al., 2003) 
Brunelli and Prefumo, 2015 
Collins criteria (Collins et al., 2011, Collins et 
al., 2013) 
Caragata et al., 2016 None reported 
Damen et al., 2016 CHARMS (Moons et al., 2014) 
Echouffo-Tcheugui et al., 2015 Authors own 
Ensor et al., 2016 PROBAST (Wolff et al., 2019) 
Gray et al., 2016 Authors own 
Haskins et al., 2015 QUIPS (Hayden et al., 2013) & Authors own 
Hilkens et al., 2016 CHARMS (Moons et al., 2014) 
Kohn et al., 2015 QUADAS-2 (Whiting et al., 2011) 
Lim et al., 2015 QUIPS (Hayden et al., 2013) 
Linsell et al., 2016 QUIPS (Hayden et al., 2013) 
Luo et al., 2015 CASP (2017) 
Mahajerin et al., 2015 None reported 
Mao et al., 2015 Authors own 
Marques et al., 2015 QUADAS (Whiting et al., 2003) 
Marufu et al., 2015 Altman framework (Altman, 2001) 
Meyer et al., 2015 QUIPS (Hayden et al., 2013) 
O'Caoimh et al., 2015 QUIPS (Hayden et al., 2013) 
Oliver et al., 2015 Altman framework (Altman, 2001) 
Quinlivan et al., 2016 
QUADAS (Whiting et al., 2003) & STARD 
(Bossuyt et al., 2003) 
Salz et al., 2015 Authors own 
Silver et al., 2015 QUIPS (Hayden et al., 2013) 
Silverberg et al., 2015 Authors own 
Smit et al., 2015 CHARMS (Moons et al., 2014) 
Tang et al., 2015 Newcastle-Ottowa scale (GA Wells, 2014) 
Usher-Smith et al., 2016 TRIPOD (Collins et al., 2015) 
Walsh et al., 2016 McGinn criteria (McGinn et al., 2000) 
Warnell et al., 2015 QUIPS (Hayden et al., 2013) 
Williams et al., 2016 CASP (2017) 
Wilson et al., 2016 TRIPOD (Collins et al., 2015) 
 
The most commonly used tool for assessment of the prediction model 
development studies was the Quality in Prognosis Studies (QUIPS) tool (Hayden et 
al., 2013), which was reportedly utilised in seven (22.6%) of the systematic reviews. 
This was followed by the Quality Assessment of Diagnostic Accuracy Studies 
(QUADAS) tool (Whiting et al., 2003, Whiting et al., 2011), used in four (12.9%) of the 
systematic reviews. A number of authors (6, 19.4%) developed their own tools or 
criteria for quality assessment, whereas four others (12.9%) replicated or amended 
tools employed in similar reviews (Altman, 2001, Collins et al., 2011, Collins et al., 
 86 
2013, McGinn et al., 2000). Two (6.5%) systematic review articles did not report 
performing a quality assessment of the included prediction model studies. 
Each of the listed quality assessment tools was examined to determine whether 
the assessment of competing events was directly advised. The PROBAST tool (Wolff 
et al., 2019), explicitly mentions competing risks in the context of the analysis of 
complexities in the data. None of the other tools explicitly refer to competing events 
and the associated biases. This may be because the other tools are not specific to 
prediction model research, and rather focus on prognostic factor research (QUIPS) 
and diagnostic tests (QUADAS). The PROBAST tool was rarely used in the systematic 
review articles identified as it was only formally released in 2019. 
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2.4 Discussion 
In this chapter, an evaluation of the presence and reporting of competing events 
in 31 systematic reviews of prediction model studies was conducted. A classification 
system for the risk of competing risks bias was developed and applied to each 
systematic review. The key findings and conclusions of this evaluation are summarised 
in Box 2.1 and discussed below. 
Box 2.1: Key findings 
1. Competing events are often present in the prediction models contained within 
systematic reviews of prediction model studies. 
2. Systematic reviews of prediction model studies rarely report the presence or 
assessment of competing risks. 
3. A wide variety of quality assessment tools are utilised in systematic reviews of 
prediction models studies, few consider competing risks. 
 
2.4.1 Key findings 
The key findings of this evaluation are presented and discussed in more detail 
below: 
2.4.1.1 Competing events are often present in the prediction models contained 
within systematic reviews of prediction model studies. 
Of the 31 systematic reviews evaluated, 90.3% were found to include prediction 
models with outcomes other than all-cause mortality, making them susceptible to 
competing events. Further, 61.3% were classified as having high potential for 
competing risks bias, when the prediction model outcome, baseline population, and 
prediction horizon were considered. This suggests that competing events are 
commonly present in prediction model development studies, and competing risks bias 
will often be a potential concern for systematic reviews of these studies. Consequently, 
the competing events should be acknowledged and examined in systematic reviews 
of prediction model studies. 
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2.4.1.2 Systematic reviews of prediction model studies rarely report the 
presence or assessment of competing risks. 
Despite the high potential for competing events in prediction model studies, few 
systematic reviews reported or assessed issues related to competing risks in the 
published articles. Only two (6.5%) of the systematic review articles evaluated directly 
reported on competing risks. If the statistical methods used to develop prediction 
models are not appropriate for the complexities of the data, the estimated predictive 
performance of the model may be biased (Moons et al., 2015). Not reporting the 
presence of competing risks could result in biases in the conclusions made by the 
systematic reviews. 
2.4.1.3 A wide variety of quality assessment tools are utilised in systematic 
reviews of prediction models studies, but few consider competing risks 
This evaluation identified a number of quality assessment tools currently being 
used to assess prediction model studies in systematic reviews. The array and 
inconsistency of quality assessment tools used by the included systematic reviews 
highlights the absence of agreed quality criteria for assessing the risk of bias in 
prognostic modelling studies. However, the Prediction study Risk Of Bias Assessment 
Tool (PROBAST) has recently been developed to address this issue. This was the only 
quality assessment tool used by the systematic reviews which explicitly referred to 
competing events. The tool directly refers to competing risks when considering the risk 
of bias in the analysis of the prediction mode study: “Were complexities in the data 
(e.g., censoring, competing risks, sampling of control participants) accounted for 
appropriately?” (Wolff et al., 2019). This tool was released in 2019, and so it hopefully 
will help to improve the assessment of competing risks bias in future systematic 
reviews of prediction model studies. 
2.4.2 Limitations and further research 
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To the author’s knowledge, this is the largest evaluation of competing events in 
systematic reviews of prediction model studies. The evaluation highlights the high 
presence of competing events in prediction model research, motivating the need to 
consider competing events in systematic reviews which aim to evaluate such studies. 
Nevertheless, the evaluation does not encompass all systematic reviews of prediction 
model studies. The systematic reviews which were not considered, due to not meeting 
inclusion criteria, may differ to those evaluated. For example, inclusion of studies 
containing the terms “systematic review” or “meta-analysis” in the article title is likely 
to identify systematic review conforming to the PRISMA reporting guidelines. However, 
reviews which follow reporting guidelines may be of better quality, or at least report on 
more key items, than those which do not. 
The classification system used to assess the potential for competing risk bias was 
developed by combining criteria from articles which similarly aimed to assess the 
presence of competing risks bias in other settings (Austin and Fine, 2017, Koller et al., 
2012, Schumacher et al., 2016, Walraven and McAlister, 2016). Criteria thought to be 
applicable to prediction model studies, and likely to be reported in the systematic 
review articles, were selected. Criteria discussed in the articles but not included in the 
classification system include: the reporting of Kaplan-Meier estimates and assessing 
the number and proportion of competing events. These were not included as criteria in 
the classification system as it was thought these would not typically be reported in 
systematic review articles. The tool was developed to pragmatically determine whether 
competing events were likely to be present in the included prediction model studies, 
as it was considered beyond the scope of the thesis to obtain individual study data for 
all included studies to determine whether competing events were truly present. Further, 
the presence of competing events in a prediction model study does not necessarily 
imply that the study contains competing risks bias. If a study identifies the competing 
events and appropriately accounts for these, for example, through competing risks 
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regression analysis, then no such bias will be observed. It is suspected by the author 
that appropriate methods are rarely utilised in prediction model research, and thus the 
presence of competing events is likely to be indicative of competing risks bias. Thus 
further research to determine whether competing events were indeed present, and 
investigating the management of these competing events, is required. 
The following chapter describes a review which investigates the presence, 
reporting, and management of competing events in prediction model studies classified 
as high potential for competing risks bias, i.e. the most susceptible to competing risks 
bias. 
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3 A REVIEW INTO THE PRESENCE, REPORTING AND 
MANAGEMENT OF COMPETING EVENTS IN 
PREDICTION MODEL DEVELOPMENT STUDIES 
3.1 Introduction 
The previous chapter established that competing events and their associated 
biases are often a potential concern in systematic reviews of prediction model studies; 
yet these are rarely considered. To emphasise why the issue of competing risks bias 
should be addressed in future systematic reviews, it is necessary to further investigate 
the magnitude of competing events and their biases at the primary study (rather than 
systematic review) level, i.e. within prediction model development studies. Therefore, 
this chapter provides a detailed assessment of the presence, reporting, and 
management of competing events in prediction model development studies. 
3.1.1 Aims 
The aim of this chapter is to review how prediction model development studies 
handle competing events in clinical settings where competing events are a likely issue. 
Specifically, this review will: 
• Investigate the potential for competing risks bias in each individual prediction 
model developed within the prediction model studies. 
• Explore how competing events are managed within prediction model development 
studies. 
• Determine whether competing events, and their associated biases, are reported in 
the published prediction model study articles. 
3.2 Methods: Review of prediction model development studies 
 92 
3.2.1 Strategy for searching and selecting relevant prediction model study 
articles 
This review focused on published prediction model study articles which describe 
the development of prediction models in clinical settings where competing events are 
a likely issue. The prediction model development studies were identified from a subset 
of systematic review articles identified in Chapter 2. Initially, the systematic reviews 
examined in Chapter 2 were screened to ascertain which were likely to contain 
prediction models affected by competing events. Consequently, only those 19 
systematic reviews categorised with a high potential for competing risk bias were 
considered. An additional list of diseases and population characteristics, suggested to 
identify populations which are susceptible to competing events (Koller et al., 2012), 
presented in Table 3.1, was applied to further reduce the subset of systematic reviews. 
Table 3.1: List of diseases and populations susceptible to competing events 
Diseases and population characteristics 
Atrial fibrillation; cardiac failure; coronary heart disease; stroke; aneurysm; prostate cancer; 
colorectal cancer; breast cancer; chronic leukaemia; cancer screening; critical care; 
transplant; chronic obstructive pulmonary disease; elderly patients (aged 65+ years). 
 
The full-text articles of all prediction model studies examined within the selected 
systematic reviews were obtained. Prediction model studies were only considered 
suitable for inclusion to this review if they met the following criteria: 
1. Described the development of a prediction model; and 
2. Applied time-to-event analysis methods to develop the prediction model; and 
3. Had a clinical setting which reflects at least one of the disease and population 
characteristics listed in Table 3.1. 
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These criteria led to the exclusion of prediction model studies which: 
1. Only identified individual prognostic factors without combining to develop a 
prediction model; or 
2. Only validated existing prediction models without developing new models; or 
3. Only developed diagnostic, and not prediction, models; or 
4. Only used analysis methods other than time-to-event regression, to develop 
prediction models; or 
5. Had a clinical setting not considered to be susceptible to competing events. 
Conference abstracts were excluded as they contained insufficient detail of the 
prediction model study for meaningful review. 
3.2.2 Data extraction 
Relevant information from the included prediction model studies was extracted 
from the published articles and compiled by the first reviewer (LT) using a data 
extraction form (Appendix III). A second reviewer (KS) independently extracted 
information from a third of the included prediction model studies. Any discrepancies 
between the data extracted by the two reviewers were resolved by discussion between 
the reviewers (LT and KS). Information was extracted and then narratively summarised 
in regards to four key items, as outlined below: 
3.2.2.1 Item 1: What were the characteristics of each prediction model study? 
Information regarding the number of individual prediction models developed 
within each prediction model study was recorded, as well as the source of the study 
data (e.g. randomised trial, cohort, or nested case-control) and the total number of 
participants included in the study. 
3.2.2.2 Item 2: What is the potential for competing risks bias affecting each 
individual prediction model? 
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The reported characteristics of each individual prediction model developed within 
each prognostic model study were examined using the same criteria and classification 
system as developed in Chapter 2. This classification system evaluates the prediction 
model outcome, baseline population, and prediction horizon in turn and combines the 
results using the process summarised in Figure 2.1. Again, where specific prediction 
horizons were not reported, the maximum reported follow-up time was recorded as an 
alternative. 
A list of potential competing events likely to prevent the prediction model outcome 
from occurring was compiled for each prediction model study. Mortality was considered 
a potential competing event for all individual prediction models predicting outcomes 
other than all-cause mortality. Potential competing events were additionally determined 
through examination of the published prediction model study articles for the mention 
of any events likely to prevent the prediction model events. Further, potential 
competing events listed for individual prediction models with similar outcomes were 
compared and added to. 
3.2.2.3 Item 3: Were competing events reported in the published prediction 
model study articles? 
The reporting of competing events was examined for the individual prediction 
models considered to have potential for competing risks bias (classified as low, 
moderate, or high in Item 2). Information was extracted on the following: 
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1. The number of prediction model events; 
2. The number of reported competing events; 
3. The proportion of all reported events which were competing events; 
4. The presence of key terms related to competing events (as listed in Table 2.2); 
5. Whether Kaplan-Meier curves are presented or discussed; 
6. The number of prognostic factors included in the final prediction models; and 
7. Any prognostic factors considered to be associated with the competing events. 
It has been demonstrated that the level of competing risks bias is strongly 
associated with the proportion of all observed outcomes that are competing events 
(Berry et al., 2010, Schumacher et al., 2016, van Walraven and Hawken, 2016, 
Wolkewitz et al., 2014). Thus this information was extracted. A search of key terms 
related to competing events (Table 2.2) was conducted using the Adobe Acrobat 
Reader DC Find function. References to, and depictions of, Kaplan-Meier curves were 
investigated, as these estimates of absolute risk over time are known to be inflated 
when competing events are present. Finally, the number of prognostic factors included 
in the final models, as well as whether these are likely to be associated with competing 
events, were considered. It has been demonstrated that associations between 
predictors (such as prognostic factors) and outcomes can change importantly when 
competing events are appropriately accounted for (Berry et al., 2010, Dignam et al., 
2012, Schatzkin and Slud, 1989, Wolkewitz et al., 2014). Appropriately accounting for 
competing events can alter the magnitude, and in some cases the direction, of the 
estimated association, particularly when the predictors are strongly associated with the 
competing event (Berry et al., 2010, Schatzkin and Slud, 1989). Prognostic factors 
shown to be associated with mortality (anticipated to be a common potential competing 
event) include age and numerous comorbidities; defined in this instance as chronic 
diseases or disorders listed in the Charlson comorbidity index (Charlson et al., 1987), 
listed in Table 3.2. 
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Table 3.2: Comorbidities listed in the Charlson comorbidity index 
Conditions included in Charlson comorbidity index 
Myocaridal infarct, Congestive heart failure, peripheral vascular disease, cerebrovascular 
disease, dementia, chronic pulmonary disease, connective tissue disorder, ulcer disease, 
mild liver disease, diabetes, hemiplegia, moderate or severe renal disease, diabetes with 
end organ damage, any tumour, leukemia, lymphoma, modersate or severe liver disease, 
matastatic solid tumor, AIDS. 
 
3.2.2.4 Item 4: How were competing events managed in each prediction model 
study? 
Information regarding how competing events were managed within each 
prediction model study was examined. Specifically: 
1. Whether statistical regression methods which appropriately account for competing 
events, were employed to develop the individual prediction models; 
2. Whether participants who experienced competing events were excluded from the 
study; 
3. Whether participants who experienced competing events were censored at the 
point of experiencing the competing events; 
4. whether participants who experienced competing events were managed in any 
other way; 
5. Whether the study also included the validation of the individual prediction models; 
and 
6. How competing events were managed during the validation process. 
3.2.3 Analysis methods 
For this review, a narrative synthesis of the information extracted from the 
prediction model studies was conducted. The preliminary synthesis consisted of 
tabulation and textual descriptions of the extracted information. 
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3.3 Results: Review of prediction model development studies 
3.3.1 Search and selection of relevant prediction model studies and individual 
prediction models 
A flow diagram depicting the selection process for prediction model development 
studies included in this review is provided in Figure 3.1. 
Figure 3.1: Flow diagram of prediction model study article selection process for 
this review 
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The initial selection criteria identified six systematic reviews with high potential 
for competing risks bias and with population characteristics that were susceptible to 
competing events. Further information on reasons to include/exclude these systematic 
reviews is provided in Appendix IV. The six included systematic reviews contained 107 
prediction model studies which developed a total of 88 individual prediction models. All 
107 published prediction model study articles were screened, and 15 (14.0%) were 
identified as eligible for this review base on the five criteria listed in Section 3.2.1. 
Further information on reasons to include/exclude these prediction model studies is 
provided in Appendix VI. A summary of the 15 included prediction model articles that 
were identified from the 6 included systematic reviews is provided in Table 3.3. The 
extracted information for items 1 to 4 are now summarised for the 15 models. 
Table 3.3: Prediction model development articles included in this review 
Systematic review 
reference 
Total number 
of prediction 
model studies 
Total number 
of individual 
prediction 
models 
Prediction model studies 
included in this review 
(Ayerbe et al., 2016) 12 13 (Sekhri et al., 2008) 
(Hilkens et al., 2016) 5 5 (Ariesen et al., 2006)  (Cuschieri et al., 2014) 
(O'Caoimh et al., 2015) 46 23 (Carey et al., 2008) (Schonberg et al., 2009)  
(Salz et al., 2015) 14 14 
(Bevilacqua et al., 2012) 
(Briganti et al., 2010) 
(Ezaz et al., 2014) 
(Kovalchik et al., 2012) 
(Mathieu et al., 2014) 
(Romond et al., 2012) 
(Travis et al., 2005) 
(Walsh et al., 2016) 12 18 (Nakagawa et al., 2008) (Nyberg and Gustafson, 1997) 
(Williams et al., 2016) 18 15 (Hippisley-Cox and Coupland, 2012) 
 
3.3.2 Item 1: What were the characteristics of each prediction model study? 
The characteristics of the 15 included prediction model studies are summarised 
in Appendix VI. In brief, the majority of the prediction model studies (9, 60.0%) develop 
one individual prediction model; only two studies (13.3%) developed two models, and 
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four studies (26.7%) developed three models. Most prediction model studies (11, 
73.3%) used cohort study data to develop the prediction models. Two (13.3%) 
prediction model studies used data from nested case-control studies to develop 
prediction models, one (6.7%) study used only randomised controlled trial (RCT) data, 
and another (6.7%) used a combination of cohort and RCT data. The total number of 
participants included in the prediction model studies ranged from 135 to 3,587,653 
participants. A number of prediction model studies used bootstrap resampling for 
model validation (Ariesen et al., 2006, Bevilacqua et al., 2012, Briganti et al., 2010, 
Cuschieri et al., 2014, Romond et al., 2012). Others opted to split the study participants 
into development and validation cohorts (Carey et al., 2008, Ezaz et al., 2014, 
Hippisley-Cox and Coupland, 2012, Schonberg et al., 2009), while one (Kovalchik et 
al., 2012) sought out additional participants to externally validate the prediction models. 
3.3.3 Item 2: What is the potential for competing risks bias affecting each 
individual prediction model? 
The potential for competing risks bias was assessed for each of the 25 individual 
prediction models identified in the 15 prediction model studies. Information relating to 
three criteria (prediction model outcome, baseline population, and prediction horizon) 
were extracted for each individual prediction model and are presented in Table 3.4. 
Each of the criteria were assessed independently prior to being combined to determine 
the overall potential for competing risks bias. The results are summarised below. 
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Table 3.4: The potential for competing risk bias in included individual prediction models developed in the prediction model studies 
Prediction 
model study 
reference 
Model 
Criterion for competing risk bias 1: 
Prediction model outcome 
Criterion for competing risk bias 2: 
Baseline populations 
Criterion for 
competing risk 
bias 3: Prediction 
horizons 
Outcomes of the 
prediction models 
Does outcome 
contain all-
cause 
mortality? 
Disease and health 
state of prediction 
model population 
Population age 
at baseline 
Prediction horizon 
of prediction 
model 
(Sekhri et al., 
2008) 
Resting ECG 
model 
Death due to coronary 
heart disease or non-fatal 
acute coronary syndrome 
No Suspected angina 
Mean 55 (SD 
13) years 
6 years 
Summary 
exercise ECG 
model 
Mean 55 (SD 
13) years 
Detailed 
exersize ECG 
model 
Mean 54 (SD 
11) years 
(Ariesen et al., 2006) 
Intracerebral 
haemorrhage No 
Patients with ischaemic 
stroke or transient 
ischemic attack 
Mean 64 (SD 
10) years* Up to 5 years
¥ 
(Cuschieri et al., 2014) 
Acute gastrointestinal (GI) 
bleeding No 
Patients with myocardial 
infarction & prescribed 
clopidogrel 
GI bleed:Mean 
66.2 (SD 10.4) 
years 
No GI bleed: 
Mean 62.4 (SD 
9.9) years 
Up to 8 years¥ 
(Carey et al., 2008) All-cause mortality Yes 
Community living frail 
elderly people with long-
term care needs 
Mean 79 (SD 9) 
years Up to 6 years
¥ 
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Prediction 
model study 
reference 
Model 
Criterion for competing risk bias 1: 
Prediction model outcome 
Criterion for competing risk bias 2: 
Baseline populations 
Criterion for 
competing risk 
bias 3: Prediction 
horizons 
Outcomes of the 
prediction models 
Does outcome 
contain all-
cause 
mortality? 
Disease and health 
state of prediction 
model population 
Population age 
at baseline 
Prediction horizon 
of prediction 
model 
(Schonberg et al., 2009) 5-year mortality Yes Community dwelling adults aged 65 and older 
65-69: 26.6% 
70-74: 26.6% 
75-79: 21.9% 
80-84: 14.6% 
85+: 10.4% 
5 years 
(Bevilacqua et 
al., 2012) 
Preoperative 
model 
Lymphedema No 
Axillary lymph node 
dissection in breast 
cancer 
≤55 years:  
582 (55.2%) 
>55 years:  
472 (44.8%) 
5 years Within 6 months model 
6 months or 
later model 
(Briganti et al., 2010) Erectile function recovery No 
Prostate cancer treated 
with bilateral nerve 
sparing prostsectomy 
Mean: 61.9 
years 
Median: 62 
years 
3 years 
(Ezaz et al., 2014) 
Heart failure and 
cardiomyopathy No 
Patients receiving 
adjuvant trastuzumab 
therapy for early-stage 
breast cancer 
Mean 73.6 (SD 
5.3) years 3 years 
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Prediction 
model study 
reference 
Model 
Criterion for competing risk bias 1: 
Prediction model outcome 
Criterion for competing risk bias 2: 
Baseline populations 
Criterion for 
competing risk 
bias 3: Prediction 
horizons 
Outcomes of the 
prediction models 
Does outcome 
contain all-
cause 
mortality? 
Disease and health 
state of prediction 
model population 
Population age 
at baseline 
Prediction horizon 
of prediction 
model 
(Kovalchik et 
al., 2012) 
Self reported 
risk factor 
model 
Second primary thyroid 
cancer No 
Survivors of childhood 
cancers 
<5 years: 41% 
5-9 years: 22% 
10-14 years: 
20% 
15+ years: 18% 
20 years 
Medical record 
abstraction 
model 
All available 
information 
model 
(Mathieu et al., 
2014) 
Urinary toxicity 
model 
Global urinary toxicity 
grade ≥2 No 
Prostate cancer 
radiotherapy 
Mean: 68 years 
Range: 45 to 83 
years 
5 years Urinary frequency 
model 
Urinary frequency grade 
≥2 No 
Dsuria model Dysuria grade ≥2 No 
(Romond et al., 2012) 
Severe congestive heart 
failure or cardiac death No 
Patients with node-
positive breast cancer Mean 49 years 5 year 
(Travis et al., 
2005) 
Without 
counselling 
model Breast cancer No Young women treated for Hodgkin’s lymphoma 
Mean: 22 years 
Median: 22 
years 
30 years 
With counselling 
model 
(Nakagawa et al., 2008) Falls No 
Stroke inpatients in 
convalescent 
rehabilitation wards 
Mean 69.7 (SD 
12.1) years 180 days
¥ 
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Prediction 
model study 
reference 
Model 
Criterion for competing risk bias 1: 
Prediction model outcome 
Criterion for competing risk bias 2: 
Baseline populations 
Criterion for 
competing risk 
bias 3: Prediction 
horizons 
Outcomes of the 
prediction models 
Does outcome 
contain all-
cause 
mortality? 
Disease and health 
state of prediction 
model population 
Population age 
at baseline 
Prediction horizon 
of prediction 
model 
(Nyberg and Gustafson, 1997) Falls No Patients in stroke rehabilitation 
Mean 74.8 (SD 
8.9) years 56 days
¥ 
(Hippisley-Cox 
and Coupland, 
2012) 
Female model 
Colorectal cancer No 
Women with suspected 
colorectal cancer Mean 50.1 (SD 
15.0) years 2 years Male model Men with suspected colorectal cancer 
*Information gained from appendix or supplementary material. 
¥Follow-up measure given as prediction horizon not directly reported in article. 
ECG = Electrocardiogram 
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Criterion for competing risk bias 1: The prediction model investigates 
outcomes other than all-cause mortality 
As mentioned, it is fundamental to consider prediction model outcomes when 
assessing for the risk of competing risks bias. Individual prediction models which 
predict the risk of all-cause mortality are unlikely to contain competing events, as few 
events can prevent the occurrence of death. Information on outcomes predicted by the 
individual prediction models is displayed in Table 3.4. All-cause mortality was the 
outcome for two (8.0%) individual prediction models, developed in two prediction 
model studies (Carey et al., 2008, Schonberg et al., 2009). The remaining 23 (92.0%) 
individual prediction models, developed in 13 prediction model studies, predicted 
outcomes other than all-cause mortality, hence met this criterion. 
Criterion for competing risk bias 2: The baseline population contains frail 
and/or elderly populations 
The susceptibility of the prediction model study populations is important when 
assessing the risk of competing risks bias. Competing events are more likely to be 
present in individual prediction models developed in elderly and frail populations, thus 
the models have an increased risk of competing risks bias. Summary information of 
the baseline populations used to develop each individual prediction model is displayed 
in Table 3.4. All of the individual prediction models were either developed in frail 
populations, such as those with or surviving cancer (16, 64.0% models from 8, 53.3% 
prediction model studies), or were developed in populations which included persons 
over 60 years of age (20, 80% models from 13, 86.7% prediction model studies). Thus, 
all included prediction models met this criterion. 
Criterion for competing risk bias 3: The prediction horizon is sufficiently long 
to enable competing events to occur 
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Assessing the duration of the prediction horizon can help to determine the risk of 
competing risks bias, as a longer prediction horizon enables a greater number of 
competing events to occur. Thus individual prediction models with long prediction 
horizons have an increased risk of competing risks bias. Information summarizing the 
prediction horizons of the individual prediction models is provided in Table 3.4. Two 
(8.0%) individual prediction models, developed in two (13.3%) prediction model 
studies, had prediction horizons shorter than a year; these models made predictions 
at 56 and 180 days (Nakagawa et al., 2008, Nyberg and Gustafson, 1997). The 
remaining individual prediction models (23, 92.0% models developed in 13, 86.7% 
prediction model studies) had prediction horizons over 1 year, thus met this criteria. 
Five (20%) of the individual prediction models, developed in two (13.3%) prediction 
model studies, made predictions after 20 and 30 years (Kovalchik et al., 2012, Travis 
et al., 2005). 
Overall assessment of the potential for competing risks bias within each 
individual prediction model 
The three criteria, discussed in detail above, were examined and an assessment 
of the potential for competing risks bias in each individual prediction model was 
performed. An overview of the final classification of the individual prediction models is 
presented in Table 3.5.Only two (8.0%) of the individual prediction model studies 
predicted all-cause mortality outcomes (Criterion 1 not present) (Carey et al., 2008, 
Schonberg et al., 2009). As it is unlikely that competing events would prevent the 
occurrence of all-cause mortality, these individual prediction models were categorised 
as no potential for competing risks bias. The remaining 23 (92.0%) individual prediction 
models predicted outcomes other than all-cause mortality (Criterion 1 present), and 
were developed in populations that were considered to be frail and elderly (Criterion 2 
present). Two (8.0%) of these individual prediction models, from two (13.3%) prediction 
model studies (Nakagawa et al., 2008, Nyberg and Gustafson, 1997), had prediction 
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horizons which were less than 1 year (Criterion 3 not present). These prediction 
horizons were considered to be sufficiently short to reduce the likelihood of competing 
events, and thus these prediction models were categorised as moderate potential for 
competing risk bias. Finally, the majority (21, 84.0% models from 11, 73.3% prediction 
model studies) of the individual prediction models met all three criteria, and were 
classified as high potential for competing risks bias. 
The 21 (84.0%) individual prediction models classified as high potential for 
competing risks bias are likely to have been developed in the presence of competing 
events. Thus, in the sample evaluated, a large majority were susceptible to competing 
risks bias affecting their prediction model development. 
Potential competing events for each prediction model study 
A list of potential competing events likely to prevent the prediction model 
outcomes from occurring is provided in Appendix VII. In brief, potential competing 
events were identified for all but two (13.3%) of the prediction model studies; as these 
only contained individual prediction models which predicted all-cause mortality (Carey 
et al., 2008, Schonberg et al., 2009). Mortality was identified as a potential competing 
event for the remaining 13 (86.7%) prediction model studies. Further potential 
competing events included; complete immobility, as immobility significantly alters the 
risk of falling; removal of the thyroid gland, as this eradicates the risk of recurrent 
thyroid cancer; and recurrence of the primary cancer or development of a secondary 
cancer, as these events would meaningfully alter the risk of any future cancer events 
from occurring. 
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Table 3.5: An assessment of the potential for competing risk bias in each individual prediction model 
Prediction 
model study 
reference 
Model 
Criterion for competing 
risk bias 1: Prediction 
model outcomes 
Criterion for competing risk 
bias 2: Baseline populations 
Criterion for competing risk bias 
3: Prediction horizons 
Overall 
potential 
for 
competing 
risks bias 
Outcomes 
other than 
all-cause 
mortality? 
Justification 
Frail or 
elderly 
baseline 
population? 
Justification 
Prediction 
horizon at 
least 1 
year? 
Justification 
(Carey et al., 2008) No 
All-cause 
mortality 
outcome 
    None 
(Schonberg et al., 2009) No 
All-cause 
mortality 
outcome 
    None 
(Nakagawa et al., 2008) Yes Other outcome Yes Stroke indicative of frail population No 
Short prediction 
horizon makes 
competng events 
unlikely 
Moderate 
(Nyberg and Gustafson, 1997) Yes Other outcome Yes Stroke indicative of frail population No 
Short prediction 
horizon makes 
competing events 
unlikely 
Moderate 
(Sekhri et al., 
2008) 
Resting ECG 
model 
Yes Other outcome Yes Angina indicative of frail population Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
Summary 
exercise ECG 
model 
Yes Other outcome Yes Angina indicative of frail population Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
Detailed 
exersize ECG 
model 
Yes Other outcome Yes Angina indicative of frail population Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
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Prediction 
model study 
reference 
Model 
Criterion for competing 
risk bias 1: Prediction 
model outcomes 
Criterion for competing risk 
bias 2: Baseline populations 
Criterion for competing risk bias 
3: Prediction horizons 
Overall 
potential 
for 
competing 
risks bias 
Outcomes 
other than 
all-cause 
mortality? 
Justification 
Frail or 
elderly 
baseline 
population? 
Justification 
Prediction 
horizon at 
least 1 
year? 
Justification 
(Ariesen et al., 2006) Yes Other outcome Yes Stroke indicative of frail population Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
(Cuschieri et al., 2014) Yes Other outcome Yes 
Myocardial 
infarction 
indicative of frail 
population 
Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
(Bevilacqua et 
al., 2012) 
Preoperative 
model 
Yes Other outcome Yes Cancer indicative of frail population Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
Within 6 
months 
model 
Yes Other outcome Yes Cancer indicative of frail population Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
6 months or 
later model 
Yes Other outcome Yes Cancer indicative of frail population Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
(Briganti et al., 2010) Yes Other outcome Yes Cancer indicative of frail population Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
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Prediction 
model study 
reference 
Model 
Criterion for competing 
risk bias 1: Prediction 
model outcomes 
Criterion for competing risk 
bias 2: Baseline populations 
Criterion for competing risk bias 
3: Prediction horizons 
Overall 
potential 
for 
competing 
risks bias 
Outcomes 
other than 
all-cause 
mortality? 
Justification 
Frail or 
elderly 
baseline 
population? 
Justification 
Prediction 
horizon at 
least 1 
year? 
Justification 
(Ezaz et al., 2014) Yes Other outcome Yes Cancer indicative of frail population Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
(Kovalchik et 
al., 2012) 
Self reported 
risk factor 
model 
Yes Other outcome Yes Cancer indicative of frail population Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
Medical 
record 
abstraction 
model 
Yes Other outcome Yes Cancer indicative of frail population Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
All available 
information 
model 
Yes Other outcome Yes Cancer indicative of frail population Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
(Mathieu et al., 
2014) 
Urinary 
toxicity model 
Yes Other outcome Yes Cancer indicative of frail population Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
Urinary 
frequency 
model 
Yes Other outcome Yes Cancer indicative of frail population Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
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Prediction 
model study 
reference 
Model 
Criterion for competing 
risk bias 1: Prediction 
model outcomes 
Criterion for competing risk 
bias 2: Baseline populations 
Criterion for competing risk bias 
3: Prediction horizons 
Overall 
potential 
for 
competing 
risks bias 
Outcomes 
other than 
all-cause 
mortality? 
Justification 
Frail or 
elderly 
baseline 
population? 
Justification 
Prediction 
horizon at 
least 1 
year? 
Justification 
Dsuria model Yes Other outcome Yes Cancer indicative of frail population Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
(Romond et al., 2012) Yes Other outcome Yes Cancer indicative of frail population Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
(Travis et al., 
2005) 
Without 
counselling 
model 
Yes Other outcome Yes Cancer indicative of frail population Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
With 
counselling 
model 
Yes Other outcome Yes Cancer indicative of frail population Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
(Hippisley-Cox 
and Coupland, 
2012) 
Feamle model Yes Other outcome Yes Cancer indicative of frail population Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
Male model Yes Other outcome Yes Cancer indicative of frail population Yes 
Prediction horizon 
sufficiently long for 
competing events to 
occur 
High 
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3.3.4 Item 3: Were competing events reported in the published prediction 
model study articles? 
Information about the reporting of competing events in the published prediction 
model study articles are reported by individual prediction models in Table 3.6. The 
observed number of prediction model events was reported for all but one of the 
individual prediction models (Carey et al., 2008). However, numbers of observed 
competing events were not reported for the majority of the individual prediction models 
(15, 60.0% models from 11, 73.3% prediction model studies); though competing events 
were not expected to be present for two of these (Carey et al., 2008, Schonberg et al., 
2009). The number of competing events was reported (either partially or fully) for ten 
(40.0%) individual prediction models from four (26.7%) prediction model studies 
(Bevilacqua et al., 2012, Kovalchik et al., 2012, Nyberg and Gustafson, 1997, Sekhri 
et al., 2008). The proportion of the total number of events which were competing events 
was calculated for these individual prediction models; this proportion was found to 
range from 12.5% to 94.0%. The proportion of all observed events which are competing 
has been shown to be positively associated with the amount of competing risk bias 
(van Walraven and Hawken, 2016), thus confirming the importance of appropriately 
accounting for competing events in prediction model studies. 
Kaplan-Meier curves were presented and discussed in 11 (73.3%) prediction 
model studies, which developed 16 (64.0%) individual prediction models. In the 
presence of competing events Kaplan-Meier estimates are known to be inflated, thus 
almost three-quarters of the prediction model studies are likely to have reported 
inflated absolute risk estimates. 
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Table 3.6: Reporting of competing events in published prediction model study articles assessed for each individual prediction model 
Prediction 
model study 
reference 
Model 
Reported number of events 
Key competing 
risks terms 
Prognostic factors 
Prediction 
model 
events 
Competing 
events 
Total 
observed 
events 
Proportion 
competing 
events 
Terms 
used 
Kaplan-
Meier 
curves  
Number 
in final 
model 
Associated with 
mortality 
(Sekhri et al., 
2008) 
Resting ECG 
model 
576 (7%) 
Deaths not 
reported; 
465 (6%) 
PTCA or 
CABG 
1,041 44.7% 
No No 
7 Age, diabetes 
Summary 
exercise ECG 
model 
351 (7%) 
Deaths not 
reported; 
354 (7%) 
PTCA or 
CABG 
705 50.2% 9 Age, diabetes 
Detailed 
exercise ECG 
model 
110 (8%) 
Deaths not 
reported; 
87 (6%) 
PTCA or 
CABG 
197 44.2% 9 Age, diabetes 
(Ariesen et al., 2006) 107 (1%) 
Deaths not 
reported   No Yes 4 Age 
(Cuschieri et al., 2014) 107 (3%) 
Deaths not 
reported   No Yes 5 
Age, diabetes, chronic 
liver disease, chronic 
kidney disease 
(Carey et al., 2008) Not reported    No Yes 8 
Age, malignant 
neoplasm, congestive 
heart failure, chronic 
obstructive pulmonary 
disease, renal failure 
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Prediction 
model study 
reference 
Model 
Reported number of events 
Key competing 
risks terms 
Prognostic factors 
Prediction 
model 
events 
Competing 
events 
Total 
observed 
events 
Proportion 
competing 
events 
Terms 
used 
Kaplan-
Meier 
curves  
Number 
in final 
model 
Associated with 
mortality 
(Schonberg et al., 2009) 4,061 (17%)    No Yes 11 
Age, chronic 
obstructive pulmonary 
disease, diabetes, 
cancer 
(Bevilacqua et 
al., 2012) 
Preoperative 
model 
247 (23%) 171 (16%) deaths 418 40.9% 
No (1) Yes 
3 Age 
Within 6 
months model 
247 (23%) 171 (16%) deaths 418 40.9% 5 Age 
6 months or 
later model 
247 (23%) 171 (16%) deaths 418 40.9% 7 Age 
(Briganti et al., 2010) 252 (58%) 
Deaths not 
reported   No Yes 3 
Age, Charlson 
comorbidity index 
score 
(Ezaz et al., 2014) 155 (19%) 
Deaths not 
reported   No No 7 
Age, coronary artery 
disease, atrial 
fibrilation, diabetes, 
hypertension, renal 
failure 
(Kovalchik et 
al., 2012) 
Self-reported 
risk factor 
model 
159 (1%) 
2,483 (20%) 
competing 
events(2) 
2,642 94.0% 
Yes No 
5 Age, Hodgkin lymphoma 
Medical record 
abstraction 
model 
159 (1%) 
2,483 (20%) 
competing 
events(2) 
2,642 94.0% 7 Age 
All available 
information 
model 
159 (1%) 
2,483 (20%) 
competing 
events(2) 
2,642 94.0% 6  
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Prediction 
model study 
reference 
Model 
Reported number of events 
Key competing 
risks terms 
Prognostic factors 
Prediction 
model 
events 
Competing 
events 
Total 
observed 
events 
Proportion 
competing 
events 
Terms 
used 
Kaplan-
Meier 
curves  
Number 
in final 
model 
Associated with 
mortality 
(Mathieu et 
al., 2014) 
Urinary 
toxicity model 
183 (19%) Deaths not reported   
No(1) Yes 
2  
Urinary 
frequency 
model 
92 (10%) Deaths not reported   3 Diabetes 
Dysuria model 36 (4%) 
Deaths not 
reported  
 2  
(Romond et al., 2012) 37 (4%) 
Deaths not 
reported   Yes Yes 2 Age 
(Travis et al., 
2005) 
Without 
counselling 
model 
105(3) Deaths not reported(4)   
Yes No 
3 Age 
With 
counselling 
model 
105(3) Deaths not reported(4)   4 Age 
(Nakagawa et al., 2008) 270 (38%) 
Deaths not 
reported   No Yes 7 
Hasegawa’s dementia 
scale 
(Nyberg and Gustafson, 1997) 49 (36%) 
Deaths not 
reported; 
7(5%) 
immobile 
56 12.5% No Yes 8  
(Hippisley-
Cox and 
Coupland, 
2012) 
Female model 4798 
(<1%)(5) 
Deaths not 
reported   No Yes 
7 Age 
Male model 
Deaths not 
reported   9 Age 
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Prediction 
model study 
reference 
Model 
Reported number of events 
Key competing 
risks terms 
Prognostic factors 
Prediction 
model 
events 
Competing 
events 
Total 
observed 
events 
Proportion 
competing 
events 
Terms 
used 
Kaplan-
Meier 
curves  
Number 
in final 
model 
Associated with 
mortality 
(1) Cumulative incidence calculated using Kaplan-Meier methods 
(2) Obtained from supplementary table S3, competing events consist of other secondary primary cancer, thyroid removal, or death. 
(3) Nested case-control study so percentage of events not reported as not appropriate. 
(4) Nested case-sontrol study reports hazard rates per 100 000 person-years (population based measures) instead. 
(5) Number of events reported for prediction model study, not stratified by sex as individual models are. 
PTCA = percutaneous transluminal coronary angioplasty; CABG = coronary artery bypass grafting;  
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Key competing risks terms were reported in three (20.0%) prediction model 
studies, which developed four (16.0%) individual prediction models (Kovalchik et al., 
2012, Romond et al., 2012, Travis et al., 2005). Competing risks terms were used when 
reporting potential competing events, as illustrated in Box 3.1, and to describe the 
statistical modelling methods used to develop the individual prediction models, as 
illustrated in Box 3.2. Other instances where competing risks terms were used are cited 
in Appendix VIII. 
Box 3.1: Competing risks terms reporting potential competing events 
“Competing events for [second primary thyroid cancer] were death, self-reported 
complete removal of the thyroid gland, and other second primary cancers…” 
(Kovalchik et al., 2012) 
 
“The competing events were any first event of recurrence, second primary cancers, and 
deaths precluding [cardiac events].” 
(Romond et al., 2012) 
 
“We estimated this future risk, taking into account … competing causes of death.” 
(Travis et al., 2005) 
 
Box 3.2: Competing risks terms describing statistical modelling methods 
“Estimates of absolute risk combined semiparametric estimates of baseline incidences 
and [relative risks] for [second primary thyroid cancer] and competing risks … 
competing event [relative risks] were estimated from the [Childhood Cancer Survivor 
Study] cohort only...Hazard models for … competing event models for [model 1], 
[model 2], and [model 3] followed a Cox proportional hazards model.” 
(Kovalchik et al., 2012) 
 
“The cumulative proportions of [cardiac events] were estimated and compared by using 
the cumulative incidence function ... The Cox cause-specific proportional hazards 
model was used to evaluate the association between time to [congestive heart failure] 
and cardiac risks factors. A parametric regression model on cause specific 
subdistribution hazard was used to build a prediction model for 5-year probability of 
developing [cardiac events] with 95% point-wise CIs, adjusting for significant risk 
factors.” 
(Romond et al., 2012) 
 
“To compute cumulative absolute risks of breast cancer, we used modified 
standardized incidence ratios to relate cohort breast cancer risks to those in the general 
population, enabling application of population-based breast cancer rates, and we 
allowed for competing risks by using population-based mortality rates in female 
[Hodgkin’s lymphoma] survivors.” 
 (Travis et al., 2005) 
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3.3.5 Item 4: How were competing events managed in each prediction model 
study? 
Information about the management of competing events in each of the 15 
prediction model studies is reported in Table 3.7. Statistical methods (such as 
competing risks regression) were applied to appropriately manage competing events 
in six (24.0%) individual prediction models from three (20.0%) prediction model studies 
(Kovalchik et al., 2012, Romond et al., 2012, Travis et al., 2005). Competing risks bias 
should not be present as the competing events have been appropriately managed. 
Competing events were censored during the development of nine (36.0%) individual 
prediction models, from four (26.7%) prognostic model studies (Bevilacqua et al., 2012, 
Hippisley-Cox and Coupland, 2012, Nyberg and Gustafson, 1997, Sekhri et al., 2008), 
and prior to the development of one individual prediction model (Sekhri et al., 2008). 
Competing risks bias is likely to affect these individual prediction models as censoring 
or excluding competing events causes inflated absolute risk estimates. The eight 
(53.3%) remaining prediction model studies, which developed ten (40.0%) individual 
prediction models, did not report on the management of competing events. While two 
of these (Carey et al., 2008, Schonberg et al., 2009) were classified as no potential for 
competing risks bias, the remaining prediction model studies were classified with 
moderate or high potential for competing risks bias, thus it is unlikely that no competing 
events occurred in these studies. For example, one cohort study followed 12,648 
stroke patients, with a mean age of 64, for 5 years (Ariesen et al., 2006); The study 
does not report any deaths (competing events) or how these were managed in the 
study, yet it is unlikely that none occurred. 
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Table 3.7: Management of competing events in each prediction model study 
Prediction model 
study reference 
Potential for 
competing risks 
bias 
Prediction model outcomes 
Competing risks 
statistical methods 
used 
Competing 
events 
censored 
Competing 
events 
excluded 
Validation 
method 
(Sekhri et al., 
2008) 
High 
Death due to coronary heart 
disease or non-fatal acute 
coronary syndrome 
No Yes No Apparent 
(Ariesen et al., 
2006)  
High Intracerebral haemorrhage No No No Internal 
(Cuschieri et al., 
2014) 
High Acute gastrointestinal (GI) bleeding No No No Apparent 
(Carey et al., 2008) No All-cause mortality No No No Internal 
(Schonberg et al., 
2009) 
No 5-year mortality No No No Internal 
(Bevilacqua et al., 
2012) 
High Lymphedema No Yes No Internal 
(Briganti et al., 
2010) 
High Erectile function recovery No No No Internal 
(Ezaz et al., 2014) High Heart failure and cardiomyopathy No No No Internal 
(Kovalchik et al., 
2012) 
High Second primary thyroid cancer Yes No No External 
(Mathieu et al., 
2014) 
High Urinary toxicity, urinary frequency, dysuria No No No Apparent 
(Romond et al., 
2012) 
High Severe congestive heart failure or cardiac death Yes No No Internal 
(Travis et al., 
2005) 
High Breast cancer Yes No No None 
(Nakagawa et al., 
2008) 
Moderate Falls No No No Apparent 
(Nyberg and 
Gustafson, 1997) 
Moderate Falls No Yes (deaths) Yes (immobility) Apparent 
 119 
Prediction model 
study reference 
Potential for 
competing risks 
bias 
Prediction model outcomes 
Competing risks 
statistical methods 
used 
Competing 
events 
censored 
Competing 
events 
excluded 
Validation 
method 
(Hippisley-Cox 
and Coupland, 
2012) 
High Colorectal cancer No Yes No Internal 
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The predictive performance of each developed model was evaluated in some way 
for the majority of models (23, 92.0% models from 14, 93.3% prediction model studies). 
Apparent performance measures were reported for nine (36.0%) individual prediction 
models from five (33.3%) prediction model studies; internal validation methods were 
reported for 11 (44.0%) prediction models from eight (53.3%) studies; and external 
validation was reported for three (12.0%) models from one (6.7%) study. None of the 
prediction model studies reported on how competing events were managed during 
model validation. 
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3.4 Discussion 
In this chapter, a review of the presence, reporting, and management of 
competing events in prediction model development studies was conducted. In total, 25 
individual prediction models were evaluated, as identified from 15 prediction model 
studies likely to be affected by competing events. The key findings and conclusions of 
this review are summarised in Box 3.3 and discussed below. 
Box 3.3: Key findings 
1. Mortality is a common competing event for prediction model outcomes. 
2. Prediction model development articles rarely report competing risks, even when 
studies are conducted in clinical settings where competing events are a likely 
issue. 
3. The management of competing events in prediction model development studies 
is inconsistent and often not appropriate. 
 
3.4.1 Key findings 
The key findings of this review are presented and discussed in more detail: 
3.4.1.1 Mortality is a common competing event in prediction models. 
Of the 25 individual prediction models included in this review, only 8.0% predicted 
all-cause mortality, and a further 16.0% predicted cause-specific mortality. Thus 
mortality, either all-cause or other-cause, was considered a competing event for 92.0% 
of the prediction models identified in this review. Further, all of the individual prediction 
models were developed in either frail or elderly populations, and these populations are 
particularly susceptible to the competing risk of death (Berry et al., 2010). More needs 
to be done to highlight the importance of appropriately accounting for mortality as a 
competing event in prediction model studies in elderly or frail populations. 
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3.4.1.2 Prediction model development articles rarely report competing risks, 
even when studies are conducted in clinical settings where competing 
events are a likely issue. 
The included prediction model studies were identified for having high potential for 
competing risks bias and population characteristics that were susceptible to competing 
events. Despite this, competing events were poorly reported in the published prediction 
model articles. Key terms related to competing events were not mentioned in 80% of 
the prediction model study articles (which developed 84.0% of individual prediction 
models). Further, the number of competing events was not reported in 73.3% of the 
prediction model study articles (60.0% of individual prediction models). It is unlikely 
that competing events were not present in the majority of the studies, given the 
selection criteria and potential for competing risks bias. Thus, the lack of reporting of 
competing events may indicate the lack of awareness of competing risks bias as an 
issue in prediction model research. 
3.4.1.3 The management of competing events in prediction model development 
studies is inconsistent and often not appropriate. 
The management of competing events during the development of the prediction 
models was inconsistent; for example, statistical methods to appropriately handle 
competing events were applied in only 20.0% of the prediction model studies (24.0% 
of individual prediction models), whilst competing events were censored in 26.7% of 
the prediction model studies (36.0% of individual prediction models). The management 
of competing events in the validation of prediction models was not discussed in any of 
the articles. Not appropriately managing competing events when they are present can 
lead to bias, inflated absolute risk predictions. Moreover, not accounting for the 
competing events when validating prediction models can lead to bias in predictive 
performance measures. Therefore, competing events need to be handled more 
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appropriately in new prediction model development studies where competing events 
are an issue. 
3.4.2 Limitations and further research 
This work adds to existing reviews and empirical evaluations of whether 
competing risks have been accounted for in medical research. Previous systematic 
reviews investigating competing risk biases have focused on articles containing 
Kaplan-Meier curves (Schumacher et al., 2016, Walraven and McAlister, 2016), 
studies with population susceptible to competing risks (Koller et al., 2012), or published 
randomised controlled trials (Austin and Fine, 2017). This systematic review focuses 
on competing risks bias in prediction model development studies and thus provides a 
novel insight into the presence, reporting, and management of competing events 
during the prediction model development process. The review highlights the high 
presence of death as a competing event in prediction model studies in elderly and frail 
populations. Nevertheless, the review does not encompass all prediction model 
development research. The high presence of competing events is unlikely to be 
generalizable to all prediction model development studies, given the selection of 
articles from of high potential for competing risks bias systematic reviews. However, 
focusing on studies likely to be affected by competing events allowed a concentrated 
investigation into the reporting and management of competing events in model 
development articles where competing events were likely to be present and cause bias 
results if inappropriately accounted for. 
There has been relatively little research about the impact of competing events in 
relation to prediction model research. The way in which competing events may affect 
prediction model outcomes (if not appropriately accounted for) include: erroneous 
estimates of prognostic factor associations, inflated absolute risk predictions, mis-
calibration, and inaccurate risk group allocation. This chapter has highlighted the high 
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proportion of prediction model development studies which do not appropriately account 
for competing events. However, further research is needed to evaluate the impact of 
this bias on the prediction model outcomes (such as absolute risk predictions, and 
measures of calibration and discrimination). In the following chapters the statistical 
methods available to appropriately account for competing events will be discussed and 
applied to develop a prediction model for the risk of antenatal adverse events using 
data from the Prediction of Risks in Early onset Pre-eclampsia (PREP) study 
(Thangaratinam et al., 2017). 
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4 A COMPARISON OF TIME-TO-EVENT PROGNOSTIC 
MODELS DEVELOPED USING COX AND FLEXIBLE 
PARAMETRIC METHODS 
4.1 Introduction 
Before investigating the application and impact of competing risks methods, it is 
helpful to introduce and apply standard time-to-event methods to develop prognostic 
models. Thus, in this chapter two prognostic models are developed using different 
popular time-to-event methods, namely Cox proportional hazards regression (Cox, 
1972a) and Royston-Parmar flexible parametric regression (Royston and Parmar, 
2002). Cox proportional hazards regression is commonly applied to develop prognostic 
models for time-to-event outcomes (Collins et al., 2015, Royston et al., 2009). 
However, due to its semi-parametric form, Cox regression does not estimate the 
baseline hazard function and consequently does not allow for direct estimation of 
absolute risks (the motivation for prognostic model research). Parametric time-to-event 
models directly estimate the baseline hazard function and thus provide estimates of 
absolute risks over time, making them appropriate for use in prognostic model research 
(Snell, 2015). Some parametric models make strong assumptions about the shape of 
the hazard function which are simplistic and unlikely, such as exponential models 
which assume the hazard function is constant over time. Royston-Parmar flexible 
parametric regression estimates the baseline hazard function using restricted cubic 
splines, which are capable of capturing complex hazard functions (Royston and 
Parmar, 2002). In this chapter both the Cox and Royston-Parmar methods will be 
applied to existing study data to develop and internally validate two new prognostic 
models which predict the risk of antenatal adverse events in women diagnosed with 
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early onset pre-eclampsia. The resulting models will be compared to illustrate their 
differences, and the findings will influence the choice of models used in later chapters 
of this thesis, where extensions to competing risks are considered. 
4.1.1 Background: The PREP study 
Pre-eclampsia is a serious disorder in pregnancy, characterised by elevated 
blood pressure and excessive protein in the urine (Sibai, 2003). When this occurs early 
in the pregnancy (before 34 weeks gestation) it can cause serious complications, 
several of which may be life-threatening for both the mother and the unborn baby 
(Sibai, 2003). The varying prognoses of early-onset pre-eclampsia necessitates 
accurate prediction of complications to allow the timely recognition, referral and 
treatment of women with a high-risk of complications (Wilkinson, 2011). 
Prior to this thesis, two multivariable prognostic models were developed in the 
Prediction of Risks in Early onset Pre-eclampsia (PREP) study (Thangaratinam et al., 
2017). This study utilized data from a prospective cohort of 946 women diagnosed with 
confirmed early-onset pre-eclampsia between December 2011 and April 2014 from 53 
maternity units in the UK. These prognostic models provide predictions for individual 
risks of adverse maternal outcomes, including delivery of a preterm infant, for women 
with early-onset pre-eclampsia. One model predicts events prior to discharge, the 
“PREP-L” logistic regression model, the other predicts events at various time points 
prior to 34 weeks gestation, the “PREP-S” Royston-Parmar parametric model. Both 
models were externally validated in the Pre-eclampsia Integrated Estimate of RiSk for 
mothers (PIERS) cohort (von Dadelszen et al., 2009) and the Pre-eclampsia 
Eclampsia Trial Amsterdam (PETRA) cohort (Ganzevoort et al., 2005), comprising of 
a total of 850 women. Further details of the PREP study can be found in 
(Thangaratinam et al., 2017). 
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The inclusion of preterm delivery in the composite outcome predicted by both 
PREP prognostic models was determined through the consensus of an expert panel 
(Thangaratinam et al., 2017). Delivery of the baby is the only known cure for pre-
eclampsia, yet delivery before 34 weeks gestation (preterm delivery) increases the 
baby’s risk of death and neurological disability (Sibai, 2003). Despite this risk, preterm 
delivery is often offered to prevent further maternal complications and is thus indicative 
of patients at considerable risk of adverse maternal outcomes (Thangaratinam et al., 
2017). As preterm delivery is thus a treatment for high risk individuals, not accounting 
for preterm delivery in the models may have introduced bias through the treatment 
paradox. 
Treatment paradox bias occurs when the presence of a strong predictor of an 
adverse event triggers an effective treatment, thereby preventing the occurrence of a 
number of adverse outcomes (Cheong‐See et al., 2016). Had the treatment not been 
given, a subsequent adverse outcome would have been highly likely to occur; thus, 
ignoring the treatment weakens the perceived associations between true predictors 
and the outcome. Hence the expert panel agreed to incorporate preterm delivery into 
the composite outcome. 
Though the use of a composite outcome reduces the risk of treatment paradox 
bias, combining the outcomes presents a number of limitations. Preterm delivery was 
the most frequent outcome, thus prognostic model predictions were found to be heavily 
influenced by the risk of preterm delivery. The composite outcome limits the 
interpretation of associations between prognostic factors and individual outcomes, as 
associations with specific outcomes were not investigated. Finally, as preterm delivery, 
by definition, only occurs prior to 34 weeks gestation, the prediction horizon of the 
PREP-S model was restricted to 34 weeks. Any events which occurred after this time 
were censored, thus the PREP-S model is not able to make predictions over a full 
pregnancy term (40 weeks). 
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4.1.2 Prediction of antenatal adverse events 
To address some of the limitations of the PREP model composite outcome, an 
alternative outcome, antenatal adverse events, is considered and used throughout this 
thesis. Antenatal adverse events refer to adverse events which occur during 
pregnancy. Following delivery of the baby (be it preterm or otherwise) the participant 
is no longer pregnant, and thus no longer able to experience an antenatal adverse 
event. In this chapter, participants who deliver will be censored at the time of delivery 
(deliveries will be managed differently in later chapters when competing risks models 
are utilised). This definition allows established time-to-event regression methods to be 
applied to develop prognostic models to predict the risks of antenatal adverse events. 
This alternative outcome definition does not invalidate the original PREP models, 
which focus on predicting the global risks of adverse outcomes by discharge or 34 
weeks. In particular, the models developed in this chapter are not directly comparable 
to the original PREP models, but may be used alongside the PREP models to further 
assist in the understanding of the risks to the participants. 
4.1.3 Aims 
Data from the PREP study cohort will be used to develop and internally validate 
two new prognostic models to predict the risks of antenatal adverse events. The first 
will be developed using the Cox proportional hazards method, and the second using 
the Royston-Parmar flexible parametric method. The parameter estimates of the 
prediction models will be compared, as will the resulting model predictions, measures 
of predictive performance, and optimism. 
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4.2 Methods: Developing two prognostic models 
Methods for development and internal validation of the two prognostic models are 
now discussed. 
4.2.1 Outcome definition 
The primary outcome, antenatal adverse events, is a composite outcome made 
up of the events listed in Table 4.1. Patients were considered to be at risk from the 
date of pre-eclampsia diagnosis. The end of follow-up was defined as the time of 
occurrence of the first antenatal adverse event or delivery of the baby. Antenatal 
adverse events by definition exclude postpartum haemorrhages and events which 
occur following delivery, both of which were included in the original PREP models. 
Participants were censored at the time of delivery, if this occurred prior to an antenatal 
adverse event. If both an adverse event and delivery occurred on the same date the 
outcome was recorded as an antenatal adverse event. A total of 75 antenatal adverse 
events were observed during the PREP study follow-up (Table 4.1). 
Table 4.1: Individual components of antenatal adverse events 
Antenatal adverse event Number (%) 
Placental abruption 25 (2.6%) 
Transfusion of blood 23 (2.4%) 
Eclamptic seizure 11 (1.2%) 
Hepatic dysfunction 5 (0.5%) 
Pulmonary oedema 4 (0.4%) 
Intubation 3 (0.3%) 
Acute renal insufficiency 2 (0.2%) 
At least 50% FIO2 for > 1hour 1 (0.1%) 
Glasgow Coma score <13 1 (0.1%) 
Total antenatal adverse events 75 (7.9%) 
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4.2.2 Candidate prognostic factors 
To reduce the risk of overfitting during model development, the number of 
candidate prognostic factors considered for inclusion in the new models was reduced. 
The candidate prognostic factors were restricted to those included within the original 
PREP models that were also available in the PIERS validation studyi. Abnormal pulse 
oximetry was not considered as a candidate prognostic factor due to the rarity of its 
occurrence, as only four cases were observed. The restricted set of candidate 
prognostic factors is listed in Table 4.2. Maternal age and gestational age are 
considered to be clinically important risk factors (Thangaratinam et al., 2017), thus 
were forced into the prognostic models to ensure clinical acceptability. 
Antihypertensive and magnesium sulphate treatment variables were also forcibly 
retained to circumvent suboptimal prognostic performance when applied to patients 
not receiving treatments (Groenwold et al., 2016). 
Table 4.2: Candidate prognostic factors for new prognostic models 
Maternal characteristics: 
Maternal age at diagnosis (years), 
Gestational age at diagnosis (weeks). 
Medical history: 
Count of pre-existing conditions (0, 1, 2 or more) from prespecified list: pre-existing 
hypertension, renal disease, diabetes mellitus, previous history of pre-eclampsia.  
Bedside examination and laboratory tests: 
Systolic blood pressure (mmHg, highest measurement over 6 hrs), 
Platelet count (x 109/L),  
Alanine amino transaminase (IU/l),  
Serum creatinine μmol/L. 
Management at baseline (before or within 1 day of diagnosis): 
Administration of oral and/or parenteral anti-hypertensives, 
Administration of magnesium sulphate. 
 
4.2.3 Descriptive analysis of PREP participants 
The study participants’ follow-up time was investigated, and the median and 
interquartile range reported. These estimates were calculated using the reverse 
Kaplan-Meier estimator (Schemper and Smith, 1996), which is calculated in the same 
                                                     
iTime-to-event information was not collected during the PETRA study, thus only data from the PIERS 
study is suitable for external validation of the prognostic models developed in this thesis. 
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way as the Kaplan-Meier estimate, after the event indicator is reversed so the event of 
interest is censored and the censored observations become events. 
The descriptive analysis of candidate prognostic factors included reporting the 
frequency and percent of participants in each category of the binary and categorical 
candidate prognostic factors. Histograms of the distribution of each continuous 
prognostic factor were inspected to determine which were normally distributed. The 
mean and standard deviation were reported for factors considered to be normal. The 
median and inter-quartile range were reported for those which were not considered 
normal. Finally, correlations between the continuous candidate prognostic factors were 
examined, none were found to be both strongly (Spearman’s rank-order correlation 
coefficient |𝜌| ≥ 0.7) and significantly (𝑝 < 0.05) correlated with each other. 
4.2.4 Missing information and multiple imputation 
The frequency and percent of missing information was reported for each of the 
candidate prognostic factors. A large proportion of participants (829, 87.5%) had 
complete data for all outcome and candidate prognostic factor variables. Multiple 
imputation using chained equations (Buuren and Oudshoorn, 2000) techniques were 
applied to account for the missing information and avoid a loss in study efficiency and 
power. Under a missing at random assumption, a total of 20 imputed datasets were 
created using the mi impute chained package in Stata 12. The chained equations 
included the candidate prognostic factors listed in Table 4.2 (with medical history 
separated into its individual components), as well as outcome information including a 
binary variable indicating whether the participant experienced an antenatal adverse 
event or not, and an estimate of the cumulative hazard function over time (White and 
Royston, 2009). Missing values from continuous prognostic factors were imputed using 
the predictive mean matching method (Little, 1988), and those from binary prognostic 
factors were imputed using augmented logistic regression (White et al., 2010). The 
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imputed values were visually inspected to determine any outliers. Information on 
outcome measures was complete, thus outcomes were not imputed. 
4.2.5 Time-to-event regression models  
Two new prognostic models for predicting the risk of antenatal adverse events in 
women diagnosed with early onset pre-eclampsia were developed using the PREP 
study data and different time-to-event methods. The first using Cox proportional 
hazards regression, the second using Royston-Parmar flexible parametric regression. 
Details of both of these regression methods are provided in Chapter 1. 
Briefly here, Cox proportional hazards regression (Cox, 1972a) was used to 
develop one prognostic model using the stcox estimation command in Stata. This 
method estimates regression coefficients through maximisation of the partial likelihood 
function on the hazards scale, as described in Chapter 1. The Efron method (Efron, 
1977) was implemented to handle tied failure times, in which the tied failures which 
occur just before time t are included into the risk set at time t with a probability equal to 
1/number of tied events. Breslow’s estimate (Equation 1.10) of the baseline cumulative 
hazard was acquired to estimate the baseline survival function (Breslow, 1972), 
allowing the calculation of absolute risk estimates over time. 
The Royston-Parmar flexible parametric model (Royston and Parmar, 2002) was 
used to develop the alternative prognostic model using the stpm2 estimation command 
in Stata. Restricted cubic splines of log-time are utilised to approximate the log 
cumulative baseline hazard function. The model regression coefficients and 
parameters of the spline function are simultaneously estimated through maximum 
likelihood estimation. The number of knots required to capture the shape of the hazard 
function was determined by visual inspection of plots of the baseline hazard function 
for null models (containing no prognostic factors) with varying degrees of freedom 
(between 2 and 6). A spline with M interior knots is estimated with M + 1 degrees of 
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freedom. Knots were positioned at equally spaced centile values of the distribution of 
uncensored failure times. 
Regardless of the regression method used for development, the form of the 
prognostic model equation can be written as the cumulative risk of an event occurring 
prior to time t, as: 
Fi(t) = 1 − S0(t)
exp(𝛃T𝐗𝐢) Equation 4.1 
Where the linear predictor 𝛃T𝐗𝐢 is the combination of estimated regression coefficients 
and prognostic factors in the model for the ith participant. 
4.2.6 Fractional polynomial terms in multiply imputed data 
In order to perform variable selection in multiply imputed data, a stacked 
approach (Wood et al., 2008) was utilised. This entails stacking the 𝜇 imputed datasets 
to produce one large dataset, and fitting weighted regression models to obtain model 
parameter estimates and adjusted standard errors. The weights assigned to each 
observation are calculated as follows: 
 wj = (1 − fj) μ⁄  Equation 4.2 
In which fj is the fraction of missing data from the jth prognostic factor. The stacked 
approach has many advantages over the well-established application of Rubin’s rules 
and inferential framework (Rubin, 2004), including being less computationally 
demanding and allowing direct estimation of likelihood ratio test statistics. An additional 
benefit is the extension of the approach to incorporate fractional polynomial terms 
(Morris et al., 2015), which allows investigations of non-linear associations between 
continuous prognostic factors and the outcome. Fractional polynomial functions with 
one dimension (FP1) were investigated for all continuous candidate prognostic factors. 
The best-fitting FP1 function was determined by estimating the best-fitting exponent 
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term ?̂?, chosen from the set e ∈ {−2, −1, −0.5,0,0.5,1,2,3}i, using maximum likelihood-ratio 
type tests in the stacked data. Centring was permitted for continuous prognostic factors 
to allow for a more meaningful interpretation of relative risk estimates. 
4.2.7 Multivariable analysis and prognostic factor selection 
For both the Cox and flexible parametric models, a multivariable analysis was 
performed to determine the effects of the prognostic factors on the outcome of 
antenatal adverse events, adjusting for the effect of other included prognostic factors. 
To determine which of the candidate prognostic factors would be included in the final 
multivariable prognostic models, a backwards elimination procedure adapted to 
multiply imputed data and which incorporated fractional polynomial terms (Morris et al., 
2015) was applied using the mfpmi command in Stata. The procedure is described in 
Box 4.1. 
Box 4.1: Backward elimination procedure adapted for multiply imputed data to 
incorporate fractional polynomial terms. 
Using a stacked dataset, begin with a full model containing all candidate prognostic factors 
with all continuous prognostic factors included as linear terms. 
 
(1) Using the stacked approach, perform weighted likelihood-ratio tests on the prognostic 
factors in the model. Order from most to least significant. 
(2) By order of significance, working through each prognostic factor in the model. Run the 
appropriate selection procedure: 
Categorical prognostic factors: 
Test for removal using weighted likelihood-ratio tests. 
If 𝑝 < 0.15 retain in the model, else drop from the modelii. 
Move on to the next significant prognostic factor. 
Continuous prognostic factors: 
(i) Select the best-fitting FP1 function (as described in 4.2.6). 
(ii) Test the model containing the best-fitting FP1 function against the model with 
the linear term using weighted likelihood-ratio tests. 
If 𝑝 < 0.15 retain the FP1 function in the model. 
Else test for removal of the linear term using weighted likelihood-ratio tests. 
If 𝑝 < 0.15 retain in the model, else drop from the modelii. 
(iii) Move on to the next significant prognostic factor. 
(3) Repeat steps 1 and 2 until the model is stable with respect to the retained prognostic 
factors and their fractional polynomial functional forms. 
 
                                                     
i Conventionally the exponent term of 𝑝 = 0 represents a log-transformation 
iiUnless prognostic factor is antihypertensive treatment or treatment with magnesium sulphate, which 
are being forcibly retained in the prognostic models (see 4.2.2). 
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Maternal and gestational age are retained in the models regardless of their statistical 
significance to ensure clinical credibility of the final models in line with the original 
PREP study (Thangaratinam et al., 2017). The treatment variables (antihypertensive 
and magnesium sulphate treatment) are likewise retained to reduce the risk of 
suboptimal prognostic performance (Groenwold et al., 2016). A significance threshold 
of 𝑃 < 0.15 was selected to improve the chances of retaining meaningful prognostic 
factors in the model. The resulting hazard ratios and 95% confidence intervals from 
the multivariable models were compared across the two modelling approaches. 
4.2.8 Baseline cumulative risk estimates 
Estimates of the baseline survival function were calculated using transformations 
of baseline cumulative hazard functions (Equation 1.7), which were obtained by fitting 
regression models with the linear predictor from the multivariable prognostic models 
as an offset term, in each of the imputed datasets separately. Baseline cumulative 
hazard estimates for the Cox proportional hazards model were obtained using the non-
parametric Breslow’s estimate (Breslow, 1972) at given time points (Equation 1.10). 
Baseline log cumulative hazard estimates for the Royston-Parmar flexible parametric 
model were calculated using the spline functions estimated in the multivariable model 
(Royston and Lambert, 2011). 
An individual’s prognostic factor information is combined with the estimated 
regression coefficients to obtain an individual linear predictor value, 𝛃T𝐗𝐢. This is then 
incorporated into the regression equation alongside the estimated baseline survival 
function, S0(t), to obtain individual risk predictions (Equation 4.1). 
4.2.9 Sensitivity analysis 
A sensitivity analysis was performed to investigate the assumptions made during 
model development, namely the proportional hazards assumption and independent 
effects. Both the Cox and Royston-Parmar models, when developed in the way 
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described above, assume the effects of each prognostic factor on the outcome are 
constant over time. This assumption was tested by incorporating interactions between 
the retained prognostic factors and the natural logarithm (ln) of time into the fitted 
multivariable models. Additionally, interactions between retained prognostic factors 
were investigated to test the assumption that the effects of each prognostic factor on 
the outcome were independent. Any statistically significant (p < 0.05) deviations from 
the assumptions were reported. 
4.2.10 Apparent prognostic performance of fitted prognostic models 
The apparent performance of the fitted models was assessed in the development 
data using measures of calibration (overall calibration and calibration slope) and 
discrimination (Harrell’s C-index and R2D), as outlined in Section 1.6.3. The model’s 
predictive performance was evaluated overall and at two days, one week, and four 
weeks. The prognostic performance was assessed in each imputed dataset 
separately, the imputation-specific measures were then pooled using Rubin’s rules 
(Rubin, 2004). 
4.2.11 Internal validation and optimism adjustment 
The optimism in apparent performance of the fitted models was assessed through 
internal validation in 100 bootstrap samples of the original PREP study data. The 
bootstrap validation procedure repeats the modelling process described above in each 
bootstrap sample; the procedure is described in Box 4.2. 
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Box 4.2: Bootstrap procedure for internal validation of fitted prognostic models 
where there is missing data in the development dataset 
(1) Generate a new bootstrap sample containing an equal number of participants as the 
PREP study by sampling with replacement from the PREP study data. 
(2) In the bootstrap sample, develop a prognostic model using the model development 
process, including: 
(i) Application of multiple imputation methods to create 20 imputed datasets. 
(ii) Performing prognostic factor selection using the backwards elimination 
procedure outlined in Box 4.1. 
(iii) Calculation of baseline survival estimates appropriate to the regression method 
being applied. 
(3) For each predictive performance statistic (e.g. c-index, calibration slope), assess the 
average (across imputation datasets) performance of the new models using: 
(i) The bootstrap sample imputation datasets in which the model was developed, 
referred to as the bootstrap apparent performance. 
(ii) The original PREP study imputed datasets, referred to as the test performance. 
(4) For each statistic, calculate the optimism as the difference between the bootstrap 
apparent performance and the test performance. 
(5) Repeat steps 1-4 100 times to obtain an estimate of the average optimism across 
bootstrap samples. 
 
Optimism adjusted prognostic performance measures were calculated by 
subtracting the average optimism from the apparent prognostic performance measures 
estimated for the fitted prognostic models previously (see Section 4.2.10). The fitted 
models were adjusted for optimism by multiplying the fitted regression coefficients by 
the optimism adjusted calibration slope obtained from the bootstrap procedure. Thus, 
the optimism adjusted calibration slope represents a uniform shrinkage factor to 
penalise for overfitting. After shrinkage, and holding the shrunken regression 
coefficients as known, the baseline survival functions were re-estimated to maintain 
overall calibration between expected and observed risks. 
This process led to two final prediction models, one developed using Cox 
regression and one using Royston-Parmar models. The final model’s included 
prognostic factors, internal validation model performance, and final optimism adjusted 
equations were compared. 
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4.3 Results: Comparison of prognostic models 
A total of 947 women with a confirmed diagnosis of pre-eclampsia were followed 
up for a median of 10.1 days (IQR: 3.4 to 25.3). The longest observed follow-up period 
for a participant was 126.6 days, none of the participants were lost to follow-up. 
Antenatal adverse events were observed in 75 (7.9%) women, the remaining 872 
patients were followed until delivery of the baby. Non-parametric estimates of 
cumulative risk of an antenatal adverse event and delivery without an adverse event 
are depicted using 1-Kaplan-Meier curves in Figure 4.1. A large proportion of 
participants delivered soon after pre-eclampsia diagnosis; the median time to delivery 
is 10 days. 
Figure 4.1: Non-parametric Kaplan-Meier estimate of pre-eclampsia events 
 
 
4.3.1 Descriptive analysis of PREP participants 
Results of the descriptive analysis of candidate prognostic factors in PREP study 
participants are given in Table 4.3. The mean maternal age of participants at pre-
eclampsia diagnosis was 30.2 (SD 6.1) years, with a median corresponding gestational 
age of 31.4 weeks (IQR: 28.7 to 32.7). Just under two-thirds of patients did not have 
any historical medical conditions (63.9%) and around one in ten had two or more 
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(10.1%). The majority of participants were receiving magnesium sulphate (79.4%), with 
a minority treated for hypertension (15.2%). 
Table 4.3: Descriptive analysis of candidate prognostic factors 
Prognostic factor 
Summary statistics 
Mean(SD), N(%), Med [IQR] 
Missing  
N (%) 
Maternal age (years) 30.2 (6.1) 2 (0.2%) 
Gestational age at diagnosis (weeks)* 31.4 [28.7 to 32.7] 0 (0%) 
Medical History¥ 
0 594 (63.9%) 
17 (1.8%) 1 242 (26.0%) 
2 or more 94 (10.1%) 
Systolic blood pressure 158.6 (19.2) 5 (0.5%) 
Platelet count 227.1 (77.7) 41 (4.3%) 
Alanine amino transaminase* 17 [13 to 26.5] 75 (7.9%) 
Serum Creatinine 61.8 (17.1) 37 (3.9%) 
Antihypertensive treatment 751 (79.4%) 1 (0.1%) 
Magnesium sulphate treatment 144 (15.2%) 1 (0.1%) 
*Median and inter-quartile range (IQR) presented for non-normally distributed 
factors. 
¥Medical history is a count of the following conditions: chronic hypertension, renal 
disease, diabetes mellitus, and previous pre-eclampsia. 
 
The continuous prognostic factors of maternal age, systolic blood pressure 
(SBP), platelet count, and serum creatinine, appeared to be approximately normally 
distributed, whereas gestational age and alanine transaminase (ALT) were not (Figure 
4.2). No strong and significant correlations were found between any of the candidate 
prognostic factors. 
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Figure 4.2: Distributions of continuous candidate prognostic factors 
  
  
  
 
One in eight women (12.5%) in the study had missing information for at least one 
candidate prognostic factor. The candidate prognostic factors with the greatest amount 
of missing information were the three laboratory tests: ALT (7.9%), platelet count 
(4.3%), and serum creatinine (3.9%). Multiple imputation using chained equations was 
applied to create 20 imputed datasets. Imputed values for each candidate prognostic 
factor were visually inspected and no anomalies were found. 
4.3.2 Flexible parametric restricted cubic splines 
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Null Royston-Parmar models, with between one and five internal knots, were 
fitted to the original PREP study data. The resulting knot locations and, AIC and BIC 
values of the models are listed in Table 4.4.  
Table 4.4: Knot selection for Royston-Parmar flexible parametric model 
Number of internal 
knots 
Degrees of 
freedom 
Knot locations 
(time in days) 
AIC BIC 
1 2 2.7 801.1 815.6 
2 3 0.7, 7.0 802.2 821.6 
3 4 0.4, 2.7, 10.1 802.6 826.9 
4 5 0.1, 1.3, 5.4, 13.3 803.2 832.3 
5 6 0.1, 0.7, 2.7, 7.0, 15.4 803.0 837.0 
 
Surprisingly the model with only one internal knot returned the lowest AIC and 
BIC values (AIC=801.1 and BIC = 815.6), although the differences between AIC and 
BIC values over the varying number of knots were small. A graphical display of the 
spline estimates with between two and four degrees of freedom is depicted in Figure 
4.3. There is little difference in the cumulative hazard function estimates between the 
models. The spline functions were compared to a non-parametric Nelson-Aalen 
cumulative hazard estimate to assess fit. The model with four degrees of freedom 
(three internal knots) appeared to sufficiently capture the shape of the observed 
cumulative hazard function (Figure 4.3) so was considered suitable for the remainder 
of the analysis. 
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Figure 4.3: Cumulative hazard function estimates using restricted cubic splines 
with varying degrees of freedom 
 
 
 
4.3.3 Multivariable analysis and prognostic factor selection process 
The backwards elimination procedure was applied using both regression 
modelling methods. The resulting hazard ratio estimates and 95% confidence intervals 
for both models are reported in Table 4.5.  
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Table 4.5: Multivariable estimates for Cox and Royston-Parmar models 
 Cox proportional hazards model Royston-Parmar flexible parametric model 
 
Transformation of 
prognostic factor 
(X) 
HR (95% CI) 
p-value 
Transformation of 
prognostic factor (X) 
HR (95% CI) 
p-value 
Maternal age (years) X-30.244 0.975 (0.938, 1.013)  
0.192 X-30.244 
0.962 (0.936, 1.011)  
0.167 
Gestational age (weeks) X-30.562 1.018 (0.939, 1.104) 
0.665 X-30.562 
1.015 (0.938, 1.098)  
0.710 
Medical history¥ 
1 
2 or more 
 
 
0.457 (0.239, 0.871) 
0.658 (0.285, 1.518) 
0.038 
 
0.460 (0.242, 0.875) 
0.634 (0.275, 1.464) 
0.037 
Systolic blood pressure X-158.634 1.015 (1.002, 1.027) 
0.020 X-158.634 
1.013 (1.003, 1.028)  
0.018 
Platelet count X-227.532 0.996 (0.992, 0.999) 
0.015 X-227.532 
0.996 (0.992, 0.999)  
0.017 
Serum creatinine  X-61.615 1.015 (1.003, 1.026) 
0.012 X-61.615 
1.015 (1.003, 1.026)  
0.012 
Antihypertensive treatment  1.291 (0.675, 2.469) 
0.440  
1.293 (0.677, 2.469)  
0.436 
Magnesium sulphate treatment  5.567 (3.005, 10.314) 
<0.001  
5.538 (2.994, 10.243)  
<0.001 
HR = Hazard Ratio, 95% CI = 95% confidence interval. 
¥Medical history is a count of the following conditions: chronic hypertension, renal disease, diabetes mellitus, and previous pre-eclampsia. 
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The Cox and Royston-Parmar regression methods produce almost identical 
results (Table 4.5). Both models exclude ALT due to a statistically insignificant 
association with the risk of antenatal adverse events, and both models include all other 
continuous candidate prognostic factors as linear terms. Maternal age, gestational age, 
antihypertensive treatment, and magnesium sulphate treatment were forcibly retained 
in both models for clinical acceptability and to account for treatment effects; however 
only magnesium sulphate treatment returned a statistically significant association 𝑝 <
0.001. Participants receiving magnesium sulphate treatment appear to have an 
increased risk of antenatal adverse events (HR 5.567 Cox, 5.538 Royston-Parmar). 
This treatment is given to minimise the risk of eclampsia and prevent pre-term labour, 
thus the association is likely to represent the identification and treatment of high risk 
participants by clinicians. Both models also identified a statistically significant 
association between the risk of antenatal adverse events and previous medical history 
(𝑝 = 0.038 Cox, 𝑝 = 0.037 Royston-Parmar). Surprisingly the risk of antenatal adverse 
events is reduced for patients with pre-existing medical conditions compared to those 
with noneThis finding is in line with existing prognostic models currently used for 
women with pre-eclampsia when predicting maternal adverse events (von Dadelszen 
et al., 2009, Thangaratinam et al., 2017), thus should not affect the face validity of the 
model. 
4.3.4 Baseline cumulative risk and fitted prognostic models 
Baseline cumulative risk estimates from the multivariable prognostic models were 
obtained through transformation of the estimated baseline cumulative hazard function. 
Estimates over time are presented graphically in Figure 4.4, and are provided for a 
number of pre-specified time points in Table 4.6. 
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Figure 4.4: Estimates of baseline cumulative risk from two multivariable 
prognostic models 
 
 
Table 4.6: Estimates of baseline cumulative risk from two multivariable 
prognostic models at given time points  
 2 days 1 week 4 weeks 
Cox proportional hazards model 0.015 0.038 0.116 
Royston-Parmar model 0.016 0.039 0.102 
Difference 0.001 0.001 -0.014 
 
The baseline cumulative risk estimates are calculated using centred values of the 
transformed prognostic factors; thus, this risk relates to a hypothetical participant with 
mean continuous prognostic factor values and 0 categorical prognostic factor values. 
Both the Cox and Royston-Parmar models produce similar baseline survival estimates 
up to three weeks following diagnosis. Differences between the baseline cumulative 
incidence estimates from the models become apparent after three weeks, due to the 
differences in the approaches used by each model to estimate the baseline survival 
functions. The Cox model requires an additional non-parametric analysis to be 
performed to calculate the baseline survival function. This approach results in a 
stepped survival function in which baseline estimates only change at the time of an 
observed event. As few events occurred after three weeks, the baseline survival 
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estimates after this time remain fairly static, resulting in a plateau in estimated baseline 
risk between weeks four and five. The Royston-Parmar model directly models the 
baseline log cumulative hazard using a smooth spline function. 
The fitted prognostic models combine the baseline survival estimates, S0(t), 
depicted in Figure 4.4 with the multivariable regression coefficients, ?̂?, from Table 4.5 
using the equation S(t) = S0(t)exp{?̂?𝐗}. The equations for these fitted models (i.e. before 
adjustment for overfitting) are provided in Table 4.7. 
Table 4.7: Equations for fitted prognostic models for antenatal adverse events 
Cox proportional hazards model 
Royston-Parmar flexible parametric 
model 
𝐿𝑖𝑛𝑒𝑎𝑟 𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑜𝑟 (?̂?𝑿)  =   
–   0.025 ×  (𝒎𝒂𝒕𝒆𝒓𝒏𝒂𝒍 𝒂𝒈𝒆 − 30.244)  
+  0.018 ×  (𝒈𝒆𝒔𝒕𝒂𝒕𝒊𝒐𝒏𝒂𝒍 𝒂𝒈𝒆 − 30.562) 
– {
0.783,       𝑖𝑓 𝟏 𝒑𝒓𝒆𝒆𝒙𝒊𝒔𝒕𝒊𝒏𝒈 𝒄𝒐𝒏𝒅𝒊𝒕𝒊𝒐𝒏
0.419,       𝑖𝑓 𝟐 𝒐𝒓 𝒎𝒐𝒓𝒆 𝒄𝒐𝒏𝒅𝒊𝒕𝒊𝒐𝒏𝒔      
  
+  0.015 ×  (𝑺𝑩𝑷 − 158.634) 
–   0.004 ×  (𝒑𝒍𝒂𝒕𝒆𝒍𝒆𝒕 𝒄𝒐𝒖𝒏𝒕 − 227.532) 
+  0.015 ×  (𝒔𝒆𝒓𝒖𝒎 𝒄𝒓𝒆𝒂𝒕𝒊𝒏𝒊𝒏𝒆 − 61.615) 
+  0.255 ×  (𝑖𝑓 𝒂𝒏𝒕𝒊𝒉𝒚𝒑𝒆𝒓𝒕𝒆𝒏𝒔𝒊𝒗𝒆)  
+  1.717 ×  (𝑖𝑓 𝑴𝒈𝑺𝑶𝟒 𝒕𝒓𝒆𝒂𝒕𝒎𝒆𝒏𝒕)  
𝐿𝑖𝑛𝑒𝑎𝑟 𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑜𝑟 (?̂?𝑿)  =   
–    0.039 ×  (𝒎𝒂𝒕𝒆𝒓𝒏𝒂𝒍 𝒂𝒈𝒆 − 30.244)  
+  0.015 ×  (𝒈𝒆𝒔𝒕𝒂𝒕𝒊𝒐𝒏𝒂𝒍 𝒂𝒈𝒆 − 30.562) 
– {
0.777,      𝑖𝑓 𝟏 𝒑𝒓𝒆𝒆𝒙𝒊𝒔𝒕𝒊𝒏𝒈 𝒄𝒐𝒏𝒅𝒊𝒕𝒊𝒐𝒏
0.456,      𝑖𝑓 𝟐 𝒐𝒓 𝒎𝒐𝒓𝒆 𝒄𝒐𝒏𝒅𝒊𝒕𝒊𝒐𝒏𝒔      
  
+  0.013 ×  (𝑺𝑩𝑷 − 158.634) 
–   0.004 ×  (𝒑𝒍𝒂𝒕𝒆𝒍𝒆𝒕 𝒄𝒐𝒖𝒏𝒕 − 227.532) 
+  0.015 ×  (𝒔𝒆𝒓𝒖𝒎 𝒄𝒓𝒆𝒂𝒕𝒊𝒏𝒊𝒏𝒆 − 61.615) 
+  0.257 ×  (𝑖𝑓 𝒂𝒏𝒕𝒊𝒉𝒚𝒑𝒆𝒓𝒕𝒆𝒏𝒔𝒊𝒗𝒆)  
+  1.712 ×  (𝑖𝑓 𝑴𝒈𝑺𝑶𝟒 𝒕𝒓𝒆𝒂𝒕𝒎𝒆𝒏𝒕)  
𝑆0(𝑡) = {
0.985, 𝑖𝑓 𝑡 = 2 𝑑𝑎𝑦𝑠  
0.962, 𝑖𝑓 𝑡 = 1 week 
0.884, 𝑖𝑓 𝑡 = 4 weeks
  𝑆0(𝑡) = {
0.984, 𝑖𝑓 𝑡 = 2 𝑑𝑎𝑦𝑠  
0.961, 𝑖𝑓 𝑡 = 1 week 
0.898, 𝑖𝑓 𝑡 = 4 weeks
  
𝑃𝑟(𝐴𝑛𝑡𝑒𝑛𝑎𝑡𝑎𝑙 𝑎𝑑𝑣𝑒𝑟𝑠𝑒 𝑒𝑣𝑒𝑛𝑡) =  1 − 𝑆0(𝑡)
𝑒𝑥𝑝(?̂?𝑿) 
 
4.3.5 Sensitivity analysis of fitted models 
A sensitivity analysis was performed to investigate the proportional hazards 
assumption made by both the Cox and Royston-Parmar modelling approaches. 
Interactions between the prognostic factors and the natural log of time were 
incorporated into the fitted models to test this assumption. The results are given in 
Appendix IX; Significant interactions were detected between magnesium sulphate 
treatment and ln(time) in both models (𝑝 = 0.009 Cox, 𝑝 < 0.001 Royston-Parmar), and 
between SBP and ln(time) in the Royston-Parmar model (𝑝 = 0.010). The inclusion of 
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these non-proportional estimates into the final prognostic model could result in further 
overfitting of the model, due to the small sample size of this study. Additionally, the 
inclusion of significant time interactions is unlikely to affect the prognostic performance 
of the models, as the time points assessed are soon after diagnosis (2 days, 1 week, 
and 4 weeks). Thus, the time interactions were intentionally disregarded from the final 
models. Not incorporating these interactions is unlikely to affect the results of this 
chapter, which focuses on the comparison of the two time-to-event modelling 
approaches. 
4.3.6 Apparent performance of fitted prognostic models 
The apparent performance of the models was assessed in the imputed PREP 
study data. The overall calibration of both prognostic models was assessed at two 
days, one week, and four weeks, the results are displayed in Table 4.8. Both models 
struggle to predict the brisk increase in risk directly after pre-eclampsia diagnosis and 
thus overall calibration at early time points (two days and one week) is suboptimal. 
However, both models appear to calibrate well at later time points. Averaging across 
multiple datasets, the calibration slope for the Cox proportional hazards model was 
found to be 0.994 (95% CI: 0.79 to 1.20), whereas the calibration slope for the flexible 
parametric model was 1.004 (95% CI: 0.80 to 1.21). The multiple imputation methods 
used to develop these models cause slightly imperfect (not equal to 1.0) calibration 
slopes, but they are almost perfect, as expected given the model was developed using 
the same data  
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Table 4.8: Overall calibration of prognostic models at time points 
 
Kaplan-Meier  
observed 
Cox proportional 
hazards model 
Royston-Parmar flexible 
parametric model 
Expected E/O Expected E/O 
2 days 3.6% 1.6% 0.444 1.6% 0.444 
1 week 6.2% 3.8% 0.613 3.9% 0.629 
4 weeks 12.6% 11.6% 0.921 12.3% 0.976 
 
The discrimination of the models was assessed using Harrell’s C-index at two 
days, one week, four weeks, and overall as well as using the R2D measure, obtained 
from the D-statistic; the results are given in Table 4.9. Both models perform similarly 
and show good ability to discriminate between those participants who experienced an 
antenatal adverse event and those who did not. 
Table 4.9: Measures of discrimination 
 
Harrell’s C-index 
Royston and Sauerbrei’s 
D-statistic 
2 
days 
1 
week 
4 
weeks 
Overall  
(95% CI) 
D-statistic R2D 
Cox model 0.847 0.801 0.784 
0.784  
(0.723, 0.845) 1.924 0.469 
Royston-Parmar 
model 
0.849 0.804 0.786 0.786  (0.726, 0.847) 1.915 0.444 
 
In summary, the apparent prognostic performance of both the models is similar. 
As expected, both are well calibrated and have good discriminative ability when 
assessed using the dataset in which they were developed. 
4.3.7 Internal calibration and optimism adjustment 
The optimism of the prognostic performance of the two prognostic models was 
assessed through internal validation using 100 bootstrap samples. The internal 
validation of the models was assessed using measures of calibration (calibration slope) 
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and discrimination (Harrell’s C and R2D). The average performance measures from the 
100 bootstrap samples are reported in Table 4.10. 
Table 4.10: Measures of prognostic performance from 100 bootstrap samples 
 
 
Average 
bootstrap 
performance 
Average test 
performance 
Average 
optimism 
Optimism-
adjusted 
performance 
Cox model 
Calibration slope 1.000 0.837 0.163 0.837 
Harrell’s C-index 0.799 0.767 0.031 0.768 
D-statistic 2.044 1.691 0.329 1.715 
R2D Statistic 0.499 0.406 0.089 0.410 
Royston-
Parmar 
model 
Calibration slope 1.000 0.837 0.163 0.837 
Harrell’s C-index 0.801 0.767 0.031 0.770 
D-statistic 2.049 1.702 0.336 1.713 
R2D Statistic 0.501 0.409 0.090 0.411 
 
Again, both of the prognostic models perform similarly in terms of prognostic 
performance and levels of optimism. The average optimism in Harrell’s C statistic was 
found to be 0.031 for both the Cox and Royston-Parmar models, resulting in optimism 
adjusted C-index of 0.799-0.031=0.768 for the Cox model and 0.801-0.031=0.770 for 
the Royston-Parmar model. The average optimism in the R2D measure was found to 
be 0.089 for the Cox model and 0.090 for the Royston-Parmar model, resulting in 
similar optimism adjusted R2D measures of 0.499-0.089=0.410 for the Cox model and 
0.501-0.090=0.411 for the Royston-Parmar model. Even after adjusting for optimism, 
the prognostic measures for discrimination for both models are promising. The average 
optimism in the calibration slope was 0.163 for both the Cox and Royston-Parmar 
models, resulting in uniform shrinkage factors of 1.000-0.163=0.837 for both models. 
4.3.8 Development of final (optimism adjusted) model equations 
The fitted models were adjusted for optimism by multiplying the uniform shrinkage 
factor for each model to all predictor coefficients within the fitted prognostic models. 
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Then. the baseline cumulated hazard functions were re-estimated with the new linear 
predictors to ensure calibration-in-the-large. The regression equations for the final 
optimism adjusted prognostic models are provided in Table 4.11. 
Table 4.11: Final regression equations for optimism adjusted prognostic models 
Cox proportional hazards model 
Royston-Parmar flexible parametric 
model 
𝐿𝑖𝑛𝑎𝑒𝑟 𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑜𝑟 (?̂?𝑿)  =   
–   0.021 ×  (𝒎𝒂𝒕𝒆𝒓𝒏𝒂𝒍 𝒂𝒈𝒆 − 30.244)  
+  0.015 ×  (𝒈𝒆𝒔𝒕𝒂𝒕𝒊𝒐𝒏𝒂𝒍 𝒂𝒈𝒆 − 30.562) 
– {
0.661,       𝑖𝑓 𝟏 𝒑𝒓𝒆𝒆𝒙𝒊𝒔𝒕𝒊𝒏𝒈 𝒄𝒐𝒏𝒅𝒊𝒕𝒊𝒐𝒏
0.347,       𝑖𝑓 𝟐 𝒐𝒓 𝒎𝒐𝒓𝒆 𝒄𝒐𝒏𝒅𝒊𝒕𝒊𝒐𝒏𝒔      
  
+  0.012 ×  (𝑺𝑩𝑷 − 158.634) 
–   0.003 ×  (𝒑𝒍𝒂𝒕𝒆𝒍𝒆𝒕 𝒄𝒐𝒖𝒏𝒕 − 227.532) 
+  0.012 ×  (𝒔𝒆𝒓𝒖𝒎 𝒄𝒓𝒆𝒂𝒕𝒊𝒏𝒊𝒏𝒆 − 61.615) 
+  0.214 ×  (𝑖𝑓 𝒂𝒏𝒕𝒊𝒉𝒚𝒑𝒆𝒓𝒕𝒆𝒏𝒔𝒊𝒗𝒆)  
+  1.437 ×  (𝑖𝑓 𝑴𝒈𝑺𝑶𝟒 𝒕𝒓𝒆𝒂𝒕𝒎𝒆𝒏𝒕)  
𝐿𝑖𝑛𝑎𝑒𝑟 𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑜𝑟 (?̂?𝑿)  =   
–    0.032 ×  (𝒎𝒂𝒕𝒆𝒓𝒏𝒂𝒍 𝒂𝒈𝒆 − 30.244)  
+  0.012 ×  (𝒈𝒆𝒔𝒕𝒂𝒕𝒊𝒐𝒏𝒂𝒍 𝒂𝒈𝒆 − 30.562) 
– {
0.650,      𝑖𝑓 𝟏 𝒑𝒓𝒆𝒆𝒙𝒊𝒔𝒕𝒊𝒏𝒈 𝒄𝒐𝒏𝒅𝒊𝒕𝒊𝒐𝒏
0.381,      𝑖𝑓 𝟐 𝒐𝒓 𝒎𝒐𝒓𝒆 𝒄𝒐𝒏𝒅𝒊𝒕𝒊𝒐𝒏𝒔      
  
+  0.011 ×  (𝑺𝑩𝑷 − 158.634) 
–   0.003 ×  (𝒑𝒍𝒂𝒕𝒆𝒍𝒆𝒕 𝒄𝒐𝒖𝒏𝒕 − 227.532) 
+  0.012 ×  (𝒔𝒆𝒓𝒖𝒎 𝒄𝒓𝒆𝒂𝒕𝒊𝒏𝒊𝒏𝒆 − 61.615) 
+  0.215 ×  (𝑖𝑓 𝒂𝒏𝒕𝒊𝒉𝒚𝒑𝒆𝒓𝒕𝒆𝒏𝒔𝒊𝒗𝒆)  
+  1.433 ×  (𝑖𝑓 𝑴𝒈𝑺𝑶𝟒 𝒕𝒓𝒆𝒂𝒕𝒎𝒆𝒏𝒕)  
𝑆0(𝑡) = {
0.980, 𝑖𝑓 𝑡 = 2 𝑑𝑎𝑦𝑠  
0.956, 𝑖𝑓 𝑡 = 1 week 
0.878, 𝑖𝑓 𝑡 = 4 weeks
  𝑆0(𝑡) = {
0.979, 𝑖𝑓 𝑡 = 2 𝑑𝑎𝑦𝑠  
0.955, 𝑖𝑓 𝑡 = 1 week 
0.893, 𝑖𝑓 𝑡 = 4 weeks
  
𝑃𝑟(𝐴𝑛𝑡𝑒𝑛𝑎𝑡𝑎𝑙 𝑎𝑑𝑣𝑒𝑟𝑠𝑒 𝑒𝑣𝑒𝑛𝑡) =  1 − 𝑆0(𝑡)
𝑒𝑥𝑝(?̂?𝑿) 
 
4.3.9 Application of final optimism adjusted models to new individuals 
The above findings show that the two prognostic modelling approaches gave 
similar results at each stage of model development and internal validation. In order to 
compare the predicted risk estimates produced by the final models, a fictitious patient 
(Patient Z) will be used for illustration. Patient Z is 25 years old and was diagnosed 
with pre-eclampsia 33.8 weeks into her pregnancy, she has no pre-existing medical 
conditions and has received treatment with magnesium sulphate. Their baseline test 
results are as follows: SBP= 159, platelet count= 226, ALT= 497, serum creatinine= 
61. Patient Z’s baseline characteristics are displayed in Table 4.12. 
In order to calculate Patient Z’s risk of experiencing an antenatal adverse event, 
the values above were incorporated into the final optimism adjusted prognostic model 
regression equations. The linear predictor equations from the optimism adjusted 
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models for Patient Z are given in Table 4.13. The difference between the linear 
predictor values from the two models for the hypothetical patient is 0.045. 
Table 4.12: Patient Z’s baseline characteristics 
Prognostic factors Patient Z 
Maternal age (MA) 25 
Gestational age (GA) 33.8 
Medical history (MH) 0 
Systolic blood pressure (SBP) 159 
Platelet count (PC) 226 
Serum Creatinine (SC) 61 
Antihypertensive treatment (AH) 0 
Magnesium sulphate treatment (MG) 1 
 
Table 4.13: Linear predictor calculation for Patient Z  
Cox proportional hazards model 
Royston-Parmar flexible parametric 
model 
𝐿𝑃 =   
–    0.021 ×  ((𝑴𝑨 = 𝟐𝟓) − 30.244)  
+  0.015 ×   ((𝑮𝑨 = 𝟑𝟑. 𝟖) − 30.562) 
+   0.012 ×  ((𝑺𝑩𝑷 = 𝟏𝟓𝟗) − 158.634) 
–   0.003 ×  ((𝑷𝑪 = 𝟐𝟐𝟔) − 227.532) 
+  0.012 ×  ((𝑺𝑪 = 𝟔𝟏) − 61.615) 
+  1.437 × (𝑴𝑮 = 𝟏) 
= 1.599  
𝐿𝑃 =   
–    0.032 ×  ((𝑴𝑨 = 𝟐𝟓) − 30.244)  
+  0.012 ×   ((𝑮𝑨 = 𝟑𝟑. 𝟖) − 30.562) 
+   0.011 ×  ((𝑺𝑩𝑷 = 𝟏𝟓𝟗) − 158.634) 
–   0.003 ×  ((𝑷𝑪 = 𝟐𝟐𝟔) − 227.532) 
+  0.012 ×  ((𝑺𝑪 = 𝟔𝟏) − 61.615) 
+  1.433 × (𝑴𝑮 = 𝟏) 
= 1.644  
 
The values from the linear predictor calculations were then combined with the re-
estimated baseline survival estimates to give the predicted cumulative risk of 
experiencing an antenatal adverse event at two days, one week, and four weeks for 
Patient Z. The calculations for predicted risks are shown in Table 4.14.  
The difference between the predicted risk estimates from the two models 
becomes larger as time progresses. A graphical display of Patient Z’s predicted 
cumulative risk of an antenatal event over time is depicted in Figure 4.5. 
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Table 4.14: Predicted cumulative risk of antenatal adverse events for Patient Z 
Cox proportional hazards model 
Royston-Parmar flexible parametric 
model 
𝑅𝑖𝑠𝑘 =  1 − 𝑆0(𝑡)
𝑒𝑥𝑝(1.599) 
1 − 0.980exp(1.599) =  9.5%, 𝑏𝑦 2 𝑑𝑎𝑦𝑠 
1 − 0.956exp(1.599) =  20.0%, 𝑏𝑦 1 𝑤𝑒𝑒𝑘 
1 − 0.878exp(1.599) =  47.5%, 𝑏𝑦 4 𝑤𝑒𝑒𝑘𝑠 
1 − 0.868exp(1.599) =  50.4%, 𝑏𝑦 40 𝑑𝑎𝑦𝑠 
1 − 0.847exp(1.599) =  56.0%, 𝑏𝑦 60 𝑑𝑎𝑦𝑠 
1 − 0.847exp(1.599) =  56.0%, 𝑏𝑦 80 𝑑𝑎𝑦𝑠  
𝑅𝑖𝑠𝑘 =  1 − 𝑆0(𝑡)
𝑒𝑥𝑝(1.644) 
1 − 0.979exp(1.644) =  10.4%, 𝑏𝑦 2 𝑑𝑎𝑦𝑠 
1 − 0.955exp(1.644) =  21.2%, 𝑏𝑦 1 𝑤𝑒𝑒𝑘 
1 − 0.893exp(1.644) =  44.3%, 𝑏𝑦 4 𝑤𝑒𝑒𝑘𝑠 
1 − 0.870exp(1.644) =  51.4%, 𝑏𝑦 40 𝑑𝑎𝑦𝑠 
1 − 0.840exp(1.644) =  59.4%, 𝑏𝑦 60 𝑑𝑎𝑦𝑠 
1 − 0.816exp(1.644) =  65.1%, 𝑏𝑦 80 𝑑𝑎𝑦𝑠  
 
Figure 4.5: Predicted cumulative risk for Patient Z 
 
 
Both models appear to give quite similar predictions of cumulative risk up to 
around 40 days, however after this time the model predictions diverge slightly. For 
example, at 60 days the predicted risk is 56.0% from the Cox model but 59.4% from 
the Royston-Parmar model. Arguably, the estimates over time produced by the 
Royston-Parmar model provide a more realistic risk profile for a patient compared 
to those produced by the Cox model. It is much more likely that the real world risk 
of an event is smoothly increasing over time, rather than jumping at specific time 
points (when an event is observed in another participant) and remaining stable in 
between these time points. 
4.4 Discussion 
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In this chapter, both Cox and Royston-Parmar regression methods were applied 
to develop two new prognostic models which predict the risk of antenatal adverse 
events in women diagnosed with early-onset pre-eclampsia. The models were 
internally validated and adjusted for optimism; the included prognostic factors, 
predictive performance, and final optimism adjusted equations were compared. The 
aim of this chapter was to demonstrate the standard time-to-event methods to develop 
prognostic models and compare models developed using two popular time-to-event 
approaches. 
Two commonly used time-to-event modelling methods, the Cox proportional 
hazards method (Cox, 1972a) and Royston-Parmar flexible parametric method 
(Royston and Parmar, 2002), were applied to develop prognostic models. Though the 
two modelling methods produced practically identical regression coefficient estimates, 
the difference between the estimation methods for the baseline survival function 
resulted in differences in predicted risks for individual patients over time, especially at 
later time points. The Royston-Parmar flexible parametric modelling approach directly 
estimates a smooth and flexible baseline cumulative hazard function, which can be 
utilised to produce smooth predicted risk estimates for study participants. This is 
advantageous over the Cox model, which requires additional modelling and estimation 
to estimate a non-parametric step function for the baseline cumulative hazard function. 
This stepped function becomes problematic at later time points as the number of 
participants and events decreases and the steps grow in size. At later time points the 
baseline hazard function from the Royston-Parmar approach extrapolates with little 
data, but the smooth function is more realistic. Hence, it is recommended the flexible 
parametric approach be used in prognostic model research and will be the focus of the 
remainder of this thesis. 
4.4.1 Limitations and further research 
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This chapter adds to the work conducted by the PREP study team 
(Thangaratinam et al., 2017) in developing prognostic models which may be used to 
inform pre-eclampsia patients of their risks of adverse events. The alteration of the 
definition of the outcome to antenatal adverse events compliments the prognostic 
models developed by the PREP study team, and both models may be used to give the 
patient a broader picture of their risk of events during pregnancy and their risk of 
preterm delivery. However, changing the outcome does not completely eradicate the 
risk of treatment paradox bias (Cheong‐See et al., 2016), as patients were censored 
at the time of delivery of the baby. Therefore, the risk predictions calculated using the 
prognostic models developed in this chapter should be interpreted as the risk of 
experiencing an antenatal adverse event over time in a hypothetical scenario where 
delivery of the baby (even for treatment) is not possible. 
Other methods have been proposed to reduce the risk of treatment paradox bias 
including: deleting the “trigger” prognostic factor from the model (Schuit et al., 2013), 
standardising treatment across predictor levels, using propensity scores (Cheong‐See 
et al., 2016), and modelling the probability of treatment (Groenwold et al., 2016). 
However, considering the definition of a competing event (an event which prevents or 
alters the risk of the event of interest from occurring (Koller et al., 2012)), a reasonable 
approach might be to model the treatment as a competing risk to the event of interest. 
By incorporating competing risks methodology into the development of prognostic 
models, one would be able to produce “real-world” risk prediction which would account 
for the presence and probability of the treatment happening. In the following chapter, 
the statistical methods to appropriately account for competing events will be utilised to 
develop prediction models for the risk of antenatal adverse events, accounting for the 
competing risk of delivery. Later, in Chapter 6, an additional dataset will be utilised to 
externally validate and compare the standard time-to-event and competing risks 
models developed in this and the following chapter.
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5 A COMPARISON OF PROGNOSTIC MODELS 
DEVELOPED USING FLEXIBLE PARAMETRIC 
COMPETING RISKS METHODS 
5.1 Introduction  
In this chapter, two prognostic models developed using different flexible 
parametric competing risks approaches (introduced in Section 1.4.5), namely the 
cause-specific (Hinchliffe and Lambert, 2013b) and subdistribution (Lambert et 
al., 2017) approaches are applied to develop two new prognostic models. Data 
from the PREP study (Thangaratinam et al., 2017), introduced in Chapter 4, will 
be used to develop and internally validate the models to predict the risk of 
antenatal adverse events in women diagnosed with early-onset pre-eclampsia, 
accounting for the competing event of delivery. The resulting models will be 
compared to illustrate similarities and differences between the two competing 
risks approaches. 
5.1.1 Prediction of antenatal adverse events with competing events 
The original PREP study (Thangaratinam et al., 2017) developed two 
multivariable prognostic models to predict the risk of adverse maternal outcomes 
in women diagnosed with confirmed early-onset pre-eclampsia. Pre-term delivery 
was included in the composite outcome, which resulted in limitations in the 
interpretation of the model predictions. Some of these limitations were addressed 
through the development of prognostic models which predict the risk of an 
alternative outcome, namely antenatal adverse events (Chapter 4). The models 
developed in Chapter 4 censor participants following delivery of the baby, as 
antenatal adverse events occur during pregnancy and delivery of the baby ends 
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the pregnancy. However, as delivery of the baby prevents antenatal adverse 
events from occurring, it is consequently a competing event and should be 
managed appropriately to avoid competing risks bias. Thus competing risks 
methods should be utilised in the development of prognostic models for antenatal 
adverse events. 
5.1.2 Aims 
This chapter expands on the analysis performed in Chapter 4 to appropriately 
account for the competing event of delivery when developing prognostic models 
for antenatal adverse events in women with early-onset pre-eclampsia. The 
developed models are presented, internally validated, and adjusted for optimism. 
The parameter estimates of the prediction models will be compared, as will the 
resulting model predictions, measures of prognostic ability, and optimism. 
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5.2 Methods: Developing two prognostic models with competing 
events 
Methods for the development and internal validation of the flexible parametric 
competing risks prognostic models are now described. 
5.2.1 Antenatal adverse events with competing risks outcome definition 
The time to an antenatal adverse event in women with pre-eclampsia can be 
considered as a multi-state structure, as depicted in Figure 5.1. Participants enter the 
initial state on the date of a confirmed diagnosis of pre-eclampsia, and remain in this 
state until they experience an event. On the date an event occurs, the patient 
transitions out of the initial state into one of the two final absorbing states. 
Figure 5.1: Competing risks multi-state structure for PREP study 
 
Boxes represent states and arrows represent transitions. 
All participants enter the study at pre-eclampsia diagnosis (the initial state). 
Following an antenatal adverse event event (the event of interest, k=1), participants 
transition into the associated absorbing state (pregnant following adverse event). 
Participants who deliver the baby (the competing event) transition into a different 
absorbing state (no longer pregnant). 
 
The definition of an antenatal adverse event remains unchanged from that 
outlined in Section 4.2.1; a composite outcome comprised of component events listed 
in Table 5.1. However, in this chapter delivery of the baby, which prevents the event 
of interest from occurring, is now considered a competing event (recall deliveries were 
censored in the previous chapter). 
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Table 5.1: Individual components of antenatal adverse events 
 
The primary aim of the prognostic models developed in this chapter is to predict 
the risk of experiencing an antenatal adverse event, which by definition occurs prior to 
delivery. The use of competing risks methods will allow the calculation of this risk while 
appropriately accounting for the presence of the competing event (delivery of the 
baby). Though delivery of the baby can occur after an antenatal adverse event, it is not 
necessary to model this transition when evaluating the risk of antenatal adverse events 
which occur before delivery. Events which occur after delivery, such as a postpartum 
haemorrhage, are again not captured by this structure so are excluded from the 
definition. If both an adverse event and delivery occurred on the same date the 
outcome was recorded as an antenatal adverse event, as it is likely that this adverse 
event would trigger induction of labour as a treatment. 
5.2.2 Candidate prognostic factors 
The restricted set of candidate prognostic factors considered in Chapter 4 (listed 
in Table 5.2) was utilised during the development of the competing risks 
prognostic models. 
Antenatal adverse events 
Placental abruption, transfusion of blood, eclamptic seizure, hepatic dysfunction, 
pulmonary oedema, intubation, acute renal insufficiency, at least 50% FIO2 for > 1hour, 
Glasgow Coma score <13 
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Table 5.2: Candidate prognostic factors for competing risks prognostic models 
Maternal characteristics: 
Maternal age at diagnosis (years), 
Gestational age at diagnosis (weeks). 
Medical history: 
Count of pre-existing conditions (0, 1, 2 or more) from pre-specified list: pre-existing 
hypertension, renal disease, diabetes mellitus, previous history of pre-eclampsia. 
Bedside examination and tests: 
Systolic blood pressure (mmHg, highest measurement over 6 hrs), 
Platelet count (x 109/L), 
Alanine amino transaminase (IU/l), 
Serum creatinine μmol/L. 
Management at baseline (before or within 1 day of diagnosis): 
Administration of oral and/or parenteral anti-hypertensives, 
Administration of magnesium sulphate. 
 
5.2.3 Competing events risk sets and data structures 
The two competing risks approaches require the study data to be re-structured to 
reflect the associated risk set (depicted in Figure 1.9). The cause-specific approach 
required the data to be restructured using the multi-state structure (see Figure 1.11), 
with multiple rows for each participant. The subdistribution approach required those 
participants who experienced a competing event to remain in the risk set (see Figure 
1.9). Thus, the time-to-event for those who delivered was replaced with the time of the 
last observed antenatal adverse event in the entire dataset (t=117 days), at which time 
these participants were censored. 
5.2.4 Non-parametric assessment of competing risks bias 
Competing risks bias was assessed by comparing the non-parametric Kaplan-
Meier curve which censor the competing event of delivery (shown in Figure 4.1) to non-
parametric cumulative incidence curves which appropriately account for competing 
events, estimated using the subdistribution risk set. The difference between these 
curves represents the amount of competing risks bias present when the competing 
events are not appropriately accounted for. 
5.2.5 Multiple imputation with competing events 
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Though complete data were available for a large proportion (829, 87.5%) of the 
PREP cohort, multiple imputation using chained equations (Van Buuren et al., 1999) 
techniques were applied to missing information to avoid a loss of information. Under a 
missing at random assumption, a total of 20 imputed datasets were created from the 
original (not restructured) PREP study data using the mi impute chained package in 
Stata 14. The chained equations included the candidate prognostic factors listed in 
Table 5.2, with medical history separated into its individual components. The 
appropriate outcome information for each competing risk approach (discussed in 
Section 1.5.1) was also incorporated into the chained equations. Missing values from 
continuous prognostic factors were imputed using the predictive mean matching 
method (Little, 1988), and those from binary prognostic factors were imputed using 
augmented logistic regression (White et al., 2010). The imputed datasets were then 
restructured to reflect the competing event risk sets as described in 5.2.3. Imputed 
values were visually inspected to determine any outliers, but none were identified. 
Information on outcome measures, including pre-eclampsia diagnosis date, date of 
event, and event type, were complete and thus were not imputed. 
5.2.6 Flexible parametric competing risks regression models 
Two new flexible parametric prognostic models were developed to predict the risk 
of antenatal adverse events in women diagnosed with early onset pre-eclampsia 
accounting for the competing event of delivery. The first was developed using the 
cause-specific approach; the second was developed using the subdistribution 
approach. Details of the statistical methods of these approaches, provided in more 
detail in Section 1.4.5, are summarised below. 
Briefly, the cause-specific approach (Hinchliffe and Lambert, 2013b) was used to 
develop one flexible parametric competing risks model using the multistate package 
with the stpm2 estimation command in Stata. Restricted cubic splines of log-time are 
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utilised to approximate the log cumulative baseline cause-specific hazard function. The 
model regression coefficients and spline function parameter estimates are calculated 
simultaneously through maximum partial likelihood techniques. Estimates of both the 
cause-specific hazard function for antenatal adverse events and the cause-specific 
hazard function for delivery are required to obtain an estimate of the cause-specific 
cumulative incidence function (i.e. risk of having an antenatal adverse event over time). 
Plots of estimated cumulative cause-specific hazard functions for null models 
(containing no prognostic factors), with splines of varying degrees of freedom (between 
two and five), were inspected for each event separately to determine the number of 
knots required to capture the shape of the underlying functions. 
The subdistribution approach (Lambert et al., 2017) was used to develop the 
other flexible parametric competing risks model using the stpm2 estimation command 
in Stata. Restricted cubic splines of log-time are utilised to approximate the log 
cumulative baseline subdistribution hazard function. The model regression coefficients 
and spline function parameter estimates are calculated simultaneously through 
maximising the weighted partial likelihood function (Lambert et al., 2017). This 
approach only requires the estimation of the subdistribution hazard function for 
antenatal adverse events to obtain an estimate of the cause-specific cumulative 
incidence function (i.e. risk of having an antenatal adverse event over time). The 
number of knots required to capture the shape of the underlying subdistribution hazard 
function was determined by visual inspection of the plots of the estimated cumulative 
subdistribution hazard function for null models (containing no prognostic factors) with 
splines of varying degrees of freedom (between two and five). 
Fractional polynomial terms were incorporated into the models to investigate non-
linear associations between continuous prognostic factors and the outcome. The 
methods for incorporating these terms are described in Section 4.2.6. 
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5.2.7 Multivariable analysis and prognostic factor selection procedure of 
prognostic models with competing events 
Multivariable analyses, using either the cause-specific or subdistribution 
approaches, were performed to develop two flexible parametric competing risks 
prognostic models. A backwards elimination procedure was applied to determine which 
of the candidate prognostic factors would be included in the final multivariable 
prognostic models. The procedure utilised the multiply imputed data adapted to 
incorporate fractional polynomial terms using the mfpmi Stata package (Morris et al., 
2015). This procedure was additionally adapted to the competing risks approaches as 
follows: 
• The cause-specific approach began with the stacked imputed and restructured 
cause-specific dataset. The full model was developed using a multi-state modelling 
approach which simultaneously models the cause-specific hazards for both the 
event of interest (antenatal adverse events) and the competing event (delivery). 
The full model incorporated the cause-specific associations of all candidate 
prognostic factors with each outcome, with all continuous candidate prognostic 
factors included as linear terms. 
• The subdistribution approach began with the stacked imputed and restructured 
subdistribution dataset. The full model was developed using the subdistribution 
risk set which models the subdistribution hazards for antenatal adverse events 
only. The full model incorporated the subdistribution associations for all candidate 
prognostic factors and the outcome of interest, with all continuous prognostic 
factors included as linear terms. 
The same backwards selection procedure outlined in Box 4.1 was applied to 
determine which candidate prognostic factors would be retained in the final models. 
Both maternal and gestational age were retained in the models regardless of their 
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significance to ensure clinical acceptability of the final models in line with the original 
PREP study (Thangaratinam et al., 2017). The treatment variables (antihypertensive 
and magnesium sulphate treatment) were likewise retained to reduce the risk of 
suboptimal prognostic performance (Groenwold et al., 2016). The multivariable model 
cause-specific or subdistribution hazard ratios, 95% confidence intervals, and 
prognostic factor selection results (including exclusion and transformations of the 
included factors) were compared across the two approaches. 
5.2.8 Baseline cumulative incidence functions 
The risk of experiencing an antenatal adverse event over time for a participant 
with “average” prognostic factor values was estimated using the baseline (all 
prognostic factors centred and set to zero) cause-specific cumulative incidence 
function. Baseline cause-specific cumulative incidence functions for antenatal adverse 
events were calculated using both the cause-specific and subdistribution approaches. 
Both approaches estimate the cumulative baseline cause-specific or subdistribution 
hazards for the event of interest using the restricted cubic spline function of log time 
(Equations 1.28 & 1.31). The cause-specific approach also derives an estimate of the 
cumulative baseline cause-specific hazard for the competing event. These estimates 
are then transformed to return baseline cause-specific cumulative incidence function 
estimates. Median baseline cause-specific cumulative incidence estimates for each 
approach were calculated at two days, one week, and four weeks for patients in the 
PREP study using the flexible parametric competing risks prognostic models. 
5.2.9 Sensitivity analysis 
A sensitivity analysis was performed to investigate the assumptions made during 
model development, namely proportional hazards assumptions and independent 
effects (i.e. no interactions). Both competing risks approaches when developed in the 
way described above, assume proportional cause-specific or subdistribution hazards. 
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That is that the corresponding hazard ratios of the prognostic factors contained within 
the model remain constant over time, which cannot hold for both models 
simultaneously. These assumptions were tested for each of the retained prognostic 
factors in turn by incorporating an interaction between the prognostic factor and time 
into the final multivariable models. Other clinically plausible interactions between the 
retained prognostic factors were also investigated in turn to test the assumption that 
the effects of each prognostic factor on the outcome were independent. Any 
statistically significant (P < 0.05) deviations from the assumptions were reported. 
5.2.10 Comparison of individual absolute risk predictions 
Each participant’s individual risk of experiencing an adverse antenatal event was 
calculated using the cause-specific cumulative incidence function. The cause-specific 
approach requires cause-specific hazard estimates for both outcomes to return 
absolute risk estimates (Equation 1.30). Cause-specific cumulative incidence 
estimates were obtained using the simulation approach (described in Section 1.4.5), 
which combines estimated regression coefficients with a transition probability matrix 
(estimated using the cumulative cause-specific hazard function). The subdistribution 
approach estimates the cause-specific cumulative incidence through the 
transformation of the combined regression coefficient estimates and the log cumulative 
subdistribution hazard estimates (Equation 1.32). The predicted risks of antenatal 
adverse events were calculated for each of the PREP study participants using the 
flexible parametric competing risks prognostic models. The predicted risks for 
participants with missing data were calculated using the median imputed value for each 
prognostic factor for that participant. Median cause-specific cumulative incidence 
estimates, and the distribution of predicted risk in the PREP study participants, were 
calculated at two days, one week, and four weeks, these were compared across the 
two approaches. 
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5.2.11 Apparent prognostic performance of the fitted prognostic models 
Four risk groups were created by splitting the PREP study participants into four 
equal groups using the 25th, 50th, and 75th centiles of the estimated cause-specific 
cumulative incidence estimates at four weeks for each approach. The median 
predicted cause-specific cumulative incidence at two days, one week, and four weeks 
was calculated for each group, estimates were compared between the modelling 
approaches. Average predicted cause-specific cumulative incidence functions for each 
group over time were calculated and compared to non-parametric cumulative 
incidence estimates. 
The apparent performance of the fitted models was assessed in the imputed 
PREP study data using measures of calibration (overall calibration and calibration 
slope) and discrimination (Harrell’s C-index, D-statistic, and R2D), assessed at two 
days, one week, and four weeks. Overall calibration was examined by comparing the 
expected number of events (from the prognostic models) to the observed number of 
events (non-parametric cause-specific cumulative incidence estimates) from the 
aforementioned risk groups at pre-specified time points. Calibration plots, which graph 
the expected vs. observed cause-specific cumulative incidence estimates, were 
utilised to estimate the calibration slope at each of the given time points. The calibration 
slope was estimated by regressing the individual expected risks (obtained from the 
prognostic models) on the individual observed outcomes (obtained from non-
parametric cumulative incidence estimates), with a Lowess smoother. Harrell’s C-index 
(Harrell et al., 1982) was calculated at the pre-specified time points, utilising the 
subdistribution risk set to determine which pairs are concordant. Finally, the D-statistic 
and R2D measures were calculated for the models. All measures were calculated in 
each imputed dataset separately (imputation-specific measures) and were then 
combined using Rubin’s rules. The apparent performance measures for both 
competing risks prognostic models were compared. 
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5.2.12 Internal validation and optimism adjustment: subdistribution approach 
The model developed using the cause-specific approach was not internally 
validated, nor adjusted for optimism. The time consuming24, computationally intensive 
nature of the simulation approach for obtaining individual risk predictions from this 
model, alongside the lack of methods for optimism adjustment, resulted in the decision 
to not proceed further with this particular model. However, the optimism in the apparent 
performance of the subdistribution model was assessed through internal validation 
using 100 bootstrap samples of the original (not restructured) PREP study data, as in 
Chapter 4. The bootstrap validation procedure is outlined in Box 4.2. Optimism 
adjusted prognostic performance measures were calculated by subtracting the 
average optimism from the original apparent performance measures as estimated for 
the fitted model previously (see Section 5.2.11). An optimism adjusted subdistribution 
model was created by multiplying the fitted regression coefficients by the optimism 
adjusted calibration slope (representing a uniform shrinkage factor) obtained from the 
bootstrap procedure. Then, the cumulative baseline subdistribution hazard function 
was re-estimated to maintain overall calibration between observed and predicted risks. 
  
                                                     
24 Fitting the multivariable cause-specific model for death (methods in 5.2.7) took 2 mins 42.8 secs, the 
multivariable cause-specific model for antenatal adverse events took 3 mins 14.7 secs. Obtaining 
individual absolute risk predictions for the PREP study participants after the models were fitted took a 
further 1 hr 17 mins 46.6 seconds. 
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5.3 Results: Comparison of prognostic models for antenatal 
adverse events developed using flexible parametric competing 
risks methods. 
The PREP study (Thangaratinam et al., 2017) data contained 947 women with a 
confirmed diagnosis of pre-eclampsia, of whom 75 (7.9%) experienced an antenatal 
adverse event (i.e. before delivery) and the remaining 872 (92.1%) delivered the baby 
without an antenatal adverse event. 
5.3.1 Non-parametric assessment of competing risks bias 
Non-parametric cumulative incidence estimates for antenatal adverse events, 
which appropriately accounts for competing events, are compared to Kaplan-Meier 
failure estimates over time: these are depicted in Figure 5.2. 
Figure 5.2: Non-parametric cumulative incidence estimates for antenatal adverse 
events after accounting for competing risks, compared to Kaplan-Meier curve 
that ignores competing risks 
 
 
By 100 days, 74 of the 947 women had experienced an antenatal adverse event. As 
there is no censoring in the study (all participants either experience the event of interest 
or the competing event) the cumulative incidence at 100 days is FAAE(t = 100) =
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947⁄ = 7.8%. Whereas the Kaplan-Meier estimate for the risk of experiencing an 
antenatal adverse event at 100 days is 14.3%. Those who experience competing 
events are removed from the denominator (risk set) of the Kaplan-Meier estimate but 
retained for the cumulative incidence estimate. Thus Kaplan-Meier risk estimates are 
larger than the cumulative incidence estimates and inflate/overestimate the absolute 
risk of the event of interest in the presence of competing events. 
The difference between the Kaplan-Meier and cumulative incidence estimates 
represents competing risks bias (the difference between ignoring and correctly 
accounting for competing events). The amount of competing risks bias increases over 
study time as more competing events occur, this is displayed in Figure 5.3. At 100 days 
the competing risks bias is 0.065. This may appear small, however when compared to 
the cumulative incidence estimate (0.079 at 100 days) indicates an 83.1% increase in 
the absolute risk estimate. Therefore, ignoring the competing events leads to a risk 
estimate that is nearly double that of the estimated risk when accounting for the 
competing events. 
Figure 5.3: Absolute measure of competing risks bias: difference in non-
parametric estimates of cumulative risk of antenatal adverse events when 
ignoring the competing risks versus when accounting for them 
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5.3.2 Estimation of baseline cumulative hazard functions 
Null models (containing no prognostic factors) were fitted, using spline functions 
with between two and five degrees of freedom, to determine the number of knots 
required to adequately capture the shape of the underlying hazard functions. For the 
subdistribution approach, the cumulative subdistribution hazard function for antenatal 
adverse events was examined. Whereas for the cause-specific approach, the 
cumulative cause-specific hazard functions for both antenatal adverse events and 
delivery were examined separately. The resulting knot locations, Akaikes information 
criterion (AIC), and Bayesian information criterion (BIC) values from the models are 
provided in Table 5.3.  
Table 5.3: Knot selection for Royston-Parmar flexible parametric model 
Approach 
Degrees of 
freedom 
Number of 
knots 
Internal knot locations 
(time in days) 
AIC BIC 
Subdistribution 
appraoch: 
antenatal 
adverse events 
2 1 2.7 886.9 901.4 
3 2 0.7, 7.0 882.0 901.4 
4 3 0.4, 2.7, 10.1 878.2 902.4 
5 4 0.1, 1.3, 5.4, 13.3 878.7 907.8 
Cause-specific 
appraoch: 
antenatal 
adverse events 
2 1 2.7 803.4 818.0 
3 2 0.7, 7.0 804.7 824.1 
4 3 0.4, 2.7, 10.1 805.3 829.6 
5 4 0.1, 1.3, 5.4, 13.3 806.1 835.2 
Cause-specific 
approach: 
delivery 
2 1 9.3 3054.4 3068.9 
3 2 4.5, 17.6 3028.8 3048.2 
4 3 3.3, 9.3, 23.4 3029.2 3053.4 
5 4 2.4, 6.3, 14.0, 29.3 3030.3 3059.4 
 
For the subdistribution approach, the spline with three internal knots (4 d.f.) gives 
the smallest AIC values whereas the splines with one and two internal knots (2 & 3 
d.f.) give the smallest BIC values. For the cause-specific approach, the spline with one 
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internal knot (2 d.f.) gives the lowest AIC and BIC values for antenatal adverse events 
model, and the spline with two internal knots (3 d.f.) gives the lowest AIC and BIC 
values for the delivery model. 
A graphical display of the spline estimates for the cumulative subdistribution and 
cause-specific hazards are depicted in Figure 5.4. Using the subdistribution approach, 
there is little observable difference between the curves with three, four, and five 
degrees of freedom. Therefore the spline with three degrees of freedom (green line) 
was considered suitable for the remainder of the analysis. Using the cause-specific 
approach, there is little observable difference between the spline functions for 
antenatal adverse events, thus two degrees of freedom was considered suitable for 
the spline function in the analysis to follow. No notable differences were found between 
the spline functions for delivery with three, four, and five degrees of freedom, thus three 
degrees of freedom was considered adequate for prognostic model development. The 
selected spline functions were compared to non-parametric Nelson-Aalen type 
cumulative subdistribution and cause-specific hazard estimates (displayed in Figure 
5.5), and appear to adequately fit the underlying hazard functions. 
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Figure 5.4: Comparison of spline functions with varying degrees of freedom for 
the cumulative subdistribution and cause-specific hazard functions 
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Figure 5.5: Comparison of spline functions selected for modelling against non-
parametric Nelson-Aalen type estimates of cumulative hazards 
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5.3.3 Multivariable analysis and prognostic factor selection procedure of 
prognostic models for competing events 
The backwards elimination procedure for multiply imputed data, incorporating 
fractional polynomial terms and adapted for competing risks, was applied using both 
the cause-specific and subdistribution approaches. The resulting cause-specific and 
subdistribution hazard ratio estimates, 95% confidence intervals and p-values are 
reported in Table 5.4. 
Using the cause-specific approach, all of the candidate prognostic factors were 
found to be significantly (p<0.15) associated with delivery (the competing event), thus 
none were excluded from that model. Applying this approach to antenatal adverse 
events (the event of interest) found medical history, systolic blood pressure, platelet 
count, serum creatinine, and magnesium sulphate to be significantly (p<0.15) 
associated with the event. Though the remaining candidate prognostic factors were 
found not to be statistically significant (p<0.15), maternal age, gestational age, and 
antihypertensive treatment were forcibly retained in the model. Thus only alanine 
amino transaminase was excluded from the cause-specific model for antenatal 
adverse events. 
Using the subdistribution approach, only medical history was found to be 
significantly (p<0.15) associated with antenatal adverse events. However, maternal 
age, gestational age, and the two treatment prognostic factors were forcibly retained 
in the model, despite not being statistically significant (p<0.15). The remaining 
prognostic factors were excluded from this model. 
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Table 5.4: Multivariable hazard ratios for included prognostic factors 
 Cause-specific model:  
delivery 
Cause-specific model:  
antenatal adverse events 
Subdistribution model:  
antenatal adverse events 
 Transformation 
of prognostic 
factor (X) 
CSHR  
(95% CI) 
p-value 
Transformation 
of prognostic 
factor (X) 
CSHR  
(95% CI) 
p-value 
Transformation of 
prognostic factor (X) 
SDHR  
(95% CI) 
p-value 
Maternal age 
(years) 
X - 30.245 
0.973 
(0.962, 0.984) 
<0.001 
X - 30.245 
0.975 
(0.938, 1.013) 
0.189 
X - 30.245 
0.993 
(0.955, 1.032) 
0.709 
Gestational age 
(weeks) 
((X/10)-2) – 
0.107 
0.000 
(0.000, 0.000) 
<0.001 
X - 30.562 
1.017 
(0.941, 1.098) 
0.676 
X - 30.562 
0.951 
(0.88, 1.028) 
0.205 
Medical 
history* 
1 
 
2 or 
more 
 
 
0.813 
(0.692, 0.955) 
0.662 
(0.522, 0.84) 
0.001 
 
0.465 
(0.245, 0.882) 
0.636 
(0.275, 1.468) 
0.040 
 
0.536 
(0.284, 1.011) 
0.830 
(0.369, 1.871) 
0.128 
Systolic blood 
pressure 
X – 158.64 
1.018 
(1.014, 1.022) 
<0.001 
X – 158.64 
1.014 
(1.002, 1.027) 
0.023 
 Excluded 
Platelet count X – 227.528 
0.997 
(0.996, 0.998) 
<0.001 
X – 227.528 
0.996 
(0.993, 0.999) 
0.017 
 Excluded 
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 Cause-specific model:  
delivery 
Cause-specific model:  
antenatal adverse events 
Subdistribution model:  
antenatal adverse events 
 Transformation 
of prognostic 
factor (X) 
CSHR  
(95% CI) 
p-value 
Transformation 
of prognostic 
factor (X) 
CSHR  
(95% CI) 
p-value 
Transformation of 
prognostic factor (X) 
SDHR  
(95% CI) 
p-value 
Alanine amino 
transaminase 
Ln(X/1000) 
+3.446 
1.212 
(1.095, 1.342) 
<0.001 
 Excluded  Excluded 
Serum creatinine X – 61.61 
1.013 
(1.009, 1.017) 
<0.001 
X – 61.61 
1.015 
(1.003, 1.026) 
0.011 
 Excluded 
Antihypertensive 
treatment 
 
1.343 
(1.134, 1.592) 
0.001 
 
1.278 
(0.67, 2.439) 
0.457 
 
1.194 
(0.633, 2.252) 
0.653 
Magnesium 
sulphate treatment 
 
3.199 
(2.553, 4.008) 
<0.001 
 
5.294 
(2.891, 9.692) 
<0.001 
 
3.136 
(0.633, 2.252) 
0.584 
CSHR = cause-specific hazard ratio, SDHR = subdistribution hazard ratio, 95% CI = 95% confidence interval. 
*Medical history is a count of the following conditions: chronic hypertension, renal disease, diabetes millitus, and previous pre-eclampsia. 
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Patients with at least one pre-existing medical condition were again found to have 
a lower risk of antenatal adverse events compared to those with no pre-existing 
medical conditions. As previously stated, this finding is consistent with existing 
prognostic models that are currently in use (von Dadelszen et al., 2009, Thangaratinam 
et al., 2017). The reduction in risk was also present in the cause-specific model for 
delivery. A potential explanation for this association may be that patients with additional 
complications were more likely to seek or receive pre-natal care, which is known to 
reduce the risks of complications and early delivery (von Dadelszen et al., 2009). Both 
antihypertensive and magnesium sulphate treatments were found to significantly 
increase the risk of delivery, and magnesium sulphate treatment was again found to 
increase the risk of antenatal events, in the cause-specific models. This is expected, 
as these treatments are given to high risk patients to minimise the risk of eclampsia its 
associated complications. 
The two competing risks approaches are applied to estimate the cause-specific 
cumulative incidence function for antenatal adverse events. However, the model 
selection procedure resulted in a simpler model being selected for the subdistribution 
approach (containing five prognostic factors) and a more complex model for the cause-
specific approach (containing all nine prognostic factors for delivery and eight for 
antenatal adverse events). The subdistribution model is more parsimonious, however 
further investigations are required to assess the prognostic ability of the models. 
5.3.4  Comparison of baseline cumulative incidence functions 
The risk of experiencing an antenatal adverse event over time for a participant 
with average continuous prognostic factor, and zero categorical prognostic factor 
values is estimated as the baseline cause-specific cumulative incidence. Estimates of 
the baseline cumulative incidence function for antenatal adverse events from the 
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subdistribution and cause-specific models are reported in Table 4.6, at given time 
points, and over time in Figure 5.6. 
Table 5.5: Baseline cumulative incidence estimates for antenatal adverse events 
from fitted competing risks prognostic models 
Time 2 days 1 week 4 weeks 
Subdistribution model 0.030 0.044 0.056 
Cause-specific model 0.018 0.034 0.056 
 
The baseline cumulative incidence estimates from each of the competing risks 
approaches indicate the risk of antenatal adverse events increases steeply in the first 
three weeks after pre-eclampsia diagnosis. After this time the absolute risk remains 
stable at around 6%. The subdistribution model predicts a steeper increase in risk in 
the first week after pre-eclampsia diagnosis compared to the cause-specific model. 
However, the difference in absolute risks at this time is 1%, and the predictions made 
by the models tend to agree at later time points (three weeks after diagnosis). 
The cause-specific approach requires estimates from all events to be combined, 
thus incorporates baseline cumulative incidence estimates for delivery (also depicted 
in Figure 5.6). The predicted risk of delivery increases steadily the first five weeks 
following pre-eclampsia diagnosis, on a much larger scale to antenatal adverse events 
(note the y axis). The absolute risk of delivery stabilizes at 94%, as deliveries are more 
common than antenatal adverse events. 
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Figure 5.6: Baseline cumulative incidence functions estimated using 
subdistribution and cause-specific approaches 
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5.3.5 Sensitivity analysis 
A sensitivity analysis was conducted to test the assumptions made during model 
development. The proportional hazards assumption, made by both the cause-specific 
and subdistribution approaches, was tested by incorporating interactions between the 
included prognostic factors and log time, using a linear (one degree of freedom) spline 
function. The results are given in Appendix X; there is evidence that the effect of 
magnesium sulphate treatment was not constant over time in both the subdistribution 
and cause-specific approaches (p<0.001), and thus the proportional hazards 
assumption was violated for all fitted models. Additionally, the proportional cause-
specific hazards assumption was violated for systolic blood pressure (p=0.003) and 
maternal age (p=0.005) for the delivery model. Again, these non-proportional 
estimates were intentionally disregarded due to the small sample size of this study and 
the concern for overfitting. Again the inclusion of significant time interactions was 
thought unlikely to affect the prognostic performance of the models, as the time points 
assessed occur soon after diagnosis (2 days, 1 week, and 4 weeks). In general, the 
assumption of proportional subdistribution hazards does not hold if the assumption of 
proportional cause-specific hazards is true (Beyersmann et al., 2009). The results from 
the subdistribution model may be interpreted as time-averaged effects on the 
cumulative incidence scale, which may affect the interpretation of the model 
predictions. However, not incorporating these interactions is unlikely to affect the 
results of this chapter, which focuses on the comparison of the two competing risks 
modelling approaches. 
5.3.6 Comparison of competing risks prognostic model predictions  
The flexible parametric competing risks prognostic models were applied to the 
PREP study participants to predict a participant’s risk of antenatal adverse events, 
accounting for the presence of competing events. Although these are not the final 
models, comparisons at this stage are presented as the subdistribution hazard will be 
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adjusted for optimism while the cause-specific hazard model will not. To enable 
predictions for the full set of individuals used within model development, any missing 
information was assigned the median imputed value for each missing prognostic factor 
for each participant. The median cause-specific cumulative incidence estimates for 
antenatal adverse events for both modelling approaches are reported in Table 5.6. 
Table 5.6: Median cumulative incidence estimates for antenatal adverse events 
 
2 days 1 week 4weeks 
Subdistribution model 3.2% 4.8% 6.0% 
Cause-specific model 1.9% 3.5% 5.7% 
 
The average predicted risk of experiencing an antenatal adverse event estimated 
using the cause-specific model is lower at all time points compared to those from the 
subdistribution model. However, the differences are small (1.3% at two days and one 
week) and lessen as time progresses (0.3% at four weeks). Distributions of the 
predicted cumulative risk of antenatal adverse events for PREP study participants at 
two days, one week, and four weeks estimated using the two competing risks 
prognostic models are displayed in Figure 5.7. 
Both models produced right-skewed risk prediction distributions, with the majority 
of participants predicted to have a low risk (<10%) of experiencing an antenatal 
adverse event. For both models the distribution of predicted risks shift steadily upwards 
as time progresses. The range of predicted risks estimated using the subdistribution 
model grows over time, with a maximum predicted risk of 15.0% at two days, and 
26.8% at four weeks. Whereas the range of predicted risks estimated using the case-
specific model remains stable, with maximum values of 42.8% and 43.8% at two days 
and four weeks respectively. 
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Figure 5.7: Predicted cumulative incidence of an antenatal adverse events from competing risks prognostic models 
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5.3.7 Apparent prognostic performance of the fitted prognostic models 
The median predicted cumulative risk of experiencing an antenatal adverse event 
at two days, one week, and four weeks for each of the four risk groups are presented 
in Table 5.7. The average predicted risks estimated using the subdistribution model 
are greater than the average risks estimated using the cause-specific model at all time 
points for all but the highest risk group. 
Table 5.7: Median predicted cumulative incidence for risk groups at given time 
points 
 Subdistribution model Cause-specific model 
 2 days 1 week 4weeks 2 days 1 week 4weeks 
<25th centile 1.8% 2.7% 3.4% 0.6% 1.6% 2.9% 
25-50th centile 3.0% 4.4% 5.6% 1.4% 2.7% 4.8% 
50-75th centile 3.4% 5.1% 6.4% 2.4% 4.3% 6.6% 
>75th centile 7.1% 10.5% 13.1% 9.1% 12.4% 12.9% 
 
The average predicted cumulative incidence of antenatal adverse events for the 
four risk groups over time are presented in Figure 5.8 (solid lines) for each model. 
These are compared to observed risks (dashed lines), calculated using the non-
parametric cumulative incidence functions which account for competing events. 
The predicted cumulative risks of both models struggle to capture the steep 
increase in cumulative incidences directly after pre-eclampsia diagnosis. The steep 
increase in risk observed in the highest risk group (>75th centile: red lines) directly 
after pre-eclampsia diagnosis is better captured by the cause-specific model than the 
subdistribution model. The average risk predictions from the subdistribution model 
agree with the observed risks from three weeks following diagnosis for all groups apart 
from the second highest (50-75th centile: yellow line). The average predicted risks from 
the cause-specific model agree with the observed risks up to three weeks following 
diagnosis for all risk groups, and at all times for the lowest risk group (<25th centile: 
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green line). There is little observable difference between the average risk in the middle 
two risk groups (25-50th centile: blue line, 50-75th centile: yellow line) after 40 days, 
though the cause-specific model predicts some difference between the groups. 
Figure 5.8: Predicted cumulative incidence of antenatal adverse events by risk 
groups for competing risks prognostic models 
 
 
The solid lines represent the average predicted cumulative incidence of 
antenatal adverse events for the four risk groups over time. 
The dashed lines represent average observed risks for each risk group, 
calculated using non-parametric cumulative incidence functions which 
account for competing events. 
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The expected and observed risks of antenatal adverse events at two days, one 
week, and four weeks were calculated for the PREP study participants using both 
prognostic models. These measures are compared in Table 5.8. The expected risks 
from the subdistribution model are closer to the observed risks than those of the cause-
specific model at all time points. The overall calibration performance of the 
subdistribution model is good (E/O>0.9) two days and one week after diagnosis, the 
performance decreases for the last time point. The overall calibration performance of 
the cause-specific model improves over time. 
Table 5.8: Apparent overall calibration of competing risks prognostic models  
 Non-parametric 
CIF estimate 
Subdistribution model Cause-specific model 
Expected E/O Expected E/O 
2 days 3.5% 3.2% 0.914 1.9% 0.543 
1 week 5.3% 4.8% 0.906 3.5% 0.660 
4 weeks 7.6% 6.0% 0.789 5.7% 0.750 
 
The apparent calibration slope for the subdistribution model was 1.001i (95% CI: 
0.65, 1.35) in the data in which the model was developed, as expected. Calibration 
plots of expected and observed risks at four weeks for both models are depicted in 
Figure 5.9. The subdistribution model again appears to perform slightly better than the 
cause-specific model. 
A potential explanation for the difference in calibration performance between the 
two models may be due to the requirement of the cause-specific model to estimate 
parameters for both the event of interest and the competing event. This approach may 
thus require a larger sample size to accurately estimate the cumulative incidence 
function for an event, hence resulting in poorer calibration performance. 
 
                                                     
iThe apparent calibration slope was found not to be exactly 1 because of the multiple imputation methods 
used in both model development and validation. 
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Figure 5.9: Calibration plots for expected and observed risks of antenatal adverse events 4 weeks following pre-eclampsia diagnosis 
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Discrimination was assessed using Harrell’s C-index at two days, one week, four 
weeks, and overall, the D-statistic, which measures prognostic separation, and R2D 
(the proportion of explained variation). The resulting measures of discrimination are 
given in Table 5.9. Both models are better able to discriminate between those who 
experience the outcome of interest and those who do not two days after diagnosis than 
four weeks after diagnosis. The cause-specific model produces larger C-index 
measures at all time points. The subdistribution model explains 16.5% of the variation 
between the two prognostic outcomes, whereas the cause-specific model (ranked 
using 4 week predictionsi) explains 15.2% of the variation. 
Table 5.9: Harrell's C-index, D-statistic, and R2D for discrimination for fitted 
prognostic models (apparent performance) 
 
Harrell’s C-index 
Royston and Sauerbrei’s  
D-statistic 
2 days 1 week 4 weeks Overall D-statistic R2D 
Subdistribution model 0.824 0.721 0.649 
0.652 
(0.59, 0.72) 0.908 0.165 
Cause-specific model 0.836 0.753 0.678 ii 0.868 0.152 
 
In summary, the apparent predictive performance of the competing risks 
prognostic models differ slightly. The subdistribution model is well calibrated and better 
able to predict the observed risks of antenatal adverse events, whereas the cause-
specific model is better able to discriminate between those who will and won’t go on to 
experience an antenatal adverse event. Both model’s ability to discriminate between 
the two competing events lessen as time progresses, as expected. 
5.3.8 Internal validation and shrinkage of subdistribution prognostic model 
                                                     
iThe D-statistic uses the ranked order of the predicted risks of a model to assess prognostic separation. 
However as the cause-specific model does not have a 1:1 relationship between the risk and rate, the 
ranked order of the predictions may change over time. Thus the D-statistic requires ranking to be 
assessed at a specified time-point. 
iiSimilarly, Harrell’s C-index cannot be calculated for the cause-specific model over all time points due 
to loss of 1:1 relationship between hazards and risk. 
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The model developed using the cause-specific approach was not internally 
validated due to the time consuming, computationally intensive nature of the simulation 
approach for obtaining individual risk predictions from this model. The optimism in 
performance of the subdistribution model was assessed using the bootstrap procedure 
outlined in Box 4.2. The bootstrap performance measures reflect the model’s 
performance in the imputed bootstrap data in which it was developed. The test 
performance measures reflect the model’s performance when assessed using the 
original PREP study data. The optimism is calculated as the difference between the 
bootstrap and the test measures. The average model performance measures are 
reported below in Table 5.10. 
Table 5.10: Internal validation measures of prognostic performance for 
subdistribution prognostic model in 100 bootstrap samples 
 Subdistribution model  
 Average bootstrap 
performance 
Average test 
performance 
Average 
optimism 
Optimism-adjusted 
performance 
Calibration 
Slope 
1.000 0.760 0.240 0.760 
Harrell’s C-
index 
0.694 0.647 0.046 0.648 
D Statistic 1.156 0.889 0.281 0.875 
R2D Statistic 0.242 0.159 0.085 0.157 
 
The average optimism in the measures of discrimination, Harrell’s C-index and 
R2D, for the subdistribution model were 0.046 and 0.085 respectively. Subtracting the 
average optimism from the fitted model’s apparent performance (see Table 5.9), 
results in an optimism-adjusted C-index of 0.652-0.046=0.606 and an optimism-
adjusted R2D of 0.165-0.085=0.080. The average optimism observed in the 
subdistribution hazards model calibration slope was 0.240, resulting in a uniform 
shrinkage factor of 1.001-0.240=0.760. 
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To adjust for the overfitting (optimism), the shrinkage factor for the subdistribution 
model (i.e. the optimism-adjusted calibration slope) was applied uniformly to all 
predictor coefficients within the prognostic model, and the baseline cumulative 
incidence function was re-estimated to ensure calibration-in-the-large. The final 
optimism-adjusted regression equation for the subdistribution model is provided in 
Table 5.11, and the updated baseline cumulative incidence function for the optimism-
adjusted model is presented in Figure 5.10. 
Table 5.11: Final regression equation for optimism-adjusted subdistribution 
model 
Optimism-adjusted subdistribution model 
𝐿𝑃 =   
–    0.005 ×  (𝒎𝒂𝒕𝒆𝒓𝒏𝒂𝒍 𝒂𝒈𝒆 − 30.245)  
−  0.038 ×   (𝒈𝒆𝒔𝒕𝒂𝒕𝒊𝒐𝒏𝒂𝒍 𝒂𝒈𝒆 − 30.562) 
– {
0.474, 𝑖𝑓 𝒐𝒏𝒆 𝒑𝒓𝒆𝒆𝒙𝒊𝒔𝒕𝒊𝒏𝒈 𝒄𝒐𝒏𝒅𝒊𝒕𝒊𝒐𝒏
0.142,         𝑖𝑓 𝒕𝒘𝒐 𝒐𝒓 𝒎𝒐𝒓𝒆 𝒄𝒐𝒏𝒅𝒊𝒕𝒊𝒐𝒏𝒔      
 
+  0.135
×  (𝑖𝑓 𝒂𝒏𝒕𝒊𝒉𝒚𝒑𝒆𝒓𝒕𝒆𝒏𝒔𝒊𝒗𝒆 𝒕𝒓𝒆𝒂𝒕𝒎𝒆𝒏𝒕) 
+  0.869 × (𝑖𝑓 𝑴𝒈𝑺𝑶𝟒 𝒕𝒓𝒆𝒂𝒕𝒎𝒆𝒏𝒕) 
𝐹𝑘(𝑡|𝟎) = {
0.033, 𝑖𝑓 𝑡 = 2 𝑑𝑎𝑦𝑠
0.049, 𝑖𝑓 𝑡 = 1 𝑤𝑒𝑒𝑘
0.061, 𝑖𝑓 𝑡 = 4 𝑤𝑒𝑒𝑘𝑠
 
𝐹𝑘(𝑡|𝑿𝑘) = 1 − (1 − 𝐹𝑘(𝑡|𝟎))
𝑒𝑥𝑝(𝐿𝑃) 
𝑃𝑟(𝐴𝑛𝑡𝑒𝑛𝑎𝑡𝑎𝑙 𝑎𝑑𝑣𝑒𝑟𝑠𝑒 𝑒𝑣𝑒𝑛𝑡) =  1 − 𝑆0(𝑡)
𝑒𝑥𝑝(?̂?𝑿) 
𝐋𝐏 = Linear predictor 
𝐅𝐤(𝐭|𝟎) = Baseline cause-specific cumulative incidence function 
𝐅𝐤(𝐭|𝐗𝐤) = Cause-sepcific cumulative incidence function 
 
Figure 5.10: Baseline cumulative incidence function estimated using optimism-
adjusted subdistribution model 
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5.4 Discussion 
In this chapter, two approaches for analysing time-to-event data in the presence 
of competing risks were applied and compared. Two flexible parametric competing risk 
models were developed to predict the risk of antenatal adverse events in patients 
diagnosed with pre-eclampsia, accounting for delivery of the baby as a competing 
event. The key findings and conclusions are summarised below. 
5.4.1 Key clinical findings 
The two prognostic models developed in this chapter can be applied to patients 
diagnosed with early-onset pre-eclampsia to predict their future risk of antenatal 
adverse events, in the real-world setting where the baby may be delivered before any 
antenatal adverse events have occurred. These models build on the work of 
Thangaratinam et al who developed models to predict the risk of the composite 
outcome of adverse events or early delivery in early-onset pre-eclampsia patients 
(Thangaratinam et al., 2017). The competing risks analyses applied in this chapter 
facilitates the disentanglement of these two outcomes, thus aiding the understanding 
of a patient’s real world risks of experiencing adverse events prior to spontaneous or 
induced labour. 
Antenatal adverse events were experienced by 7.9% of the participants in the 
PREP study cohort, with a cumulative incidence at 100 days of 7.8%. It is shown that 
when assessing the cumulative incidence of these events, not accounting for delivery 
as a competing event results in a biased estimate nearly twice the size of the true value 
(Figure 5.2). 
5.4.2 Key statistical findings 
Two approaches were utilised to account for competing events during prognostic 
model development, the cause-specific and subdistribution approaches. Both aim to 
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predict the same function; however, the cause-specific cumulative incidence function 
produced by these methods are noticeably different. A number of statistical 
advantages were identified for using the subdistribution approach over the cause-
specific approach in prognostic model research. 
Firstly, the subdistribution approach estimates the direct effect of the included 
prognostic factors on the real world risk of the event of interest through subdistribution 
hazard functions. Subdistribution hazards adjust for the indirect effects of the 
prognostic factors on the competing events. The cause-specific approach estimates 
the direct effect of the included prognostic factors on the event of interest, while 
ignoring (censoring) the competing event. Cause-specific hazards are thus better 
suited to prognostic factor research than prognostic modelling. 
Secondly, the subdistribution approach retains the one-to-one relationship with 
the cause-specific cumulative incidence function. This aids the interpretation of 
subdistribution hazard ratios as an increasing hazard ratio indicates an increased 
cumulative incidence, which is not always the case with cause-specific hazard ratios. 
The one-to-one relationship also simplifies estimation of the cumulative incidence 
function; the subdistribution approach does not require the estimation of hazard 
functions for all outcomes, whereas the cause-specific approach does. The added 
complexity of the cause-specific model requires more parameters to be estimated for 
the model, resulting in the need for a larger sample size to develop a prognostic model. 
Finally, the subdistribution approach results in a model of a similar form to that of 
the standard time-to-event analysis approach. Obtaining individual predictions from 
these models is simple, as is adapting standard modelling processes (such as 
shrinkage) for competing events, and comparisons between these and standard time-
to event models is intuitive. The complexity of the cause-specific approach means that 
additional measures, such as simulation methods, are require to obtain individual 
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predictions, there is some difficulty in adapting internal validation processes, and 
comparisons with standard time-to-event models is difficult.  
Overall, the subdistribution approach is better suited to prognostic model 
research, it often results in simpler models which are easier to understand, apply, and 
internally validate, compared to the cause-specific approach. 
5.4.3 Strengths and limitations 
In the current literature, relatively few prognostic models have been developed 
using competing risks statistical methods, the majority of which use semi-parametric 
modelling approaches to obtain hazard ratios without the need to estimate the baseline 
hazard functions (Mazzaferro et al., 2018, Scrutinio et al., 2018, Wolbers et al., 2009). 
The Fine and Gray (Fine and Gray, 1999) subdistribution approach features in the 
majority of the published articles, whereas comparison of models developed using this 
approach to a cause-specific model is uncommon (Wolbers et al., 2009). In this 
chapter, flexible parametric competing risks prognostic model were developed using 
the two modelling approaches. This allows for a comparison of the cause-specific 
cumulative incidence estimates, the primary purpose of prognostic model research, 
from both the subdistribution and cause-specific approaches. 
Utilising competing risks statistical methods for the development of prognostic 
models is relatively novel, thus some of the methods required for adequate evaluation 
of prognostic models are yet to be developed. Little guidance is currently available for 
methods of multiple imputation or for the application of some internal validation 
methods, such as shrinkage, in the presence of competing events. Though convenient 
solutions were found to enable the analysis to proceed for the purpose of this thesis, 
additional research on the true effects of the methods employed and any biases 
produced is required to establish if the findings are robust. 
5.4.4 Further work 
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The prognostic models developed in this chapter highlight the importance of 
incorporating the competing risks of delivery when assessing patient risks during 
pregnancy. A comparison of pregnancy models developed using competing risks and 
standard time-to-event methods will further highlight the differences in predicted risks, 
and the need to account for competing events to ensure accuracy of real world 
predictions in prognostic models. An external validation study of the prognostic models 
developed within this thesis for the prediction of antenatal adverse events will enable 
such a comparison. The following chapter will directly compare and externally validate 
the models developed in Chapters 4 and 5. 
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6 EXTERNAL VALIDATION OF PROGNOSTIC MODELS 
DEVELOPED USING STANDARD AND COMPETING 
RISKS METHODS 
6.1 Introduction 
Prognostic models to predict the risk of antenatal adverse events in women 
diagnosed with early-onset pre-eclampsia were developed in previous chapters (4 & 
5). In this chapter, the key models are externally validated. 
In Chapter 4, the two prognostic models developed using standard time-to-event 
(Cox and Royston-Parmar) approaches, which did not appropriately account for the 
competing events, performed similarly during internal validation. However, the 
Royston-Parmar model was developed using a flexible parametric approach which 
enabled the direct estimation of a smooth underlying baseline hazard function. 
Therefore, the optimism adjusted Royston-Parmar model (and not the Cox model) is 
externally validated in this chapter. This model will henceforth be referred to as the 
“PREP-RP” model. 
Similarly, in Chapter 5 two prognostic models were developed using flexible 
parametric competing risks (subdistribution and cause-specific approaches) 
approaches. The subdistribution model performed better than the cause-specific model 
during apparent validation, and a number of other statistical advantages of this model 
were identified. For these reasons, the optimism-adjusted subdistribution model (and 
not the cause-specific model) is externally validated in this chapter. This model will 
henceforth be referred to as the “PREP-SD” model. 
6.1.1 Overview of validation methods for competing risks setting 
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It is recommended to evaluate the performance of a prognostic model using data 
independent from those used to develop the model (Collins et al., 2016), via external 
validation; especially where the generalisability of the model needs to be assessed for 
a wider range of populations or settings. It is also important to account for competing 
events, if present, when validating a time-to-event prognostic model. The assessment 
of model calibration compares absolute risk predictions from the prognostic models to 
estimates of observed risk (Royston and Altman, 2013). If the methods used to 
estimate the observed risk do not appropriately account for the competing events (for 
example, using risk estimates derived via the Kaplan-Meier rather than the actual 
cumulative incidence function) then the resulting model calibration measures will be 
biased (Wolbers et al., 2009). The subdistribution hazard risk set, which retains 
participants in the risk set following the occurrence of a competing event, is used to 
appropriately account for competing events when calculating the cumulative incidence 
function during external validation. 
The PREP-RP model, developed in Chapter 4, was developed using a standard 
time-to-event analysis approach in which deliveries were censored as they occurred. 
However, the model only utilises information from the event of interest (antenatal 
adverse events) and does not incorporate the hazards for the competing event 
(deliveries) and so does not appropriately manage the competing events. Therefore, 
this model is expected to perform poorly during external validation, particularly when 
measuring calibration, as it is likely to overestimate the risk of antenatal adverse events 
in the presence of competing events. Whereas the PREP-SD model, developed in 
Chapter 5, incorporates the risks of the competing event and so is expected to produce 
representative estimates of absolute risks, and thus perform better than the PREP-RP 
model in terms of measures of calibration during external validation. 
6.1.2 External validation dataset 
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Both the PREP-RP and PREP-SD models were developed using data from the 
PREP study (Thangaratinam et al., 2017). The original prognostic models developed 
in this study (“PREP-L” and “PREP-S”) were externally validated using data from the 
Pre-eclampsia Integrated Estimate of RiSk for mothers (PIERS) cohort (von Dadelszen 
et al., 2009). The aim of the PIERS model research programme was to develop an 
evidence based framework to enable clinicians to better define maternal risks 
associated with diagnosis of pre-eclampsia (von Dadelszen et al., 2009). The study 
cohort included 1,259 pregnant women admitted to hospital with pre-eclampsia, 
diagnosed at any time during pregnancy. The study collected baseline participant 
information for similar prognostic factors as examined in the PREP study, as well as 
time-to-event information for comparable adverse event outcomes. 
6.1.3 Aims 
The overall aim of this chapter is to investigate the impact of the management of 
competing events during prognostic model development on measures of predictive 
performance. Data from the PIERS study cohort was used to externally validate the 
PREP-RP and PREP-SD prognostic models. The measures of calibration and 
discrimination reported in this chapter are adapted to appropriately account for 
competing events. Differences between the two model’s predictions and prognostic 
performance are discussed. 
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6.2 Methods: External validation of prognostic models 
Methods for the external validation of the PREP-RP and PREP-SD models using 
data from the PIERS study cohort are now discussed. The following methods are 
structured to adhere to the TRIPOD guidelines (Collins et al., 2015) for reporting 
prediction model development and validation studies. 
6.2.1 External validation study participants 
The PIERS study cohort includes participants who were admitted to hospital 
following a diagnosis of pre-eclampsia, and participants diagnosed with pre-eclampsia 
following delivery of the baby. The PREP study (and thus the PREP-RP and PREP-
SD models) focuses on participants with early-onset pre-eclampsia (diagnosed prior to 
34 weeks gestation) and events which occur after diagnosis. To create a comparable 
external validation dataset, a subset of the PIERS study participants was selected. 
This subset, henceforth be referred to as the “validation set”, contains PIERS cohort 
participants with: 
1. a confirmed diagnosis of pre-eclampsia prior to 34 weeks gestation, and 
2. a diagnosis of pre-eclampsia prior to adverse events or delivery of the baby, and 
3. a known delivery date, and 
4. no missing information for all prognostic factors contained in the PREP-RP and 
PREP-SD models. 
A flow diagram depicting the exclusion of PIERS participants to form the 
validation set is provided in the results. 
6.2.2 Outcome definition 
The definition of antenatal adverse events differs from that outlined in Section 
4.2.1, due to some disparities in the recording of the component events in the PIERS 
study. Although the majority of adverse events investigated in the PREP study were 
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also investigated in the PIERS study, some differences exist. Information on the 
following adverse events were not recorded in the PIERS study: retinal detachment, 
posterior reversible encephalopathy, subcapsular haematoma, postpartum 
haemorrhages, and placental abruptions. As none of the PREP study participants 
experienced a retinal detachment, posterior reversible encephalopathy, or subcapsular 
haematoma as their first event, and as postpartum haemorrhages were excluded from 
the definition of antenatal adverse events (as they occur after delivery of the baby), the 
absence of information on these adverse events is unlikely to impact the validation 
performance of the prognostic models. However, placental abruptions were the most 
commonly observed antenatal adverse events in PREP study participants (1/3 of all 
antenatal adverse events). The absence of information on this adverse event is likely 
to affect the validation performance of the prognostic models in these data. A summary 
of the incidence of antenatal adverse events in the PIERS validation set is reported 
and compared to the PREP study; the sample size is discussed. 
The time to antenatal adverse events in participants with early-onset pre-
eclampsia is defined in Section 5.2.1. Participants are at risk from the date of confirmed 
pre-eclampsia diagnosis, and remain at risk until they experience either an antenatal 
adverse events or delivery the baby. Unlike the PREP study, the PIERS study data 
only included the date (and not the time) of a number of outcomes, so for simplicity this 
analysis only included date information. A random follow-up time (taken from a 
Uniform[0, 0.01] distribution) was generated for participants who experienced an event 
on the same date as pre-eclampsia diagnosis, to retain the participant in the analysis. 
If both an antenatal adverse event and delivery of the baby occurred on the same day, 
the outcome was recorded as an antenatal adverse event (i.e. assuming the adverse 
event occurred just before delivery). This assumption was previously used in the PREP 
dataset, and reflects “real world” clinical practice in which an adverse event prompts 
induction of labour. 
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6.2.3 Descriptive analysis of external validation (PIERS) participants 
The average follow-up time (calculated using the reverse Kaplan-Meier estimator 
(Schemper and Smith, 1996)) and non-parametric cumulative incidence estimates of 
pre-eclampsia events for the validation participants are reported and compared to the 
model development population. 
A descriptive analysis of prognostic factors included in the PREP-RP and PREP-
SD models in the validation set was performed. The distribution of each continuous 
prognostic factor was investigated; the mean and standard deviation are reported for 
prognostic factors which were normally distributed, whereas the median and 
interquartile range are reported for those with skewed distributions. The frequency and 
percent of participants in each category of binary and categorical prognostic factors 
are also reported. The resulting prognostic factor summaries are compared to those 
from the model development data to investigate the relatedness of the populations 
(Debray et al., 2015). 
Due to the small number of participants missing prognostic factor and outcome 
information, multiple imputation methods were not considered necessary. Thus, a 
complete case analysis was performed in this validation study. 
6.2.4 Deriving predicted risks of antenatal adverse events 
Individual linear predictor and cumulative risk estimates were obtained using the 
equations reported in Table 4.11 (PREP-RP model) and Table 5.11 (PREP-SD model). 
For each model, linear predictor estimates for each participant in the validation set 
were obtained by applying the optimism adjusted regression coefficients and 
prognostic factor transformations to the participant data. The distributions of the linear 
predictor estimates in the validation set for the PREP-RP and PREP-SD models are 
compared to linear predictor distributions in the model development population 
(Royston and Altman, 2013). For each model, individual estimates of the cumulative 
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risk of experiencing an antenatal adverse event two days, one week, and four weeks 
after early-onset pre-eclampsia diagnosis were estimated for each participant in the 
validation set. Individual risk estimates from the PREP-RP and PREP-SD models were 
compared at the given time points, as were the distributions of the predicted risks from 
each model for participants in the validation set. 
6.2.5 External validation of prognostic models 
The predictive performance of the PREP-RP and PREP-SD models was 
assessed in the validation set using measures of calibration and discrimination. For 
each model, four risk groups were created by splitting the validation set into equal sized 
groups using the 25th, 50th, and 75th centiles of the model’s cumulative risk 
predictions at four weeksi. Overall calibration was examined by comparing the 
expected event risk (calculated using cumulative risk estimates from PREP-RP and 
PREP-SD models) to the observed event risk (estimated using non-parametric 
cumulative incidence function for the validation set). Calibration was assessed for each 
model at two days, one week, and four weeks following pre-eclampsia diagnosis using 
the validation set as a whole, and for each of the aforementioned risk groups. For each 
model, the average predicted risk in each risk group over time is presented alongside 
non-parametric cumulative incidence curves, enabling a comparison of the expected 
and observed risk over time. 
For each model, the distribution of predicted risk for participants who had 
experienced an antenatal adverse event (event of interest) by four weeks was 
compared to the distribution of predicted risk for participants who had delivered a baby 
(competing event) by four weeks. The discriminative ability of the PREP-RP and 
PREP-SD models was assessed using Harrell’s C-index (Harrell et al., 1982), the D-
statistic, and R2D. The C-index was calculated as an overall measure and at two days, 
                                                     
iThese risk groups created for each of the PREP-RP and PREP-SD models are likely to contain different 
sets of individuals. 
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one week, and four weeks, and the D-statistic and R2D was calculated and compared 
for both the PREP-RP and PREP-SD models. 
6.3 Results: External validation of prognostic models 
The results of the external validation of the PREP-RP and PREP-SD models 
using data from the PIERS study cohort are now discussed. 
6.3.1 External validation study participants 
The original PIERS study cohort includes 2,023 participants. A subset of the 
PIERS cohort were retained for this external validation study by applying four inclusion 
criteria (outlined in 6.2.1). A flow diagram depicting the selection of PIERS participants 
for the validation set is depicted in Figure 6.1. 
Figure 6.1: Flow diagram of selection of PIERS participants for validation set 
 
 
The validation set consists of 637 women with an early-onset pre-eclampsia 
diagnosis. A large proportion (1,369, 67.7%) of the PIERS study participants were 
excluded from the validation set as they were diagnosed with pre-eclampsia after 34 
weeks gestation (i.e. not early-onset pre-eclampsia diagnoses). These participants are 
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expected to have fewer serious complications than those diagnosed before 34 weeks 
gestation (Sibai, 2003). As both the PREP-RP and PREP-SD models were developed 
in populations with early-onset pre-eclampsia, not excluding these participants is likely 
to adversely affect the validation performance of the models. Few participants were 
excluded for diagnosis after an adverse event or delivery (5, 0.2%) and for missing 
outcome or prognostic factor information (12, 0.6%).  
6.3.2 Outcome definition 
Disparities in the recording of the component events in the PIERS study results 
in a modified definition of antenatal adverse events in this validation study. Similar to 
the PREP study, none of the participants were lost to follow up, and all either 
experienced an antenatal adverse event (79 women, 12.4%), or delivered the baby 
without an adverse event. The incidence of first antenatal adverse events observed in 
the development (PREP) and validation set (PIERS) are reported in Table 6.1. 
Table 6.1: Incidence of components of antenatal adverse events in development 
(PREP) and validation (PIERS) cohorts 
First antenatal adverse event 
PIERS cohort, 
Number (%) 
PREP cohort, 
% 
Pulmonary oedema 37 (5.8%) 0.4% 
Transfusion of blood 19 (3.0%) 2.4% 
At least 50% FIO2 for > 1hour 12 (2.0%) 0.1% 
Acute renal insufficiency 4 (0.6%) 0.2% 
Eclamptic seizure 3 (0.5%) 1.2% 
Hepatic dysfunction 3 (0.5%) 0.5% 
Positive inotrope support 1 (0.2%) 0 
Total antenatal adverse events 79 (12.4%) 7.9% 
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A similar percentage of participants in both cohorts required a blood transfusion 
(3.0% in PIERS vs 2.4% in PREP) and experienced hepatic dysfunction (0.5% in both 
cohorts) as their first adverse event. A greater percentage of participants experienced 
a pulmonary oedema as a first adverse event in the PIERS cohort (5.8%) compared to 
the PREP cohort (0.4%), though the number of observed events is small. The overall 
proportion of all antenatal adverse events was greater in the PIERS cohort (12.4%) 
than the PREP cohort (7.9%). Although ideally an external validation sample requires 
a minimum of 100 events and 100 non-events for unbiased and precise estimation of 
predictive performance measures (Collins et al., 2016, Vergouwe et al., 2005), only 79 
events are observed in this validation set. Regardless, this is the only cohort available 
to validate the two models without the need for a new cohort study which would take a 
number of years to conduct. 
The participants in the validation set were followed up for a median of 7 days 
(IQR: 3 to 18), with the longest observed follow-up period equal to 114 days. The 
average follow-up is slightly shorter than that observed in the PREP study (median of 
10.1 days). Non-parametric cumulative incidence estimates for the time to antenatal 
adverse events and delivery without an adverse event are depicted in Figure 6.2. A 
greater proportion of antenatal adverse events (red lines) were observed in the PIERS 
study (solid lines) than the PREP study (dashed lines). 
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Figure 6.2: Non-parametric cumulative incidence estimates of pre-eclampsia 
outcomes, accounting for competing risks, in development (PREP) and 
validation (PIERS) cohorts 
 
 
6.3.3 Descriptive analysis of validation set 
Results from the descriptive analysis of the prognostic factors included in the 
PREP-RP and PREP-SD models in both the development (PREP) and validation 
(PIERS) set are given in Table 6.2. The mean maternal age of participants at pre-
eclampsia diagnosis is 31.2 years, with a median corresponding gestational age of 
31.0 weeks (IQR: 28.4 to 32.9), similar to the PREP study participants. Just under half 
of participants did not have any historical medical conditions (44.4%), implying more 
PIERS study participants had at least one pre-existing medical condition (55.6%) in 
comparison to the PREP study (36.1%). The majority of participants were receiving 
antihypertensive treatment (87.0%) and just over half were receiving magnesium 
sulphate treatment (51.0%), more than observed in the PREP study participants 
(79.4% and 15.2% respectively). 
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Table 6.2: Descriptive analysis of prognostic factors in development (PREP) and 
validation (PIERS) cohorts 
Prognostic Factor 
PIERS 
Summary Statistics 
Mean(SD), N(%), Med 
[IQR] 
PREP  
Summary Statistics 
Mean(SD), N(%), Med 
[IQR] 
Maternal age (years) 31.2 (6.2) 30.2 (6.1) 
Gestational age at diagnosis 
(weeks)* 
31.0 [28.4 to 32.9] 31.4 [28.7 to 32.7] 
Medical 
History¥ 
0 283 (44.4%) 594 (63.9%) 
1 251 (39.4%) 242 (26.0%) 
2 or more 103 (16.2%) 94 (10.1%) 
Systolic blood pressure 168.3 (20.5) 158.6 (19.2) 
Platelet count 205.0 (75.6) 227.1 (77.7) 
Alanine amino 
transaminase* 
25 [15 o 43] 17 [13 to 26.5] 
Serum Creatinine 69.2 (20.4) 61.8 (17.1) 
Antihypertensive treatment 554 (87.0%) 751 (79.4%) 
Magnesium sulphate 
treatment 
325 (51.0%) 144 (15.2%) 
*Median and inter-quartile range (IQR) presented for non-normally distributed 
factors. 
¥Medical history is a count of the following conditions: chronic hypertension, renal 
disease, diabetes mellitus, and previous pre-eclampsia. 
 
The difference in the number of patients with pre-existing medical conditions 
implies poorer health in the validation population, as demonstrated by higher SBP, ALT 
and serum creatinine measurements. In the developed models, patients with at least 
one pre-existing medical condition had reduce risks of antenatal adverse events, thus 
the poorer health of the population may explain the reduced incidence of the event of 
interest. The validation population also received more antihypertensive and 
magnesium sulphate treatments than the development population. This may be due to 
patients having poorer health, or could be an indicator of different care strategies for 
pre-eclampsia in Canada (validation study) and the UK (development study). In the 
developed models, patients receiving treatments had significantly increased risks of 
antenatal adverse events. The reduced incidence of antenatal adverse events in the 
validation study suggests the difference in proportion of patients treated may be due 
to different care pathways. 
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6.3.4 Deriving predicted risks of antenatal adverse events 
The distributions of the individual linear predictor estimates for the PREP-RP and 
PREP-SD models in the development and validation set are provided in Figure 6.3. 
The range of linear predictor estimates for both the PREP-RP and PREP-SD models 
are similar across the development and validation sets. The shape of the distributions 
differs between studies; in particular, a greater proportion of the linear predictor 
estimates in the validation set are positive values, which may reflect the increase in 
risk of antenatal adverse events observed in the PIERS study (12.4%) in comparison 
to the PREP study (7.9%). Additionally, the linear predictor distributions observed in 
the validation set are more uniform than those observed in the development set, which 
clearly peak at estimates around zero. 
Figure 6.3: Distribution of individual linear predictor estimates from PREP 
prognostic models for PIERS validation cohort participants 
 
 
The PREP-RP and PREP-SD model equations were applied to the validation set 
to predict individual cumulative risks of experiencing an antenatal adverse event by 
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two days, one week, and four weeks after pre-eclampsia diagnosis. The model 
predictions for each participant at each time point, and the distributions of the 
cumulative risks, are depicted in Figure 6.4. The range of individual risks estimated 
using the PREP-RP model, which censors deliveries, was larger than the PREP-SD 
model, which treats deliveries as competing events, for all time points. This is a result 
of the inflated absolute risk estimates produced by the PREP-RP model due to 
inappropriate management of competing events. The model predicts the hypothetical 
risk of experiencing an antenatal adverse event in participants who do not deliver 
without an adverse event. Whereas the PREP-SD model predicts “real-world” risks for 
all pre-eclampsia participants which account for the competing event. Thus, there is 
little observed agreement between individual risk estimates from the PREP-RP and 
PREP-SD models. 
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Figure 6.4: Comparison of individual cumulative risks from PREP-RP and PREP-SD models in validation set participants 
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6.3.5 External validation of prognostic models 
The expected proportion of antenatal adverse events in the validation set by two 
days, one week, and four weeks after diagnosis was calculated using predicted 
cumulative risk estimates from each prognostic model. These expected outcome 
incidences were compared with the observed incidences of antenatal adverse events, 
accounting for the competing event of delivery, to provide a measure of overall 
calibration. The results are provided in Table 6.3. The overall expected risk of antenatal 
adverse events from the PREP-RP model exceeds the observed risk at later time 
points, as the model does not appropriately account for the competing events. 
Whereas the expected risks from the PREP-SD model underestimate the observed 
risks at these time points, which may be due to the differences in baseline risks of 
antenatal events (Figure 6.2). 
Table 6.3: Overall calibration of prognostic models externally validated at 
specified time points 
 
Observed risk 
(O) 
PREP-RP model PREP-SD model 
Expected 
risk (E)* 
E/O 
Expected 
risk (E)* 
E/O 
2 days 5.7% 5.6% 0.98 4.8% 0.84 
1 week 9.4% 11.7% 1.24 7.1% 0.76 
4 weeks 11.3% 26.3% 2.33 8.9% 0.79 
*Expected risk calculated as median predicted risk for PIERS study participants 
derrived from prognostic model at time point 
 
Overall calibration was also assessed in four risk groups, created by splitting the 
validation set into equal sized groups using the 25th, 50th, and 75th centiles of each 
model’s predicted cumulative risk at four weeks. The expected proportion of antenatal 
adverse event at two days, one week, and four weeks for each risk group are given in 
Table 6.4. The risk groups for the PREP-RP and PREP-SD model contain different 
sets of participants. In general, the predicted risks from the PREP-RP model are 
greater than those predicted by the PREP-SD model, with the exception of the low risk 
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groups at early time points, reflecting the difference in management of competing 
events between the models. For the two highest risks group (50-75th centile and >75th 
centile) the risk predictions at four weeks from the PREP-RP model are over three 
times those predicted by the PREP-SD model. By this time, the majority of the 
competing events (delivery without antenatal adverse events) have occurred (see 
Figure 6.2) resulting in larger levels of competing risks bias. 
Table 6.4: Expected proportion of antenatal adverse events by risk groups 
 PREP-RP model PREP-SD model 
 2 days 1 week 4weeks 2 days 1 week 4weeks 
<25th centile 1.3% 2.8% 6.7% 2.4% 3.6% 4.4% 
25-50th centile 3.5% 7.4% 17.2% 3.6% 5.4% 6.7% 
50-75th centile 8.0% 16.6% 35.9% 5.7% 8.4% 10.4% 
>75th centile 15.2% 30.1% 58.5% 8.8% 12.8% 15.8% 
 
The predicted and observed risks of antenatal adverse events for the risk groups 
over time are depicted in Figure 6.5. The PREP-RP model appears to perform well at 
early time points, when fewer competing events have occurred. However, at later time 
points the model greatly overestimates the risks for all four risk groups. At time t = 100 
the predicted risk (solid line) for the highest risk group (red line) is 84.4% in comparison 
to an observed risk (dashed lines) of 22.0%, a severe level of competing risks bias. 
There is little distinction between the observed risk in the lowest two (<25th centile: 
green line, 25-50th centile: blue line) risk groups. The PREP-SD model produces risk 
predictions that better reflect the observed incidence, though it tends to underestimate 
the observed risk, particularly in the highest (>75th centile: red line) risk group (this is 
because the baseline risk is higher in PIERS than in PREP, as shown in Figure 6.2). 
There is little distinction between the observed risk in the middle (25-50th centile: blue 
line, 50-75th centile: yellow line) risk groups generated using the PREP-SD model. 
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Figure 6.5: Expected and observed risk of antenatal adverse events by risk group 
in PIERS validation set 
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The distribution of the predicted risks at four weeks were compared between 
participants who had experienced an antenatal adverse event and those who had 
delivered by four weeks. These distributions are depicted in Figure 6.6. For both 
prognostic models the distributions overlap, but some separation is observed in 
median risk estimates. As the absolute risk estimates from the PREP-SD model are 
smaller than those of the PREP-RP model, the separation between predictions for the 
events appears to be less prominent than that observed in the PREP-RP predictions. 
Figure 6.6: Box and whisker plot of distribution of predicted risks four weeks 
following diagnosis in participants who experienced an event by four weeks 
 
 
The discriminative ability of both prognostic models was assessed, the results 
are provided in Table 4.9. For both models, Harrell’s C-index measures are greater at 
earlier time points. The PREP-RP model appears to have an advantage over the 
PREP-SD model in terms of discriminative performance. While overall Harrell’s C-
index measures were similar, 0.65 for PREP-RP and 0.63 for PREP-SD, the PREP-
RP model returns much higher C-index when assessed at two days. The proportion of 
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explained variation, represented by the R2D measures, is 12.4% for the PREP-RP 
model and 11.2% for the PREP-SD model, again very similar. 
Table 6.5: Measures of discrimination for prognostic models in validation set 
  PREP-RP model PREP-SD model 
Harrell’s C-index 
2 days 
0.759 
(0.67, 0.85) 
0.656 
(0.57, 0.74) 
1 week 
0.704 
(0.64, 0.77) 
0.658 
(0.59, 0.72) 
4weeks 
0.683 
(0.62, 0.74) 
0.649 
(0.59, 0.71) 
Overall 
0.646 
(0.58, 0.71) 
0.626 
(0.57, 0.69) 
D-statistic 
D 0.771 0.726 
R2D 0.124 0.112 
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6.4 Discussion 
In this chapter two prognostic models, which predict the risk of antenatal adverse 
events in women diagnosed with early-onset pre-eclampsia, were externally validated 
in data from an independent study. The PREP-RP and PREP-SD models were 
developed earlier in this thesis using different approaches; one using a standard time-
to-event approach which ignores the competing event of delivery, the other using a 
subdistribution approach which appropriately accounts for deliveries. The overall aim 
of this chapter is to investigate the impact of the management of competing events 
during prognostic model development on measures of predictive performance. The key 
findings and conclusions of this external validation study are summarised below. 
6.4.1 Key findings 
Measures of calibration were used to quantify the accuracy of absolute risk 
predictions from the prognostic models. The PREP-RP model is well calibrated for 
earlier time-points, this may be may be due to fewer competing events occurring 
directly after diagnosis (see Figure 6.2). The model is also able to capture the steep 
increase in risk of antenatal adverse events that occurs directly after pre-eclampsia 
diagnosis (see Figure 6.5). However, the model overestimates the risk of antenatal 
adverse events at later time-points, after more competing events have occurred (see 
Table 6.3). Whereas the PREP-SD model underestimates the risk of antenatal adverse 
events in the validation set at all time points (see Table 6.3); this is more apparent in 
higher risk groups (see Figure 6.5). The expected risk of antenatal adverse events in 
the validation set predicted by the PREP-SD model better reflects the observed 
incidence, which account for competing risks, than those predicted by the PREP-RP 
model (see Figure 6.5). The difference in absolute predicted risks from each model is 
due to differences in the management of competing events during model development. 
The PREP-RP model censors competing events as they occur, and fails to account for 
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the competing event (delivery) when estimating absolute risks, thus produces inflated 
absolute risk predictions (competing risks bias). Whereas the PREP-SD model 
appropriately incorporates the competing risks (delivery) when estimating absolute 
risks, thus produces more representative absolute risk predictions. The 
underestimation of absolute risks in this study may be due to disparities in the 
incidence of antenatal adverse events between the development (PREP) and 
validation (PIERS) studies (see Table 6.1). Model updating and recalibration strategies 
could be applied to improve both models’ predictive performance (Altman et al., 2009, 
Riley et al., 2016), for example by recalibrating the intercept term in the baseline 
hazard. 
Measures of discrimination were used to quantify how well the models distinguish 
between those who experience each event, and the time to the event of interest. When 
assessed in the validation set, the PREP-RP model produced higher C-index and D-
statistic measures than the PREP-SD model (see Table 6.5). It is possible that the 
wider range of absolute risk predictions from the PREP-RP model (see Figure 6.4) give 
the model an advantage when considering measures of discrimination. Regardless, 
the discriminative ability of a model does not indicate that a model is suitable for use 
in clinical practice, particularly when measures of calibration are poor, and the impact 
of competing risks bias is large, as observed at later time points for the PREP-RP 
model. 
6.4.2 Recommendations 
This external validation study highlights the impact of the management of 
competing events during prognostic model development on measures of predictive 
performance. The PREP-RP model, which censors competing events as they occur, 
performs well at earlier time points where fewer competing events have occurred. The 
model is able to discriminate between those who experience antenatal adverse events 
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and those who do not, particularly at the earlier time points (such as 2 days after pre-
eclampsia diagnosis). This model may be preferred for assessing the immediate or 
short-term risks of antenatal adverse events following early-onset pre-eclampsia 
diagnosis. The PREP-SD model, which appropriately accounts for competing events, 
was expected to produce absolute risk estimates that better reflect the observed risks, 
particularly at later time points after more competing events had occurred. The model 
consistently underestimated the absolute risk of antenatal adverse events. However, 
it is suspected the underestimation is due to disparities in the incidence and recording 
of the event of interest, rather than attributable to the statistical methods. This model 
may be preferred for assessing the risks of antenatal adverse events at later time 
points (such as 1 week after pre-eclampsia diagnosis). However, model updating and 
re-calibration methods would be advised if using the model in settings other than those 
in which it was developed. 
The external validation exercise also shows the importance of accounting for 
competing risks during the validation itself; here, the predictive performance measures 
were derived after accounting for the competing event of delivery. In general, it is 
recommended that competing risks be appropriately accounted for during both the 
development and validation of prognostic models by utilising appropriate statistical 
methods. 
However, the impact of competing risks on absolute risk predictions, and thus 
predictive performance, is associated with the number of observed competing events. 
If the incidence of observed competing events is small in comparison to the event of 
interest, the impact on the model’s predictive performance will likewise be small. The 
incidence of delivery in the validation set is lower at earlier time points, when assessed 
at two days the PREP-RP model outperformed the PREP-SD model in terms of 
calibration and discrimination. The amount of competing risks bias in the PREP-RP 
model predictions grows as time progresses and a greater number of competing 
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events are observed (see Figure 6.5). Thus, it may not always be necessary or 
impactful to account for competing events during the development and validation of 
prognostic models. 
6.4.3 Limitations and further research 
As previously discussed, ideally a minimum of 100 events are required for an 
external validation study (Collins et al., 2016, Vergouwe et al., 2005). Hence the 
external validation study in this chapter may be slightly underpowered for unbiased 
and precise estimation of predictive performance measures, as only 79 events are 
observed. However, the PIERS cohort was the only one available to validate the 
models without the need to conduct a lengthy cohort study, which would be considered 
out of scope for this thesis. 
Disparities in the incidence and recording of antenatal adverse events between 
the development (PREP) and validation (PIERS) studies may have contributed to the 
difference in predictive performance in this study. A greater proportion of antenatal 
adverse events were observed in the validation set (see Figure 6.2), however the 
PREP-SD model consistently underestimated the observed risks (see Table 6.3). 
Abruptions, the most common antenatal adverse event observed in 25 PREP study 
participants (representing 2.6% of all PREP participants and 33.3% of all observed 
antenatal adverse events), were not recorded in the PIERS study participants. Thus, 
participants in the validation set who experienced abruptions may have been 
misclassified as experiencing a delivery without an adverse event in the external 
validation analysis. Additionally, as abruptions were the most common antenatal 
adverse event in the development study, the relationships between the prognostic 
factors included in both models and the risk of adverse events reflect the risks of these 
events. Similarly, differences in the incidence of antenatal adverse events in each 
study are also likely to affect the predictive performance of the models. Despite these 
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discrepancies, the PREP-SD model performs well in the validation set, suggesting the 
impact of the discrepancies is small. Again, the PIERS cohort was the only one 
available to validate the models, and a new cohort study, which would take years to 
conduct, was considered out of scope for this thesis. 
In practice, the prognostic models assessed in this external validation study could 
be utilised alongside clinical expertise to prompt clinical action. For example, in pre-
eclampsia high risk patients may be kept in hospital for observation, and delivery of 
the pre-term baby may be induced in those considered at risk of maternal death 
(Wilkinson, 2011). Though out of scope for this thesis, further research into the 
performance of these models could utilise net benefit approaches and decision curves 
to compare the impact of each model’s risk prediction at different time points on clinical 
actions (Vickers et al., 2015). 
Finally, the impact of accounting for competing events in prognostic model 
development and validation is associated with the incidence of competing events. If 
the incidence of competing events is low, for example due to short prediction horizon, 
the impact of not accounting for competing risks is small, and there is little need to 
account for the competing events. Conversely when the incidence of competing events 
is high, the impact is large, and it is imperative that competing events are appropriately 
accounted for. The two models validated in this chapter explore a single competing 
risk scenario, with a relatively rare event of interest and a relatively common competing 
event. However, little is known about the impact of the management of competing 
events on measures of predictive performance under different competing risk 
scenarios. Current guidance suggests it may only be necessary to account for 
competing events “when the proportion of subjects experiencing a competing risk is 
equal or greater to the proportion of subjects experiencing the primary outcome” (Berry 
et al., 2010). This guidance is often considered as a “rule-of-thumb” for helping 
researchers decide when competing risks models are needed. The next chapter of this 
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thesis investigates the impact of accounting for competing events in relation to this 
rule-of-thumb for a number of competing risks scenarios. 
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7 WHEN ARE COMPETING RISKS STATISTICAL 
METHODS NEEDED IN PROGNOSTIC MODEL 
RESEARCH? 
7.1 Introduction 
The impact of competing risks statistical methods, during the development of 
prognostic models for early-onset pre-eclampsia, on measures of predictive 
performance was examined in the previous chapter. The external validation study 
identified a substantial difference in predictive performance between the prognostic 
models developed with and without competing risks statistical methods, when 
evaluated using a competing risks framework. The difference in predictive performance 
between the models increased over time, as more competing events occurred. This 
indicates an association between the impact of the statistical methods and the 
incidence of both the event of interest and the competing event. 
7.1.1 The rule-of-thumb 
The scenario studied throughout this thesis (early-onset pre-eclampsia) 
examines a rare event of interest (antenatal adverse events) and a common competing 
event (deliveries). This combination is not usually observed in prognostic model 
research, and the recommendation to always account for competing events, made in 
earlier chapters, may not be generalizable to all prognostic model scenarios. Indeed, 
in some circumstances where the incidence of the competing event is low, the effect 
of not appropriately accounting for competing events may be small and unimportant. It 
is suggested that it may only be necessary to use the more complex competing risks 
statistical methods “when the proportion of subjects experiencing a competing risk is 
equal or greater to the proportion of subjects experiencing the primary outcome, or 
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when follow-up exceeds 5-years.” (Berry et al., 2010). This guidance is often 
considered a “rule-of-thumb” for helping researchers decide when competing risks 
statistical methods are required, but has received little evaluation. 
7.1.2 Simulation studies 
Simulation studies are used to assess statistical analysis methods in relation to 
a known truth (Burton et al., 2006, Morris et al., 2019). Previous simulation studies 
which compare standard and competing risks time-to-event analyses have focused on 
assessing differences between cause-specific and subdistribution hazard ratios and 
regression coefficient estimates (Beyersmann et al., 2009, Dignam et al., 2012, 
Grambauer et al., 2010, Latouche et al., 2007, Leoce, 2016). However, these 
measures are not of primary interest in prognostic model research, where the focus is 
the model’s prognostic performance (assessed using measures of calibration and 
discrimination). For prognostic model research, simulation studies which investigate 
bias in measures of calibration and discrimination would be more applicable. The 
calibration of a prognostic model represents the prediction accuracy of the model; how 
well absolute risk predictions estimated using the model reflect the observed risk in 
that population on average. Not appropriately accounting for competing events when 
they are present may lead to inflated absolute risk estimates (competing risks bias), 
when considering “real-world” risks of an event. The bias is measured as the difference 
between a non-parametric Kaplan-Meier estimate of the absolute risk of the event of 
interest and the cumulative incidence at that time. The amount of bias is likely to be 
affected by the same factors found to cause differences between cause-specific and 
subdistribution hazard estimates, including those described in the rule-of-thumb (i.e. 
incidence of the event of interest and competing event). Therefore, this chapter will 
investigate whether the rule-of-thumb is appropriate for avoiding substantial bias in 
measures of calibration when developing prognostic models. Investigations into the 
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effects of competing risks bias on measures of discrimination are not considered in this 
thesis. 
7.1.3 Aims 
The overall aim of this chapter is to investigate bias in measures of calibration, 
specifically bias in cumulative incidence estimates, from prognostic models developed 
using standard time-to-event methods in the presence of competing events; and hence 
provide guidance on when competing risks statistical methods are required in 
prognostic model research. 
A simulation study was conducted to assess bias in estimates of the cumulative 
incidence function across a range of scenarios, in which both the proportion of 
participants that experience the event of interest and the proportion of participants that 
experience the competing event are varied. The cumulative incidence function is 
estimated for a prognostic model developed using standard time-to-event methods. 
Bias in the cumulative incidence function is calculated as the deviation of these 
estimates from the “real world” risks, which appropriately account for the competing 
events. The resulting bias measurements are inspected against the rule-of-thumb to 
determine whether the rule is appropriate for avoiding substantial bias. 
Recommendations on the use of competing risks statistical methods for prognostic 
model research are then provided. 
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7.2 Methods: Simulating competing risks and evaluating bias 
The methods for simulating competing risks data, the simulation scenarios 
examined in this study, and the simulation procedure are now discussed. 
7.2.1 Simulating competing risks data 
Methods for generating survival times for time-to-event analyses are summarised 
by Bender et al. (Bender et al., 2005). These methods were extended by Beyersmann 
(Beyersmann et al., 2009) to simulate competing risks data using cause-specific 
hazards and a multi-state framework. Beyersmann ascertains the stochastic behaviour 
of the competing risks process is completely determined through the cause-specific 
hazards (Beyersmann et al., 2009). Utilising this, cause-specific hazard 
functions ℎ𝑘(𝑡|𝑿) are first specified, and then survival times are simulated using the all-
cause hazard function h(t|𝐗): 
h(t|𝐗) = ∑ hk(t|𝐗)
K
k=1  Equation 7.1 
A multinomial distribution is then used to decide which of the competing events 
occurred at each event time T. The probability of an individual experiencing event k 
given the individual fails at time T is: 
P(event = k|T ∈ dt, T ≥ t) =
hk(T|𝐗)
∑ hk(T|𝐗)
K
k=1
⁄  Equation 7.2 
In which dt is the infinitesimal interval [t, t + dt). The above is equal to the cause-specific 
hazard at time T divided by the all-cause hazard at time T, or rather the contribution of 
the cause-specific hazard as a proportion of the total hazard at time T. 
The data for this study are simulated using the survsim statistical package 
(Crowther and Lambert, 2013) in Stata 14, which was developed to simulate complex 
time-to-event data. 
7.2.2 Simulation scenarios 
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All scenarios to investigate the impact of competing events on predictive 
performance in this simulation study assess the risk of an event of interest in the 
presence of a single competing event (i.e. K = 2). For simplicity, the cause-specific 
hazard functions for both the event of interest and the competing event are assumed 
to remain constant over time (i.e. the time-to-event is exponentially distributed). 
It is advised that simulated data should resemble a real study in order for the 
results to be generalizable and have credibility (Burton et al., 2006). A recent study 
which developed a competing risks prognostic model for coronary risk prediction 
(Wolbers et al., 2009) is used as a motivating example, and provides parameter values 
to define the “base scenario” in this simulation study. Wolbers et al. predict the ten-
year risk of coronary heart disease (CHD) in 4,144 women, 465 (11.2%) of which 
experienced a CHD event (event of interest) and 1,263 (30.5%) experienced a non-
CHD death (competing event) during follow-up (10 years). 
To assess the rule of thumb proposed by Berry (Berry et al., 2010), the proportion 
of participants who experience each event is required (i.e. cause-specific cumulative 
incidences, 𝐹𝑘(𝑡)). The rule-of-thumb advises the use of competing risk statistical 
methods to account for competing events when the proportion of competing events is 
at least that of the event of interest. Thus, a constant scaling factor γ > 0 is introduced 
to determine the relationship between the proportion of participants who experience 
the event of interest: 
γF1(t) = F2(t),   0 < {F1(t) + F2(t)} ≤ 1 Equation 7.3 
Competing risk statistical methods should be used when γ ≥ 1. 
For the base scenario of this simulation study, the cumulative incidence for the 
event of interest  F1(10), is 0.112 and the cumulative incidence for the competing 
event  F2(10), is 0.335 resulting in a scaling factor γ = 0.335 0.112⁄ = 2.72. The proportion 
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of participants who experience competing events is 2.72 times the proportion who 
experience the event of interest. In this instance, the rule-of-thumb would advise the 
use of competing risks statistical methods to account for the competing events. 
Within this simulation study, a range of plausible scenarios are investigated with 
varying event of interest and competing event incidences. The event of interest 
incidences were selected to reflect a range from rare events ( F1(10) = 0.05) to more 
common events ( F1(10) = 0.50), with values of γ ranging from 0.25 to 2.72 (observed 
by (Wolbers et al., 2009). The scenarios are specified in detail in Table 7.2. 
Previous simulation studies which compare standard and competing risks time-
to-event analyses (Beyersmann et al., 2009, Dignam et al., 2012, Grambauer et al., 
2010, Latouche et al., 2007, Leoce, 2016) found that uninformative censoring did not 
introduce bias or significantly alter study findings. Thus, censoring was not introduced 
during simulation study follow-up. However, a maximum follow-up time of t = 10 was 
enforced and any individual who had not experienced either event was censored at 
that time. 
7.2.3 The simulation process 
In order to investigate bias in measures of calibration for each scenario listed 
above, the following simulation process outlined in Table 7.1 was applied. 
Table 7.1: The simulation process for evaluating overall calibration bias 
Step 1 Select one of the scenarios from Table 7.2. 
Step 2 
Determine the cause-specific hazards for the event of interest and the 
competing event, using Equation 7.4. 
Step 3 
Simulate a single study containing 4,144 participants using the survsim 
command in Stata. 
Step 4 Calculate the naïve cumulative incidence and difference in cumulative risk. 
Step 5 Repeat steps 3 & 4 x500 times. 
Step 6 Evaluate cumulative incicdence bias. 
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The simulation process is discussed in more detail below. 
7.2.3.1 Step 1) Define the scenario 
Define the proportion of participants that experience the event of interest by time 
10, F1(10), and the scaling factor for the relative proportion of competing events, γ (i.e. 
select one of the scenarios from Table 7.2). 
7.2.3.2 Step 2) Determine cause-specific hazards 
In order to simulate competing risks time-to-event data using an exponential model, 
the constant cause-specific hazards for both the event of interest and competing event 
are required. Given the proportion of participants who experience the event of 
interest F1(t), and the scaling factor γ, and utilising exponential models with constant 
hazards; h1(t) = α1 for the event of interest, and h2(t) = α2 for the competing event; it is 
possible to determine the constant cause-specific hazard term for both the event of 
interest and the competing event: 
F1(t) = ∫ α1exp{−(α1 + α2)s}
t
0
ds 
=  α1 [
exp{−(α1 + α2)t}
−(α1 + α2)
]
0
t
 
= α1 [
exp{−(α1 + α2)t}
−(α1 + α2)
−
1
−(α1 + α2)
] 
F1(t) =
α1
α1+α2
[1 − exp{−(α1 + α2)t}] Equation 7.4 
The derivation of this equation is provided in Appendix X. 
For example, in the base scenario the cumulative incidence for the event of 
interest  F1(10) = 11.2% and the scaling factor γ = 2.72, the corresponding cause-
specific hazards are calculated as follows: 
α1 = −
ln[1−
1+2.72
2.72
×0.305]
(1+2.72)10
= 0.01451, and α2 = 2.72 × 0.01451 = 0.03947 
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7.2.3.3 Step 3) Generate time-to-event data for a single study 
Generate a single study containing 4,144 participants (the sample size in 
(Wolbers et al., 2009)), with time-to-event and event indicator variables simulated with 
exponential distributions for both the event of interest and competing event. Specify 
the cause-specific hazards as calculated in Step 2 and restrict follow-up time to a 
maximum of t = 10. Study data are simulated using the survsim command in Stata. 
7.2.3.4 Step 4) Calculate naïve cumulative incidence and difference in 
cumulative risk 
Using the simulated study data, calculate the non-parametric Kaplan-Meier 
estimate of the cumulative incidence, naïve to the occurrence of competing events, 
at t = 10. Determine the difference in cumulative risk as the difference between the 
Kaplan-Meier estimate at t = 10 and the specified cumulative incidence F1(10), based 
on the true model. 
7.2.3.5 Step 5) Repeat simulations  
Repeat steps three and four 500 times to obtain the distribution of bias in 
estimates of the cumulative risk for the specified scenario. 
7.2.3.6 Step 6) Evaluate cumulative incidence bias 
Summarise the distribution of bias in estimates of the cumulative risk across the 
500 simulations by calculating summary statistics for absolute measures (mean, SD) 
and measures relative to the expected cumulative incidence F1(10) as specified in Step 
1 (mean percentage). 
An example of the Stata code used to simulate the data and evaluate cumulative 
incidence bias is provided in Appendix XIII. 
The results for each scenario will be considered alongside the rule-of-thumb to 
scrutinise whether the rule is appropriate for avoiding substantial cumulative incidence 
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bias in prognostic model studies. Differences in estimates of the cumulative incidence 
function are shown graphically by plotting Kaplan-Meier estimates of cumulative risk, 
naïve to the occurrence of competing events, and the non-parametric cumulative 
incidence estimates, which account for the competing events, for the first 30 simulated 
studies for each scenario. 
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7.3 Results: Simulating competing risks and evaluating bias. 
The results of the simulation study to investigate bias in measures of calibration, 
from prognostic models developed using standard time-to-event methods in the 
presence of competing events, are now discussed. 
7.3.1 Determining cause-specific hazards 
For each scenario, the constant cause-specific hazard for both the event of 
interest and the competing event were calculated using Equation 7.4. The resulting 
hazards are reported in Table 7.2. 
7.3.2 Evaluating overall calibration bias 
For the first 30 simulated studies in each scenario, Kaplan-Meier estimates of the 
cumulative incidence of the event of interest, naïve to the occurrence of competing 
events, are depicted alongside non-parametric cumulative incidence estimates, which 
account for competing events. The resulting graphs are depicted in Figure 7.1, Figure 
7.2, Figure 7.3, and Figure 7.4. The difference between the Kaplan-Meier (blue lines) 
and cumulative incidence (red lines) estimates reflects the impact of not accounting for 
competing events when estimating absolute risks for the event of interest. 
Separation between the non-parametric estimates becomes more apparent as 
the event of interest incidence F1(t) and relative proportion of competing 
events γ increase, i.e. a greater number of competing events are observed. In 
scenarios where there is little observable separation between the non-parametric 
estimates (i.e. scenarios A1-A8, B1-B6, and C1-C4), applying standard time-to-event 
analysis methods will give similar cumulative risk estimates to an analysis using 
competing risks analysis methods. Whereas, substantial differences are likely to be 
observed in cumulative risk estimates resulting from those scenarios with notable 
separation (i.e. scenarios B7-B8, C5-C6, and D1-D4). 
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Table 7.2: Constant cause-specific hazards for event of interest and competing 
event for scenarios investigated in this simulation study 
Scenario 
Incidences 
Scaling 
factor 
𝜸 
Cause-specific hazards 
Event of 
interest 
𝑭𝟏(𝟏𝟎) 
Competing 
event 
𝑭𝟐(𝟏𝟎) 
Event of 
interest 
𝜶𝟏 
Competing 
event 
𝜶𝟐 
A1 
5.0% 
1.25% 0.25 0.00516 0.00129 
A2 2.5% 0.50 0.00520 0.00260 
A3 3.75% 0.75 0.00523 0.00392 
A4 4.5% 0.90 0.00525 0.00473 
A5 5.0% 1.00 0.00527 0.00527 
A6 7.5% 1.50 0.00534 0.00801 
A7 10.0% 2.00 0.00542 0.01083 
A8 13.6% 2.72 0.00553 0.01505 
B1 
11.2% 
2.8% 0.25 0.01207 0.00302 
B2 5.6% 0.50 0.01226 0.00613 
B3 8.4% 0.75 0.01247 0.00935 
B4 12.4% 0.90 0.01259 0.01133 
B5 11.2% 1.00 0.01268 0.01268 
B6 16.8% 1.50 0.01314 0.01971 
B7 22.4% 2.00 0.01365 0.02730 
B8: 
Base Scenario 
30.5% 2.72 0.01449 0.03946 
C1 
20.0% 
5.0% 0.25 0.02301 0.00575 
C2 10.0% 0.50 0.02378 0.01189 
C3 15.0% 0.75 0.02462 0.01846 
C4 18.0% 0.90 0.02516 0.02264 
C5 20.0% 1.0 0.02554 0.02554 
C6 30.0% 1.5 0.02773 0.04159 
C7 40.0% 2.0 0.03054 0.06109 
C8 54.4% 2.72 0.03663 0.09963 
D1 
50.0%* 
12.5% 0.25 0.07847 0.01962 
D2 25.0% 0.50 0.09242 0.04621 
D3 37.5% 0.75 0.11883 0.08912 
D4 45.0% 0.90 0.15767 0.14190 
*It is impossible for the sum of the proportion of events of interest (𝑭𝟏(𝟏𝟎)) and 
competing events (𝑭𝟐(𝟏𝟎)) to exceed 100%, thus Scenario D (𝑭𝟏(𝟏𝟎) = 𝟓𝟎%) is limited 
to instances where 𝜸 ≤ 𝟏.  
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Figure 7.1: Difference in non-parametric estimates of cumulative incidence when ignoring (Kaplan-Meier – blue lines) and accounting 
for (cumulative incidence – red lines) competing events in simulation scenarios with 5% event of interest incidence. 
 
Blue lines represent Kaplan-Meier estimates which censor the competing events. 
Red lines represent cumulative incidnce function estimates which appropriately account for the competing events. 
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Figure 7.2: Difference in non-parametric estimates of cumulative incidence when ignoring (Kaplan-Meier – blue lines) and accounting 
for (cumulative incidence – red lines) competing events in simulation scenarios with 10% event of interest incidence. 
 
Blue lines represent Kaplan-Meier estimates which censor the competing events. 
Red lines represent cumulative incidnce function estimates which appropriately account for the competing events. 
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Figure 7.3: Difference in non-parametric estimates of cumulative incidence when ignoring (Kaplan-Meier – blue lines) and accounting 
for (cumulative incidence – red lines) competing events in simulation scenarios with 20% event of interest incidence. 
 
Blue lines represent Kaplan-Meier estimates which censor the competing events. 
Red lines represent cumulative incidnce function estimates which appropriately account for the competing events. 
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Figure 7.4: Difference in non-parametric estimates of cumulative incidence when ignoring (Kaplan-Meier – blue lines) and accounting 
for (cumulative incidence – red lines) competing events in simulation scenarios with 50% event of interest incidence. 
 
Blue lines represent Kaplan-Meier estimates which censor the competing events. 
Red lines represent cumulative incidnce function estimates which appropriately account for the competing events. 
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Summary measures for cumulative risk bias in each simulation scenario are 
provided in Table 7.3. It is again evident that both measures of absolute and 
percentage bias escalate as the event of interest incidence F1(t) and relative 
proportion of competing events γ increase. 
7.3.3 Evaluation of the rule-of-thumb 
The rule-of-thumb (Berry et al., 2010) advises competing risk analysis methods 
need only be applied when the incidence of the competing event is at least as large as 
the event of interest, i.e. when γ ≥ 1 (scenarios A5-A8, B5-B8, and C5-C8). Thus, 
advises the use of standard time-to-event analysis methods for scenarios where the 
incidence of the competing event is less than the event of interest (i.e. scenarios A1-
A4, B1-B4, C1-C4, and D1-D4). 
The above advice seems to be appropriate for avoiding substantial bias in a 
number of the simulation scenarios investigated. Nonetheless, the advice seems less 
appropriate for scenarios with relatively rare (5%) or common (50%) incidences for the 
event of interest. In scenarios A5-A6, the rule would advise the use of the more 
complex methods to account for the competing events. However, the bias in 
cumulative incidence estimates resulting from the application of standard time-to-event 
methods in these scenarios is small (ranging from 0.001 to 0.004) and potentially 
unimportant. Conversely, in scenarios D1-D4 the rule suggests competing risk analysis 
methods need not be applied to account for the competing events. However, the bias 
in cumulative incidence estimates in these scenarios is large (ranging from 0.043 to 
0.294) and likely to be important. 
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Table 7.3: Summary of cumulative risk bias in simulation study scenarios 
Scenario 
Incidence 
of event 
of interest 
𝑭𝟏(𝟏𝟎) 
Scaling 
factor 
𝜸 
Kaplan-Meier 
estimate 𝑭?̂?(𝟏𝟎) 
Mean (SD) 
Absolute 
bias 
𝑭?̂? − 𝑭𝟏 
Mean (SD) 
Percentage 
bias 
(𝑭?̂? − 𝑭𝟏)
𝑭𝟏
⁄  
Mean 
A1 
5.0% 
0.25 0.051 (0.003) 0.001 (0.003) 1.02% 
A2 0.50 0.051 (0.003) 0.001 (0.003) 1.37% 
A3 0.75 0.051 (0.003) 0.001 (0.003) 2.17% 
A4 0.90 0.051 (0.003) 0.001 (0.003) 2.40% 
A5 1.00 0.051 (0.003) 0.001 (0.003) 2.47% 
A6 1.50 0.052 (0.004) 0.002 (0.004) 3.80% 
A7 2.00 0.053 (0.004) 0.003 (0.004) 5.71% 
A8 2.72 0.054 (0.004) 0.004 (0.004) 7.51% 
B1 
11.2% 
0.25 0.113 (0.005) 0.001 (0.005) 1.21% 
B2 0.50 0.116 (0.005) 0.004 (0.005) 3.19% 
B3 0.75 0.117 (0.005) 0.005 (0.005) 4.09% 
B4 0.90 0.118 (0.005) 0.006 (0.005) 5.36% 
B5 1.00 0.119 (0.005) 0.007 (0.005) 6.51% 
B6 1.50 0.124 (0.006) 0.012 (0.006) 10.48% 
B7 2.00 0.128 (0.006) 0.016 (0.006) 13.98% 
B8: 
Base Scenario 
2.72 0.135 (0.006) 0.023 (0.006) 20.32% 
C1 
20.0% 
0.25 0.206 (0.006) 0.006 (0.006) 2.81% 
C2 0.50 0.212 (0.007) 0.012 (0.007) 5.91% 
C3 0.75 0.219 (0.007) 0.019 (0.007) 9.47% 
C4 0.90 0.223 (0.007) 0.023 (0.007) 11.48% 
C5 1.0 0.226 (0.007) 0.026 (0.007) 12.81% 
C6 1.5 0.242 (0.007) 0.042 (0.007) 21.00% 
C7 2.0 0.263 (0.008) 0.063 (0.008) 31.63% 
C8 2.72 0.307 (0.009) 0.107 (0.009) 53.57% 
D1 
50.0%* 
0.25 0.543 (0.008) 0.043 (0.008) 8.69% 
D2 0.50 0.603 (0.008) 0.103 (0.008) 20.63% 
D3 0.75 0.695 (0.01) 0.195 (0.01) 39.03% 
D4 0.90 0.794 (0.01) 0.294 (0.01) 58.77% 
*It is impossible for the sum of the proportion of events of interest (𝑭𝟏(𝟏𝟎)) and 
competing events (𝑭𝟐(𝟏𝟎)) to exceed 100%, thus Scenario D (𝑭𝟏(𝟏𝟎) = 𝟓𝟎%) is limited 
to instances where 𝜸 ≤ 𝟏. 
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7.4 Extension to assess overall calibration bias over all possible 
values of γ 
The results from the above simulation study provoked further investigation into 
the levels of cumulative risk bias resulting from applying standard time-to-event 
analysis methods in the presence of competing risks. 
7.4.1 The simulation process 
This second simulation study process followed many of the same steps as the 
one previously, with the following alterations: 
7.4.1.1 Step 1) New scenarios 
Scenarios with event of interest incidences, F1(10), equal to 5%, 10%, 20%, 30%, 
40%, 50%, 60%, 70%, 80%, and 90% were investigated. For each event of interest 
incidence, cumulative risk bias was assessed for all possible values of γ, divided into 
200 equally spaced intervalsi. 
7.4.1.2 Step 3) Study size 
The number of participants simulated in each scenario was increased to 
1,000,000 to reduce the variance in bias estimates due to sample size. 
7.4.1.3 Step 5) No repetitions 
Following investigations of the increased study sample size in Step 3, the study 
team felt it unnecessary to repeatedly simulate the scenarios due to the small amount 
of variance in the simulation estimates. 
7.4.2 Results 
                                                     
i As γF1(t) = F2(t),   0 < {F1(t) + F2(t)} ≤ 1, (Equation 7.4) it follows 0 < γ ≤
1
F1(10)
− 1. 
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Absolute bias in cumulative incidence estimates for each scenario, over all 
possible values of γ are displayed in Figure 7.5. Again, the amount of cumulative risk 
bias increased as the incidence of the event of interest and the relative proportion of 
competing events increased. This is due to the increase in the incidence of the 
competing event (a graph depicting bias related to competing event incidence is 
reported in Appendix XIV). The amount of absolute bias is restricted; in a scenario with 
an event of interest incidence of 80%, the absolute bias cannot be more than 100%-
80%=20%. To observe 0.1 bias in the cumulative incidence estimate when the event 
of interest incidence is 90%, the competing event incidence need only be γF1(10) =
0.11 × 0.9 = 9.9%. Whereas, to observe the same bias with an event of interest 
incidence of 5%, the competing event incidence needs to be γF1(10) = 18.2 × 0.05 =
91%. Still, an absolute bias of 0.1 is more substantial when the expected event of 
interest incidence is 0.05 compared to when it is 0.90. In prognostic model research, 
this level of bias would result in predicted absolute risks for the event of interest 
estimated as 0.15, a threefold increase on observed risks. In prognostic model 
research, measures of percentage bias may be considered more intuitive. Bias in 
overall calibration, relative to the event of interest incidence, for all possible values of 𝛾 
are displayed in Figure 7.6 (a graph depicting bias related to competing event 
incidence is reported in Appendix XIV). 
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Figure 7.5: Absolute bias in cumulative incidence estimates for all possible values of 𝜸 with 𝑭𝟏(𝟏𝟎) from 5% to 90% 
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Figure 7.6: Percentage bias in cumulative incidence estimates for all possible values of 𝜸 with 𝑭𝟏(𝟏𝟎) from 5% to 90% 
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7.4.3 Evaluation of the rule-of-thumb 
The rule-of-thumb (Berry et al., 2010) considers the incidence of the event of 
interest and the competing event, and suggests actions based on γ ≥ 1. This would 
advise the use of standard time-to-event analysis methods for scenarios on the left-
hand side of Figure 7.5 and Figure 7.6, and advise competing risks analysis methods 
for scenarios on the right-hand side of the graphs. It is evident that this rule could result 
in substantial cumulative risk bias if applied in some circumstances; Such as when 
event of interest incidence is high (e.g. 60%) and the proportion of participants not 
expected to experience either event is low (e.g. competing event incidence is 30%, 
resulting in only 10% not experiencing either event). 
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7.5 Discussion 
The simulation studies performed in this chapter assess the bias in measures of 
overall calibration when standard time-to-event analysis methods are applied to 
scenarios with competing events. A number of factors, including the incidence of the 
event of interest and the incidence of the competing event, were varied in scenarios 
within the simulations to investigate associations with bias in cumulative incidence 
estimates. A rule-of-thumb was examined to determine whether it is appropriate to 
apply in prognostic model research to avoid substantial calibration bias. The key 
findings and conclusions of these simulation studies are summarised below. 
7.5.1 Key findings and recommendations 
Bias in cumulative incidence estimates was found to be strongly associated with 
the incidence of both the event of interest and the competing event. The two simulation 
studies conducted in this chapter found systematic differences in calibration of risk 
predictions when estimated using standard time-to-event analysis methods rather than 
competing risk modelling. The bias in cumulative incicdence estimates, which 
overestimates the absolute risk of the event of interest, increases as the event of 
interest incidence and the relative proportion of competing events increase. Statistical 
methods which appropriately account for the competing events can be applied to avoid 
this bias. However the added complexity of the analyses, interpretation, and 
communication of the hazard and cumulative incidence functions (which have 
prompted a number of tutorials including: (Allignol et al., 2011, Andersen et al., 2012, 
Dignam et al., 2012, Wolbers et al., 2009)) may be off-putting for researchers. 
Current guidance on when the more complex competing risks methods should be 
applied (Berry et al., 2010), was found not to be appropriate for avoiding substantial 
cumulative risk bias. The rule advised against the use of competing risks methods 
when the competing event was not as prevalent as the event of interest. This advice 
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results in high levels of bias in cumulative incidence estimates in scenarios with large 
event of interest incidences, such as in scenarios D1-D4. The rule also suggests using 
competing risks methods when the competing event is at least as prevalent as the 
event of interest. This advice made negligible differences to estimates of calibration in 
scenarios with a small event of interest incidence, such as in scenarios A5-A8. The 
existing rule was thus found to be incompatible with avoiding biases in estimates of 
cumulative risk. The primary purpose of prognostic model research is the accurate 
prediction of the absolute risks of the event of interest, thus large biases in measures 
of calibration are unacceptable. 
Though bias was observed in all of the scenarios investigated in the initial 
simulation study (Table 7.3), some researchers may determine the amount of bias to 
be clinically negligible and thus choose to apply standard time-to-event analysis 
methods. For example, when the observed event of interest incidence is 11.2% 
(scenarios B1-B8), a cumulative risk estimate equal to 11.9% (a 6.5% percentage 
increase due to bias, scenario B5) may be sufficiently adequate, to avoid using the 
more complex competing risks methods. However, a cumulative risk estimate equal to 
13.5% (a 20.3% increase due to bias, scenario 8) may be unsatisfactory, thus the more 
complex analyses are justified. 
A suggested update to the existing rule could utilise these thresholds for 
acceptable levels of percentage bias. Competing risks methods should be applied 
when the expected value of percentage bias exceeds a determined threshold ε, and 
need not be applied if the expected bias is less than the threshold. Table 7.4 displays 
the maximum competing event incidence to prompt the use of competing risks 
methods for event of interest incidences of 5, 20, 50, and 80%, if a threshold of ε = 0.10 
is accepted. This allows the cumulative incidence estimate to be up to 1.10 times the 
expected value. 
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Table 7.4: Limits for updated rule for competing risks methods with ε=0.1 
Incidences 
Absolute bias 
𝜺 × 𝑭𝟏(𝟏𝟎) 
Scaling factor 
𝜸 
Event of interest 
𝑭𝟏(𝟏𝟎) 
Event of interest 
𝑭𝟐(𝟏𝟎) 
5% 17% 0.5% 3.40 
20% 16% 2.0% 0.80 
50% 14% 5.0% 0.28 
80% 11% 8.0% 0.135 
 
For example, when the incidence of the event of interest is 5% the 
recommendation would be to apply competing risks methods if the bias in absolute risk 
predictions exceeds 0.5% (10% of 5%). This occurs when the expected competing 
event incidence is at least 17% (3.4 times greater). However, when the incidence of 
the event of interest is 50% the new rule advises applying competing risks methodology 
once bias in absolute risk predictions exceeds 5%, which occurs when the competing 
event incidence exceeds 14% (0.28 times greater). The guidance takes into account 
differences in absolute risk predictions from standard and competing risks statistical 
approaches, and can be used as a guide by researchers wanting to develop accurate 
prognostic models in the presence of competing events. 
7.5.2 Limitations and further research 
All simulation studies within this chapter were developed with constant cause-
specific hazard functions through use of the exponential time-to-event model. This 
assumption was considered sufficient for these initial investigations into the effects of 
competing events on measures of prognostic model calibration. Furthermore, solving 
the integral to obtain the cumulative hazard function is straightforward when the hazard 
function is constant; even after combining multiple cause-specific hazards to obtain the 
all-cause hazard (Equation 7.4). Additionally, inverting the cumulative hazard function 
to allow simulation of survival times is also straightforward when an exponential model 
is used. However, the assumption of constant hazards is often considered not to be 
biologically plausible in medical research, where often at least one turning point in the 
hazard is observed over time (Crowther and Lambert, 2013). Their article discusses 
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methods to obtain the cumulative hazard function when the integral is analytically 
intractable (numerical integration techniques). As well as methods to solve the 
equation to generate survival times when the cumulative hazard function is not 
invertible (iterative root finding methods). Thus, extensions to this research include 
incorporating more complex hazard functions, through flexible parametric modelling of 
the underlying hazard functions, to increase the biological plausibility of the models 
and check the recommendations are consistent with the current findings. Other 
potential extensions to this work include the incorporation of time-dependent 
prognostic factor associations and prognostic factors which vary over time. 
The included simulation studies utilise non-parametric estimates of the 
cumulative risk of the event of interest. However, prognostic models apply regression 
modelling techniques to incorporate associations between multiple prognostic factors 
and the event of interest (Steyerberg et al., 2013). A recent literature review of 
competing risks simulation studies (Leoce, 2016) identified studies which investigated 
varying strengths of associations between a single binary exposure variable and both 
the event of interest and a single competing event using a range of scenarios (Dignam 
et al., 2012, Grambauer et al., 2010, Latouche et al., 2007). The studies found the 
difference between the regression coefficient estimates to be negligible when the 
exposure is only associated with the event of interest and not the competing event. 
However, when the exposure is associated with an increase in the risk of event of 
interest but a reduction in the risk of the competing event, attenuated standard time-
to-event analysis regression coefficient estimates were observed. The focus of these 
previously published studies was to compare cause-specific and subdistribution 
regression coefficient estimates. However, little is known regarding how these 
differences, caused by varying associations between a prognostic factor and the 
competing event, affect prognostic model calibration. Thus, further research is needed 
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to investigate the effect of varying associations between prognostic factors and the 
competing event on prognostic model calibration. 
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8 DISCUSSION 
This chapter concludes the thesis with a general discussion of the research 
presented in previous chapters. Limitations of the research are presented alongside 
suggestions of future work in the area. 
8.1 Thesis Overview 
Prognostic model research is important as it aids understanding of the risks of 
future health outcomes in individuals. Communicating these risks enables clinicians to 
help their patients understand the likely course of their disease or condition, enhancing 
the process of informed decision making (Steyerberg et al., 2013). The time to a given 
health outcome can be of interest in prognostic model research, and thus time-to-event 
regression methods are often utilised to develop prognostic models. It is often the case 
that competing events prevent or alter the risk of the event of interest from occurring. 
If not appropriately accounted for, the presence of these competing events can result 
in inflated absolute risk estimates, affecting the predictive accuracy of a prognostic 
model. Though the statistical methods which account for competing risks theory has 
existed since 1760 (Bernoulli, 1760), there is increasing evidence that the methods are 
not being utilised (Austin and Fine, 2017, Koller et al., 2012, Schumacher et al., 2016, 
Walraven and McAlister, 2016), and there is relatively little empirical research which 
investigates the presence and impact of competing events in prognostic model 
research. 
The overall aim of previous chapters was to improve understanding of the 
influence of competing risks issues in prognostic model research. In particular, early 
chapters (Chapters 2 and 3) investigated the presence, reporting, and management of 
competing events in existing prognostic model research, focusing on systematic 
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reviews and development articles. In the middle section of this thesis (Chapters 4 to 
6), flexible parametric prognostic models for the risks of antenatal adverse events in 
pre-eclampsia patients were developed and externally validated using standard and 
competing risks statistical methods. In the penultimate chapter (Chapter 7), the impact 
of competing risks on prognostic performance measures were evaluated in a 
competing risks simulation study. A short summary of the chapters contained in this 
thesis is provided below: 
8.1.1 Chapter 2: An empirical evaluation of the presence and reporting of 
competing events in systematic reviews of prediction model studies. 
The aim of this chapter was to empirically investigate the presence and reporting 
of competing events in published systematic reviews of prediction model development 
studies. The empirical review identified 31 systematic review articles, published 
between January 2015 and April 2017, which were assessed on the potential for 
competing risks bias and acknowledgement of competing events. The key findings was 
that the majority (61.3%) of the systematic review articles in the review were classified 
as being “high risk” of competing risks bias, but very few (6.5%) reported the presence 
of competing events. 
8.1.2 Chapter 3: A review into the presence, reporting, and management of 
competing events in prediction model development studies. 
Given the majority of systematic reviews were considered to be “high risk” in 
Chapter 2, further research was needed on the management of competing events in 
prognostic model development studies. Therefore, this chapter aimed to review how 
prediction model development studies actually handle competing events. The review 
identified 15 prediction model development studies, producing 25 prediction models in 
clinical settings where competing events are a likely issue. These prediction models 
were assessed for the potential for competing risks bias and the management of 
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competing events. Though the majority (84.0%) of the prediction models were 
classified as “high risk” of competing risks bias, relatively few (24.0%) utilised statistical 
methods to appropriately manage the competing events, emphasising that important 
competing events are often ignored in practice. 
8.1.3 Chapter 4: A comparison of time-to-event prognostic models developed 
using Cox and flexible parametric methods. 
To illustrate the application of survival analysis methods without accounting for 
competing events, this chapter developed two prognostic models to predict the risk of 
antenatal adverse events in women diagnosed with early-onset pre-eclampsia. The 
aim was to compare prognostic modelling using Cox proportional hazards regression 
(Cox, 1972a) and Royston-Parmar flexible parametric regression (Royston and 
Parmar, 2002). Both models produced almost identical regression coefficient estimates 
for included predictors. However, the Royston-Parmar model was recommended for 
use in prognostic model research due to the direct estimation of a flexible and smooth 
baseline survival function, which allows risk predictions for new individuals, unlike the 
Cox model which does not estimate the baseline function and so requires non-
parametric estimates of the baseline hazard to be incorporated. 
8.1.4 Chapter 5: A comparison of prognostic models developed using flexible 
parametric competing risks methods. 
To illustrate the application of survival analysis methods that account for 
competing risks, this chapter developed two prognostic models which predict the risk 
of antenatal adverse events in women diagnosed with early-onset pre-eclampsia, while 
accounting for the competing event of delivery using either cause-specific (Hinchliffe 
and Lambert, 2013b) or subdistribution (Lambert et al., 2017) approaches within a 
flexible parametric framework. Both models performed similarly when assessed for 
predictive performance, however the subdistribution approach resulted in a more 
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parsimonious model which could be internally validated and adjusted for overfitting, 
and thus represented important advantages over the cause-specific approach. 
8.1.5 Chapter 6: External validation of prognostic models developed using 
standard and competing risks methods. 
In this chapter, the Royston-Parmar (PREP-RP) model developed in Chapter 4 
and the subdistribution (PREP-SD) model developed in Chapter 5 were externally 
validated using measures adapted to appropriately account for competing events. The 
PREP-RP model, which ignored competing events, performed well at early time points 
in terms of both calibration and discrimination. However, the calibration of the model 
was poorer at later time points as the model substantially overestimated the absolute 
risk of antenatal adverse events. In contrast, the PREP-SD model, which accounted 
for competing events, consistently underestimated the absolute risks of antenatal 
adverse events. Nevertheless, the model produced risk predictions that better reflect 
the observed risk of antenatal adverse events at later time-points. 
8.1.6 Chapter 7: When are competing risk statistical methods needed in 
prognostic model research? A simulation study. 
Following the findings of the previous chapters, this study used a simulation study 
to identify how competing risks bias in measures of calibration is affected by the 
incidence of both the event of interest and competing events. Multiple scenarios were 
investigated with a range of incidences for the main event of interest and the competing 
event. Measures of absolute and percentage cumulative risk bias were found to grow 
as the incidence of the event of interest and the relative proportion of competing events 
increase. An existing rule-of-thumb, which advises competing events need only be 
accounted for if the competing event occur at least as often as the event of interest 
(Berry et al., 2010), was found not to be appropriate for avoiding substantial calibration 
bias. 
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8.2 Key findings and recommendations 
The findings of the research conducted in this thesis are summarised in the 
discussion section of each chapter. Four key findings of the thesis are presented in 
Box 8.1 and are discussed in more detail below: 
Box 8.1: Key findings from this thesis 
1. Competing events are often present but rarely reported or appropriately 
managed in prognostic model research. 
2. Flexible parametric subdistribution models are recommended to account for 
competing risks in prognostic model research. 
3. Competing risks bias increases with increased incidence of the event of interest 
and the competing event. 
4. Researchers should not use the current rule of thumb for deciding when to use 
competing risks methods rather than standard survival analysis methods. 
 
8.2.1 Competing events are often present but rarely reported or appropriately 
managed in prognostic model research. 
A consistent finding of the reviews conducted in Chapters 2 & 3 is that in 
prognostic model research, the presence of competing events is high. In the evaluation 
of systematic reviews, 90.3% were found to include prediction models with outcomes 
other than all-cause mortality, and 61.3% were classified as high potential for 
competing risks bias. In the review of prediction model development studies, mortality 
was a competing event for 92.0% of the prognostic models, and 73.3% of the prediction 
model studies were classified as high potential for competing risks bias. These findings 
are similar to those observed in other systematic reviews; competing risks were found 
to be present in 78% of reports of randomised controlled trials (Austin and Fine, 2017), 
74% of articles published in high impact medical journals (Koller et al., 2012), and 46% 
of articles which reported Kaplan-Meier curves (Walraven and McAlister, 2016). 
Though the presence of competing events was found to be high, the reporting of 
competing events was low. In the evaluation of systematic reviews, only 6.5% directly 
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reported the competing events. In the review of prediction model development studies, 
key terms related to competing events were reported in 20% of the study articles, and 
the incidence of the competing events was only reported in 26.7% of the study articles. 
Again these findings appear to be in line with the findings of other systematic reviews; 
competing risks were discussed as a possible issue in only 18% of articles published 
in high impact medical journals (Koller et al., 2012), and 34.8% of articles deemed to 
be susceptible to competing risks bias cited the number of competing events that 
occurred during the study (Walraven and McAlister, 2016). 
When competing events are ignored, this may cause bias in a developed model’s 
absolute risk predictions for the main event of interest. The review of prediction model 
development studies found that competing events are often not appropriately 
managed, with only 20% of studies using appropriate methods. Again this reflects the 
findings of other systematic reviews, with 20% of articles published in high impact 
journal using appropriate methods (Koller et al., 2012), and 16% of reports of 
randomised controlled trials (Austin and Fine, 2017). 
To the author’s knowledge, these are the first reviews that investigate the 
presence, reporting, and management of competing risks and its associated bias in 
prediction model research. These reviews aid the understanding of the high presence 
but rare reporting and appropriate management of competing events; indeed, the 
findings suggest that a large proportion of prediction model research is susceptible to 
competing risks bias. However, it has been shown in the later chapters of this thesis 
(e.g. Chapters 6 and 7) that being susceptible to bias does not always result in biased 
measures of prognostic performance. The calibration of a prognostic model that 
predicts an event of interest with low incidence, is developed in the presence of a 
completing event with a relatively low incidence (compared to the event of interest), or 
that has a short prediction horizon (resulting in a low occurrence of competing events), 
is likely to be unaffected by competing risks bias. Additionally, findings from the thesis 
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suggest the discriminative performance of prognostic models may be hindered by 
applying competing risks statistical methods (see Table 6.5), though further 
investigation in a wider range of scenarios is required for a better understanding of this 
finding. It is argued that the application of competing risks statistical methods to 
manage competing events whenever they are present would reduce any risk for 
competing risks bias. However, the requirement for use of competing risks statistical 
methods in prognostic model research has been shown to depend on the amount of 
bias expected in measures of prognostic performance, which is influenced by the 
incidence of both the event of interest and the competing event. The use of these 
methods may also be influenced by a researcher’s decision to use more familiar 
(standard) time-to-event methods over the more complicated competing risks 
methods, in order to aid the user’s interpretation and understanding of the final 
prognostic model. Current guidance aimed, at improving the quality of prognostic 
models (such as the TRIPOD statement), should be updated to specifically mention 
competing events and encourage researchers to consider the potential for competing 
risks bias in their prognostic model studies. 
The tool developed within these chapters (Figure 2.1) to assess the risk of 
competing risks bias could be used either when planning the development of, or when 
assessing, prediction model studies. If a study is considered to be at high risk of 
competing risks bias, researchers must use competing risks statistical methods to 
appropriately manage the competing events. These competing events should also be 
better reported; for example, competing risk specific information could be incorporated 
into updates and extensions of the TRIPOD reporting guidelines to ensure researchers 
consider and report the presence and proportion of competing events in their studies. 
Currently the TRIPOD guidance does not mention competing events specifically. It is 
encouraging that the recent PROBAST (risk of bias assessment tool for prediction 
model studies) guidance has a specific item on competing risks (“Were complexities in 
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the data (e.g., censoring, competing risks, sampling of control participants) accounted 
for appropriately?”) 
8.2.2 Flexible parametric subdistribution models are recommended to 
incorporate competing risks in prognostic model research 
The benefits of using flexible parametric models, as opposed to parametric or 
semi-parametric models, are outlined in Chapter 4. The key benefits of using this 
approach specifically to develop prognostic models are: 
1. The direct estimation of a smooth underlying baseline hazard function, and 
2. The derivation of absolute risk predictions for individual patients. 
The benefits of this approach have been discussed in depth in current literature 
(Royston and Lambert, 2011), including articles which discuss benefits specifically in 
terms of prognostic model research (Snell, 2015). Most notably, Professor Sir David 
Cox, developer of the Cox model, in an interview with Nancy Reid has stated “I would 
normally want to tackle a problem parametrically… I’m not keen on nonparametric 
formulations” and “if you want to do things like predict the outcome for a particular 
patient, it’s much more convenient to do that parametrically” (Reid, 1994). 
Similarly, the benefits of applying the subdistribution, rather than the cause-
specific, approach for modelling competing events are discussed in Chapter 5. The 
key benefits of this approach for developing prognostic models are: 
1. Retaining the one-to-one association between the hazard and risk functions, which 
aids the interpretation of prognostic factors on real world risks, 
2. Returning a parsimonious and simpler model, than the cause-specific approach, 
as only the event of interest needs to be modelled, and 
3. The ease of applying standard prognostic model research methods for internal 
validation, shrinkage, and model updating. 
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The cause-specific and subdistribution approaches are often compared in the 
literature (Dignam et al., 2012, Hinchliffe, 2013, Koller et al., 2012, Lau et al., 2009, 
Putter et al., 2007, Varadhan et al., 2010, Wolkewitz et al., 2014) with some articles 
again focusing specifically on their use in prognostic model research (Leoce, 2016, 
Wolbers et al., 2009). It is commonly suggested the two approaches be utilised side-
by-side to aid understanding of both the direct and indirect effects of the prognostic 
factors on the event of interest and competing events (Dignam et al., 2012, Lau et al., 
2009, Varadhan et al., 2010, Wolkewitz et al., 2014). However, in prognostic model 
research these effects are of little importance; instead the key outcome is the accurate 
estimation of absolute risk predictions. Some authors discuss the convenience of the 
subdistribution approach, which directly regresses on the cause-specific cumulative 
incidence function, for answering prognostic modelling research questions (Dignam et 
al., 2012, Koller et al., 2012). 
Given the findings of Chapters 4 & 5, a key recommendation from this thesis is 
the use of flexible parametric subdistribution models for the development of prognostic 
models in the presence of competing events. The combination of the two approaches 
results in the development of parsimonious prognostic models which directly estimate 
smooth underlying baseline subdistribution hazards that can be modelled without the 
need to model associations with the competing events. 
8.2.3 Competing risks bias increases with increased incidence of the event of 
interest and the competing event. 
The simulation study performed in Chapter 7 demonstrated the strong 
association between the amount of competing risks bias in measures of calibration and 
the incidence of both the event of interest and the competing event. Higher levels of 
competing risks bias were observed in simulation scenarios with lower event of interest 
incidence and higher competing event incidence (see Figure 7.5). These associations 
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are similar to those observed by Walraven and team, who found competing risks bias 
could be determined using the “biased Kaplan-Meier risk estimates and the proportion 
of all outcomes that were competing events” (van Walraven and Hawken, 2016). A rule 
of thumb, which advises when the more complex competing risks methods should be 
applied (Berry et al., 2010), was evaluated in Chapter 7. This rule was found to be 
insufficient in avoiding substantial bias in cumulative incidence estimates in prediction 
model studies. An alternative recommendation to evaluate the need for the more 
complex analysis using a threshold for acceptable percentage bias was proposed. For 
example, if 10% was considered an acceptable level of percentage bias, then with an 
event of interest incidence of 5% competing risks should be accounted for if the 
competing event incidence is at least 17% (Table 7.4). However, to avoid any bias the 
best approach is to apply competing risks methods whenever competing risks were 
suspected. 
While not appropriately accounting for competing events has been shown to 
cause bias absolute risk predictions, and thus affects measures of calibration, the 
inappropriate management of competing events does not appear to have much of an 
effect of the discriminative performance of the models. In Chapter 6, two models 
developed to predict the risk of antenatal adverse events in women with early-onset 
pre-eclampsia were externally validated. Differences between the model’s calibration 
performance grew as time progressed and more competing events were observed 
(Figure 6.5), however little difference was observed between the models discriminative 
performance measures (Table 6.5). 
8.3 Discussion points 
Many advances in prognostic model and competing risks research have been 
made throughout the duration of this thesis, while some challenges still remain. These 
are now summarised. 
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8.3.1 Current prognostic model research literature 
There is a growing interest in prognostic model research, evidenced by the 
increasing number of scientific articles published on the topic each year (Collins et al., 
2015). Many articles investigate the challenges related to the methodology and 
reporting of prognostic model research (Groenwold et al., 2016, Moons et al., 2009a, 
Royston and Altman, 2013, Royston et al., 2009, Steyerberg et al., 2013), with some 
focusing specifically on the presence of competing events (Leoce, 2016, Wolbers et 
al., 2009). A number of tools have been developed in an attempt to improve the quality 
of prognostic model research; including the TRIPODi statement, developed to “improve 
the transparency of the reporting of a prediction models study” (Collins et al., 2015); 
and the PROBASTii tool, developed to “aid the assessment of the risk of bias and 
applicability of prediction modelling studies in a systematic review” (Wolff et al., 2019). 
Additionally, in 2017 a new journal, titled “Diagnostic and Prognostic Research”, was 
created to “ensure that the results of all well-conducted diagnostic and prognostic 
research are published, regardless of their outcome” (Moons et al., 2017). 
A number of systematic reviews highlight the proliferation of prognostic models 
developed for the same health state to predict similar outcomes, for example 363 
prediction models were identified for cardiovascular disease (Damen et al., 2016), 91 
for improving the quality of liver resection (Lim et al., 2015), and 63 were identified for 
functional outcomes post-stroke (Meyer et al., 2015). The large number of available 
prognostic models could be another barrier which perturbs clinicians from using 
models to inform clinical decisions (Wessler et al., 2017, Wyatt and Altman, 1995). 
Further, the development of new prognostic models for the same health states and 
outcomes as existing models is inefficient, as information captured in previous studies 
and models is lost (Moons et al., 2012a). Methods for updating and recalibrating 
                                                     
i Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis. 
ii Prediction modelling Risk Of Bias ASsessment Tool. 
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existing models are recommended over the continual development of new prognostic 
models (Moons et al., 2012a, Royston, 2010). It has been shown that simple 
recalibration methods are often sufficient to improve the predictive performance of 
existing prognostic models in new populations or settings (Janssen et al., 2008). 
Prognostic models are developed to predict the risk of a future outcome from the 
intended moment of use (Moons et al., 2015), typically a primary consultation or 
diagnosis. However, there are many reasons why a patient’s risk could change over 
time; a patient’s biomarker measurements may change as the disease progresses, 
patients may actively alter their behaviour to reduce their risk, and advances in medical 
treatments could improve risks. Research into the statistical methods to incorporate 
the change of individual risks over time into prognostic models is advancing. Dynamic 
prediction models retain prognostic accuracy by “evolving over time in response to 
observed changes” (Jenkins et al., 2018). Models are updated, either at discrete time-
points as populations, treatments, and clinical practices change, or continually over 
time. Landmark prediction models allow predictions to be made from different time 
points, for example at diagnosis, then again three years after diagnosis (Lambie et al., 
2019). Landmark models update expected risk predictions over time, allowing 
clinicians and patients to reassess risks at different time points. Finally, joint modelling 
methods can be applied to prognostic models to allow repeated prognostic factor 
measurements to be incorporated into the risk predictions (Proust-Lima and Taylor, 
2009). This can aid prediction when a prognostic factor measurement is highly variable 
within individuals (such as blood pressure), or when risk is associated with the 
trajectory (pattern over time) of the prognostic factor. 
The prognostic model literature supports the investigation of a single specific outcome 
(Steyerberg et al., 2013). However, in clinical practice multiple outcomes may be of 
interest. The multistate framework was introduced for standard time-to-event and 
competing risks analysis in Chapter 1. This framework can be extended to incorporate 
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numerous events of interest as well as intermediate events, such as recovery or 
adverse events, as depicted in Figure 8.1. Multi-state prognostic models allow the 
prediction of multiple outcomes of interest and help describe the patients transitions 
between different health states (Javanmardi et al., 2018), providing a broader view of 
future disease progression. 
Figure 8.1: Complex multi-state model for prognosis following bone marrow 
transplantation in leukaemia patients 
 
mstate R package (de Wreede et al.), published in Journal of Statistical Software, is 
licensed under CC BY 3.0 
 
8.3.2 Current competing risks literature 
It has been shown that competing events are rarely utilised in prognostic model 
research. There are increasing efforts to make competing risks methods more 
accessible to researchers. A number of user friendly statistical software packages have 
been developed in Stata to enable competing risks analysis, including the stpm2 
function (Lambert and Royston, 2009), an extension stpm2cif (Hinchliffe and Lambert, 
2013a), and the multistate function (Crowther and Lambert, 2019). Multiple online tools 
have been developed for use as teaching tools and to aid understanding of key 
methodological concepts, including an interactive graph which demonstrates the link 
between cause-specific hazards and the cumulative incidence function (Lambert) and 
an interactive cancer survival prediction tool (Mozumder). Earlier tutorials on 
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competing risks analysis focused on applications in cancer progression (Fine and 
Gray, 1999, Hinchliffe, 2013, Pintilie, 2007). However, recently there has been an 
increase in discussions of the use of these methods for other health states, including 
coronary heart disease (Wolbers et al., 2009), nephrology (Noordzij et al., 2013), and 
pneumonia (Wolkewitz et al., 2014). All of the aforementioned resources aim to 
increase the accessibility of competing risks methods to researchers, in an attempt to 
increase the use of the methods in practice. 
The more popular Fine and Gray model (Fine and Gray, 1999) is not discussed 
in detail during this thesis, as the focus is on the use of flexible parametric competing 
risks approaches. In brief, the Fine and Gray model is a semi-parametric model on the 
subdistribution hazards scale. As such, the model does not directly estimate the 
underlying cumulative baseline subdistribution hazard function and does not provide 
absolute risk predictions. However, the model may be useful in prognostic model 
research for identifying associations between prognostic factors and the real-world risk 
of the event of interest, accounting for the competing event. 
The statistical methods which allow for adaptive prognostic model predictions, 
discussed previously, are also being extended to incorporate competing events. The 
landmark model approach has been extended to allow dynamic prediction of 
competing risks while incorporating time-dependant covariates (Nicolaie et al., 2013), 
allowing prediction to be made at specified timepoints after initial diagnosis. Advances 
to joint modelling methods have been made to model multiple longitudinal 
measurements with competing risks time-to-event outcomes (Andrinopoulou et al., 
2017), producing dynamically updated absolute risk predictions. 
8.4 Limitations and further research 
Some limitations of the work contained within this thesis are outlined below, 
alongside suggestions of further research that will address these limitations. 
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Neither of the reviews conducted in Chapters 2 and 3 encompass the entirety of 
the prediction model research literature. These reviews were performed to provide a 
snapshot of the literature in order to assess the presence, management, and reporting 
of competing events in prediction model research. As such, many systematic reviews 
of prediction model development studies, and prediction model development study 
articles are not considered. To the authors knowledge, these are the largest reviews 
to assess competing risks bias in prediction model literature that have been conducted. 
The finding of high competing risk incidence from the evaluation of systematic reviews 
of prediction model development studies (Chapter 2) is likely to be generalisable, as 
most of the included systematic reviews searched for articles from database inception 
and prediction model outcomes are unlikely to have changed over time. The prediction 
model development studies identified for inclusion in the review conducted in Chapter 
3 were purposefully selected from clinical settings where competing events are likely 
to be an issue. The finding of high incidence of competing events in these articles is 
thus likely to be inflated compared to the incidence in all prediction model research. 
Further research could extend both of the reviews conducted in this thesis to 
incorporate all prediction model literature, including articles published since the review 
was conducted (April 2017). This would allow for a better understanding of the 
presence of competing risks in all prognostic model research, and could perhaps 
identify whether there were trends in the presence, reporting, and management of 
competing events over different health states, or indeed over time. 
The presence of competing risks bias in the studies included in Chapters 2 & 3 
was not known, and thus was evaluated using a risk tool which assessed three criteria 
(Figure 2.1). It was considered out of the scope of the thesis to obtain individual 
participant data from each study to thoroughly assess the presence of competing 
events. The risk tool simply combines factors which were thought to be applicable to 
competing risks bias in prediction model studies, and which were likely to be reported. 
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However, this tool has not been evaluated. Further research could go on to evaluate 
the risk tool in prediction model studies to identify how accurate it is at identifying the 
presence of competing events. If found to be accurate, the tool could be utilised to 
inform the study design and statistical methods used in future prediction model 
development studies. 
The prognostic models developed for predicting outcomes in early-onset pre-
eclampsia patients (Chapters 4 & 5) were potentially underpowered. The PREP study 
was designed and powered to predict the risk of maternal complication, including 
delivery before 34 weeks, of which there were 633 events (Thangaratinam et al., 2017). 
In this thesis, the alternative outcome of antenatal adverse events was investigated, 
either ignoring or incorporating delivery as a competing event, of which there were only 
75 events. This was a pragmatic use of available data, and was considered a sufficient 
sample size to indicate differences in semi-parametric and flexible parametric, and 
standard time-to-event and competing risks, approaches. Furthermore, the small 
number of antenatal adverse events restricted the analysis to the composite outcome; 
there were too few events to examine individual components separately. The adverse 
events differ in severity and would be managed differently, thus the evaluation of each 
type of adverse event would be more clinically meaningful but would require a much 
larger study. External validation in other settings could be explored to determine the 
generalisability of the competing risks model. Finally, the adverse events which 
occurred following delivery of the baby were not considered during this thesis, as the 
focus was on competing events. Further research into early-onset pre-eclampsia 
prognosis would include conducting a larger study, powered to reduce the potential for 
overfitting, and thus to develop a more robust prognostic model for adverse events. If 
the sample size were sufficiently large, this study could investigate the risks for each 
different type of adverse event separately, or indeed could use multi-state modelling 
methods to develop a prognostic model for transitions between antenatal adverse 
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events, delivery, and postnatal adverse events. Such a model would be beneficial to 
clinicians and patients and would facilitate informed treatment decision making for 
women diagnosed with early-onset pre-eclampsia. 
There is currently little research into methods for validation or recalibration of 
prognostic models developed using competing risks methods. Recent research has 
focused on developing calibration curves for competing risks models (Gerds et al., 
2014) and adapting concordance for competing events (Wolbers et al., 2014). Further 
methodological research into measures of calibration and discrimination, adapted for 
the presence of competing events is required. Additionally, standard prognostic model 
updating and recalibration methods are not easily transferable to cause-specific 
competing risks models, and further methodological research is required. 
The simulation studies conducted in Chapter 7 utilise simple constant hazard 
functions (exponential models), which are usually not considered to be biologically 
plausible in medical research (Crowther and Lambert, 2013). The studies also focused 
on parametric absolute risk estimates, and failed to incorporate prognostic factor 
associations. To reflect prognostic model research the simulations should have 
incorporated the effects of prognostic factor associations with both the event of interest 
and the competing event, and assessed absolute risk predictions from flexible 
parametric regression equations against expected risks. Further simulation studies 
which incorporate more complex and realistic hazard functions, modelled using flexible 
parametric modelling of the underlying hazard functions, are planned for future 
research. This future research will also investigate the impact of incorporating 
prognostic factor associations with the event of interest and the competing event, and 
evaluate bias in both measures of calibration and discrimination. This research will 
provide a greater understanding of the impact of event of interest and competing event 
incidences, and associations between prognostic factors and the event of interest or 
competing event, on the biases caused by mismanaging competing events. 
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8.5 Final conclusions 
This thesis has evaluated the use of statistical methods for developing and 
validating competing risks prognostic models for use in clinical practice, including an 
applied example in early-onset pre-eclampsia prognosis. It provides new empirical 
evidence that competing events are often ignored in prognostic model research, 
including development studies and systematic reviews. It also highlights the potential 
for large bias in risk predictions when ignoring competing risks methods. While 
methods for developing competing risks prognostic models are advanced and widely 
accessible, further methodological research is required to ensure models can be 
properly validated and updated. 
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9 APPENDIX I 
Data Extraction Sheet: 
Evaluation of Systematic Reviews of Prediction Model Studies 
Version 3.0 
Item 1: What were the characteristics of each systematic review? 
Title of systematic 
review article:  
Endnote reference:  
Date restrictions 
reported in search 
strategy: 
Start date:  End date:  
Primary aim of 
systematic review*:  
Aims to identify prediction models for a specific outcome? 
 ☐ YES ☐ NO ☐ UNCLEAR 
Aims to identify prediction models in a specific population? 
 ☐ YES ☐ NO ☐ UNCLEAR 
Number of prediction 
models (& studies) 
identified by 
systematic review¥ 
 
*The primary aim is taken from systematic review abstract. 
¥Some systematic reviews may identify a study article which describes the development of 
multiple prediction models, additionally some articles may identify both development and 
validation articles, thus the number of models and studies may not be equal. 
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Item 2: What is the potential for competing risks bias affecting each 
systematic review? 
Criterion 1: The prediction model investigates outcomes other than all-cause 
mortality 
Outcomes of the 
prediction models 
identified by the 
review 
All-cause mortality or composite ☐ 
Single (not ACM / PFS) ☐ 
 
Criterion 2: The baseline population contains frail and/or elderly populations 
Disease and health 
states of prediction 
model populations 
 
Population age at 
baseline 
Measures: Results: 
  
Criterion 3: The prediction horizon is sufficiently long to enable competing events 
to occur 
Prediction horizon of 
prediction models 
identified by the 
review* 
Measures: Results: 
  
Assessing the potential for competing risks bias within each systematic review 
Criterion 1: The review contains prediction models with 
outcomes other than all-cause mortality. 
If no select None, if yes proceed to Criterion 2: 
None ☐ 
Criterion 2: The review contains prediction models 
developed in elderly or frail populations. 
If no select Low, if yes proceed to Criterion 3: 
Low ☐ 
Criterion 3: The review contains prediction models 
which predict outcomes after 1 year or more? 
If no select Moderate, if yes select High. 
Moderate ☐ 
High ☐ 
*If specific prediction time horizon not reported, report measure of follow-up times 
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Item 3: Were competing events reported in the systematic review article? 
Term “competing risk(s)” or “competing event(s)” used? ☐ YES ☐ NO 
If yes copy text: 
 
Other competing risks terms used in the article? ☐ YES ☐ NO 
Such as:  
competing cause(s); competing bias; cause-specific; subdistribution; cumulative 
incidence; Fine and Gray; 
If yes copy text: 
 
Kaplan-Meier estimates or curves presented or discussed? ☐ YES ☐ NO 
If yes copy text: 
 
 
Item 4: Was competing risks part of the quality assessment performed within 
the systematic review? 
Quality assessment performed? ☐ YES ☐ NO 
Tool used:  
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10 APPENDIX II 
Table 10.1: Characteristics of systematic reviews included in evaluation of systematic reviews of prediction model studies (Chapter 
2) 
Systematic 
review 
reference 
Publication title 
Search dates 
of the review 
Primary 
outcome(s) 
specified in the 
review? 
Primary 
population 
specified in the 
review? 
No. of models 
(primary study 
articles) in each 
review 
(Ayerbe et al., 
2016) 
Clinical assessment of patients with chest pain; a 
systematic review of predictive tools 
Inception to  
July 2015 Yes Yes 13 (12) 
(Brunelli and 
Prefumo, 
2015) 
Quality of first trimester risk prediction models for pre-
eclampsia: a systematic review 
Inception to  
July 2013 Yes Yes 38 (24) 
(Caragata et 
al., 2016)  
Acute kidney injury following liver transplantation: a 
systematic review of published predictive models 
Inception to  
May 2015 Yes Yes 7 (7) 
(Damen et al., 
2016) 
Prediction models for cardiovascular disease risk in the 
general population: systematic review 
Inception to  
June 2013 Yes Yes 363 (125) 
(Echouffo-
Tcheugui et 
al., 2015)  
Population risk prediction models for incident heart 
failure: a systematic review 
January 1990 
to August 2014 Yes Yes 28 (13) 
(Ensor et al., 
2016)  
Prediction of risk of recurrence of venous 
thromboembolism following treatment for a first 
unprovoked venous thromboembolism: systematic 
review, prognostic model and clinical decision rule, and 
economic evaluation 
Inception to  
June 2014 Yes Yes 3(3) 
(Gray et al., 
2016)  
Risk Prediction Models for Lung Cancer: A Systematic 
Review 
 1985 to  
July 2014 Yes No 16 (25) 
(Haskins et al., 
2015)  
Validation and impact analysis of prognostic clinical 
prediction rules for low back pain is needed: a 
systematic review 
Inception to  
July 2013 No Yes 30 (35) 
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Systematic 
review 
reference 
Publication title 
Search dates 
of the review 
Primary 
outcome(s) 
specified in the 
review? 
Primary 
population 
specified in the 
review? 
No. of models 
(primary study 
articles) in each 
review 
(Hilkens et al., 
2016) 
Prediction models for intracranial hemorrhage or major 
bleeding in patients on antiplatelet therapy: a 
systematic review and external validation study 
Inception to 
December 
2014 
Yes Yes 5 (5) 
(Kohn et al., 
2015) 
Prognostic Accuracy of Clinical Prediction Rules for 
Early Post-Pulmonary Embolism All-Cause Mortality: A 
Bivariate Meta-analysis 
January 2000 
to March 2014 Yes Yes 11 (40) 
(Lim et al., 
2015) 
Improving the quality of liver resection: a systematic 
review and critical analysis of the available prognostic 
models 
May 1999 to 
March 2012 No Yes 91 (91) 
(Linsell et al., 
2016) 
Prognostic Factors for Behavioral Problems and 
Psychiatric Disorders in Children Born Very Preterm or 
Very Low Birth Weight: A Systematic Review 
January 1990 
to June 2014 No Yes 30 (15) 
(Luo et al., 
2015) 
A systematic review of predictive models for asthma 
development in children 
Inception to  
June 2015 Yes Yes 30 (32) 
(Mahajerin et 
al., 2015) 
Hospital-associated venous thromboembolism in 
pediatrics: a systematic review and meta-analysis of 
risk factors and risk-assessment models 
Inception to  
May 2014 Yes Yes 3 (60) 
(Mao et al., 
2015) 
Predictors associated with stroke after coronary artery 
bypass grafting: A systematic review 
January 1990 
to September 
2014 
Yes Yes 14 (14) 
(Marques et 
al., 2015) 
The accuracy of osteoporotic fracture risk prediction 
tools: a systematic review and meta-analysis 
2003 to 
September 
2014 
Yes Yes 13 (45) 
(Marufu et al., 
2015) 
Risk scoring models for predicting perioperative 
morbidity and mortality in people with fragility hip 
fractures: Qualitative systematic review 
1966 to  
April 2015 Yes Yes 25 (29) 
(Meyer et al., 
2015) 
A systematic review of studies reporting multivariable 
models to predict functional outcomes after post-stroke 
inpatient rehabilitation 
Inception to  
January 2013 Yes Yes 63 (27) 
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Systematic 
review 
reference 
Publication title 
Search dates 
of the review 
Primary 
outcome(s) 
specified in the 
review? 
Primary 
population 
specified in the 
review? 
No. of models 
(primary study 
articles) in each 
review 
(O'Caoimh et 
al., 2015) 
Risk prediction in the community: A systematic review 
of case-finding instruments that predict adverse 
healthcare outcomes in community-dwelling older 
adults 
1965 to  
November 
2014 
No Yes 23 (46) 
(Oliver et al., 
2015) 
Risk assessment tools validated for patients 
undergoing emergency laparotomy: a systematic 
review 
1980 to  
November 
2014 
No Yes 25 (20) 
(Quinlivan et 
al., 2016) 
Which are the most useful scales for predicting repeat 
self-harm? A systematic review evaluating risk scales 
using measures of diagnostic accuracy 
Inception to  
February 2015 Yes Yes 11 (8) 
(Salz et al., 
2015) 
Are we ready to predict late effects? A systematic 
review of clinically useful prediction models 
Inception to  
April 2014 No Yes 16 (14) 
(Silver et al., 
2015) 
Risk prediction models for contrast induced 
nephropathy: systematic review 
Inception to 
March 2015 Yes Yes 12 (16) 
(Silverberg et 
al., 2015) 
Systematic review of multivariable prognostic models 
for mild traumatic brain injury 
1970 to 
June 2013 No Yes 49 (26) 
(Smit et al., 
2015) 
Childhood asthma prediction models: a systematic 
review 
Inception to  
June 2014 Yes Yes 12 (12) 
(Tang et al., 
2015) 
Current Developments in Dementia Risk Prediction 
Modelling: An Updated Systematic Review 
January 2009 
to  
March 2014 
Yes No Unclear* (21) 
(Usher-Smith 
et al., 2016) 
Risk Prediction Models for Colorectal Cancer: A 
Systematic Review 
January 2000 
to  
March 2014 
Yes Yes 52 (40) 
(Walsh et al., 
2016) 
Systematic review of risk prediction models for falls 
after stroke. 
Inception to  
June 2015 Yes Yes 18 (12) 
(Warnell et al., 
2015) 
Predicting perioperative mortality after 
oesophagectomy: a systematic review of performance 
and methods of multivariate models 
1990 to 2012 Yes Yes 11 (20) 
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Systematic 
review 
reference 
Publication title 
Search dates 
of the review 
Primary 
outcome(s) 
specified in the 
review? 
Primary 
population 
specified in the 
review? 
No. of models 
(primary study 
articles) in each 
review 
(Williams et 
al., 2016) 
Risk prediction models for colorectal cancer in people 
with symptoms: a systematic review 
January 2000 
to  
March 2014 
Yes Yes 15 (18) 
(Wilson et al., 
2016) 
Risk prediction models for acute kidney injury following 
major noncardiac surgery: systematic review 
Inception to  
June 2014 Yes Yes 7 (6) 
*Multiple models listed multiple times with different cut points for assessment 
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Data Extraction Sheet:  
Review of Prediction Model Development Studies 
Version 3.0 
Item 1: What were the characteristics of each prediction model development 
study? 
Title of prediction 
model study:  
Endnote reference:  
Systematic review 
reference:  
Number of individual 
prediction models 
developed in 
prediction model 
study: 
 
Source of study data: 
Cohort ☐ RCT ☐ 
Case-control ☐ Other (list below) ☐ 
 
Number of 
participants*: 
Development  
Validation  
Total  
*if multiple models are reported in the article then report the greatest number of eligible 
participants 
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Item 2: What is the potential for competing risks bias affecting each 
prediction model? 
Criterion 1: The prediction model investigates outcomes other than all-cause 
mortality 
Outcomes of the 
prediction model 
All-cause mortality or composite ☐ 
Single (not ACM / PFS) ☐ 
 
Criterion 2: The baseline population contains frail and/or elderly populations 
Disease and health 
states of prediction 
model population 
 
Population age at 
baseline 
Measures: Results: 
  
Criterion 3: The prediction horizon is sufficiently long to enable competing events 
to occur 
Prediction horizon of 
prediction model * 
Measures: Results: 
  
Assessing the potential for competing risks bias within each prediction model 
Criterion 1: The prediction model investigates outcomes 
other than all-cause mortality. 
If no select None, if yes proceed to Criterion 2: 
None ☐ 
Criterion 2: The prediction model was developed in 
elderly or frail populations. 
If no select Low, if yes proceed to Criterion 3: 
Low ☐ 
Criterion 3: The prediction models predict outcomes 
after 1 year or more? 
If no select Moderate, if yes select High. 
Moderate ☐ 
High ☐ 
Potential competing events 
Potential competing 
events likely to prevent the 
prediction model outcome 
from occurring: 
 
*If specific prediction horizon not reported, report measure of follow-up time 
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Item 3: Were competing events reported in the published prediction model 
study articles? 
Reported number (%) 
of events: 
Prediction model events: Competing events: 
Total observed events: Proportion competing events: 
Term “competing risk(s)” or “competing event(s)” used? ☐ YES ☐ NO 
If yes copy text: 
 
Other competing risks terms used in the article? ☐ YES ☐ NO 
Such as:  
competing cause(s); competing bias; cause-specific; subdistribution; cumulative incidence; 
Fine and Gray; 
If yes copy text: 
 
Kaplan-Meier estimates or curves presented or discussed? ☐ YES ☐ NO 
Number of prognostic 
factors in final 
prediction models: 
 
Prognostic factors 
associated with 
competing events: 
Age ☐ Comorbidities ☐ 
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Item 4: How were competing events managed in each prediction model 
study? 
Competing risks statistical methodology used? ☐ YES ☐ NO 
Competing events censored? ☐ YES ☐ NO 
Competing events excluded? ☐ YES ☐ NO 
How was the model 
validated? 
None ☐ Apparent validation ☐ 
Internal validation ☐ External validation ☐ 
How were competing 
events managed?   
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Table 12.1: Reasons for inclusion/exclusion of systematic reviews (from chapter 
2) likely to contain models affected by competing events 
Systematic 
review 
reference 
Potential 
for 
competing 
risks bias 
Baseline 
populations 
Corresponding 
characteristic 
(Koller et al., 2012) 
Include/exclude 
and reason 
(Kohn et al., 
2015) 
None Acute pulmonary embolism  
Exclude 
No potential 
(Oliver et 
al., 2015) 
None Emergency laparotomy  
Exclude 
No potential 
(Warnell et 
al., 2015) 
None 
Oesophagectomy 
for cancer in 
adults 
 Exclude No potential 
(Luo et al., 
2015) 
Low Children  Exclude Low potential 
(Smit et al., 
2015) 
Low 
Children with 
asthma-like 
symptoms 
 Exclude Low potential 
(Caragata et 
al., 2016) 
Moderate Liver transplantation Transplant 
Exclude 
Moderate 
potential 
(Lim et al., 
2015) 
Moderate 
Patients 
undergoing liver 
resection 
 
Exclude 
Moderate 
potential 
(Mao et al., 
2015) 
Moderate Coronary artery bypass grafting 
Coronary heart 
disease 
Exclude 
Moderate 
potential 
(Meyer et 
al., 2015) 
Moderate 
Patients receiving 
post-stroke 
inpatient 
rehabillitation 
Stroke 
Exclude 
Moderate 
potential 
(Silver et al., 
2015) 
Moderate 
Undergoing 
procedure using 
iodinated 
radiocontrast 
 
Exclude 
Moderate 
potential 
(Brunelli 
and 
Prefumo, 
2015) 
Moderate First trimester pregnancy  
Exclude 
Moderate 
potential 
(Mahajerin 
et al., 2015) 
Moderate Pediactric hospital patients  
Exclude 
Moderate 
potential 
(Ayerbe et 
al., 2016) 
High Recent onset chest pain Cardiac failure Include 
(Damen et 
al., 2016) 
High General population  
Exclude 
Not susceptible 
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Systematic 
review 
reference 
Potential 
for 
competing 
risks bias 
Baseline 
populations 
Corresponding 
characteristic 
(Koller et al., 2012) 
Include/exclude 
and reason 
(Echouffo-
Tcheugui et 
al., 2015) 
High General population  
Exclude 
Not susceptible 
(Ensor et 
al., 2016) 
High 
Cessation of 
treatment venous 
thrombembolism 
 Exclude Not susceptible 
(Gray et al., 
2016)  
High General population  
Exclude 
Not susceptible 
(Haskins et 
al., 2015)  
High Low back pain  Exclude Not susceptible 
(Hilkens et 
al., 2016) 
High 
Patients on 
antiplatelet 
therapy 
Cardiac failure Include 
(Linsell et 
al., 2016) 
High 
Very preterm or 
very low birth 
weight infants 
 Exclude Not susceptible 
(Marques et 
al., 2015) 
High General population  
Exclude 
Not susceptible 
(Marufu et 
al., 2015) 
High Hip fracture operation  
Exclude 
Not susceptible 
(O'Caoimh 
et al., 2015) 
High 
Community-
dwelling older 
adults 
Elderly patients Include 
(Quinlivan 
et al., 2016) 
High 
Presenting with 
self-harm or 
attempted suicide 
 Exclude Not susceptible 
(Salz et al., 
2015) 
High 
Completing 
treatment for 
cancer 
Prostate cancer, 
colorectal cancer, 
breast cancer 
Include 
(Silverberg 
et al., 2015) 
High Mild traumatic brain injury  
Exclude 
Not susceptible 
(Tang et al., 
2015) 
High 
Varied, including 
general 
population, 
elderly, and with 
diabetes 
 Exclude Not susceptible 
(Usher-
Smith et al., 
2016) 
High General population  
Exclude 
Not susceptible 
(Walsh et 
al., 2016) 
High Stroke Stroke Include 
(Williams et 
al., 2016) 
High Symptomatic of colorectal cancer Colorectal cancer Include 
(Wilson et 
al., 2016) 
High Major non-cardiac surgery  
Exclude 
Not susceptible 
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Full list of published prediction model study articles identified from six systematic review articles, including reasons for inclusion/exclusion. 
Systematic review  Articles Include/Exclude Reason 
(Ayerbe et al., 2016) 
Bassan 2004 Exclude Neural tree – machine learning 
Bjork 2006 Exclude Logistic regression 
Bosner 2010 Exclude Logistic regression 
Gencer 2010 Exclude Logistic regression 
Genders 2012 Exclude Logistic regression 
Goodacre 2002 Exclude Logistic regression 
Gruseels 1995 Exclude Logistic regression 
Pryor 1993 Exclude Model validation study 
Sanchez 2007 Exclude Logistic regression 
Sekhri 2008 Include Cox regression 
Sox 1990 Exclude Logistic regression 
Tierney 1985 Exclude Logistic regression 
(Hilkens et al., 2016) 
Ariesen 2006 Include Cox regression 
Barra 2013 Exclude Risk score: derrivation of weights not through regression methods 
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Systematic review  Articles Include/Exclude Reason 
Cuschieri 2014 Include Cox regression 
Ducrocq 2010 Exclude Logistic regression 
Geraghty 2012 Exclude Conference abstract – insufficient information 
(O'Caoimh et al., 2015)* 
Alessi 2003 Exclude Risk score: derrivation of weights not through regression methods 
Boult 1993 Exclude Logistic regression 
Carey 2004 Exclude Logistic regression 
Carey 2008 Include Cox regression 
Covinsky 2006 Exclude Logistic regression 
Crane 2010 Exclude Logistic regression 
Dalby 1990 Exclude Risk score: derrivation of weights not through regression methods 
Damush 2004 Exclude Logistic regression 
Fitzgerald 2015 Exclude Conference abstract – insufficient information 
Freedman 1996 Exclude Logistic regression 
Han 2012 Exclude Logistic regression 
Herbert 1996 Exclude Logistic regression 
Kerse 2008 Exclude Risk score: derrivation of weights not through regression methods 
Lee 2006 Exclude Logistic regression 
Lyon 2007 Excluded Logistic regression 
Mazzaglia 2007 Exclude Logistic regression 
Reuben 2002 Exclude Logistic regression 
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Systematic review  Articles Include/Exclude Reason 
Roos 1988 Exclude Logistic regression 
Saliba 2001 Exclude Logistic regression 
Schoenberg 2009 Include Cox regression 
Shelton 2000 Exclude Logistic regression 
St John 2014 Exclude Risk score: derrivation of weights not through regression methods 
Suijker 2014 Exclude Logistic regression 
(Salz et al., 2015)  
Alemozaffar 2011 Exclude Logistic regression 
Bevilacqua 2012 Include Cox regression 
Briganti 2010 Include Cox regression 
Chipman 2014 Exclude Generalized estimating equations 
Eastham 2008 Exclude Generalized estimating equations 
Ezaz 2014 Include Cox regression 
Gallina 2008 Exclude Conference abstract – insufficient information 
Ganz 1993 Exclude Logistic regression 
Kilminster 2011 Exclude Logistic regression 
Kovalchik 2013 Include Cox regression 
Langendijk 2009 Exclude Logistic regression 
Mathieu 2013 Include Cox regression 
Romond 2012 Include Parametric and Cox regression 
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Systematic review  Articles Include/Exclude Reason 
Travis 2005 Include Time-to-event methods 
(Walsh et al., 2016) 
Ashburn 2008 Exclude Logistic regression 
Baetens 2011 Exclude Logistic regression 
Chen 2015 Exclude Poisson regression 
Kerse 2008 Exclude Logistic regression 
Mackintosh 2006 Exclude Logistic regression 
Nakagawa 2008 Include Cox regression 
Nyberg 1997 Include Cox regression 
Olsson 2005 Exclude Conference abstract – insufficient information 
Rabadi 2008 Exclude Logistic regression 
Rapport 1993 Exclude Risk score: derrivation of weights not through regression methods 
Sze 2001 Exclude Logistic regression 
Tilson 2012 Exclude Classification and regression tree – Machine learning 
(Williams et al., 2016)  
Adelstein 2010 Exclude Logistic regression 
Adelstein 2011 Exclude Logistic regression 
Ballal 2010 Exclude Model validation study 
Collins 2012 Exclude Model validation study 
Fijten 1995 Exclude Logistic regression 
Hamilton 2005 Exclude Logistic regression 
Hamilton 2009 Exclude Logistic regression 
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Systematic review  Articles Include/Exclude Reason 
Hamilton 2013 Exclude Model validation study 
Hippisley-Cox 2012 Include Cox regression 
Hippisley-Cox 2013 (1) Exclude Logistic regression 
Hippisley-Cox 2013 (2) Exclude Logistic regression 
Hodder 2004 Exclude Model validation study 
Hurst 2007 Exclude Logistic regression 
Lam 2002 Exclude Risk score: derrivation of weights not through regression methods 
Mahadavan 2012 Exclude Logistic regression 
Marshall 2011 Exclude Model validation study 
Rai 2008 Exclude Model validation study 
Selvachandran 2002 Exclude Model validation study 
*O’Caoimh found a further 23 papers eligible for the systematic review; However as the published article focused on the unique instuments, 
and these articles described the external validation of the instruments, it is hard to identify these from the published article and thus they are 
not reported in this table. 
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Table 14.1: Characteristics of prediction model studies included in review of prediction model development studies (Chapter 3) 
Systematic 
review 
reference 
Prediction 
model study 
reference 
Prediction model study article title 
Number of 
individual 
models 
developed(1) 
Source 
of study 
data(2) 
Number of 
participants(3): 
Development 
Validation 
Total 
(Ayerbe et 
al., 2016) 
(Sekhri et al., 
2008) 
Incremental prognostic value of the exercise electrocardiogram in 
the initial assessment of patients with suspected angina: cohort 
study 
3 Cohort 
8,176 
N/A 
8,176 
(Hilkens et 
al., 2016) 
(Ariesen et al., 
2006)  
Predictors of risk of intracerebral haemorrhage in patients with a 
history of TIA or minor ischaemic stroke 1 Cohort 
12,648 
12,648 
12,648 
(Cuschieri et 
al., 2014) 
Risk factors for acute gastrointestinal bleeding following 
myocardial infarction in veteran patients who are prescribed 
clopidogrel 
1 Cohort 
3,218 
3,218 
3,218 
(O'Caoimh et 
al., 2015) 
(Carey et al., 
2008) 
Prediction of Mortality in Community-Living Frail Elderly People 
with Long-Term Care Needs 1 Cohort 
2,232 
1,667 
3,899 
(Schonberg et 
al., 2009) 
Index to Predict 5-Year Mortality of Community-Dwelling Adults 
Aged 65 and Older Using Data from the National Health Interview 
Survey 
1 Cohort 
16,077 
8,038 
24,115 
(Salz et al., 
2015) 
(Bevilacqua et 
al., 2012) 
Nomograms for Predicting the Risk of Arm Lymphedema after 
Axillary Dissection in Breast Cancer 3 Cohort 
1,054 
1,054 
1,054 
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Systematic 
review 
reference 
Prediction 
model study 
reference 
Prediction model study article title 
Number of 
individual 
models 
developed(1) 
Source 
of study 
data(2) 
Number of 
participants(3): 
Development 
Validation 
Total 
(Briganti et al., 
2010) 
Predicting Erectile Function Recovery after Bilateral Nerve 
Sparing Radical Prostatectomy: A Proposal of a Novel 
Preoperative Risk Stratification 
1 Cohort 
435 
435 
435 
(Ezaz et al., 
2014) 
Risk Prediction Model for Heart Failure and Cardiomyopathy 
After Adjuvant Trastuzumab Therapy for Breast Cancer 1 Cohort 
832 
832 
1,664 
(Kovalchik et 
al., 2012) 
Absolute Risk Prediction of Second Primary Thyroid Cancer 
Among 5-Year Survivors of Childhood Cancer 3 
Nested 
case-
control  
12,150 
2,966 
15,116 
(Mathieu et al., 
2014) 
Nomograms to predict late urinary toxicity after prostate cancer 
radiotherapy 3 
Cohort & 
RCT 
965 
N/A 
965 
(Romond et al., 
2012) 
Seven-Year Follow-Up Assessment of Cardiac Function in 
NSABP B-31, a Randomized Trial Comparing Doxorubicin and 
Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus 
Trastuzumab As Adjuvant Therapy for Patients With Node-
Positive, Human Epidermal Growth Factor Receptor 2–Positive 
Breast Cancer 
1 RCT 
1,690 
1,690 
1,690 
(Travis et al., 
2005) 
Cumulative Absolute Breast Cancer Risk for Young Women 
Treated for Hodgkin Lymphoma 2 
Nested 
case-
control  
370 
92 
462 
(Walsh et al., 
2016) 
(Nakagawa et 
al., 2008) 
Development of an assessment sheet for fall prediction in stroke 
inpatients in convalescent rehabilitation wards in Japan 1 Cohort 
704 
N/A 
704 
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Systematic 
review 
reference 
Prediction 
model study 
reference 
Prediction model study article title 
Number of 
individual 
models 
developed(1) 
Source 
of study 
data(2) 
Number of 
participants(3): 
Development 
Validation 
Total 
(Nyberg and 
Gustafson, 
1997) 
Fall Prediction Index for Patients in Stroke Rehabilitation 1 Cohort 
135 
N/A 
135 
(Williams et 
al., 2016) 
(Hippisley-Cox 
and Coupland, 
2012) 
Identifying patients with suspected colorectal cancer in primary 
care: derivation and validation of an algorithm 2 Cohort 
2,351,052 
1,236,601 
3,587,653 
(1)Number of individual prediction models developed within prediction model study 
(2)Source of model development data 
(3)The number of participants included in prediction model study, including those for model development (top), for validation (middle), and 
total number of participants (bottom). Some participants were used for both model development and validation (internal validation with 
bootstrapping). Where multiple individual prediction models were developed in the same prediction model study, the maximum number of 
participants used to develop or validate a model is reported. 
TIA=Transient ischaemic attack, NSABP=National Surgical Adjuvant Breast and Bowel Project, RCT= Randomised controlled trial 
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Table 15.1: Potential competing events for each prediction model study included in the review of prediction model development 
studies (Chapter 3) 
Prediction model 
study reference 
Prediction model outcomes 
Disease and health state of prediction 
model population 
Potential competing events 
(Sekhri et al., 2008) 
Death due to coronary heart disease or 
non-fatal acute coronary syndrome Suspected angina 
Other mortality, preventative 
treatments. 
(Ariesen et al., 2006) Intracerebral haemorrhage Patients with ischaemic stroke or transient ischemic attack Mortality 
(Cuschieri et al., 2014) Acute gastrointestinal (GI) bleeding Patients with myocardial infarction & prescribed clopidogrel Mortality 
(Carey et al., 2008) All-cause mortality Community living frail elderly people with long-term care needs  
(Schonberg et al., 
2009) 
5-year mortality Community dwelling adults aged 65 and older  
(Bevilacqua et al., 
2012) 
Lymphedema Axillary lymph node dissection in breast cancer 
Mortality, breast cancer 
recurrence, other cancer. 
(Briganti et al., 2010) Erectile function recovery Prostate cancer treated with bilateral nerve sparing prostsectomy 
Mortality, prostate cancer 
recurrence, other cancer. 
(Ezaz et al., 2014) Heart failure and cardiomyopathy Patients receiving adjuvant trastuzumab therapy for early-stage breast cancer 
Mortality, breast cancer 
recurrence, other cancer. 
(Kovalchik et al., 2012) Second primary thyroid cancer Survivors of childhood cancers Mortality, complete removal of thyroid gland, other cancer. 
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Prediction model 
study reference 
Prediction model outcomes 
Disease and health state of prediction 
model population 
Potential competing events 
(Mathieu et al., 2014) Urinary toxicity, urinary frequency, dysuria Prostate cancer radiotherapy Mortality, prostate cancer recurrence, other cancer. 
(Romond et al., 2012) 
Severe congestive heart failure or cardiac 
death Patients with node-positive breast cancer 
Mortality, breast cancer 
recurrence, other cancer. 
(Travis et al., 2005) Breast cancer Young women treated for Hodgkin’s lymphoma 
Mortality, Hodgkin’s lymphoma 
recurrence, other cancer. 
(Nakagawa et al., 2008) Falls Stroke inpatients in convalescent rehabilitation wards 
Mortality, immobility, hospital 
discharge 
(Nyberg and 
Gustafson, 1997) 
Falls Patients in stroke rehabilitation Mortality, immobility, hospital discharge 
(Hippisley-Cox and 
Coupland, 2012) 
Colorectal cancer Patients with suspected colorectal cancer Mortality, other cancer. 
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Instances in which competing risks terms were used within published prediction model 
study articles. 
(Kovalchik et al., 2012) 
 
Absolute risk is the probability that an individual with a specific risk profile will develop 
disease by a given age in the presence of competing events. 
 
Competing risks. Competing events for [second primary thyroid cancer] were death, 
self-reported complete removal of the thyroid gland, and other second primary cancers, 
which were determined from pathology reports with follow-up to January 1, 2010.  
 
Estimates of absolute risk combined semiparametric estimates of baseline incidences and 
[relative risks] for [second primary thyroid cancer] and competing risk comprising death, 
thyroid removal, or other second primary cancers. 
 
[Relative risks] for [second primary thyroid cancer] were estimated from the pooled cohort 
and case-control studies, but competing event [relative risks] were estimated from the 
[Childhood Cancer Survivor Study] cohort only. 
 
Hazard models for [second primary thyroid cancer] under [model 1] and [model 2] and 
competing event models for [model 1], [model 2], and [model 3] followed a Cox 
proportional hazards model. 
 
An [first primary cancer] diagnosis of Hodgkin lymphoma ([relative risk], 1.7; 95% CI, 1.6 to 
1.9) and any prior diagnosis of a thyroid nodule ([relative risk], 1.7; 95% CI, 1.3 to 2.2) 
were also found to be significant prognostic variables for competing events in the self-
report-only model. 
 
In the competing events model, the presence of treatment variables with large [relative 
risk] —1.6 (95% CI, 1.5 to 1.7) for alkylating agents (yes/no), 2.1 (95% CI, 1.8 to 2.3) for 
radiation (yes/no), and 1.8 (95% CI, 1.6 to 1.9) for radiation to the neck (yes/no)—resulted 
in an attenuation of the [relative risk] associated with thyroid nodules ([relative risk], 1.4; 
95% CI, 1.1 to 1.8). 
 
All treatment-related factors were strongly associated with the competing risk model for 
[model 3]; the risk association for thyroid nodules ([relative risk], 1.5; 95% CI, 1.1 to 1.9) 
was unchanged from [model 2]. 
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(Romond et al., 2012) 
 
For this purpose, we have developed a prediction model for cumulative incidence of 
cardiac events based on identified pretreatment risk factors. 
 
Patients who crossed over from [Paclitaxel] to [Paclitaxel + Trstuzumab] were censored at 
the time of crossover for the cumulative incidence analysis. 
 
The cumulative proportions of [cardiac events] were estimated and compared by using the 
cumulative incidence function. The competing events were any first event of 
recurrence, second primary cancers, and deaths precluding [cardiac events]. The Cox 
cause-specific proportional hazards model was used to evaluate the association between 
time to [congestive heart failure] and cardiac risks factors. A parametric regression model 
on cause specific subdistribution hazard was used to build a prediction model for 5-
year probability of developing [cardiac events] with 95% point-wise CIs, adjusting for 
significant risk factors. 
 
These five patients were censored at the time of first dose of trastuzumab for the 
cumulative incidence analysis… Among patients assigned to receive [Paclitaxel + 
Trstuzumab], 947 had follow-up information for the cumulative incidence analysis. 
 
On the basis of parametric regression on cause-specific subdistribution hazard, a 
Cardiac Risk Score can be calculated as follows: 
 
The cumulative incidence of [cardiac events] in the control arm 7 years after day 1 of 
cycle 5 was 1.3% (95% CI, 0.5% to 2.1%), and the cumulative incidence among 
trastuzumab-treated evaluable patients was 4.0% (95% CI, 2.8% to 5.2%). 
 
In [National Surgical Adjuvent Breast and Bowel Project protocol B-31], the 7-year 
difference in cumulative incidence of protocol-defined [cardiac events] between the 
experimental and control arms is 2.7% (4.0% v 1.3%, respectively). In the Herceptin 
Adjuvant trial, which required for random assignment an [left venticular ejection fraction] 
55% after completion of all chemotherapy and radiation, the cumulative incidence of 
severe [congestive heart failure] with trastuzumab therapy was only 0.8% at a median 
follow-up of 3.6 years. 
 
 
(Travis et al., 2005) 
 
We estimated this future risk, taking into account age and calendar year of [Hodgkin’s 
lymphoma] diagnosis, [Hodgkin’s lymphoma] treatment information, population breast 
cancer incidence rates, and competing causes of death. 
 
To compute cumulative absolute risks of breast cancer, we used modified standardized 
incidence ratios to relate cohort breast cancer risks to those in the general population, 
enabling application of population-based breast cancer rates, and we allowed for 
competing risks by using population-based mortality rates in female [Hodgkin’s 
lymphoma] survivors. 
 
Estimates of the cumulative incidence of breast cancer after treatment for [Hodgkin’s 
lymphoma] at age 30 years or younger have been sparse, inconsistent, and series 
specific, ranging from 4.2% to 34% at 20 – 25 years of followup. Moreover, most 
estimates have not taken into account the influence of competing causes of mortality, 
which can be substantial among [Hodgkin’s lymphoma] patients, or the effect of 
alkylating agent therapy, which can lower subsequent breast cancer risk. 
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We also took into account age and calendar year of [Hodgkin’s lymphoma] diagnosis, 
age at counselling, baseline breast cancer incidence rates, and competing causes of 
mortality. 
 
Finally, combining information on external relative risks with data on population breast 
cancer incidence rates from the Surveillance, Epidemiology, and End Results Program 
and with [Surveillance, Epidemiology, and End Results] Program data on competing 
causes of death in [Hodgkin’s lymphoma] survivors, we estimated cumulative absolute 
risk of breast cancer, as described in detail below. 
 
Our risk estimates derived from a large international population-based study; 
projections take into account age and calendar year at [Hodgkin’s lymphoma] diagnosis, 
time since treatment, and competing causes of mortality. 
 
Mortality rates for competing risk calculations, stratified by calendar year period and 
age range at [Hodgkin’s lymphoma] diagnosis, were similarly derived from U.S. 
population-based data. 
 
In most studies in which the absolute excess risk of breast cancer among women 
treated for [Hodgkin’s lymphoma] at age 30 years or younger have been presented, 
numbers of case patients are also small (range = 14 – 19 case patients), resulting in 
highly variable estimates, and competing risks are not considered. 
 
Two recent investigations of breast cancer after childhood or adolescent [Hodgkin’s 
lymphoma], however, accounted for competing causes of death. Among girls treated 
with mantle radiotherapy for [Hodgkin’s lymphoma] before age 17 years, the 
cumulative incidence of all invasive breast cancer (27 unilateral case patients plus 12 
patients with contralateral tumors = 39) was 5.6% (95% CI = 2.8 to 8.3) and 16.9% 
(95% CI = 9.4 to 24.5%) at 20 and 30 years of follow-up, respectively. 
 
These risks are calculated by using general population Surveillance, Epidemiology, and 
End Results Program rates for breast cancer and national rates for competing causes 
of mortality. 
 
These values are not corrected for competing causes of mortality and are thus slightly 
larger than comparable estimates of absolute risk in Tables 2 and 3. 
 
The mortality rates from competing risks are assumed to be known with negligible 
random error. 
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A sensitivity analysis was conducted to test the assumptions made in modelling 
the risk of antenatal adverse events. The proportional hazards assumption, made by 
both the Cox and Royston-Parmar models, was tested by incorporating interactions 
between prognostic factors and log-time. The results are given in Table 17.1: 
Table 17.1: Significance (p-values) of interactions of prognostic factors and 
ln(time) in fitted prognostic models 
 Cox proportional 
hazards model 
Royston-Parmar 
flexible parametric model 
Maternal age 0.254 0.294 
Gestational age 0.414 0.777 
Medical history 0.676 0.564 
Systolic blood pressure 0.178 0.010 
Platelet count 0.058 0.181 
Serum creatinine 0.960 0.561 
Antihypertensive treatment 0.828 0.877 
Magnesium sulphate 
treatment 
0.009 <0.001 
 
Significant interactions were detected between magnesium sulphate treatment 
and ln(time) in both models (p-value: 0.009 Cox, <0.001 Royston-Parmar). This 
treatment is given to minimise the risk of eclampsia and prevent preterm labour, its 
effects significantly decrease over time. The interaction between SBP and ln(time) was 
found to be significant in the Royston-Parmar model (p-value 0.010), whereas the 
interaction between platelet count and ln(time) was found to be significant in the Cox 
model (p-value: 0.058). 
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A sensitivity analysis was conducted to test the assumptions made during model 
development. The proportional hazards assumption, made by both the cause-specific 
and subdistribution approaches, was tested by incorporating interactions between the 
included prognostic factors and log time, using a linear (one degree of freedom) spline 
function. The results are given in Table 17.1. 
Table 18.1: Significance (p-values) of interactions of prognostic factors and 
ln(time) in fitted prognostic models 
 Cause-specific 
model:  
delivery 
 
Cause-specific 
model:  
antenatal adverse 
events 
Subdistribution 
model:  
antenatal adverse 
events 
Maternal age 
(years) 
0.005 0.298 0.426 
Gestational age 
(weeks) 
0.447 0.488 0.462 
Medical history* 0.642 0.699 0.221 
Systolic blood 
pressure 
0.003 0.177 N/A 
Platelet count 0.101 0.145 N/A 
Alanine amino 
transaminase 
0.511 N/A N/A 
Serum creatinine 0.652 0.838 N/A 
Antihypertensive 
treatment 
0.562 0.809 0.321 
Magnesium 
sulphate treatment 
<0.001 <0.001 <0.001 
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The following describes the process for determining the constant cause-specific 
hazard functions for the simulations study conducted in Chapter 7: 
The cause-specific cumulative incidence function Fk(t) for event k at time t is written in 
terms of the overall survival function F̅(t) and the cause-specific hazard function hk(t): 
Fk(t) = ∫ F̅(s)hk(s)
t
0
ds Equation 19.1 
The overall survival function F̅(t) is written in terms of all cause-specific hazard 
functions, with two competing events K = 2: 
F̅(t) = ∏ exp {− ∫ hk(s)
t
0
ds}2k=1  Equation 19.2 
Utilising exponential models with constant hazards h1(t) = α1 for the event of interest 
and h2(t) = α2, the overall survival function becomes: 
F̅(t) = exp{−α1t} × exp{−α2t} = exp{−(α1 + α2)t} Equation 19.3 
Incorporating this into the cause-specific cumulative incidence function for the event of 
interest F1(t), gives: 
F1(t) = ∫ α1exp{−(α1 + α2)s}
t
0
ds 
=  α1 [
exp{−(α1 + α2)t}
−(α1 + α2)
]
0
t
 
= α1 [
exp{−(α1 + α2)t}
−(α1 + α2)
−
1
−(α1 + α2)
] 
F1(t) =
α1
α1+α2
[1 − exp{−(α1 + α2)t}] Equation 19.4 
Similarly, the cause-specific cumulative incidence for the competing event, F2(t) is: 
F2(t) =
α2
α1+α2
[1 − exp{−(α1 + α2)t}] Equation 19.5 
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The relationship between the constant cause-specific hazards can be 
represented using the constant scaling factor γ: 
𝛾
𝛼1
𝛼1+𝛼2
[1 − 𝑒𝑥𝑝{−(𝛼1 + 𝛼2)𝑡}] =  
𝛼2
𝛼1+𝛼2
[1 − 𝑒𝑥𝑝{−(𝛼1 + 𝛼2)𝑡}] ∴  𝛾𝛼1 = 𝛼2  
Thus, given the proportion of participants who experience the event of 
interest F1(t), and the scaling factor γ, the constant cause-specific hazard term for both 
the event of interest and the competing event can be determined as follows: 
F1(t) = ∫ α1exp{−(α1 + α2)s}
t
0
ds  
=  α1 [
exp{−(α1+α2)t}
−(α1+α2)
]
0
t
  
= α1 [
exp{−(α1+α2)t}
−(α1+α2)
−
1
−(α1+α2)
]  
F1(t) =
α1
α1+α2
[1 − exp{−(α1 + α2)t}] Equation 19.6 
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Methods for generating survival times for time-to-event analyses are summarised by 
Bender et al. (Bender et al., 2005). Briefly, the hazard function of a proportional 
hazards model, h(t|𝐗), may be expressed as a function of the baseline hazard 
function, h(t|𝟎); a vector of prognostic factors, 𝐗; and corresponding regression 
coefficients, 𝛃; as: 
h(t|𝐗) = h(t|𝟎)exp(𝐗𝛃) Equation 20.1 
The cumulative hazard function, H(t|𝐗), survival function, S(t|𝐗), and cumulative 
distribution function, F(t|𝐗), are expressed as: 
H(t|𝐗) = H(t|𝟎)exp(𝐗𝛃), in which H(t|𝟎) = ∫ h(u|𝟎)dut0  Equation 20.2 
S(t|𝐗) = exp[−H(t|𝐗)] Equation 20.3 
F(t|𝐗) = 1 −  exp[−H(t|𝐗)] Equation 20.4 
Bender et al. (Bender et al., 2005) showed if T is the simulated survival time, then by 
letting:  
F(T|𝐗) = 1 −  exp[−H(T|𝐗)] = u, where u~Uniform(0,1) Equation 20.5 
We can write; 
S(T|𝐗) =  exp[−H(T|𝐗)] = u Equation 20.6 
If h(T|𝟎) > 0 and H(t|𝟎) can be directly inverted, the above equation can be rearranged 
and solved fo T: 
T = H−1(−ln(U)exp(−𝐗𝛃)|𝟎) Equation 20.7 
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An example of Stata code used to generate data for the base scenario and 
evaluate overall calibration bias. 
****************************************************************** 
* COMPETING RISKS PROGNOSTIC MODELS * 
* SIMULATION STUDY * 
****************************************************************** 
 
*(1)* Generate data and overall calibration bias for 500 studies 
*Base scenarios 5-8: N=4144 participants, Exponential, EOI= 11.2% 
*Gamma = 1.0, 1.5, 2.0, 2.72 
 
*Set working directory 
cd "C:\Users\rpd97\Desktop\Stata Simulations" 
 
*Set seed for reproducibility 
set seed 545245 
 
*Set up loop to run through all base scenarios 
local Scen = 4 
foreach lam in "0.01449 0.03946" "0.01365 0.02730" /// 
    "0.01314 0.01971" "0.01268 0.01268" { 
 local Scen = `Scen' + 1  
 
*Set expected cumulative incidence for time t=10* 
 local CIF = 0.112 
 
*Create a post file to save bias estimates to after each study 
 postfile Scenario`Scen' Sim_No KM_Est Bias /// 
using "Scenario`Scen'", replace 
 
*Loop through 500 studies 
 forvalues i = 1/500 { 
  clear 
*Create 4,144 participants 
  set obs 4144 
 
*Simulate the time and event data 
  survsim Time Event, cr ncr(2) maxtime(10) /// 
   distribution(exponential) lambdas(`lam') 
 
*Survival set the data 
  stset Time, failure(Event==1) 
 
*Obtain Kaplan-Meier estimates* 
  sts gen surv = s   
  sum surv if Event==1 
 
*Calculate Kaplan-Meier and Bias estimates at time t=10 
local KMest = 1 - r(min) 
  local Bias = `KMest' - `CIF' 
 
*Save bias estimates for each study to the post file 
 304 
  post Scenario`Scen' (`i') (`KMest') (`Bias') 
} 
postclose Scenario`Scen' 
} 
 
*(2)* Histograms of distribution of overall calibration bias 
 
*Set up loop to run through all base scenarios 
forvalues i = 5/8 { 
 use "Scenario`i'", clear 
 
*generate histograms for each scenario 
hist Bias, percent lcolor("39 36 73") fcolor("39 36 73") /// 
fintensity(inten50) bin(10) graphregion(color(white))   /// title("Scenario 
`j'") ylabel(0 (5) 25, angle(0))    /// 
xscale(range(-0.03 0.15)) xlabel(-0.03 (0.03) 0.15)    /// yscale(range(0 
25)) scale(1.2) saving("Graph`j'", replace) 
} 
 
*Combine all histograms into one plot 
graph combine "Graph5" "Graph6" "Graph7" "Graph8",   /// 
scale(0.8) graphregion(color(white)) rows(4)  /// 
title("Distribution of overall calibration bias", span)  
 
*(3)* Summary statistics of overall calibration bias 
 
*Create a post file to save bias estimates to after each study 
postfile Calibation_bias Scenario_No KM_mean KM_sd Abs_Bias_m /// 
Abs_Bias_sd Rel_Bias_m Rel_Bias_sd       /// 
using "Calibration_bias", replace 
 
*Set up loop to run through base scenarios 
forvalues k = 5/8 { 
 use " Scenario`k'", clear 
*Summarise Kaplan-Meier failure estimates 
 sum KM_Est 
 local kmmean = r(mean) 
 local kmsd = r(sd) 
 
*Summarise absolute bias estimates 
 sum Bias 
 local absmean = r(mean) 
 local abssd = r(sd) 
 
*Generate and summarise relative bias estimates 
 local CIF = 0.112 
 gen Rel_Bias = Bias / `CIF' 
 sum Rel_Bias 
 local relmean = r(mean) 
 local relsd = r(sd) 
 
*Save bias summary statistics for each study to the post file 
 post Calibation_bias (`k') (`kmmean') (`kmsd') (`absmean')/// 
(`abssd') (`relmean') (`relsd')  
} 
postclose Calibation_bias 
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Table 22.1: Absolute bias in overall calibration over competing event incidence 
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